,use_code,use_code_desc,edition
0,U,PATENT USE CODE,1988
1,U-1,PREVENTION OF PREGNANCY,1988
2,U-2,CYCLIC CONTROL,1988
3,U-3,"TREATMENT OF AMENORRHEA, DYSMENORRHEA, AND FUNCTIONAL UTERINE BLEEDING",1988
4,U-4,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1988
5,U-5,TREATMENT OF HYPERTENSION,1988
6,U-6,TREATING MAMMALS SUFFERING [FROM] ANXIETY,1988
7,U-7,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1988
8,U-8,REDUCING INTRAVASCULAR PRESSURE IN MAMMALS,1988
9,U-9,METHOD OF PRODUCING BRONCHODILATION,1988
10,U-10,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1988
11,U-11,INCREASING CARDIAC CONTRACTILITY,1988
12,U-12,TREATMENT OF BURNS,1988
13,U-13,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1988
14,U-14,TREATMENT OF STRESS-INDUCED DEPRESSION,1988
15,U-15,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1988
16,U-16,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1988
17,U-17,METHOD FOR TREATMENT OF HERPETIC INFECTIONS,1988
18,U-18,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1988
19,U-19,PROCESS FOR PRODUCING ANALGESIA OR REDUCING HYPERALGESIA IN AN ANIMAL,1988
20,U-20,USE OF FLUOXETINE AND MORPHINE FOR PRODUCING ANALGESIA OR REDUCING HYPERALGESIA IN AN ANIMAL,1988
21,U-21,USING FLUOXETINE AND L-5-HYDROXTRYPTOPHANE IN A METHOD FOR LOWERING BLOOD PRESSURE IN A HYPERTENSIVE MAMMAL IN NEED OF TREATMENT,1988
22,U-22,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1988
23,U-23,A METHOD OF POTENTIATING DEXTROPROPOXYPHENE ANALGESIA IN MAMMALS,1988
24,U-24,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1988
25,U-25,METHOD OF LOWERING INTRAOCULAR PRESSURE,1988
26,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1989
27,U-1,PREVENTION OF PREGNANCY,1989
28,U-2,CYCLIC CONTROL,1989
29,U-3,"TREATMENT OF AMENORRHEA, DYSMENORRHEA, AND FUNCTIONAL UTERINE BLEEDING",1989
30,U-4,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1989
31,U-5,TREATMENT OF HYPERTENSION,1989
32,U-6,"TREATING MAMMALS, SUFFERING [FROM] ANXIETY",1989
33,U-7,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1989
34,U-8,REDUCING INTRAVASCULAR PRESSURE IN MAMMALS,1989
35,U-9,METHOD OF PRODUCING BRONCHODILATION,1989
36,U-10,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1989
37,U-11,INCREASING CARDIAC CONTRACTILITY,1989
38,U-12,TREATMENT OF BURNS,1989
39,U-13,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1989
40,U-14,TREATMENT OF STRESS-INDUCED DEPRESSION,1989
41,U-15,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1989
42,U-16,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1989
43,U-17,METHOD FOR TREATMENT OF HERPETIC INFECTIONS,1989
44,U-18,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1989
45,U-19,PROCESS FOR PRODUCING ANALGESIA OR REDUCING HYPERALGESIA IN AN ANIMAL,1989
46,U-20,USE OF FLUOXETINE AND MORPHINE FOR PRODUCING ANALGESIA OR REDUCING HYPERALGESIA IN AN ANIMAL,1989
47,U-21,USING FLUOXETINE AND L-5-HYDROXTRYPTOPHANE IN A METHOD FOR LOWERING BLOOD PRESSURE IN A HYPERTENSIVE MAMMAL IN NEED OF TREATMENT,1989
48,U-22,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1989
49,U-23,A METHOD OF POTENTIATING DEXTROPROPOXYPHENE ANALGESIA IN MAMMALS,1989
50,U-24,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1989
51,U-25,METHOD OF LOWERING INTRAOCULAR PRESSURE,1989
52,U-26,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,1989
53,U-27,METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1989
54,U-28,METHOD FOR IMPROVING MEMORY IN MAMMALS,1989
55,U-29,METHOD FOR TREATING AMNESIA,1989
56,U-30,METHOD OF POTENTIATING CODEINE ANALGESIA IN MAMMALS,1989
57,U-31,USE IN LUNG SCANNING PROCEDURES,1989
58,U-32,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1989
59,U-33,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1989
60,U-34,TREATMENT OF INFLAMMATION,1989
61,U-35,A PROCESS FOR INHIBITING THE SECRETION OF PROLACTIN IN MAMMALS,1989
62,U-36,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON’S SYNDROME AND IN NEED OF TREATMENT,1989
63,U-37,METHOD FOR CHOLESTEROL LOWERING,1989
64,U-38,TREATMENT OF HUMANS SUFFERING FROM UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1989
65,U-39,"METHOD OF COMBATING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1989
66,U-40,METHOD OF EFFECTING CORONARY VASCULAR DILATION IN HUMANS AND ANIMALS,1989
67,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1990
68,U-1,PREVENTION OF PREGNANCY,1990
69,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1990
70,U-3,TREATMENT OF HYPERTENSION,1990
71,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1990
72,U-5,METHOD OF PRODUCING BRONCHODILATION,1990
73,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1990
74,U-7,INCREASING CARDIAC CONTRACTILITY,1990
75,U-8,ACUTE MYOCARDIAL INFARCTION,1990
76,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1990
77,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1990
78,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1990
79,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1990
80,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1990
81,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1990
82,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1990
83,U-16,USE IN LUNG SCANNING PROCEDURES,1990
84,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1990
85,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1990
86,U-19,TREATMENT OF INFLAMMATION,1990
87,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON’S SYNDROME AND IN NEED OF TREATMENT,1990
88,U-21,TREATMENT OF HUMANS SUFFERING FROM UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1990
89,U-22,"METHOD OF COMBATING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1990
90,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1990
91,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1990
92,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1990
93,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1990
94,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1990
95,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1990
96,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1990
97,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1990
98,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1990
99,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1990
100,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1990
101,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1990
102,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1990
103,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1990
104,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1990
105,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1990
106,U-39,ANGINA PECTORIS,1990
107,U-40,METHOD OF TREATMENT OF BURNS,1990
108,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1990
109,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1991
110,U-1,PREVENTION OF PREGNANCY,1991
111,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1991
112,U-3,TREATMENT OF HYPERTENSION,1991
113,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1991
114,U-5,METHOD OF PRODUCING BRONCHODILATION,1991
115,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1991
116,U-7,INCREASING CARDIAC CONTRACTILITY,1991
117,U-8,ACUTE MYOCARDIAL INFARCTION,1991
118,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1991
119,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1991
120,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1991
121,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1991
122,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1991
123,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1991
124,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1991
125,U-16,USE IN LUNG SCANNING PROCEDURES,1991
126,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1991
127,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1991
128,U-19,TREATMENT OF INFLAMMATION,1991
129,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1991
130,U-21,TREATMENT OF HUMANS SUFFERING FROM UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1991
131,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1991
132,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1991
133,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1991
134,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1991
135,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1991
136,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1991
137,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1991
138,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1991
139,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1991
140,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1991
141,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1991
142,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1991
143,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1991
144,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1991
145,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1991
146,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1991
147,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1991
148,U-39,ANGINA PECTORIS,1991
149,U-40,METHOD OF TREATMENT OF BURNS,1991
150,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1991
151,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES’ STAGE C COLON CANCER,1991
152,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1991
153,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1992
154,U-1,PREVENTION OF PREGNANCY,1992
155,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1992
156,U-3,TREATMENT OF HYPERTENSION,1992
157,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1992
158,U-5,METHOD OF PRODUCING BRONCHODILATION,1992
159,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1992
160,U-7,INCREASING CARDIAC CONTRACTILITY,1992
161,U-8,ACUTE MYOCARDIAL INFARCTION,1992
162,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1992
163,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1992
164,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1992
165,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1992
166,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1992
167,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1992
168,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1992
169,U-16,USE IN LUNG SCANNING PROCEDURES,1992
170,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1992
171,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1992
172,U-19,TREATMENT OF INFLAMMATION,1992
173,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1992
174,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1992
175,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1992
176,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1992
177,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1992
178,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1992
179,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1992
180,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1992
181,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1992
182,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1992
183,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1992
184,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1992
185,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1992
186,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1992
187,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1992
188,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1992
189,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1992
190,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1992
191,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1992
192,U-39,ANGINA PECTORIS,1992
193,U-40,METHOD OF TREATMENT OF BURNS,1992
194,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1992
195,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1992
196,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1992
197,U-44,RELIEF OF NAUSEA AND VOMITING,1992
198,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1992
199,U-46,TREATMENT OF PANIC DISORDER,1992
200,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1992
201,U-48,ANALGESIA,1992
202,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1992
203,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1992
204,U-51,"BLOOD POOL IMAGING, INCLUDING FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1992
205,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1992
206,U-53,HYPERCALCEMIA OF MALIGNANCY,1992
207,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1992
208,U-55,TREATMENT OF PAIN,1992
209,U-56,AID TO SMOKING CESSATION,1992
210,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1993
211,U-1,PREVENTION OF PREGNANCY,1993
212,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1993
213,U-3,TREATMENT OF HYPERTENSION,1993
214,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1993
215,U-5,METHOD OF PRODUCING BRONCHODILATION,1993
216,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1993
217,U-7,INCREASING CARDIAC CONTRACTILITY,1993
218,U-8,ACUTE MYOCARDIAL INFARCTION,1993
219,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1993
220,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1993
221,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1993
222,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1993
223,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1993
224,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1993
225,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1993
226,U-16,USE IN LUNG SCANNING PROCEDURES,1993
227,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1993
228,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1993
229,U-19,TREATMENT OF INFLAMMATION,1993
230,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1993
231,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1993
232,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1993
233,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1993
234,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1993
235,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1993
236,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1993
237,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1993
238,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1993
239,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1993
240,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1993
241,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1993
242,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1993
243,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1993
244,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1993
245,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1993
246,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1993
247,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1993
248,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1993
249,U-39,ANGINA PECTORIS,1993
250,U-40,METHOD OF TREATMENT OF BURNS,1993
251,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1993
252,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1993
253,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1993
254,U-44,RELIEF OF NAUSEA AND VOMITING,1993
255,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1993
256,U-46,TREATMENT OF PANIC DISORDER,1993
257,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1993
258,U-48,ANALGESIA,1993
259,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1993
260,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1993
261,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1993
262,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1993
263,U-53,HYPERCALCEMIA OF MALIGNANCY,1993
264,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1993
265,U-55,TREATMENT OF PAIN,1993
266,U-56,AID TO SMOKING CESSATION,1993
267,U-57,OPHTHALMIC USE OF NORFLOXACIN,1993
268,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1993
269,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1993
270,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1993
271,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1993
272,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1993
273,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1993
274,U-64,TREATMENT OF VIRAL INFECTIONS,1993
275,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1993
276,U-66,TRIPHASIC REGIMEN,1993
277,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1993
278,U-68,TREATMENT OF ACTINIC KERATOSIS,1993
279,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1993
280,U-70,TREATMENT OF TRANSIENT INSOMNIA,1993
281,U-71,METHOD OF TREATMENT OF HEART FAILURE,1993
282,U-72,TREATMENT OF MIGRAINES,1993
283,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1993
284,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1994
285,U-1,PREVENTION OF PREGNANCY,1994
286,U-2,TREATMENT OF PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1994
287,U-3,TREATMENT OF HYPERTENSION,1994
288,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1994
289,U-5,METHOD OF PRODUCING BRONCHODILATION,1994
290,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1994
291,U-7,INCREASING CARDIAC CONTRACTILITY,1994
292,U-8,ACUTE MYOCARDIAL INFARCTION,1994
293,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1994
294,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,1994
295,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1994
296,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1994
297,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1994
298,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1994
299,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1994
300,U-16,USE IN LUNG SCANNING PROCEDURES,1994
301,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1994
302,U-18,METHOD FOR NHIBITING GASTRIC SECRETION IN MAMMALS,1994
303,U-19,TREATMENT OF INFLAMMATION,1994
304,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1994
305,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1994
306,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1994
307,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1994
308,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1994
309,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1994
310,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1994
311,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1994
312,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1994
313,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1994
314,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1994
315,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1994
316,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1994
317,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1994
318,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1994
319,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1994
320,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1994
321,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1994
322,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1994
323,U-39,ANGINA PECTORIS,1994
324,U-40,METHOD OF TREATMENT OF BURNS,1994
325,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1994
326,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1994
327,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1994
328,U-44,RELIEF OF NAUSEA AND VOMITING,1994
329,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1994
330,U-46,TREATMENT OF PANIC DISORDER,1994
331,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1994
332,U-48,ANALGESIA,1994
333,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1994
334,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1994
335,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1994
336,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1994
337,U-53,HYPERCALCEMIA OF MALIGNANCY,1994
338,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1994
339,U-55,TREATMENT OF PAIN,1994
340,U-56,AID TO SMOKING CESSATION,1994
341,U-57,OPHTHALMIC USE OF NORFLOXACIN,1994
342,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1994
343,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1994
344,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1994
345,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1994
346,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1994
347,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1994
348,U-64,TREATMENT OF VIRAL INFECTIONS,1994
349,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1994
350,U-66,TRIPHASIC REGIMEN,1994
351,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1994
352,U-68,TREATMENT OF ACTINIC KERATOSIS,1994
353,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1994
354,U-70,TREATMENT OF TRANSIENT INSOMNIA,1994
355,U-71,METHOD OF TREATMENT OF HEART FAILURE,1994
356,U-72,TREATMENT OF MIGRAINES,1994
357,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1994
358,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,1994
359,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,1994
360,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,1994
361,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,1994
362,U-78,ULCERATIVE COLITIS,1994
363,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,1994
364,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,1994
365,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,1994
366,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,1994
367,U-83,TREATMENT OF SEIZURES,1994
368,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1994
369,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,1994
370,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,1994
371,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",1994
372,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,1994
373,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,1994
374,U-90,TREATMENT OF PSYCHOTIC DISORDERS,1994
375,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1995
376,U-1,PREVENTION OF PREGNANCY,1995
377,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1995
378,U-3,TREATMENT OF HYPERTENSION,1995
379,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1995
380,U-5,METHOD OF PRODUCING BRONCHODILATION,1995
381,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1995
382,U-7,INCREASING CARDIAC CONTRACTILITY,1995
383,U-8,ACUTE MYOCARDIAL INFARCTION,1995
384,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1995
385,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,1995
386,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1995
387,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1995
388,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1995
389,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1995
390,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1995
391,U-16,USE IN LUNG SCANNING PROCEDURES,1995
392,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1995
393,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1995
394,U-19,TREATMENT OF INFLAMMATION,1995
395,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1995
396,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1995
397,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1995
398,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1995
399,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1995
400,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1995
401,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1995
402,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1995
403,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1995
404,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1995
405,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1995
406,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1995
407,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1995
408,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1995
409,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1995
410,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1995
411,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1995
412,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1995
413,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1995
414,U-39,ANGINA PECTORIS,1995
415,U-40,METHOD OF TREATMENT OF BURNS,1995
416,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1995
417,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES STAGE C COLON CANCER,1995
418,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1995
419,U-44,RELIEF OF NAUSEA AND VOMITING,1995
420,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1995
421,U-46,TREATMENT OF PANIC DISORDER,1995
422,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1995
423,U-48,ANALGESIA,1995
424,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1995
425,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1995
426,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1995
427,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1995
428,U-53,HYPERCALCEMIA OF MALIGNANCY,1995
429,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1995
430,U-55,TREATMENT OF PAIN,1995
431,U-56,AID TO SMOKING CESSATION,1995
432,U-57,OPHTHALMIC USE OF NORFLOXACIN,1995
433,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1995
434,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1995
435,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1995
436,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1995
437,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1995
438,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1995
439,U-64,TREATMENT OF VIRAL INFECTIONS,1995
440,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1995
441,U-66,TRIPHASIC REGIMEN,1995
442,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1995
443,U-68,TREATMENT OF ACTINIC KERATOSIS,1995
444,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1995
445,U-70,TREATMENT OF TRANSIENT INSOMNIA,1995
446,U-71,METHOD OF TREATMENT OF HEART FAILURE,1995
447,U-72,TREATMENT OF MIGRAINES,1995
448,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1995
449,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,1995
450,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,1995
451,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,1995
452,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,1995
453,U-78,ULCERATIVE COLITIS,1995
454,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,1995
455,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,1995
456,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,1995
457,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,1995
458,U-83,TREATMENT OF SEIZURES,1995
459,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1995
460,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,1995
461,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,1995
462,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",1995
463,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,1995
464,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,1995
465,U-90,TREATMENT OF PSYCHOTIC DISORDERS,1995
466,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,1995
467,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1995
468,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,1995
469,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,1995
470,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,1995
471,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,1995
472,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,1995
473,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,1995
474,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,1995
475,U-100,METHOD OF TREATING OCULAR INFLAMMATION,1995
476,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,1995
477,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1996
478,U-1,PREVENTION OF PREGNANCY,1996
479,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1996
480,U-3,TREATMENT OF HYPERTENSION,1996
481,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1996
482,U-5,METHOD OF PRODUCING BRONCHODILATION,1996
483,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1996
484,U-7,INCREASING CARDIAC CONTRACTILITY,1996
485,U-8,ACUTE MYOCARDIAL INFARCTION,1996
486,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1996
487,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,1996
488,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1996
489,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1996
490,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1996
491,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1996
492,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1996
493,U-16,USE IN LUNG SCANNING PROCEDURES,1996
494,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1996
495,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1996
496,U-19,TREATMENT OF INFLAMMATION,1996
497,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1996
498,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1996
499,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1996
500,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1996
501,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1996
502,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1996
503,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1996
504,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1996
505,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1996
506,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1996
507,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1996
508,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1996
509,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1996
510,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1996
511,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1996
512,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1996
513,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1996
514,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1996
515,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1996
516,U-39,ANGINA PECTORIS,1996
517,U-40,METHOD OF TREATMENT OF BURNS,1996
518,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1996
519,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1996
520,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1996
521,U-44,RELIEF OF NAUSEA AND VOMITING,1996
522,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1996
523,U-46,TREATMENT OF PANIC DISORDER,1996
524,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1996
525,U-48,ANALGESIA,1996
526,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1996
527,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1996
528,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1996
529,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1996
530,U-53,HYPERCALCEMIA OF MALIGNANCY,1996
531,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1996
532,U-55,TREATMENT OF PAIN,1996
533,U-56,AID TO SMOKING CESSATION,1996
534,U-57,OPHTHALMIC USE OF NORFLOXACIN,1996
535,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1996
536,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1996
537,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1996
538,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1996
539,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1996
540,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1996
541,U-64,TREATMENT OF VIRAL INFECTIONS,1996
542,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1996
543,U-66,TRIPHASIC REGIMEN,1996
544,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1996
545,U-68,TREATMENT OF ACTINIC KERATOSIS,1996
546,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1996
547,U-70,TREATMENT OF TRANSIENT INSOMNIA,1996
548,U-71,METHOD OF TREATMENT OF HEART FAILURE,1996
549,U-72,TREATMENT OF MIGRAINES,1996
550,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1996
551,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,1996
552,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,1996
553,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,1996
554,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,1996
555,U-78,ULCERATIVE COLITIS,1996
556,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,1996
557,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,1996
558,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,1996
559,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,1996
560,U-83,TREATMENT OF SEIZURES,1996
561,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1996
562,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,1996
563,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,1996
564,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",1996
565,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,1996
566,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,1996
567,U-90,TREATMENT OF PSYCHOTIC DISORDERS,1996
568,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,1996
569,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1996
570,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,1996
571,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,1996
572,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,1996
573,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,1996
574,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,1996
575,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,1996
576,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,1996
577,U-100,METHOD OF TREATING OCULAR INFLAMMATION,1996
578,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,1996
579,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,1996
580,U-103,TREATMENT OF OCULAR HYPERTENSION,1996
581,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,1996
582,U-105,EMESIS,1996
583,U-106,TREATMENT OF EPILEPSY,1996
584,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,1996
585,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",1996
586,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,1996
587,U-110,USE AS A RETRIEVABLE PESSARY,1996
588,U-111,DIABETES,1996
589,U-112,CONTRACEPTION,1996
590,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,1996
591,U-114,USE FOR INHIBITING BONE RESORPTION,1996
592,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",1996
593,U-116,METHOD OF MYOCARDIAL IMAGING,1996
594,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,1996
595,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,1996
596,U-119,TREATMENT OF NASAL HYPERSECRETION,1996
597,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASAR SURGICAL PROCEDURES,1996
598,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1997
599,U-1,PREVENTION OF PREGNANCY,1997
600,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1997
601,U-3,TREATMENT OF HYPERTENSION,1997
602,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1997
603,U-5,METHOD OF PRODUCING BRONCHODILATION,1997
604,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1997
605,U-7,INCREASING CARDIAC CONTRACTILITY,1997
606,U-8,ACUTE MYOCARDIAL INFARCTION,1997
607,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1997
608,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,1997
609,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1997
610,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,1997
611,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1997
612,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1997
613,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1997
614,U-16,USE IN LUNG SCANNING PROCEDURES,1997
615,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1997
616,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1997
617,U-19,TREATMENT OF INFLAMMATION,1997
618,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1997
619,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1997
620,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL.INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1997
621,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1997
622,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1997
623,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1997
624,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1997
625,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1997
626,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1997
627,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1997
628,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1997
629,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1997
630,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1997
631,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1997
632,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1997
633,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1997
634,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1997
635,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1997
636,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1997
637,U-39,ANGINA PECTORIS,1997
638,U-40,METHOD OF TREATMENT OF BURNS,1997
639,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1997
640,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1997
641,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1997
642,U-44,RELIEF OF NAUSEA AND VOMITING,1997
643,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1997
644,U-46,TREATMENT OF PANIC DISORDER,1997
645,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1997
646,U-48,ANALGESIA,1997
647,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1997
648,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1997
649,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1997
650,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1997
651,U-53,HYPERCALCEMIA OF MALIGNANCY,1997
652,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1997
653,U-55,TREATMENT OF PAIN,1997
654,U-56,AID TO SMOKING CESSATION,1997
655,U-57,OPHTHALMIC USE OF NORFLOXACIN,1997
656,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1997
657,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1997
658,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1997
659,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1997
660,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1997
661,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1997
662,U-64,TREATMENT OF VIRAL INFECTIONS,1997
663,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1997
664,U-66,TRIPHASIC REGIMEN,1997
665,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1997
666,U-68,TREATMENT OF ACTINIC KERATOSIS,1997
667,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1997
668,U-70,TREATMENT OF TRANSIENT INSOMNIA,1997
669,U-71,METHOD OF TREATMENT OF HEART FAILURE,1997
670,U-72,TREATMENT OF MIGRAINES,1997
671,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1997
672,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,1997
673,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,1997
674,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,1997
675,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,1997
676,U-78,ULCERATIVE COLITIS,1997
677,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,1997
678,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,1997
679,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,1997
680,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,1997
681,U-83,TREATMENT OF SEIZURES,1997
682,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1997
683,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,1997
684,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,1997
685,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",1997
686,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,1997
687,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,1997
688,U-90,TREATMENT OF PSYCHOTIC DISORDERS,1997
689,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,1997
690,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1997
691,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,1997
692,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,1997
693,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,1997
694,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,1997
695,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,1997
696,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,1997
697,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,1997
698,U-100,METHOD OF TREATING OCULAR INFLAMMATION,1997
699,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,1997
700,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,1997
701,U-103,TREATMENT OF OCULAR HYPERTENSION,1997
702,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,1997
703,U-105,EMESIS,1997
704,U-106,TREATMENT OF EPILEPSY,1997
705,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,1997
706,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",1997
707,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,1997
708,U-110,USE AS A RETRIEVABLE PESSARY,1997
709,U-111,DIABETES,1997
710,U-112,CONTRACEPTION,1997
711,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,1997
712,U-114,USE FOR INHIBITING BONE RESORPTION,1997
713,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",1997
714,U-116,METHOD OF MYOCARDIAL IMAGING,1997
715,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,1997
716,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,1997
717,U-119,TREATMENT OF NASAL HYPERSECRETION,1997
718,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,1997
719,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,1997
720,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,1997
721,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,1997
722,U-124,TREATMENT OF ACNE,1997
723,U-125,TREATING NEUROGENERATIVE DISEASES,1997
724,U-126,TREATMENT OF GASTRITIS,1997
725,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,1997
726,U-128,METHODS FOR TREATMENT OF TUMORS,1997
727,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,1997
728,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,1997
729,U-131,PHOTODAMAGED SKIN,1997
730,U-132,INHIBITING HIV PROTEASE,1997
731,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,1997
732,U-134,TREATMENT OF ACNE VULGARIS,1997
733,U-135,ANTITUMOR AGENT,1997
734,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,1997
735,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,1997
736,U-138,TREATMENT OF ALLERGIC RHINITIS,1997
737,U-139,TREATMENT OF ALLERGIC REACTIONS,1997
738,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,1997
739,U-141,TREATMENT OF ULCERATIVE COLITIS,1997
740,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,1997
741,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MRIMAGING,1997
742,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,1997
743,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,1997
744,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,1997
745,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,1997
746,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,1997
747,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",1997
748,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,1997
749,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,1997
750,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,1997
751,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,1997
752,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,1997
753,U-155,TREATMENT OF ERECTILE DYSFUNCITON,1997
754,U-156,METHOD OF PROVIDING ANESTHESIA,1997
755,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,1997
756,U-158,ANGINA,1997
757,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,1997
758,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,1997
759,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1998
760,U-1,PREVENTION OF PREGNANCY,1998
761,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1998
762,U-3,TREATMENT OF HYPERTENSION,1998
763,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1998
764,U-5,METHOD OF PRODUCING BRONCHODILATION,1998
765,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1998
766,U-7,INCREASING CARDIAC CONTRACTILITY,1998
767,U-8,ACUTE MYOCARDIAL INFARCTION,1998
768,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1998
769,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,1998
770,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1998
771,U-12,METHOD OF TREATING |A| HUMAN SUFFERING FROM DEPRESSION,1998
772,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1998
773,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1998
774,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1998
775,U-16,USE IN LUNG SCANNING PROCEDURES,1998
776,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1998
777,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1998
778,U-19,TREATMENT OF INFLAMMATION,1998
779,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1998
780,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1998
781,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1998
782,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1998
783,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1998
784,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1998
785,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1998
786,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1998
787,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1998
788,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1998
789,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1998
790,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1998
791,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1998
792,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1998
793,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1998
794,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1998
795,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1998
796,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1998
797,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1998
798,U-39,ANGINA PECTORIS,1998
799,U-40,METHOD OF TREATMENT OF BURNS,1998
800,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1998
801,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1998
802,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1998
803,U-44,RELIEF OF NAUSEA AND VOMITING,1998
804,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1998
805,U-46,TREATMENT OF PANIC DISORDER,1998
806,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1998
807,U-48,ANALGESIA,1998
808,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1998
809,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1998
810,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1998
811,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1998
812,U-53,HYPERCALCEMIA OF MALIGNANCY,1998
813,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1998
814,U-55,TREATMENT OF PAIN,1998
815,U-56,AID TO SMOKING CESSATION,1998
816,U-57,OPHTHALMIC USE OF NORFLOXACIN,1998
817,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1998
818,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1998
819,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1998
820,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1998
821,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1998
822,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1998
823,U-64,TREATMENT OF VIRAL INFECTIONS,1998
824,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1998
825,U-66,TRIPHASIC REGIMEN,1998
826,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1998
827,U-68,TREATMENT OF ACTINIC KERATOSIS,1998
828,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1998
829,U-70,TREATMENT OF TRANSIENT INSOMNIA,1998
830,U-71,METHOD OF TREATMENT OF HEART FAILURE,1998
831,U-72,TREATMENT OF MIGRAINES,1998
832,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1998
833,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,1998
834,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,1998
835,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,1998
836,U-77,TREATM ENT OF SYMPTOMS OF SEASONAL ALLERG IC RHINITIS,1998
837,U-78,ULCERATIVE COLITIS,1998
838,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,1998
839,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,1998
840,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,1998
841,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,1998
842,U-83,TREATMENT OF SEIZURES,1998
843,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1998
844,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,1998
845,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,1998
846,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",1998
847,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,1998
848,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,1998
849,U-90,TREATMENT OF PSYCHOTIC DISORDERS,1998
850,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,1998
851,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT MELLITUS AND RETINOPATHYDIABETES,1998
852,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,1998
853,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,1998
854,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,1998
855,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,1998
856,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,1998
857,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,1998
858,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,1998
859,U-100,METHOD OF TREATING OCULAR INFLAMMATION,1998
860,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,1998
861,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,1998
862,U-103,TREATMENT OF OCULAR HYPERTENSION,1998
863,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,1998
864,U-105,EMESIS,1998
865,U-106,TREATMENT OF EPILEPSY,1998
866,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,1998
867,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",1998
868,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,1998
869,U-110,USE AS A RETRIEVABLE PESSARY,1998
870,U-111,DIABETES,1998
871,U-112,CONTRACEPTION,1998
872,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,1998
873,U-114,USE FOR INHIBITING BONE RESORPTION,1998
874,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",1998
875,U-116,METHOD OF MYOCARDIAL IMAGING,1998
876,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,1998
877,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,1998
878,U-119,TREATMENT OF NASAL HYPERSECRETION,1998
879,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,1998
880,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,1998
881,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,1998
882,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,1998
883,U-124,TREATMENT OF ACNE,1998
884,U-125,TREATING NEUROGENERATIVE DISEASES,1998
885,U-126,TREATMENT OF GASTRITIS,1998
886,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,1998
887,U-128,METHODS FOR TREATMENT OF TUMORS,1998
888,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,1998
889,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,1998
890,U-131,PHOTODAMAGED SKIN,1998
891,U-132,INHIBITING HIV PROTEASE,1998
892,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,1998
893,U-134,TREATMENT OF ACNE VULGARIS,1998
894,U-135,ANTITUMOR AGENT,1998
895,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,1998
896,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,1998
897,U-138,TREATMENT OF ALLERGIC RHINITIS,1998
898,U-139,TREATMENT OF ALLERGIC REACTIONS,1998
899,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,1998
900,U-141,TREATMENT OF ULCERATIVE COLITIS,1998
901,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,1998
902,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,1998
903,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,1998
904,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,1998
905,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,1998
906,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,1998
907,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,1998
908,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",1998
909,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,1998
910,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,1998
911,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,1998
912,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,1998
913,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,1998
914,U-155,TREATMENT OF ERECTILE DYSFUNCTION,1998
915,U-156,METHOD OF PROVIDING ANESTHESIA,1998
916,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,1998
917,U-158,ANGINA,1998
918,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,1998
919,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,1998
920,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,1998
921,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,1998
922,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,1998
923,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,1998
924,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1998
925,U-166,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,1998
926,U-167,METHOD FOR TREATING HIV-1 INFECTION,1998
927,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,1998
928,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,1998
929,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,1998
930,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,1998
931,U-172,TREATMENT OF GENITAL WARTS,1998
932,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,1998
933,U-174,USE AS AN ANTIHISTAMINE AGENT,1998
934,U-175,METHOD OF TREATING MALIGNANT TUMORS,1998
935,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS",1998
936,U-177,FUNGICIDE,1998
937,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,1998
938,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,1998
939,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1998
940,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,1998
941,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,1998
942,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,1998
943,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,1998
944,U-185,METHOD OF TREATING HYPERTENSION,1998
945,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,1998
946,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,1998
947,U-188,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,1998
948,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,1998
949,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,1998
950,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,1998
951,U-192,USE IN TREATING ALLERGIC REACTIONS,1998
952,U-193,PSORIASIS,1998
953,U-194,TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE,1998
954,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,1998
955,U-196,TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,1998
956,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,1998
957,U-198,"TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA",1998
958,U-199,METHOD OF TREATING INFECTIOUS UPPER GL TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,1998
959,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,1998
960,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,1998
961,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",1998
962,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,1998
963,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA,1998
964,U-205,METHOD FOR TREATING HEARTBURN,1998
965,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION",1998
966,U-207,USE AS NASAL SPRAY,1998
967,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,1998
968,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,1998
969,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,1998
970,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,1998
971,U-212,METHOD OF TREATMENT OF PARKINSON’S DISEASE,1998
972,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,1998
973,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,1998
974,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",1999
975,U-1,PREVENTION OF PREGNANCY,1999
976,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,1999
977,U-3,TREATMENT OF HYPERTENSION,1999
978,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,1999
979,U-5,METHOD OF PRODUCING BRONCHODILATION,1999
980,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,1999
981,U-7,INCREASING CARDIAC CONTRACTILITY,1999
982,U-8,ACUTE MYOCARDIAL INFARCTION,1999
983,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,1999
984,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,1999
985,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,1999
986,U-12,METHOD OF TREATING |A| HUMAN SUFFERING FROM DEPRESSION,1999
987,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,1999
988,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,1999
989,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,1999
990,U-16,USE IN LUNG SCANNING PROCEDURES,1999
991,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,1999
992,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,1999
993,U-19,TREATMENT OF INFLAMMATION,1999
994,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,1999
995,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,1999
996,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",1999
997,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,1999
998,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,1999
999,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,1999
1000,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1999
1001,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,1999
1002,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",1999
1003,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",1999
1004,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",1999
1005,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,1999
1006,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",1999
1007,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,1999
1008,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,1999
1009,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,1999
1010,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,1999
1011,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,1999
1012,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,1999
1013,U-39,ANGINA PECTORIS,1999
1014,U-40,METHOD OF TREATMENT OF BURNS,1999
1015,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,1999
1016,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,1999
1017,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,1999
1018,U-44,RELIEF OF NAUSEA AND VOMITING,1999
1019,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,1999
1020,U-46,TREATMENT OF PANIC DISORDER,1999
1021,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,1999
1022,U-48,ANALGESIA,1999
1023,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,1999
1024,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,1999
1025,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",1999
1026,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1999
1027,U-53,HYPERCALCEMIA OF MALIGNANCY,1999
1028,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,1999
1029,U-55,TREATMENT OF PAIN,1999
1030,U-56,AID TO SMOKING CESSATION,1999
1031,U-57,OPHTHALMIC USE OF NORFLOXACIN,1999
1032,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,1999
1033,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,1999
1034,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,1999
1035,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,1999
1036,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",1999
1037,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,1999
1038,U-64,TREATMENT OF VIRAL INFECTIONS,1999
1039,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,1999
1040,U-66,TRIPHASIC REGIMEN,1999
1041,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,1999
1042,U-68,TREATMENT OF ACTINIC KERATOSIS,1999
1043,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,1999
1044,U-70,TREATMENT OF TRANSIENT INSOMNIA,1999
1045,U-71,METHOD OF TREATMENT OF HEART FAILURE,1999
1046,U-72,TREATMENT OF MIGRAINES,1999
1047,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,1999
1048,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,1999
1049,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,1999
1050,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,1999
1051,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,1999
1052,U-78,ULCERATIVE COLITIS,1999
1053,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,1999
1054,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,1999
1055,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,1999
1056,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,1999
1057,U-83,TREATMENT OF SEIZURES,1999
1058,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,1999
1059,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,1999
1060,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,1999
1061,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",1999
1062,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,1999
1063,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,1999
1064,U-90,TREATMENT OF PSYCHOTIC DISORDERS,1999
1065,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,1999
1066,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,1999
1067,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,1999
1068,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,1999
1069,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,1999
1070,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,1999
1071,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,1999
1072,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,1999
1073,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,1999
1074,U-100,METHOD OF TREATING OCULAR INFLAMMATION,1999
1075,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,1999
1076,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,1999
1077,U-103,TREATMENT OF OCULAR HYPERTENSION,1999
1078,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,1999
1079,U-105,EMESIS,1999
1080,U-106,TREATMENT OF EPILEPSY,1999
1081,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,1999
1082,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",1999
1083,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,1999
1084,U-110,USE AS A RETRIEVABLE PESSARY,1999
1085,U-111,DIABETES,1999
1086,U-112,CONTRACEPTION,1999
1087,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,1999
1088,U-114,USE FOR INHIBITING BONE RESORPTION,1999
1089,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",1999
1090,U-116,METHOD OF MYOCARDIAL IMAGING,1999
1091,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,1999
1092,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,1999
1093,U-119,TREATMENT OF NASAL HYPERSECRETION,1999
1094,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,1999
1095,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,1999
1096,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,1999
1097,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,1999
1098,U-124,TREATMENT OF ACNE,1999
1099,U-125,TREATING NEUROGENERATIVE DISEASES,1999
1100,U-126,TREATMENT OF GASTRITIS,1999
1101,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,1999
1102,U-128,METHODS FOR TREATMENT OF TUMORS,1999
1103,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,1999
1104,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,1999
1105,U-131,PHOTODAMAGED SKIN,1999
1106,U-132,INHIBITING HIV PROTEASE,1999
1107,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,1999
1108,U-134,TREATMENT OF ACNE VULGARIS,1999
1109,U-135,ANTITUMOR AGENT,1999
1110,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,1999
1111,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,1999
1112,U-138,TREATMENT OF ALLERGIC RHINITIS,1999
1113,U-139,TREATMENT OF ALLERGIC REACTIONS,1999
1114,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,1999
1115,U-141,TREATMENT OF ULCERATIVE COLITIS,1999
1116,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,1999
1117,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,1999
1118,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,1999
1119,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,1999
1120,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,1999
1121,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,1999
1122,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,1999
1123,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",1999
1124,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,1999
1125,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,1999
1126,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,1999
1127,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,1999
1128,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,1999
1129,U-155,TREATMENT OF ERECTILE DYSFUNCTION,1999
1130,U-156,METHOD OF PROVIDING ANESTHESIA,1999
1131,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,1999
1132,U-158,ANGINA,1999
1133,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,1999
1134,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,1999
1135,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,1999
1136,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,1999
1137,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,1999
1138,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,1999
1139,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,1999
1140,U-166,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,1999
1141,U-167,METHOD FOR TREATING HIV-1 INFECTION,1999
1142,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,1999
1143,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,1999
1144,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,1999
1145,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,1999
1146,U-172,TREATMENT OF GENITAL WARTS,1999
1147,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,1999
1148,U-174,USE AS AN ANTIHISTAMINE AGENT,1999
1149,U-175,METHOD OF TREATING MALIGNANT TUMORS,1999
1150,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS",1999
1151,U-177,FUNGICIDE,1999
1152,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,1999
1153,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,1999
1154,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,1999
1155,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,1999
1156,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,1999
1157,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,1999
1158,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,1999
1159,U-185,METHOD OF TREATING HYPERTENSION,1999
1160,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,1999
1161,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,1999
1162,U-188,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,1999
1163,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,1999
1164,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,1999
1165,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,1999
1166,U-192,USE IN TREATING ALLERGIC REACTIONS,1999
1167,U-193,PSORIASIS,1999
1168,U-194,TREATING AG INA PECTORIS AND HIGH BLOOD PRESSURE,1999
1169,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,1999
1170,U-196,TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,1999
1171,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,1999
1172,U-198,"TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA",1999
1173,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,1999
1174,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,1999
1175,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,1999
1176,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",1999
1177,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,1999
1178,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA,1999
1179,U-205,METHOD FOR TREATING HEARTBURN,1999
1180,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION",1999
1181,U-207,USE AS NASAL SPRAY,1999
1182,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,1999
1183,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,1999
1184,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,1999
1185,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,1999
1186,U-212,METHOD OF TREATMENT OF PARKINSON’S DISEASE,1999
1187,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,1999
1188,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,1999
1189,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,1999
1190,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE",1999
1191,U-217,METHOD OF PRODUCING ANESTHESIA,1999
1192,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,1999
1193,U-219,TREATMENT OF PARKISON’S DISEASE,1999
1194,U-220,METHOD OF DIAGNOSIS,1999
1195,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,1999
1196,U-222,METHOD OF TREATING PAGETS DISEASE USING ACTONEL,1999
1197,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,1999
1198,U-224,CONTROLLING INTRAOCULAR PRESSURE,1999
1199,U-225,METHOD FOR DELIVERY,1999
1200,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,1999
1201,U-227,NASAL ADMINISTRATION,1999
1202,U-228,ASTHMA,1999
1203,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),1999
1204,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,1999
1205,U-231,USE IN PARKINSON’S DISEASE,1999
1206,U-232,METHOD OF TREATING MIGRAINE,1999
1207,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,1999
1208,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,1999
1209,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,1999
1210,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY,1999
1211,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,1999
1212,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",1999
1213,U-239,"TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",1999
1214,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,1999
1215,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORTTERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",1999
1216,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,1999
1217,U-243,TOPICAL ADMINISTRATION,1999
1218,U-244,PLATELET AGGREGATION INHIBITORS,1999
1219,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,1999
1220,U-246,PHOSPHATE BINDING,1999
1221,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,1999
1222,U-248,TREATMENT OF HIV,1999
1223,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,1999
1224,U-250,TREATMENT OF HEPATITIS B INFECTION,1999
1225,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,1999
1226,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER’S DISEASE,1999
1227,U-253,ORAL TRANSMUCOSAL USE,1999
1228,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",2000
1229,U-1,PREVENTION OF PREGNANCY,2000
1230,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2000
1231,U-3,TREATMENT OF HYPERTENSION,2000
1232,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2000
1233,U-5,METHOD OF PRODUCING BRONCHODILATION,2000
1234,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2000
1235,U-7,INCREASING CARDIAC CONTRACTILITY,2000
1236,U-8,ACUTE MYOCARDIAL INFARCTION,2000
1237,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2000
1238,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,2000
1239,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2000
1240,U-12,METHOD OF TREATING |A| HUMAN SUFFERING FROM DEPRESSION,2000
1241,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2000
1242,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2000
1243,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2000
1244,U-16,USE IN LUNG SCANNING PROCEDURES,2000
1245,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2000
1246,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2000
1247,U-19,TREATMENT OF INFLAMMATION,2000
1248,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2000
1249,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2000
1250,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2000
1251,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2000
1252,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2000
1253,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2000
1254,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2000
1255,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2000
1256,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2000
1257,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2000
1258,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2000
1259,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2000
1260,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2000
1261,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2000
1262,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2000
1263,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2000
1264,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2000
1265,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2000
1266,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2000
1267,U-39,ANGINA PECTORIS,2000
1268,U-40,METHOD OF TREATMENT OF BURNS,2000
1269,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2000
1270,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES STAGE C COLON CANCER,2000
1271,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2000
1272,U-44,RELIEF OF NAUSEA AND VOMITING,2000
1273,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2000
1274,U-46,TREATMENT OF PANIC DISORDER,2000
1275,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2000
1276,U-48,ANALGESIA,2000
1277,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2000
1278,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2000
1279,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2000
1280,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2000
1281,U-53,HYPERCALCEMIA OF MALIGNANCY,2000
1282,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2000
1283,U-55,TREATMENT OF PAIN,2000
1284,U-56,AID TO SMOKING CESSATION,2000
1285,U-57,OPHTHALMIC USE OF NORFLOXACIN,2000
1286,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2000
1287,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2000
1288,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2000
1289,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2000
1290,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2000
1291,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2000
1292,U-64,TREATMENT OF VIRAL INFECTIONS,2000
1293,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2000
1294,U-66,TRIPHASIC REGIMEN,2000
1295,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2000
1296,U-68,TREATMENT OF ACTINIC KERATOSIS,2000
1297,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2000
1298,U-70,TREATMENT OF TRANSIENT INSOMNIA,2000
1299,U-71,METHOD OF TREATMENT OF HEART FAILURE,2000
1300,U-72,TREATMENT OF MIGRAINES,2000
1301,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2000
1302,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2000
1303,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2000
1304,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2000
1305,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2000
1306,U-78,ULCERATIVE COLITIS,2000
1307,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,2000
1308,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2000
1309,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2000
1310,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2000
1311,U-83,TREATMENT OF SEIZURES,2000
1312,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2000
1313,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2000
1314,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2000
1315,U-87,"METHOD FOR NONLNVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS AND ANESTHETICS",2000
1316,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2000
1317,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2000
1318,U-90,TREATMENT OF PSYCHOTIC DISORDERS,2000
1319,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2000
1320,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2000
1321,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2000
1322,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,2000
1323,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2000
1324,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2000
1325,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2000
1326,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2000
1327,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2000
1328,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2000
1329,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2000
1330,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST MENOPAUSAL DISORDERS IN WOMEN,2000
1331,U-103,TREATMENT OF OCULAR HYPERTENSION,2000
1332,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2000
1333,U-105,EMESIS,2000
1334,U-106,TREATMENT OF EPILEPSY,2000
1335,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2000
1336,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",2000
1337,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2000
1338,U-110,USE AS A RETRIEVABLE PESSARY,2000
1339,U-111,DIABETES,2000
1340,U-112,CONTRACEPTION,2000
1341,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2000
1342,U-114,USE FOR INHIBITING BONE RESORPTION,2000
1343,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2000
1344,U-116,METHOD OF MYOCARDIAL IMAGING,2000
1345,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2000
1346,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2000
1347,U-119,TREATMENT OF NASAL HYPERSECRETION,2000
1348,U-120,CONTROLLING OR PREVENTING POST OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2000
1349,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2000
1350,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2000
1351,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2000
1352,U-124,TREATMENT OF ACNE,2000
1353,U-125,TREATING NEUROGENERATIVE DISEASES,2000
1354,U-126,TREATMENT OF GASTRITIS,2000
1355,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2000
1356,U-128,METHODS FOR TREATMENT OF TUMORS,2000
1357,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2000
1358,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2000
1359,U-131,PHOTODAMAGED SKIN,2000
1360,U-132,INHIBITING HIV PROTEASE,2000
1361,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2000
1362,U-134,TREATMENT OF ACNE VULGARIS,2000
1363,U-135,ANTITUMOR AGENT,2000
1364,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2000
1365,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2000
1366,U-138,TREATMENT OF ALLERGIC RHINITIS,2000
1367,U-139,TREATMENT OF ALLERGIC REACTIONS,2000
1368,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2000
1369,U-141,TREATMENT OF ULCERATIVE COLITIS,2000
1370,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2000
1371,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2000
1372,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2000
1373,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2000
1374,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2000
1375,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2000
1376,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2000
1377,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2000
1378,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2000
1379,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2000
1380,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2000
1381,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2000
1382,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2000
1383,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2000
1384,U-156,METHOD OF PROVIDING ANESTHESIA,2000
1385,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2000
1386,U-158,ANGINA,2000
1387,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2000
1388,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2000
1389,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2000
1390,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2000
1391,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2000
1392,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2000
1393,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2000
1394,U-166,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,2000
1395,U-167,METHOD FOR TREATING HIV-1 INFECTION,2000
1396,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2000
1397,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2000
1398,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2000
1399,U-171,METHODS OF USING THE COMPOLLND/DRLIG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2000
1400,U-172,TREATMENT OF GENITAL WARTS,2000
1401,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2000
1402,U-174,USE AS AN ANTIHISTAMINE AGENT,2000
1403,U-175,METHOD OF TREATING MALIGNANT TUMORS,2000
1404,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS",2000
1405,U-177,FUNGICIDE,2000
1406,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2000
1407,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2000
1408,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2000
1409,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2000
1410,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2000
1411,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2000
1412,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2000
1413,U-185,METHOD OF TREATING HYPERTENSION,2000
1414,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2000
1415,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2000
1416,U-188,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,2000
1417,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2000
1418,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2000
1419,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2000
1420,U-192,USE IN TREATING ALLERGIC REACTIONS,2000
1421,U-193,PSORIASIS,2000
1422,U-194,TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE,2000
1423,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2000
1424,U-196,TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2000
1425,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2000
1426,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA",2000
1427,U-199,METHOD OF TREATING INFECTIOUS UPPER GL TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2000
1428,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2000
1429,U-201,METHOD OF TREATING GL DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2000
1430,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2000
1431,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2000
1432,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA,2000
1433,U-205,METHOD FOR TREATING HEARTBURN,2000
1434,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION",2000
1435,U-207,USE AS NASAL SPRAY,2000
1436,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2000
1437,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2000
1438,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2000
1439,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2000
1440,U-212,METHOD OF TREATMENT OF PARKINSON’S DISEASE,2000
1441,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2000
1442,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2000
1443,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2000
1444,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE",2000
1445,U-217,METHOD OF PRODUCING ANESTHESIA,2000
1446,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2000
1447,U-219,TREATMENT OF PARKISON’S DISEASE,2000
1448,U-220,METHOD OF DIAGNOSIS,2000
1449,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2000
1450,U-222,METHOD OF TREATING PAGET’S DISEASE USING ACTONEL,2000
1451,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2000
1452,U-224,CONTROLLING INTRAOCULAR PRESSURE,2000
1453,U-225,METHOD FOR DELIVERY,2000
1454,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2000
1455,U-227,NASAL ADMINISTRATION,2000
1456,U-228,ASTHMA,2000
1457,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2000
1458,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2000
1459,U-231,USE IN PARKINSON’S DISEASE,2000
1460,U-232,METHOD OF TREATING MIGRAINE,2000
1461,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2000
1462,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2000
1463,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2000
1464,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY,2000
1465,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2000
1466,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2000
1467,U-239,"TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2000
1468,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2000
1469,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORTTERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2000
1470,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2000
1471,U-243,TOPICAL ADMINISTRATION,2000
1472,U-244,PLATELET AGGREGATION INHIBITORS,2000
1473,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2000
1474,U-246,PHOSPHATE BINDING,2000
1475,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2000
1476,U-248,TREATMENT OF HIV,2000
1477,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FLLROATE,2000
1478,U-250,TREATMENT OF HEPATITIS B INFECTION,2000
1479,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2000
1480,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER’S DISEASE,2000
1481,U-253,ORAL TRANSMUCOSAL USE,2000
1482,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2000
1483,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2000
1484,U-256,TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2000
1485,U-257,TREATMENT OF HIV INFECTION,2000
1486,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2000
1487,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE,2000
1488,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2000
1489,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2000
1490,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2000
1491,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.,2000
1492,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.,2000
1493,U-265,USE AS A LAXATIVE,2000
1494,U-266,OSTEOARTHRITIS,2000
1495,U-267,METHOD FOR PREVENTING HEARTBURN,2000
1496,U-268,ACROMEGALY,2000
1497,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2000
1498,U-270,METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2000
1499,U-271,METHOD OF TREATING TUMORS,2000
1500,U-272,METHOD OF TREATING CARCINOMA,2000
1501,U-273,CUTANEOUS T-CELL LYMPHOMA,2000
1502,U-274,ZANAMIVIR FOR INHALATION,2000
1503,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2000
1504,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2000
1505,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2000
1506,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2000
1507,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2000
1508,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2000
1509,U-281,"ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS",2000
1510,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2000
1511,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2000
1512,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2000
1513,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2000
1514,U-286,DEPRESSION,2000
1515,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2000
1516,U-288,THERAPY OF INFLUENZA,2000
1517,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2000
1518,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2000
1519,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2000
1520,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2000
1521,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2000
1522,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2000
1523,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2000
1524,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY",2000
1525,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2000
1526,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2000
1527,U-299,TREATMENT OF ADENOMATOUS POLYPS,2000
1528,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2000
1529,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2000
1530,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2000
1531,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET’S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS",2000
1532,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2000
1533,U-305,METHODS FOR USING THE DRUG PRODUCT,2000
1534,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2000
1535,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2000
1536,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2000
1537,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",2001
1538,U-1,PREVENTION OF PREGNANCY,2001
1539,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2001
1540,U-3,TREATMENT OF HYPERTENSION,2001
1541,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2001
1542,U-5,METHOD OF PRODUCING BRONCHODILATION,2001
1543,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2001
1544,U-7,INCREASING CARDIAC CONTRACTILITY,2001
1545,U-8,ACUTE MYOCARDIAL INFARCTION,2001
1546,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2001
1547,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,2001
1548,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2001
1549,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2001
1550,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2001
1551,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2001
1552,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2001
1553,U-16,USE IN LUNG SCANNING PROCEDURES,2001
1554,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2001
1555,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2001
1556,U-19,TREATMENT OF INFLAMMATION,2001
1557,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON’S SYNDROME AND IN NEED OF TREATMENT,2001
1558,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2001
1559,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2001
1560,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2001
1561,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2001
1562,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2001
1563,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2001
1564,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2001
1565,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2001
1566,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2001
1567,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2001
1568,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2001
1569,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2001
1570,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2001
1571,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2001
1572,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2001
1573,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2001
1574,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2001
1575,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2001
1576,U-39,ANGINA PECTORIS,2001
1577,U-40,METHOD OF TREATMENT OF BURNS,2001
1578,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2001
1579,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2001
1580,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2001
1581,U-44,RELIEF OF NAUSEA AND VOMITING,2001
1582,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2001
1583,U-46,TREATMENT OF PANIC DISORDER,2001
1584,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2001
1585,U-48,ANALGESIA,2001
1586,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2001
1587,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2001
1588,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2001
1589,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2001
1590,U-53,HYPERCALCEMIA OF MALIGNANCY,2001
1591,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2001
1592,U-55,TREATMENT OF PAIN,2001
1593,U-56,AID TO SMOKING CESSATION,2001
1594,U-57,OPHTHALMIC USE OF NORFLOXACIN,2001
1595,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2001
1596,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2001
1597,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2001
1598,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2001
1599,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2001
1600,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2001
1601,U-64,TREATMENT OF VIRAL INFECTIONS,2001
1602,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2001
1603,U-66,TRIPHASIC REGIMEN,2001
1604,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2001
1605,U-68,TREATMENT OF ACTINIC KERATOSIS,2001
1606,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2001
1607,U-70,TREATMENT OF TRANSIENT INSOMNIA,2001
1608,U-71,METHOD OF TREATMENT OF HEART FAILURE,2001
1609,U-72,TREATMENT OF MIGRAINES,2001
1610,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2001
1611,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2001
1612,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2001
1613,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2001
1614,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2001
1615,U-78,ULCERATIVE COLITIS,2001
1616,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,2001
1617,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2001
1618,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2001
1619,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2001
1620,U-83,TREATMENT OF SEIZURES,2001
1621,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2001
1622,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2001
1623,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2001
1624,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2001
1625,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2001
1626,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2001
1627,U-90,TREATMENT OF PSYCHOTIC DISORDERS,2001
1628,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2001
1629,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2001
1630,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2001
1631,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,2001
1632,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2001
1633,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2001
1634,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2001
1635,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2001
1636,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2001
1637,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2001
1638,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2001
1639,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2001
1640,U-103,TREATMENT OF OCULAR HYPERTENSION,2001
1641,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2001
1642,U-105,EMESIS,2001
1643,U-106,TREATMENT OF EPILEPSY,2001
1644,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2001
1645,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",2001
1646,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2001
1647,U-110,USE AS A RETRIEVABLE PESSARY,2001
1648,U-111,DIABETES,2001
1649,U-112,CONTRACEPTION,2001
1650,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2001
1651,U-114,USE FOR INHIBITING BONE RESORPTION,2001
1652,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2001
1653,U-116,METHOD OF MYOCARDIAL IMAGING,2001
1654,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2001
1655,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2001
1656,U-119,TREATMENT OF NASAL HYPERSECRETION,2001
1657,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2001
1658,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2001
1659,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2001
1660,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2001
1661,U-124,TREATMENT OF ACNE,2001
1662,U-125,TREATING NEUROGENERATIVE DISEASES,2001
1663,U-126,TREATMENT OF GASTRITIS,2001
1664,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2001
1665,U-128,METHODS FOR TREATMENT OF TUMORS,2001
1666,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2001
1667,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2001
1668,U-131,PHOTODAMAGED SKIN,2001
1669,U-132,INHIBITING HIV PROTEASE,2001
1670,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2001
1671,U-134,TREATMENT OF ACNE VULGARIS,2001
1672,U-135,ANTITUMOR AGENT,2001
1673,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2001
1674,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2001
1675,U-138,TREATMENT OF ALLERGIC RHINITIS,2001
1676,U-139,TREATMENT OF ALLERGIC REACTIONS,2001
1677,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2001
1678,U-141,TREATMENT OF ULCERATIVE COLITIS,2001
1679,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2001
1680,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2001
1681,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2001
1682,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2001
1683,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2001
1684,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2001
1685,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2001
1686,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2001
1687,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2001
1688,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2001
1689,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2001
1690,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2001
1691,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2001
1692,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2001
1693,U-156,METHOD OF PROVIDING ANESTHESIA,2001
1694,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN BI2 DEFICIENCY,2001
1695,U-158,ANGINA,2001
1696,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2001
1697,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2001
1698,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2001
1699,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2001
1700,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2001
1701,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2001
1702,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2001
1703,U-166,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,2001
1704,U-167,METHOD FOR TREATING HIV-1 INFECTION,2001
1705,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2001
1706,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2001
1707,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2001
1708,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2001
1709,U-172,TREATMENT OF GENITAL WARTS,2001
1710,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2001
1711,U-174,USE AS AN ANTIHISTAMINE AGENT,2001
1712,U-175,METHOD OF TREATING MALIGNANT TUMORS,2001
1713,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS",2001
1714,U-177,FUNGICIDE,2001
1715,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2001
1716,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2001
1717,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2001
1718,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2001
1719,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2001
1720,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2001
1721,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2001
1722,U-185,METHOD OF TREATING HYPERTENSION,2001
1723,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2001
1724,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2001
1725,U-188,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,2001
1726,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2001
1727,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2001
1728,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2001
1729,U-192,USE IN TREATING ALLERGIC REACTIONS,2001
1730,U-193,PSORIASIS,2001
1731,U-194,TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE,2001
1732,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2001
1733,U-196,TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2001
1734,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2001
1735,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA",2001
1736,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2001
1737,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2001
1738,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2001
1739,U-202,METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5.000MG BISMUTH DAILY FOR 3-56 DAYS,2001
1740,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2001
1741,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA,2001
1742,U-205,METHOD FOR TREATING HEARTBURN,2001
1743,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION",2001
1744,U-207,USE AS NASAL SPRAY,2001
1745,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2001
1746,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2001
1747,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2001
1748,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2001
1749,U-212,METHOD OF TREATMENT OF PARKINSON’S DISEASE,2001
1750,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2001
1751,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2001
1752,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2001
1753,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE",2001
1754,U-217,METHOD OF PRODUCING ANESTHESIA,2001
1755,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2001
1756,U-219,TREATMENT OF PARKISON’S DISEASE,2001
1757,U-220,METHOD OF DIAGNOSIS,2001
1758,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2001
1759,U-222,METHOD OF TREATING PAGET’S DISEASE USING ACTONEL,2001
1760,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2001
1761,U-224,CONTROLLING INTRAOCULAR PRESSURE,2001
1762,U-225,METHOD FOR DELIVERY,2001
1763,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2001
1764,U-227,NASAL ADMINISTRATION,2001
1765,U-228,ASTHMA,2001
1766,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2001
1767,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2001
1768,U-231,USE IN PARKINSON’S DISEASE,2001
1769,U-232,METHOD OF TREATING MIGRAINE,2001
1770,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2001
1771,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2001
1772,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2001
1773,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY,2001
1774,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2001
1775,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2001
1776,U-239,"TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2001
1777,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2001
1778,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT- TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2001
1779,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2001
1780,U-243,TOPICAL ADMINISTRATION,2001
1781,U-244,PLATELET AGGREGATION INHIBITORS,2001
1782,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2001
1783,U-246,PHOSPHATE BINDING,2001
1784,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2001
1785,U-248,TREATMENT OF HIV,2001
1786,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2001
1787,U-250,TREATMENT OF HEPATITIS B INFECTION,2001
1788,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2001
1789,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER’S DISEASE,2001
1790,U-253,ORAL TRANSMUCOSAL USE,2001
1791,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2001
1792,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2001
1793,U-256,TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2001
1794,U-257,TREATMENT OF HIV INFECTION,2001
1795,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2001
1796,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE,2001
1797,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2001
1798,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2001
1799,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2001
1800,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.,2001
1801,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.,2001
1802,U-265,USE AS A LAXATIVE,2001
1803,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA,2001
1804,U-267,METHOD FOR PREVENTING HEARTBURN,2001
1805,U-268,ACROMEGALY,2001
1806,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2001
1807,U-270,METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2001
1808,U-271,METHOD OF TREATING TUMORS,2001
1809,U-272,METHOD OF TREATING CARCINOMA,2001
1810,U-273,CUTANEOUS T-CELL LYMPHOMA,2001
1811,U-274,ZANAMIVIR FOR INHALATION,2001
1812,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2001
1813,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2001
1814,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2001
1815,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2001
1816,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2001
1817,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2001
1818,U-281,"ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS",2001
1819,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2001
1820,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2001
1821,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2001
1822,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2001
1823,U-286,DEPRESSION,2001
1824,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2001
1825,U-288,THERAPY OF INFLUENZA,2001
1826,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2001
1827,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2001
1828,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2001
1829,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2001
1830,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2001
1831,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2001
1832,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2001
1833,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY",2001
1834,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2001
1835,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2001
1836,U-299,TREATMENT OF ADENOMATOUS POLYPS,2001
1837,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2001
1838,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2001
1839,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2001
1840,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET’S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS",2001
1841,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2001
1842,U-305,METHODS FOR USING THE DRUG PRODUCT,2001
1843,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2001
1844,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2001
1845,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2001
1846,U-309,TREATING SJOEGREN SYNDROME,2001
1847,U-310,TREATMENT OF XEROSTOMIA,2001
1848,U-311,HORMONE REPLACEMENT,2001
1849,U-312,PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER,2001
1850,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2001
1851,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2001
1852,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2001
1853,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2001
1854,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2001
1855,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2001
1856,U-319,TREATMENT OF MICROBIAL INFECTIONS,2001
1857,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2001
1858,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2001
1859,U-322,TREATMENT OF ALZHEIMER’S DEMENTIA,2001
1860,U-323,USE AS A BILE ACID SEQUESTRANT,2001
1861,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2001
1862,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS” EMPLOYING OLANZAPINE",2001
1863,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2001
1864,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE,2001
1865,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2001
1866,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2001
1867,U-330,TREATMENT OF NAUSEA AND VOMITING,2001
1868,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2001
1869,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2001
1870,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2001
1871,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2001
1872,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2001
1873,U-336,DIAGNOSTIC RADIOIMAGING,2001
1874,U-337,USE OF CARDIOLITEZMIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2001
1875,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2001
1876,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2001
1877,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2001
1878,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2001
1879,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2001
1880,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2001
1881,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2001
1882,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2001
1883,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2001
1884,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2001
1885,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2001
1886,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2001
1887,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2001
1888,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR,2001
1889,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2001
1890,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2001
1891,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2001
1892,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2001
1893,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2001
1894,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2001
1895,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2001
1896,U-359,METHOD OF USE OF VISICOL,2001
1897,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2001
1898,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2001
1899,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2001
1900,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATER OF THIS SNDA-011,2001
1901,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2001
1902,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2001
1903,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2001
1904,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2001
1905,U-368,HEARTBURN,2001
1906,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2001
1907,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2001
1908,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2001
1909,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",2002
1910,U-1,PREVENTION OF PREGNANCY,2002
1911,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2002
1912,U-3,TREATMENT OF HYPERTENSION,2002
1913,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2002
1914,U-5,METHOD OF PRODUCING BRONCHODILATION,2002
1915,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2002
1916,U-7,INCREASING CARDIAC CONTRACTILITY,2002
1917,U-8,ACUTE MYOCARDIAL INFARCTION,2002
1918,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2002
1919,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS,2002
1920,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2002
1921,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2002
1922,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2002
1923,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2002
1924,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2002
1925,U-16,USE IN LUNG SCANNING PROCEDURES,2002
1926,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2002
1927,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2002
1928,U-19,TREATMENT OF INFLAMMATION,2002
1929,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2002
1930,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2002
1931,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2002
1932,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2002
1933,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2002
1934,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2002
1935,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2002
1936,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2002
1937,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2002
1938,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2002
1939,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2002
1940,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2002
1941,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2002
1942,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2002
1943,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2002
1944,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2002
1945,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2002
1946,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2002
1947,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2002
1948,U-39,ANGINA PECTORIS,2002
1949,U-40,METHOD OF TREATMENT OF BURNS,2002
1950,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2002
1951,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2002
1952,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2002
1953,U-44,RELIEF OF NAUSEA AND VOMITING,2002
1954,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2002
1955,U-46,TREATMENT OF PANIC DISORDER,2002
1956,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2002
1957,U-48,ANALGESIA,2002
1958,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2002
1959,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2002
1960,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2002
1961,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2002
1962,U-53,HYPERCALCEMIA OF MALIGNANCY,2002
1963,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2002
1964,U-55,TREATMENT OF PAIN,2002
1965,U-56,AID TO SMOKING CESSATION,2002
1966,U-57,OPHTHALMIC USE OF NORFLOXACIN,2002
1967,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2002
1968,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2002
1969,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2002
1970,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2002
1971,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2002
1972,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2002
1973,U-64,TREATMENT OF VIRAL INFECTIONS,2002
1974,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2002
1975,U-66,TRIPHASIC REGIMEN,2002
1976,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2002
1977,U-68,TREATMENT OF ACTINIC KERATOSIS,2002
1978,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2002
1979,U-70,TREATMENT OF TRANSIENT INSOMNIA,2002
1980,U-71,METHOD OF TREATMENT OF HEART FAILURE,2002
1981,U-72,TREATMENT OF MIGRAINE,2002
1982,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2002
1983,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2002
1984,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTP/ITIS,2002
1985,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2002
1986,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2002
1987,U-78,ULCERATIVE COLITIS,2002
1988,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD,2002
1989,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2002
1990,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2002
1991,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2002
1992,U-83,TREATMENT OF SEIZURES,2002
1993,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2002
1994,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2002
1995,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2002
1996,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2002
1997,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2002
1998,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2002
1999,U-90,TREATMENT OF PSYCHOTIC DISORDERS,2002
2000,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2002
2001,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY,2002
2002,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2002
2003,U-94,TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED,2002
2004,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITUS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2002
2005,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2002
2006,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2002
2007,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2002
2008,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2002
2009,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2002
2010,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2002
2011,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2002
2012,U-103,TREATMENT OF OCULAR HYPERTENSION,2002
2013,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2002
2014,U-105,EMESIS,2002
2015,U-106,TREATMENT OF EPILEPSY,2002
2016,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2002
2017,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS",2002
2018,U-109,USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2002
2019,U-110,USE AS A RETRIEVABLE PESSARY,2002
2020,U-111,DIABETES,2002
2021,U-112,CONTRACEPTION,2002
2022,U-113,METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2002
2023,U-114,USE FOR INHIBITING BONE RESORPTION,2002
2024,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2002
2025,U-116,METHOD OF MYOCARDIAL IMAGING,2002
2026,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2002
2027,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2002
2028,U-119,TREATMENT OF NASAL HYPERSECRETION,2002
2029,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2002
2030,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2002
2031,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2002
2032,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2002
2033,U-124,TREATMENT OF ACNE,2002
2034,U-125,TREATING NEUROGENERATIVE DISEASES,2002
2035,U-126,TREATMENT OF GASTRITIS,2002
2036,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2002
2037,U-128,METHODS FOR TREATMENT OF TUMORS,2002
2038,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2002
2039,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2002
2040,U-131,PHOTODAMAGED SKIN,2002
2041,U-132,INHIBITING HIV PROTEASE,2002
2042,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2002
2043,U-134,TREATMENT OF ACNE VULGARIS,2002
2044,U-135,ANTITUMOR AGENT,2002
2045,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2002
2046,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2002
2047,U-138,TREATMENT OF ALLERGIC RHINITIS,2002
2048,U-139,TREATMENT OF ALLERGIC REACTIONS,2002
2049,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2002
2050,U-141,TREATMENT OF ULCERATIVE COLITIS,2002
2051,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2002
2052,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2002
2053,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2002
2054,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2002
2055,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2002
2056,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF L3CO2,2002
2057,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2002
2058,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2002
2059,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2002
2060,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2002
2061,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2002
2062,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2002
2063,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2002
2064,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2002
2065,U-156,METHOD OF PROVIDING ANESTHESIA,2002
2066,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2002
2067,U-158,ANGINA,2002
2068,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2002
2069,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2002
2070,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2002
2071,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2002
2072,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2002
2073,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2002
2074,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2002
2075,U-166,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,2002
2076,U-167,METHOD FOR TREATING HIV-1 INFECTION,2002
2077,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2002
2078,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2002
2079,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2002
2080,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2002
2081,U-172,TREATMENT OF GENITAL WARTS,2002
2082,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2002
2083,U-174,USE AS AN ANTIHISTAMINE AGENT,2002
2084,U-175,METHOD OF TREATING MALIGNANT TUMORS,2002
2085,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS",2002
2086,U-177,FUNGICIDE,2002
2087,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2002
2088,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2002
2089,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2002
2090,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2002
2091,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2002
2092,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2002
2093,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2002
2094,U-185,METHOD OF TREATING HYPERTENSION,2002
2095,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2002
2096,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2002
2097,U-188,TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER,2002
2098,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2002
2099,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2002
2100,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2002
2101,U-192,USE IN TREATING ALLERGIC REACTIONS,2002
2102,U-193,PSORIASIS,2002
2103,U-194,TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE,2002
2104,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2002
2105,U-196,TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2002
2106,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2002
2107,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA",2002
2108,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2002
2109,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2002
2110,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2002
2111,U-202,METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5.000MG BISMUTH DAILY FOR 3-56 DAYS,2002
2112,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2002
2113,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA,2002
2114,U-205,METHOD FOR TREATING HEARTBURN,2002
2115,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION",2002
2116,U-207,USE AS NASAL SPRAY,2002
2117,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2002
2118,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2002
2119,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2002
2120,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2002
2121,U-212,METHOD OF TREATMENT OF PARKINSON’S DISEASE,2002
2122,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2002
2123,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2002
2124,U-215,"TREATMENT OF EPILEPSY TWICE DAILY, TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS",2002
2125,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE",2002
2126,U-217,METHOD OF PRODUCING ANESTHESIA,2002
2127,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2002
2128,U-219,TREATMENT OF PARKISON’S DISEASE,2002
2129,U-220,METHOD OF DIAGNOSIS,2002
2130,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2002
2131,U-222,METHOD OF TREATING PAGET’S DISEASE USING ACTONEL,2002
2132,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2002
2133,U-224,CONTROLLING INTRAOCULAR PRESSURE,2002
2134,U-225,METHOD FOR DELIVERY,2002
2135,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2002
2136,U-227,NASAL ADMINISTRATION,2002
2137,U-228,ASTHMA,2002
2138,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2002
2139,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2002
2140,U-231,USE IN PARKINSON’S DISEASE,2002
2141,U-232,METHOD OF TREATING MIGRAINE,2002
2142,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2002
2143,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2002
2144,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2002
2145,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY,2002
2146,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2002
2147,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2002
2148,U-239,"TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2002
2149,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2002
2150,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT- TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2002
2151,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2002
2152,U-243,TOPICAL ADMINISTRATION,2002
2153,U-244,PLATELET AGGREGATION INHIBITORS,2002
2154,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2002
2155,U-246,PHOSPHATE BINDING,2002
2156,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2002
2157,U-248,TREATMENT OF HIV,2002
2158,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2002
2159,U-250,TREATMENT OF HEPATITIS B INFECTION,2002
2160,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2002
2161,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER’S DISEASE,2002
2162,U-253,ORAL TRANSMUCOSAL USE,2002
2163,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2002
2164,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2002
2165,U-256,TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2002
2166,U-257,TREATMENT OF HIV INFECTION,2002
2167,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2002
2168,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE,2002
2169,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2002
2170,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2002
2171,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2002
2172,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.,2002
2173,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.,2002
2174,U-265,USE AS A LAXATIVE,2002
2175,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA,2002
2176,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2002
2177,U-268,ACROMEGALY,2002
2178,U-269,EXCESS GII-SECRETION OR GASTRO-INTESTINAL DISORDERS,2002
2179,U-270,METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2002
2180,U-271,METHOD OF TREATING TUMORS,2002
2181,U-272,METHOD OF TREATING CARCINOMA,2002
2182,U-273,CUTANEOUS T-CELL LYMPHOMA,2002
2183,U-274,ZANAMFVIR FOR INHALATION,2002
2184,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2002
2185,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2002
2186,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2002
2187,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2002
2188,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2002
2189,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2002
2190,U-281,"ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS",2002
2191,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2002
2192,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2002
2193,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2002
2194,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2002
2195,U-286,DEPRESSION,2002
2196,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2002
2197,U-288,THERAPY OF INFLUENZA,2002
2198,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2002
2199,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2002
2200,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2002
2201,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2002
2202,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2002
2203,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2002
2204,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2002
2205,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY",2002
2206,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2002
2207,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2002
2208,U-299,TREATMENT OF ADENOMATOUS POLYPS,2002
2209,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2002
2210,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2002
2211,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2002
2212,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET’S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS",2002
2213,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2002
2214,U-305,METHODS FOR USING THE DRUG PRODUCT,2002
2215,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2002
2216,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2002
2217,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2002
2218,U-309,TREATING SJOEGREN SYNDROME,2002
2219,U-310,TREATMENT OF XEROSTOMIA,2002
2220,U-311,HORMONE REPLACEMENT,2002
2221,U-312,PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER,2002
2222,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2002
2223,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2002
2224,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2002
2225,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2002
2226,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2002
2227,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2002
2228,U-319,TREATMENT OF MICROBIAL INFECTIONS,2002
2229,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2002
2230,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2002
2231,U-322,TREATMENT OF ALZHEIMER’S DEMENTIA,2002
2232,U-323,USE AS A BILE ACID SEQUESTRANT,2002
2233,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2002
2234,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS” EMPLOYING OLANZAPINE",2002
2235,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2002
2236,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE,2002
2237,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2002
2238,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2002
2239,U-330,TREATMENT OF NAUSEA AND VOMITING,2002
2240,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2002
2241,U-332,TREATMENT OR PREVENTION OF BRONCFIOSPASM,2002
2242,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2002
2243,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2002
2244,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2002
2245,U-336,DIAGNOSTIC RADIOIMAGING,2002
2246,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2002
2247,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2002
2248,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2002
2249,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2002
2250,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2002
2251,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2002
2252,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2002
2253,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2002
2254,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2002
2255,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2002
2256,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2002
2257,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2002
2258,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2002
2259,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2002
2260,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR,2002
2261,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2002
2262,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2002
2263,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2002
2264,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2002
2265,U-356,DELP/ERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A,2002
2266,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2002
2267,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2002
2268,U-359,METHOD OF USE OF VISICOL,2002
2269,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2002
2270,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2002
2271,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2002
2272,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATER OF THIS SNDA-011,2002
2273,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2002
2274,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2002
2275,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2002
2276,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2002
2277,U-368,HEARTBURN,2002
2278,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2002
2279,U-370,INTRA VAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2002
2280,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2002
2281,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2002
2282,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2002
2283,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2002
2284,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2002
2285,U-376,TREATMENT OF INFLUENZA,2002
2286,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2002
2287,U-378,METHOD FOR TREATING INCONTINENCE,2002
2288,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2002
2289,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2002
2290,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2002
2291,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2002
2292,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2002
2293,U-384,TREATMENT OF CMV RETINITIS,2002
2294,U-385,TREATMENT OF PEPTIC ULCERS,2002
2295,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2002
2296,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2002
2297,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2002
2298,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2002
2299,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2002
2300,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2002
2301,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2002
2302,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2002
2303,U-394,METHOD OF USE OF ALPHAGAN,2002
2304,U-395,METHOD OF USE OF ALPHAGAN P,2002
2305,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2002
2306,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2002
2307,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2002
2308,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2002
2309,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AN D INFESTATIONS",2002
2310,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2002
2311,U-402,TREATMENT OF ACTINIC KERATOSES,2002
2312,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2002
2313,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2002
2314,U-405,METHOD OF USE OF LOTRONEX,2002
2315,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2002
2316,U-407,METHOD OF TREATING OTOPATHY,2002
2317,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2002
2318,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2002
2319,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2002
2320,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2002
2321,U-412,TREATMENT OF TYPE 2 DIABETES,2002
2322,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2002
2323,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2002
2324,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2002
2325,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2002
2326,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2002
2327,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2002
2328,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2002
2329,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2002
2330,U-421,USE FOR SEDATION,2002
2331,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2002
2332,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2002
2333,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2002
2334,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER,2002
2335,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2002
2336,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2002
2337,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2002
2338,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2002
2339,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2002
2340,U-431,POSTTRAUMATIC STRESS DISORDER,2002
2341,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION, OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2002
2342,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2002
2343,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2002
2344,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2002
2345,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2002
2346,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2002
2347,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",2003
2348,U-1,PREVENTION OF PREGNANCY,2003
2349,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2003
2350,U-3,TREATMENT OF HYPERTENSION,2003
2351,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2003
2352,U-5,METHOD OF PRODUCING BRONCHODILATION,2003
2353,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2003
2354,U-7,INCREASING CARDIAC CONTRACTILITY,2003
2355,U-8,ACUTE MYOCARDIAL INFARCTION,2003
2356,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2003
2357,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2003
2358,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2003
2359,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2003
2360,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2003
2361,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2003
2362,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2003
2363,U-16,USE IN LUNG SCANNING PROCEDURES,2003
2364,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2003
2365,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2003
2366,U-19,TREATMENT OF INFLAMMATION,2003
2367,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2003
2368,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2003
2369,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2003
2370,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2003
2371,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2003
2372,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2003
2373,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2003
2374,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2003
2375,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2003
2376,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2003
2377,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2003
2378,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2003
2379,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2003
2380,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2003
2381,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2003
2382,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2003
2383,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2003
2384,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2003
2385,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2003
2386,U-39,ANGINA PECTORIS,2003
2387,U-40,METHOD OF TREATMENT OF BURNS,2003
2388,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2003
2389,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2003
2390,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2003
2391,U-44,RELIEF OF NAUSEA AND VOMITING,2003
2392,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2003
2393,U-46,TREATMENT OF PANIC DISORDER,2003
2394,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2003
2395,U-48,ANALGESIA,2003
2396,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2003
2397,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2003
2398,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2003
2399,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2003
2400,U-53,HYPERCALCEMIA OF MALIGNANCY,2003
2401,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2003
2402,U-55,TREATMENT OF PAIN,2003
2403,U-56,AID TO SMOKING CESSATION,2003
2404,U-57,OPHTHALMIC USE OF NORFLOXACIN,2003
2405,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2003
2406,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2003
2407,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2003
2408,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2003
2409,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2003
2410,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2003
2411,U-64,TREATMENT OF VIRAL INFECTIONS,2003
2412,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2003
2413,U-66,TRIPHASIC REGIMEN,2003
2414,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2003
2415,U-68,TREATMENT OF ACTINIC KERATOSIS,2003
2416,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2003
2417,U-70,TREATMENT OF TRANSIENT INSOMNIA,2003
2418,U-71,METHOD OF TREATMENT OF HEART FAILURE,2003
2419,U-72,TREATMENT OF MIGRAINE,2003
2420,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2003
2421,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2003
2422,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2003
2423,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2003
2424,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2003
2425,U-78,ULCERATIVE COLITIS,2003
2426,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2003
2427,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2003
2428,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2003
2429,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2003
2430,U-83,TREATMENT OF SEIZURES,2003
2431,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2003
2432,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2003
2433,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2003
2434,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2003
2435,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2003
2436,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2003
2437,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2003
2438,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2003
2439,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2003
2440,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2003
2441,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2003
2442,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2003
2443,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2003
2444,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2003
2445,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2003
2446,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2003
2447,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2003
2448,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2003
2449,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2003
2450,U-103,TREATMENT OF OCULAR HYPERTENSION,2003
2451,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2003
2452,U-105,EMESIS,2003
2453,U-106,TREATMENT OF EPILEPSY,2003
2454,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2003
2455,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITS",2003
2456,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2003
2457,U-110,USE AS A RETRIEVABLE PERSSARY,2003
2458,U-111,DIABETES,2003
2459,U-112,CONTRACEPTION,2003
2460,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2003
2461,U-114,USE FOR INHIBITING BONE RESORPTION,2003
2462,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2003
2463,U-116,METHOD OF MYOCARDIAL IMAGING,2003
2464,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2003
2465,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2003
2466,U-119,TREATMENT OF NASAL HYPERSECRETION,2003
2467,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2003
2468,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2003
2469,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2003
2470,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2003
2471,U-124,TREATMENT OF ACNE,2003
2472,U-125,TREATMENT NEUROGENERATIVE DISEASES,2003
2473,U-126,TREATMENT OF GASTRITIS,2003
2474,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2003
2475,U-128,METHOD FOR TREATMENT OF TUMORS,2003
2476,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2003
2477,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2003
2478,U-131,PHOTODAMAGED SKIN,2003
2479,U-132,INHIBITING HIV PROTEASE,2003
2480,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2003
2481,U-134,TREATMENT OF ACNE VULGARIS,2003
2482,U-135,ANTITUMOR AGENT,2003
2483,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2003
2484,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2003
2485,U-138,TREATMENT OF ALLERGIC RHINITIS,2003
2486,U-139,TREATMENT OF ALLERGIC REACTIONS,2003
2487,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2003
2488,U-141,TREATMENT OF ULCERATIVE COLITIS,2003
2489,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2003
2490,U-143,BIODEGRADABLE SUPERPARAMACNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2003
2491,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2003
2492,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2003
2493,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2003
2494,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2003
2495,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2003
2496,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2003
2497,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2003
2498,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2003
2499,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2003
2500,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2003
2501,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2003
2502,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2003
2503,U-156,METHOD OF PROVIDING ANESTHESIA,2003
2504,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN BI2 DEFICIENCY,2003
2505,U-158,ANGINA,2003
2506,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2003
2507,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2003
2508,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2003
2509,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2003
2510,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2003
2511,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2003
2512,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2003
2513,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2003
2514,U-167,METHOD FOR TREATING HIV-1 INFECTION,2003
2515,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2003
2516,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2003
2517,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2003
2518,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2003
2519,U-172,TREATMENT OF GENITAL WARTS,2003
2520,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2003
2521,U-174,USE AS AN ANTIHISTAMINE AGENT,2003
2522,U-175,METHOD OF TREATING MALIGNANT TUMORS,2003
2523,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2003
2524,U-177,FUNGICIDE,2003
2525,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2003
2526,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2003
2527,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2003
2528,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2003
2529,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2003
2530,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2003
2531,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2003
2532,U-185,METHOD OF TREATING HYPERTENSION,2003
2533,U-186,METHOD FOR TREATING GL DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2003
2534,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2003
2535,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2003
2536,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2003
2537,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2003
2538,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2003
2539,U-192,USE IN TREATING ALLERGIC REACTIONS,2003
2540,U-193,PSORIASIS,2003
2541,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2003
2542,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2003
2543,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2003
2544,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2003
2545,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2003
2546,U-199,METHOD OF TREATING INFECTIOUS UPPER GL TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2003
2547,U-200,METHOD OF TREATING GL DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2003
2548,U-201,METHOD OF TREATING GL DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2003
2549,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MC BISMUTH DAILY FOR 3-56 DAYS",2003
2550,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2003
2551,U-204,USE OF TAXOL IN COMBINATION WITH C-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2003
2552,U-205,METHOD FOR TREATING HEARTBURN,2003
2553,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2003
2554,U-207,USE AS NASAL SPRAY,2003
2555,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2003
2556,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2003
2557,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2003
2558,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2003
2559,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2003
2560,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2003
2561,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2003
2562,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2003
2563,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2003
2564,U-217,METHOD OF PRODUCING ANESTHESIA,2003
2565,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2003
2566,U-219,TREATMENT OF PARKINSON'S DISEASE,2003
2567,U-220,METHOD OF DIAGNOSIS,2003
2568,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2003
2569,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2003
2570,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2003
2571,U-224,CONTROLLING INTRAOCULAR PRESSURE,2003
2572,U-225,METHOD FOR DELIVERY,2003
2573,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2003
2574,U-227,NASAL ADMINISTRATION,2003
2575,U-228,ASTHMA,2003
2576,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2003
2577,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2003
2578,U-231,USE IN PARKINSON'S DISEASE,2003
2579,U-232,METHOD OF TREATING MIGRAINE,2003
2580,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2003
2581,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2003
2582,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2003
2583,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2003
2584,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2003
2585,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2003
2586,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2003
2587,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2003
2588,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2003
2589,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2003
2590,U-243,TOPICAL ADMINISTRATION,2003
2591,U-244,PLATELET AGGREGATION INHIBITORS,2003
2592,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2003
2593,U-246,PHOSPHATE BINDING,2003
2594,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2003
2595,U-248,TREATMENT OF HIV,2003
2596,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2003
2597,U-250,TREATMENT OF HEPATITIS B INFECTION,2003
2598,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2003
2599,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2003
2600,U-253,ORAL TRANSMUCOSAL USE,2003
2601,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2003
2602,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2003
2603,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2003
2604,U-257,TREATMENT OF HIV INFECTION,2003
2605,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2003
2606,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2003
2607,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2003
2608,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2003
2609,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2003
2610,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2003
2611,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2003
2612,U-265,USE AS LAXATIVE,2003
2613,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA,2003
2614,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10 MG FAMOTIDINE",2003
2615,U-268,ACROMEGALY,2003
2616,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2003
2617,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2003
2618,U-271,METHOD OF TREATING TUMORS,2003
2619,U-272,METHOD OF TREATING CARCINOMA,2003
2620,U-273,CUTANEOUS T-CELL LYMPHOMA,2003
2621,U-274,ZANAMIVIR FOR INHALATION,2003
2622,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2003
2623,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2003
2624,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2003
2625,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2003
2626,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2003
2627,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2003
2628,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2003
2629,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2003
2630,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2003
2631,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2003
2632,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2003
2633,U-286,DEPRESSION,2003
2634,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2003
2635,U-288,THERAPY OF INFLUENZA,2003
2636,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2003
2637,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2003
2638,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2003
2639,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2003
2640,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2003
2641,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2003
2642,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2003
2643,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2003
2644,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2003
2645,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2003
2646,U-299,TREATMENT OF ADENOMATOUS POLYPS,2003
2647,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2003
2648,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2003
2649,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2003
2650,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2003
2651,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2003
2652,U-305,METHODS FOR USING THE DRUG PRODUCT,2003
2653,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2003
2654,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2003
2655,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2003
2656,U-309,TREATING SJOEGREN SYNDROME,2003
2657,U-310,TREATMENT OF XEROSTOMIA,2003
2658,U-311,HORMONE REPLACEMENT,2003
2659,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2003
2660,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2003
2661,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2003
2662,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2003
2663,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2003
2664,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2003
2665,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2003
2666,U-319,TREATMENT OF MICROBIAL INFECTIONS,2003
2667,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2003
2668,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2003
2669,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2003
2670,U-323,USE AS A BILE ACID SEQUESTRANT,2003
2671,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2003
2672,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2003
2673,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2003
2674,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2003
2675,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2003
2676,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2003
2677,U-330,TREATMENT OF NAUSEA AND VOMITING,2003
2678,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2003
2679,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2003
2680,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2003
2681,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2003
2682,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2003
2683,U-336,DIAGNOSTIC RADIOIMAGING,2003
2684,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2003
2685,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2003
2686,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2003
2687,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2003
2688,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2003
2689,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2003
2690,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2003
2691,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2003
2692,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2003
2693,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2003
2694,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2003
2695,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2003
2696,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2003
2697,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2003
2698,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2003
2699,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2003
2700,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2003
2701,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2003
2702,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2003
2703,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2003
2704,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2003
2705,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2003
2706,U-359,METHOD OF USE OF VISICOL,2003
2707,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2003
2708,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2003
2709,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2003
2710,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2003
2711,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2003
2712,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2003
2713,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2003
2714,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2003
2715,U-368,HEARTBURN,2003
2716,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2003
2717,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2003
2718,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2003
2719,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GL TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2003
2720,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H. PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2003
2721,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2003
2722,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2003
2723,U-376,TREATMENT OF INFLUENZA,2003
2724,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2003
2725,U-378,METHOD FOR TREATING INCONTINENCE,2003
2726,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2003
2727,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2003
2728,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2003
2729,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2003
2730,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2003
2731,U-384,TREATMENT OF CMV RETINITIS,2003
2732,U-385,TREATMENT OF PEPTIC ULCERS,2003
2733,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2003
2734,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2003
2735,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2003
2736,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2003
2737,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2003
2738,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2003
2739,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2003
2740,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2003
2741,U-394,METHOD OF USE OF ALPHAGAN,2003
2742,U-395,METHOD OF USE OF ALPHAGAN P,2003
2743,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2003
2744,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2003
2745,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2003
2746,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2003
2747,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2003
2748,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2003
2749,U-402,TREATMENT OF ACTINIC KERATOSES,2003
2750,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2003
2751,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2003
2752,U-405,METHOD OF USE OF LOTRONEX,2003
2753,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2003
2754,U-407,METHOD OF TREATING OTOPATHY,2003
2755,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2003
2756,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2003
2757,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2003
2758,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2003
2759,U-412,TREATMENT OF TYPE 2 DIABETES,2003
2760,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2003
2761,U-414,A METHOD OF TREATING CLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2003
2762,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2003
2763,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2003
2764,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2003
2765,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2003
2766,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2003
2767,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2003
2768,U-421,USE FOR SEDATION,2003
2769,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2003
2770,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2003
2771,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2003
2772,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2003
2773,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2003
2774,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2003
2775,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2003
2776,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2003
2777,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2003
2778,U-431,POSTTRAUMATIC STRESS DISORDER,2003
2779,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2003
2780,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2003
2781,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2003
2782,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2003
2783,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2003
2784,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2003
2785,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2003
2786,U-439,TREATMENT OF OBESITY,2003
2787,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2003
2788,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2003
2789,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2003
2790,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2003
2791,U-444,METHOD OF TREATING,2003
2792,U-445,USE AS AN ANTIMYCOTIC AGENT,2003
2793,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2003
2794,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2003
2795,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2003
2796,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2003
2797,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2003
2798,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2003
2799,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI = H.PYLORI),2003
2800,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2003
2801,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEC 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KC, ONCE WEEKLY, AND RIBAVIRIN",2003
2802,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2003
2803,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2003
2804,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2003
2805,U-458,METHOD OF USE OF IMAGENT,2003
2806,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2003
2807,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2003
2808,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2003
2809,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2003
2810,U-463,VENOGRAPHY,2003
2811,U-464,PERIPHERAL ARTERIOGRAPHY,2003
2812,U-465,CT IMAGING OF THE HEAD,2003
2813,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2003
2814,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2003
2815,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2003
2816,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H. PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2003
2817,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2003
2818,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2003
2819,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2003
2820,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2003
2821,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2003
2822,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2003
2823,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2003
2824,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2003
2825,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2003
2826,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2003
2827,U-480,CONTRAST AGENT FOR MRI,2003
2828,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOIDLIKE ACTIVITY,2003
2829,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2003
2830,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2003
2831,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2003
2832,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2003
2833,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2003
2834,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2003
2835,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2003
2836,U-489,EXPECTORANT,2003
2837,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2003
2838,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2003
2839,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2003
2840,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2003
2841,U,"PATENT USE CODE (SEE REFERENCES, BELOW)",2004
2842,U-1,PREVENTION OF PREGNANCY,2004
2843,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2004
2844,U-3,TREATMENT OF HYPERTENSION,2004
2845,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2004
2846,U-5,METHOD OF PRODUCING BRONCHODILATION,2004
2847,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2004
2848,U-7,INCREASING CARDIAC CONTRACTILITY,2004
2849,U-8,ACUTE MYOCARDIAL INFARCTION,2004
2850,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2004
2851,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2004
2852,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2004
2853,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2004
2854,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2004
2855,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2004
2856,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2004
2857,U-16,USE IN LUNG SCANNING PROCEDURES,2004
2858,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2004
2859,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2004
2860,U-19,TREATMENT OF INFLAMMATION,2004
2861,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2004
2862,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2004
2863,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2004
2864,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2004
2865,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2004
2866,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2004
2867,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2004
2868,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2004
2869,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2004
2870,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2004
2871,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2004
2872,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2004
2873,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2004
2874,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2004
2875,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2004
2876,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2004
2877,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2004
2878,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2004
2879,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2004
2880,U-39,ANGINA PECTORIS,2004
2881,U-40,METHOD OF TREATMENT OF BURNS,2004
2882,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2004
2883,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES’ STAGE C COLON CANCER,2004
2884,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2004
2885,U-44,RELIEF OF NAUSEA AND VOMITING,2004
2886,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2004
2887,U-46,TREATMENT OF PANIC DISORDER,2004
2888,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2004
2889,U-48,ANALGESIA,2004
2890,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2004
2891,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2004
2892,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2004
2893,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2004
2894,U-53,HYPERCALCEMIA OF MALIGNANCY,2004
2895,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2004
2896,U-55,TREATMENT OF PAIN,2004
2897,U-56,AID TO SMOKING CESSATION,2004
2898,U-57,OPHTHALMIC USE OF NORFLOXACIN,2004
2899,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2004
2900,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2004
2901,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2004
2902,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2004
2903,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2004
2904,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2004
2905,U-64,TREATMENT OF VIRAL INFECTIONS,2004
2906,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2004
2907,U-66,TRIPHASIC REGIMEN,2004
2908,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2004
2909,U-68,TREATMENT OF ACTINIC KERATOSIS,2004
2910,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2004
2911,U-70,TREATMENT OF TRANSIENT INSOMNIA,2004
2912,U-71,METHOD OF TREATMENT OF HEART FAILURE,2004
2913,U-72,TREATMENT OF MIGRAINE,2004
2914,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2004
2915,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2004
2916,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2004
2917,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2004
2918,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2004
2919,U-78,ULCERATIVE COLITIS,2004
2920,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2004
2921,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2004
2922,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2004
2923,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2004
2924,U-83,TREATMENT OF SEIZURES,2004
2925,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2004
2926,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2004
2927,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2004
2928,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2004
2929,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2004
2930,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2004
2931,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2004
2932,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2004
2933,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2004
2934,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2004
2935,U-94,"TREATMENT-ADULTS WZ ADVANCED HIV, INTOLERANT OF APPROVED THERAPIES, INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2004
2936,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2004
2937,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2004
2938,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2004
2939,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2004
2940,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2004
2941,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2004
2942,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2004
2943,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2004
2944,U-103,TREATMENT OF OCULAR HYPERTENSION,2004
2945,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2004
2946,U-105,EMESIS,2004
2947,U-106,TREATMENT OF EPILEPSY,2004
2948,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2004
2949,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2004
2950,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2004
2951,U-110,USE AS A RETRIEVABLE PERSSARY,2004
2952,U-111,DIABETES,2004
2953,U-112,CONTRACEPTION,2004
2954,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2004
2955,U-114,USE FOR INHIBITING BONE RESORPTION,2004
2956,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2004
2957,U-116,METHOD OF MYOCARDIAL IMAGING,2004
2958,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2004
2959,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2004
2960,U-119,TREATMENT OF NASAL HYPERSECRETION,2004
2961,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2004
2962,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2004
2963,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2004
2964,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2004
2965,U-124,TREATMENT OF ACNE,2004
2966,U-125,TREATMENT NEUROGENERATIVE DISEASES,2004
2967,U-126,TREATMENT OF GASTRITIS,2004
2968,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2004
2969,U-128,METHOD FOR TREATMENT OF TUMORS,2004
2970,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2004
2971,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2004
2972,U-131,PHOTODAMAGED SKIN,2004
2973,U-132,INHIBITING HIV PROTEASE,2004
2974,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2004
2975,U-134,TREATMENT OF ACNE VULGARIS,2004
2976,U-135,ANTITUMOR AGENT,2004
2977,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2004
2978,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2004
2979,U-138,TREATMENT OF ALLERGIC RHINITIS,2004
2980,U-139,TREATMENT OF ALLERGIC REACTIONS,2004
2981,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2004
2982,U-141,TREATMENT OF ULCERATIVE COLITIS,2004
2983,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2004
2984,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2004
2985,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2004
2986,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2004
2987,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2004
2988,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2004
2989,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2004
2990,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2004
2991,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2004
2992,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2004
2993,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2004
2994,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2004
2995,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2004
2996,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2004
2997,U-156,METHOD OF PROVIDING ANESTHESIA,2004
2998,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2004
2999,U-158,ANGINA,2004
3000,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2004
3001,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2004
3002,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2004
3003,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2004
3004,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2004
3005,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2004
3006,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2004
3007,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2004
3008,U-167,METHOD FOR TREATING HIV-1 INFECTION,2004
3009,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2004
3010,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2004
3011,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2004
3012,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2004
3013,U-172,TREATMENT OF GENITAL WARTS,2004
3014,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2004
3015,U-174,USE AS AN ANTIHISTAMINE AGENT,2004
3016,U-175,METHOD OF TREATING MALIGNANT TUMORS,2004
3017,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2004
3018,U-177,FUNGICIDE,2004
3019,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2004
3020,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2004
3021,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2004
3022,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2004
3023,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2004
3024,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2004
3025,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2004
3026,U-185,METHOD OF TREATING HYPERTENSION,2004
3027,U-186,METHOD FOR TREATING GL DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2004
3028,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2004
3029,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2004
3030,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2004
3031,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2004
3032,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2004
3033,U-192,USE IN TREATING ALLERGIC REACTIONS,2004
3034,U-193,PSORIASIS,2004
3035,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2004
3036,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2004
3037,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2004
3038,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2004
3039,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2004
3040,U-199,METHOD OF TREATING INFECTIOUS UPPER GL TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2004
3041,U-200,METHOD OF TREATING GL DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2004
3042,U-201,METHOD OF TREATING GL DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2004
3043,U-202,METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5.000MG BISMUTH DAILY FOR 3-56 DAYS,2004
3044,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2004
3045,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI’S SARCOMA,2004
3046,U-205,METHOD FOR TREATING HEARTBURN,2004
3047,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2004
3048,U-207,USE AS NASAL SPRAY,2004
3049,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2004
3050,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2004
3051,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2004
3052,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2004
3053,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2004
3054,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2004
3055,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2004
3056,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2004
3057,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2004
3058,U-217,METHOD OF PRODUCING ANESTHESIA,2004
3059,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2004
3060,U-219,TREATMENT OF PARKINSON'S DISEASE,2004
3061,U-220,METHOD OF DIAGNOSIS,2004
3062,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2004
3063,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2004
3064,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2004
3065,U-224,CONTROLLING INTRAOCULAR PRESSURE,2004
3066,U-225,MEHTOD FOR DELIVERY,2004
3067,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2004
3068,U-227,NASAL ADMINISTRATION,2004
3069,U-228,ASTHMA,2004
3070,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2004
3071,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2004
3072,U-231,USE IN PARKINSON'S DISEASE,2004
3073,U-232,METHOD OF TREATING MIGRAINE,2004
3074,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2004
3075,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2004
3076,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2004
3077,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2004
3078,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2004
3079,U-238,"I MAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2004
3080,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2004
3081,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2004
3082,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2004
3083,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2004
3084,U-243,TOPICAL ADMINISTRATION,2004
3085,U-244,PLATELET AGGREGATION INHIBITORS,2004
3086,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2004
3087,U-246,PHOSPHATE BINDING,2004
3088,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2004
3089,U-248,TREATMENT OF HIV,2004
3090,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2004
3091,U-250,TREATMENT OF HEPATITIS B INFECTION,2004
3092,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2004
3093,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2004
3094,U-253,ORAL TRANSMUCOSAL USE,2004
3095,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2004
3096,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2004
3097,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2004
3098,U-257,TREATMENT OF HIV INFECTION,2004
3099,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2004
3100,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2004
3101,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2004
3102,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2004
3103,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2004
3104,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2004
3105,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2004
3106,U-265,USE AS LAXATIVE,2004
3107,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA,2004
3108,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2004
3109,U-268,ACROMEGALY,2004
3110,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2004
3111,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2004
3112,U-271,METHOD OF TREATING TUMORS,2004
3113,U-272,METHOD OF TREATING CARCINOMA,2004
3114,U-273,CUTANEOUS T-CELL LYMPHOMA,2004
3115,U-274,ZANAMIVIR FOR INHALATION,2004
3116,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2004
3117,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2004
3118,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2004
3119,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2004
3120,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2004
3121,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2004
3122,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2004
3123,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2004
3124,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2004
3125,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2004
3126,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2004
3127,U-286,DEPRESSION,2004
3128,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2004
3129,U-288,THERAPY OF INFLUENZA,2004
3130,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2004
3131,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2004
3132,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2004
3133,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2004
3134,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2004
3135,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2004
3136,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2004
3137,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2004
3138,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2004
3139,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2004
3140,U-299,TREATMENT OF ADENOMATOUS POLYPS,2004
3141,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPFRCHOLESTEROLEMIA,2004
3142,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2004
3143,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2004
3144,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET’S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2004
3145,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2004
3146,U-305,METHODS FOR USING THE DRUG PRODUCT,2004
3147,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2004
3148,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2004
3149,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2004
3150,U-309,TREATING SJOEGREN SYNDROME,2004
3151,U-310,TREATMENT OF XEROSTOMIA,2004
3152,U-311,HORMONE REPLACEMENT,2004
3153,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2004
3154,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2004
3155,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2004
3156,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2004
3157,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2004
3158,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2004
3159,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2004
3160,U-319,TREATMENT OF MICROBIAL INFECTIONS,2004
3161,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2004
3162,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2004
3163,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2004
3164,U-323,USE AS A BILE ACID SEQUESTRANT,2004
3165,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2004
3166,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2004
3167,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2004
3168,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2004
3169,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2004
3170,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2004
3171,U-330,TREATMENT OF NAUSEA AND VOMITING,2004
3172,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2004
3173,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2004
3174,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2004
3175,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2004
3176,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2004
3177,U-336,DIAGNOSTIC RADIOIMAGING,2004
3178,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2004
3179,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2004
3180,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2004
3181,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2004
3182,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2004
3183,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2004
3184,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2004
3185,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2004
3186,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2004
3187,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2004
3188,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2004
3189,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2004
3190,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2004
3191,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2004
3192,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2004
3193,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2004
3194,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2004
3195,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENTLIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2004
3196,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2004
3197,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2004
3198,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2004
3199,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2004
3200,U-359,METHOD OF USE OF VISICOL,2004
3201,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2004
3202,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2004
3203,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2004
3204,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2004
3205,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2004
3206,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2004
3207,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2004
3208,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2004
3209,U-368,HEARTBURN,2004
3210,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2004
3211,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2004
3212,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2004
3213,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GL TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2004
3214,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H. PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2004
3215,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2004
3216,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2004
3217,U-376,TREATMENT OF INFLUENZA,2004
3218,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2004
3219,U-378,METHOD FOR TREATING INCONTINENCE,2004
3220,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2004
3221,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2004
3222,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2004
3223,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2004
3224,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2004
3225,U-384,TREATMENT OF CMV RETINITIS,2004
3226,U-385,TREATMENT OF PEPTIC ULCERS,2004
3227,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2004
3228,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2004
3229,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2004
3230,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2004
3231,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2004
3232,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2004
3233,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2004
3234,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2004
3235,U-394,METHOD OF USE OF ALPHAGAN,2004
3236,U-395,METHOD OF USE OF ALPHAGAN P,2004
3237,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2004
3238,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2004
3239,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2004
3240,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2004
3241,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2004
3242,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2004
3243,U-402,TREATMENT OF ACTINIC KERATOSES,2004
3244,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2004
3245,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2004
3246,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2004
3247,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2004
3248,U-407,METHOD OF TREATING OTOPATHY,2004
3249,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2004
3250,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2004
3251,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2004
3252,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2004
3253,U-412,TREATMENT OF TYPE 2 DIABETES,2004
3254,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2004
3255,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2004
3256,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2004
3257,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2004
3258,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2004
3259,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2004
3260,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2004
3261,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2004
3262,U-421,USE FOR SEDATION,2004
3263,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2004
3264,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2004
3265,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2004
3266,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2004
3267,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2004
3268,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2004
3269,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2004
3270,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2004
3271,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2004
3272,U-431,POSTTRAUMATIC STRESS DISORDER,2004
3273,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2004
3274,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2004
3275,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2004
3276,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2004
3277,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2004
3278,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2004
3279,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2004
3280,U-439,TREATMENT OF OBESITY,2004
3281,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2004
3282,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2004
3283,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2004
3284,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2004
3285,U-444,METHOD OF TREATING,2004
3286,U-445,USE AS AN ANTIMYCOTIC AGENT,2004
3287,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2004
3288,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2004
3289,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENTLIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2004
3290,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2004
3291,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2004
3292,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2004
3293,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2004
3294,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2004
3295,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2004
3296,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2004
3297,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2004
3298,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2004
3299,U-458,METHOD OF USE OF IMAGENT,2004
3300,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2004
3301,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2004
3302,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2004
3303,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2004
3304,U-463,VENOGRAPHY,2004
3305,U-464,PERIPHERAL ARTERIOGRAPHY,2004
3306,U-465,CT IMAGING OF THE HEAD,2004
3307,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2004
3308,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2004
3309,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2004
3310,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2004
3311,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2004
3312,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2004
3313,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BL-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2004
3314,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2004
3315,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2004
3316,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2004
3317,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2004
3318,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2004
3319,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2004
3320,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2004
3321,U-480,CONTRAST AGENT FOR MRI,2004
3322,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2004
3323,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2004
3324,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2004
3325,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2004
3326,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2004
3327,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2004
3328,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2004
3329,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2004
3330,U-489,EXPECTORANT,2004
3331,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2004
3332,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2004
3333,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2004
3334,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2004
3335,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2004
3336,U-495,PERITONEAL DIALYSIS SOLUTION,2004
3337,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2004
3338,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2004
3339,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2004
3340,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2004
3341,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2004
3342,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2004
3343,U-502,PITYRIASIS VERSICOLOR,2004
3344,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2004
3345,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2004
3346,U-505,ULTRASOUND CONTRAST AGENT,2004
3347,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2004
3348,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2004
3349,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2004
3350,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEIOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2004
3351,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2004
3352,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2004
3353,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2004
3354,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2004
3355,U-514,PREVENTION OF OVULATION IN A WOMAN,2004
3356,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2004
3357,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2004
3358,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2004
3359,U-518,OBSESSIVE COMPULSIVE DISORDER,2004
3360,U-519,POST OPERATIVE NAUSEA AND VOMITING,2004
3361,U-520,PREMENOPAUSAL OSTEOPOROSIS,2004
3362,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2004
3363,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2004
3364,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2004
3365,U-524,METHOD OF TREATING DIARRHEA,2004
3366,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2004
3367,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2004
3368,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2004
3369,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2004
3370,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2004
3371,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2004
3372,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2004
3373,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2004
3374,U-533,ERECTILE DYSFUNCTION,2004
3375,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2004
3376,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2004
3377,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2004
3378,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2004
3379,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2004
3380,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2004
3381,U-540,TREATMENT OF FUNGAL INFECTIONS,2004
3382,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2004
3383,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2004
3384,U-543,TREATMENT OF SCHIZOPHRENIA,2004
3385,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2004
3386,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2004
3387,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2004
3388,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2005
3389,U-1,PREVENTION OF PREGNANCY,2005
3390,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2005
3391,U-3,TREATMENT OF HYPERTENSION,2005
3392,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2005
3393,U-5,METHOD OF PRODUCING BRONCHODILATION,2005
3394,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2005
3395,U-7,INCREASING CARDIAC CONTRACTILITY,2005
3396,U-8,ACUTE MYOCARDIAL INFARCTION,2005
3397,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2005
3398,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2005
3399,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2005
3400,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2005
3401,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2005
3402,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2005
3403,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2005
3404,U-16,USE IN LUNG SCANNING PROCEDURES,2005
3405,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2005
3406,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2005
3407,U-19,TREATMENT OF INFLAMMATION,2005
3408,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2005
3409,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2005
3410,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2005
3411,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2005
3412,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2005
3413,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2005
3414,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2005
3415,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2005
3416,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2005
3417,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2005
3418,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2005
3419,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2005
3420,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2005
3421,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2005
3422,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2005
3423,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2005
3424,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2005
3425,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2005
3426,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2005
3427,U-39,ANGINA PECTORIS,2005
3428,U-40,METHOD OF TREATMENT OF BURNS,2005
3429,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2005
3430,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2005
3431,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2005
3432,U-44,RELIEF OF NAUSEA AND VOMITING,2005
3433,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2005
3434,U-46,TREATMENT OF PANIC DISORDER,2005
3435,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2005
3436,U-48,ANALGESIA,2005
3437,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2005
3438,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2005
3439,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2005
3440,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2005
3441,U-53,HYPERCALCEMIA OF MALIGNANCY,2005
3442,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2005
3443,U-55,TREATMENT OF PAIN,2005
3444,U-56,AID TO SMOKING CESSATION,2005
3445,U-57,OPHTHALMIC USE OF NORFLOXACIN,2005
3446,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2005
3447,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2005
3448,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2005
3449,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2005
3450,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2005
3451,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2005
3452,U-64,TREATMENT OF VIRAL INFECTIONS,2005
3453,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2005
3454,U-66,TRIPHASIC REGIMEN,2005
3455,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2005
3456,U-68,TREATMENT OF ACTINIC KERATOSIS,2005
3457,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2005
3458,U-70,TREATMENT OF TRANSIENT INSOMNIA,2005
3459,U-71,METHOD OF TREATMENT OF HEART FAILURE,2005
3460,U-72,TREATMENT OF MIGRAINE,2005
3461,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2005
3462,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2005
3463,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2005
3464,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2005
3465,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2005
3466,U-78,ULCERATIVE COLITIS,2005
3467,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2005
3468,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2005
3469,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2005
3470,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2005
3471,U-83,TREATMENT OF SEIZURES,2005
3472,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2005
3473,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2005
3474,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2005
3475,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2005
3476,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2005
3477,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2005
3478,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2005
3479,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2005
3480,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2005
3481,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2005
3482,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2005
3483,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2005
3484,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2005
3485,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2005
3486,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2005
3487,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2005
3488,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2005
3489,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2005
3490,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2005
3491,U-103,TREATMENT OF OCULAR HYPERTENSION,2005
3492,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2005
3493,U-105,EMESIS,2005
3494,U-106,TREATMENT OF EPILEPSY,2005
3495,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2005
3496,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2005
3497,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2005
3498,U-110,USE AS A RETRIEVABLE PERSSARY,2005
3499,U-111,DIABETES,2005
3500,U-112,CONTRACEPTION,2005
3501,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2005
3502,U-114,USE FOR INHIBITING BONE RESORPTION,2005
3503,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2005
3504,U-116,METHOD OF MYOCARDIAL IMAGING,2005
3505,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2005
3506,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2005
3507,U-119,TREATMENT OF NASAL HYPERSECRETION,2005
3508,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2005
3509,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2005
3510,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2005
3511,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2005
3512,U-124,TREATMENT OF ACNE,2005
3513,U-125,TREATMENT NEUROGENERATIVE DISEASES,2005
3514,U-126,TREATMENT OF GASTRITIS,2005
3515,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2005
3516,U-128,METHOD FOR TREATMENT OF TUMORS,2005
3517,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2005
3518,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2005
3519,U-131,PHOTODAMAGED SKIN,2005
3520,U-132,INHIBITING HIV PROTEASE,2005
3521,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2005
3522,U-134,TREATMENT OF ACNE VULGARIS,2005
3523,U-135,ANTITUMOR AGENT,2005
3524,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2005
3525,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2005
3526,U-138,TREATMENT OF ALLERGIC RHINITIS,2005
3527,U-139,TREATMENT OF ALLERGIC REACTIONS,2005
3528,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2005
3529,U-141,TREATMENT OF ULCERATIVE COLITIS,2005
3530,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2005
3531,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2005
3532,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2005
3533,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2005
3534,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2005
3535,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2005
3536,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2005
3537,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2005
3538,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2005
3539,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2005
3540,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2005
3541,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2005
3542,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2005
3543,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2005
3544,U-156,METHOD OF PROVIDING ANESTHESIA,2005
3545,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2005
3546,U-158,ANGINA,2005
3547,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2005
3548,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2005
3549,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2005
3550,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2005
3551,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2005
3552,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2005
3553,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2005
3554,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2005
3555,U-167,METHOD FOR TREATING HIV-1 INFECTION,2005
3556,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2005
3557,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2005
3558,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2005
3559,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2005
3560,U-172,TREATMENT OF GENITAL WARTS,2005
3561,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2005
3562,U-174,USE AS AN ANTIHISTAMINE AGENT,2005
3563,U-175,METHOD OF TREATING MALIGNANT TUMORS,2005
3564,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2005
3565,U-177,FUNGICIDE,2005
3566,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2005
3567,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2005
3568,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2005
3569,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2005
3570,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2005
3571,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2005
3572,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2005
3573,U-185,METHOD OF TREATING HYPERTENSION,2005
3574,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2005
3575,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2005
3576,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2005
3577,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2005
3578,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2005
3579,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2005
3580,U-192,USE IN TREATING ALLERGIC REACTIONS,2005
3581,U-193,PSORIASIS,2005
3582,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2005
3583,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2005
3584,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2005
3585,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2005
3586,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2005
3587,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2005
3588,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2005
3589,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2005
3590,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2005
3591,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2005
3592,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2005
3593,U-205,METHOD FOR TREATING HEARTBURN,2005
3594,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2005
3595,U-207,USE AS NASAL SPRAY,2005
3596,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2005
3597,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2005
3598,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2005
3599,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2005
3600,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2005
3601,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2005
3602,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2005
3603,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2005
3604,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2005
3605,U-217,METHOD OF PRODUCING ANESTHESIA,2005
3606,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2005
3607,U-219,TREATMENT OF PARKINSON'S DISEASE,2005
3608,U-220,METHOD OF DIAGNOSIS,2005
3609,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2005
3610,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2005
3611,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2005
3612,U-224,CONTROLLING INTRAOCULAR PRESSURE,2005
3613,U-225,MEHTOD FOR DELIVERY,2005
3614,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2005
3615,U-227,NASAL ADMINISTRATION,2005
3616,U-228,ASTHMA,2005
3617,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2005
3618,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2005
3619,U-231,USE IN PARKINSON'S DISEASE,2005
3620,U-232,METHOD OF TREATING MIGRAINE,2005
3621,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2005
3622,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2005
3623,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2005
3624,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2005
3625,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2005
3626,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2005
3627,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2005
3628,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2005
3629,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2005
3630,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2005
3631,U-243,TOPICAL ADMINISTRATION,2005
3632,U-244,PLATELET AGGREGATION INHIBITORS,2005
3633,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2005
3634,U-246,PHOSPHATE BINDING,2005
3635,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2005
3636,U-248,TREATMENT OF HIV,2005
3637,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2005
3638,U-250,TREATMENT OF HEPATITIS B INFECTION,2005
3639,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2005
3640,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2005
3641,U-253,ORAL TRANSMUCOSAL USE,2005
3642,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2005
3643,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2005
3644,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2005
3645,U-257,TREATMENT OF HIV INFECTION,2005
3646,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2005
3647,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2005
3648,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2005
3649,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2005
3650,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2005
3651,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2005
3652,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2005
3653,U-265,USE AS LAXATIVE,2005
3654,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2005
3655,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2005
3656,U-268,ACROMEGALY,2005
3657,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2005
3658,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2005
3659,U-271,METHOD OF TREATING TUMORS,2005
3660,U-272,METHOD OF TREATING CARCINOMA,2005
3661,U-273,CUTANEOUS T-CELL LYMPHOMA,2005
3662,U-274,ZANAMIVIR FOR INHALATION,2005
3663,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2005
3664,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2005
3665,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2005
3666,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2005
3667,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2005
3668,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2005
3669,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2005
3670,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2005
3671,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2005
3672,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2005
3673,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2005
3674,U-286,DEPRESSION,2005
3675,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2005
3676,U-288,THERAPY OF INFLUENZA,2005
3677,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2005
3678,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2005
3679,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2005
3680,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2005
3681,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2005
3682,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2005
3683,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2005
3684,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2005
3685,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2005
3686,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2005
3687,U-299,TREATMENT OF ADENOMATOUS POLYPS,2005
3688,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2005
3689,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2005
3690,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2005
3691,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2005
3692,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2005
3693,U-305,METHODS FOR USING THE DRUG PRODUCT,2005
3694,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2005
3695,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2005
3696,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2005
3697,U-309,TREATING SJOEGREN SYNDROME,2005
3698,U-310,TREATMENT OF XEROSTOMIA,2005
3699,U-311,HORMONE REPLACEMENT,2005
3700,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2005
3701,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2005
3702,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2005
3703,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2005
3704,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2005
3705,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2005
3706,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2005
3707,U-319,TREATMENT OF MICROBIAL INFECTIONS,2005
3708,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2005
3709,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2005
3710,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2005
3711,U-323,USE AS A BILE ACID SEQUESTRANT,2005
3712,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2005
3713,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2005
3714,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2005
3715,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2005
3716,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2005
3717,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2005
3718,U-330,TREATMENT OF NAUSEA AND VOMITING,2005
3719,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2005
3720,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2005
3721,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2005
3722,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2005
3723,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2005
3724,U-336,DIAGNOSTIC RADIOIMAGING,2005
3725,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2005
3726,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2005
3727,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2005
3728,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2005
3729,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2005
3730,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2005
3731,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2005
3732,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2005
3733,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2005
3734,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2005
3735,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2005
3736,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2005
3737,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2005
3738,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2005
3739,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2005
3740,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2005
3741,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2005
3742,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2005
3743,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2005
3744,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2005
3745,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2005
3746,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2005
3747,U-359,METHOD OF USE OF VISICOL,2005
3748,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2005
3749,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2005
3750,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2005
3751,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2005
3752,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2005
3753,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2005
3754,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2005
3755,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2005
3756,U-368,HEARTBURN,2005
3757,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2005
3758,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2005
3759,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2005
3760,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2005
3761,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2005
3762,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2005
3763,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2005
3764,U-376,TREATMENT OF INFLUENZA,2005
3765,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2005
3766,U-378,METHOD FOR TREATING INCONTINENCE,2005
3767,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2005
3768,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2005
3769,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2005
3770,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2005
3771,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2005
3772,U-384,TREATMENT OF CMV RETINITIS,2005
3773,U-385,TREATMENT OF PEPTIC ULCERS,2005
3774,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2005
3775,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2005
3776,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2005
3777,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2005
3778,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2005
3779,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2005
3780,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2005
3781,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2005
3782,U-394,METHOD OF USE OF ALPHAGAN,2005
3783,U-395,METHOD OF USE OF ALPHAGAN P,2005
3784,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2005
3785,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2005
3786,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2005
3787,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2005
3788,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2005
3789,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2005
3790,U-402,TREATMENT OF ACTINIC KERATOSES,2005
3791,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2005
3792,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2005
3793,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2005
3794,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2005
3795,U-407,METHOD OF TREATING OTOPATHY,2005
3796,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2005
3797,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2005
3798,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2005
3799,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2005
3800,U-412,TREATMENT OF TYPE 2 DIABETES,2005
3801,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2005
3802,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2005
3803,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2005
3804,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2005
3805,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2005
3806,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2005
3807,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2005
3808,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2005
3809,U-421,USE FOR SEDATION,2005
3810,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2005
3811,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2005
3812,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2005
3813,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2005
3814,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2005
3815,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2005
3816,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2005
3817,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2005
3818,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2005
3819,U-431,POSTTRAUMATIC STRESS DISORDER,2005
3820,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2005
3821,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2005
3822,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2005
3823,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2005
3824,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2005
3825,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2005
3826,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2005
3827,U-439,TREATMENT OF OBESITY,2005
3828,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2005
3829,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2005
3830,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2005
3831,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2005
3832,U-444,TREATMENT OF MIGRAINE,2005
3833,U-445,USE AS AN ANTIMYCOTIC AGENT,2005
3834,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2005
3835,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2005
3836,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2005
3837,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2005
3838,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2005
3839,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2005
3840,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2005
3841,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2005
3842,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2005
3843,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2005
3844,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2005
3845,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2005
3846,U-458,METHOD OF USE OF IMAGENT,2005
3847,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2005
3848,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2005
3849,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2005
3850,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2005
3851,U-463,VENOGRAPHY,2005
3852,U-464,PERIPHERAL ARTERIOGRAPHY,2005
3853,U-465,CT IMAGING OF THE HEAD,2005
3854,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2005
3855,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2005
3856,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2005
3857,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2005
3858,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2005
3859,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2005
3860,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2005
3861,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2005
3862,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2005
3863,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2005
3864,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2005
3865,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2005
3866,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2005
3867,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2005
3868,U-480,CONTRAST AGENT FOR MRI,2005
3869,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2005
3870,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2005
3871,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2005
3872,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2005
3873,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2005
3874,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2005
3875,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2005
3876,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2005
3877,U-489,EXPECTORANT,2005
3878,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2005
3879,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2005
3880,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2005
3881,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2005
3882,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2005
3883,U-495,PERITONEAL DIALYSIS SOLUTION,2005
3884,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2005
3885,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2005
3886,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2005
3887,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2005
3888,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2005
3889,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2005
3890,U-502,PITYRIASIS VERSICOLOR,2005
3891,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2005
3892,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2005
3893,U-505,ULTRASOUND CONTRAST AGENT,2005
3894,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2005
3895,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2005
3896,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2005
3897,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEIOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2005
3898,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2005
3899,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2005
3900,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2005
3901,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2005
3902,U-514,PREVENTION OF OVULATION IN A WOMAN,2005
3903,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2005
3904,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2005
3905,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2005
3906,U-518,OBSESSIVE COMPULSIVE DISORDER,2005
3907,U-519,POST OPERATIVE NAUSEA AND VOMITING,2005
3908,U-520,PREMENOPAUSAL OSTEOPOROSIS,2005
3909,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2005
3910,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2005
3911,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2005
3912,U-524,METHOD OF TREATING DIARRHEA,2005
3913,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2005
3914,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2005
3915,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2005
3916,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2005
3917,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2005
3918,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2005
3919,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2005
3920,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2005
3921,U-533,ERECTILE DYSFUNCTION,2005
3922,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2005
3923,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2005
3924,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2005
3925,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2005
3926,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2005
3927,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2005
3928,U-540,TREATMENT OF FUNGAL INFECTIONS,2005
3929,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2005
3930,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2005
3931,U-543,TREATMENT OF SCHIZOPHRENIA,2005
3932,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2005
3933,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2005
3934,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2005
3935,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2005
3936,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2005
3937,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2005
3938,U-550,TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA,2005
3939,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2005
3940,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2005
3941,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2005
3942,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2005
3943,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2005
3944,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2005
3945,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2005
3946,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2005
3947,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2005
3948,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2005
3949,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2005
3950,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2005
3951,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2005
3952,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2005
3953,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2005
3954,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2005
3955,U-567,METHOD OF TREATING INFERTILITY,2005
3956,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2005
3957,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2005
3958,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2005
3959,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2005
3960,U-572,INTENSIVE CARE UNIT SEDATION,2005
3961,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2005
3962,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2005
3963,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2005
3964,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2005
3965,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2005
3966,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2005
3967,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2005
3968,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2005
3969,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2005
3970,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2005
3971,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2005
3972,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2005
3973,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2005
3974,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2005
3975,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2005
3976,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2005
3977,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2005
3978,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2005
3979,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2005
3980,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)",2005
3981,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2005
3982,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2005
3983,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2005
3984,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2005
3985,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2005
3986,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2005
3987,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2005
3988,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2005
3989,U-601,TREATMENT OF BIPOLAR DISORDERS,2005
3990,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2005
3991,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2005
3992,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2005
3993,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2005
3994,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2005
3995,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2005
3996,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2005
3997,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2005
3998,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2005
3999,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2005
4000,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2005
4001,U-613,REDUCTION OF SERUM PHOSPHATE,2005
4002,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2005
4003,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2005
4004,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2005
4005,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2005
4006,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB,NONHDL-C OR TG LEVELS;TO INCREASE HDL-C; AND TO TREAT PATIENTS WITH PRIMARY HYPERCHOLESTROLEMIA",2005
4007,U-620,TREATMENT OF INSOMNIA,2005
4008,U-621,METHOD OF TREATING CANCER,2005
4009,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2005
4010,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2005
4011,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2005
4012,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2005
4013,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2005
4014,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2005
4015,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2006
4016,U-1,PREVENTION OF PREGNANCY,2006
4017,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2006
4018,U-3,TREATMENT OF HYPERTENSION,2006
4019,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2006
4020,U-5,METHOD OF PRODUCING BRONCHODILATION,2006
4021,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2006
4022,U-7,INCREASING CARDIAC CONTRACTILITY,2006
4023,U-8,ACUTE MYOCARDIAL INFARCTION,2006
4024,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2006
4025,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2006
4026,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2006
4027,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2006
4028,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2006
4029,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2006
4030,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2006
4031,U-16,USE IN LUNG SCANNING PROCEDURES,2006
4032,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2006
4033,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2006
4034,U-19,TREATMENT OF INFLAMMATION,2006
4035,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2006
4036,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2006
4037,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2006
4038,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2006
4039,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2006
4040,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2006
4041,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2006
4042,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2006
4043,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2006
4044,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2006
4045,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2006
4046,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2006
4047,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2006
4048,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2006
4049,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2006
4050,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2006
4051,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2006
4052,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2006
4053,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2006
4054,U-39,ANGINA PECTORIS,2006
4055,U-40,METHOD OF TREATMENT OF BURNS,2006
4056,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2006
4057,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2006
4058,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2006
4059,U-44,RELIEF OF NAUSEA AND VOMITING,2006
4060,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2006
4061,U-46,TREATMENT OF PANIC DISORDER,2006
4062,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2006
4063,U-48,ANALGESIA,2006
4064,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2006
4065,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2006
4066,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2006
4067,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2006
4068,U-53,HYPERCALCEMIA OF MALIGNANCY,2006
4069,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2006
4070,U-55,TREATMENT OF PAIN,2006
4071,U-56,AID TO SMOKING CESSATION,2006
4072,U-57,OPHTHALMIC USE OF NORFLOXACIN,2006
4073,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2006
4074,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2006
4075,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2006
4076,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2006
4077,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2006
4078,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2006
4079,U-64,TREATMENT OF VIRAL INFECTIONS,2006
4080,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2006
4081,U-66,TRIPHASIC REGIMEN,2006
4082,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2006
4083,U-68,TREATMENT OF ACTINIC KERATOSIS,2006
4084,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2006
4085,U-70,TREATMENT OF TRANSIENT INSOMNIA,2006
4086,U-71,METHOD OF TREATMENT OF HEART FAILURE,2006
4087,U-72,TREATMENT OF MIGRAINE,2006
4088,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2006
4089,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2006
4090,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2006
4091,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2006
4092,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2006
4093,U-78,ULCERATIVE COLITIS,2006
4094,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2006
4095,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2006
4096,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2006
4097,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2006
4098,U-83,TREATMENT OF SEIZURES,2006
4099,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2006
4100,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2006
4101,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2006
4102,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2006
4103,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2006
4104,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2006
4105,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2006
4106,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2006
4107,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2006
4108,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2006
4109,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2006
4110,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2006
4111,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2006
4112,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2006
4113,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2006
4114,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2006
4115,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2006
4116,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2006
4117,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2006
4118,U-103,TREATMENT OF OCULAR HYPERTENSION,2006
4119,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2006
4120,U-105,EMESIS,2006
4121,U-106,TREATMENT OF EPILEPSY,2006
4122,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2006
4123,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2006
4124,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2006
4125,U-110,USE AS A RETRIEVABLE PERSSARY,2006
4126,U-111,DIABETES,2006
4127,U-112,CONTRACEPTION,2006
4128,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2006
4129,U-114,USE FOR INHIBITING BONE RESORPTION,2006
4130,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2006
4131,U-116,METHOD OF MYOCARDIAL IMAGING,2006
4132,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2006
4133,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2006
4134,U-119,TREATMENT OF NASAL HYPERSECRETION,2006
4135,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2006
4136,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2006
4137,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2006
4138,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2006
4139,U-124,TREATMENT OF ACNE,2006
4140,U-125,TREATMENT NEUROGENERATIVE DISEASES,2006
4141,U-126,TREATMENT OF GASTRITIS,2006
4142,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2006
4143,U-128,METHOD FOR TREATMENT OF TUMORS,2006
4144,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2006
4145,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2006
4146,U-131,PHOTODAMAGED SKIN,2006
4147,U-132,INHIBITING HIV PROTEASE,2006
4148,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2006
4149,U-134,TREATMENT OF ACNE VULGARIS,2006
4150,U-135,ANTITUMOR AGENT,2006
4151,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2006
4152,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2006
4153,U-138,TREATMENT OF ALLERGIC RHINITIS,2006
4154,U-139,TREATMENT OF ALLERGIC REACTIONS,2006
4155,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2006
4156,U-141,TREATMENT OF ULCERATIVE COLITIS,2006
4157,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2006
4158,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2006
4159,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2006
4160,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2006
4161,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2006
4162,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2006
4163,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2006
4164,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2006
4165,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2006
4166,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2006
4167,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2006
4168,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2006
4169,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2006
4170,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2006
4171,U-156,METHOD OF PROVIDING ANESTHESIA,2006
4172,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2006
4173,U-158,ANGINA,2006
4174,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2006
4175,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2006
4176,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2006
4177,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2006
4178,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2006
4179,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2006
4180,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2006
4181,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2006
4182,U-167,METHOD FOR TREATING HIV-1 INFECTION,2006
4183,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2006
4184,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2006
4185,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2006
4186,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2006
4187,U-172,TREATMENT OF GENITAL WARTS,2006
4188,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2006
4189,U-174,USE AS AN ANTIHISTAMINE AGENT,2006
4190,U-175,METHOD OF TREATING MALIGNANT TUMORS,2006
4191,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2006
4192,U-177,FUNGICIDE,2006
4193,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2006
4194,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2006
4195,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2006
4196,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2006
4197,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2006
4198,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2006
4199,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2006
4200,U-185,METHOD OF TREATING HYPERTENSION,2006
4201,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2006
4202,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2006
4203,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2006
4204,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2006
4205,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2006
4206,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2006
4207,U-192,USE IN TREATING ALLERGIC REACTIONS,2006
4208,U-193,PSORIASIS,2006
4209,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2006
4210,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2006
4211,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2006
4212,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2006
4213,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2006
4214,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2006
4215,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2006
4216,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2006
4217,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2006
4218,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2006
4219,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2006
4220,U-205,METHOD FOR TREATING HEARTBURN,2006
4221,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2006
4222,U-207,USE AS NASAL SPRAY,2006
4223,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2006
4224,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2006
4225,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2006
4226,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2006
4227,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2006
4228,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2006
4229,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2006
4230,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2006
4231,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2006
4232,U-217,METHOD OF PRODUCING ANESTHESIA,2006
4233,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2006
4234,U-219,TREATMENT OF PARKINSON'S DISEASE,2006
4235,U-220,METHOD OF DIAGNOSIS,2006
4236,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2006
4237,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2006
4238,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2006
4239,U-224,CONTROLLING INTRAOCULAR PRESSURE,2006
4240,U-225,MEHTOD FOR DELIVERY,2006
4241,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2006
4242,U-227,NASAL ADMINISTRATION,2006
4243,U-228,ASTHMA,2006
4244,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2006
4245,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2006
4246,U-231,USE IN PARKINSON'S DISEASE,2006
4247,U-232,METHOD OF TREATING MIGRAINE,2006
4248,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2006
4249,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2006
4250,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2006
4251,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2006
4252,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2006
4253,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2006
4254,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2006
4255,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2006
4256,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2006
4257,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2006
4258,U-243,TOPICAL ADMINISTRATION,2006
4259,U-244,PLATELET AGGREGATION INHIBITORS,2006
4260,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2006
4261,U-246,PHOSPHATE BINDING,2006
4262,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2006
4263,U-248,TREATMENT OF HIV,2006
4264,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2006
4265,U-250,TREATMENT OF HEPATITIS B INFECTION,2006
4266,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2006
4267,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2006
4268,U-253,ORAL TRANSMUCOSAL USE,2006
4269,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2006
4270,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2006
4271,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2006
4272,U-257,TREATMENT OF HIV INFECTION,2006
4273,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2006
4274,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2006
4275,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2006
4276,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2006
4277,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2006
4278,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2006
4279,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2006
4280,U-265,USE AS LAXATIVE,2006
4281,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2006
4282,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2006
4283,U-268,ACROMEGALY,2006
4284,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2006
4285,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2006
4286,U-271,METHOD OF TREATING TUMORS,2006
4287,U-272,METHOD OF TREATING CARCINOMA,2006
4288,U-273,CUTANEOUS T-CELL LYMPHOMA,2006
4289,U-274,ZANAMIVIR FOR INHALATION,2006
4290,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2006
4291,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2006
4292,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2006
4293,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2006
4294,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2006
4295,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2006
4296,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2006
4297,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2006
4298,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2006
4299,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2006
4300,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2006
4301,U-286,DEPRESSION,2006
4302,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2006
4303,U-288,THERAPY OF INFLUENZA,2006
4304,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2006
4305,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2006
4306,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2006
4307,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2006
4308,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2006
4309,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2006
4310,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2006
4311,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2006
4312,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2006
4313,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2006
4314,U-299,TREATMENT OF ADENOMATOUS POLYPS,2006
4315,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2006
4316,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2006
4317,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2006
4318,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2006
4319,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2006
4320,U-305,METHODS FOR USING THE DRUG PRODUCT,2006
4321,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2006
4322,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2006
4323,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2006
4324,U-309,TREATING SJOEGREN SYNDROME,2006
4325,U-310,TREATMENT OF XEROSTOMIA,2006
4326,U-311,HORMONE REPLACEMENT,2006
4327,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2006
4328,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2006
4329,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2006
4330,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2006
4331,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2006
4332,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2006
4333,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2006
4334,U-319,TREATMENT OF MICROBIAL INFECTIONS,2006
4335,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2006
4336,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2006
4337,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2006
4338,U-323,USE AS A BILE ACID SEQUESTRANT,2006
4339,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2006
4340,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2006
4341,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2006
4342,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2006
4343,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2006
4344,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2006
4345,U-330,TREATMENT OF NAUSEA AND VOMITING,2006
4346,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2006
4347,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2006
4348,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2006
4349,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2006
4350,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2006
4351,U-336,DIAGNOSTIC RADIOIMAGING,2006
4352,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2006
4353,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2006
4354,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2006
4355,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2006
4356,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2006
4357,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2006
4358,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2006
4359,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2006
4360,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2006
4361,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2006
4362,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2006
4363,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2006
4364,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2006
4365,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2006
4366,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2006
4367,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2006
4368,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2006
4369,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2006
4370,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2006
4371,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2006
4372,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2006
4373,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2006
4374,U-359,METHOD OF USE OF VISICOL,2006
4375,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2006
4376,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2006
4377,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2006
4378,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2006
4379,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2006
4380,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2006
4381,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2006
4382,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2006
4383,U-368,HEARTBURN,2006
4384,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2006
4385,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2006
4386,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2006
4387,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2006
4388,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2006
4389,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2006
4390,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2006
4391,U-376,TREATMENT OF INFLUENZA,2006
4392,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2006
4393,U-378,METHOD FOR TREATING INCONTINENCE,2006
4394,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2006
4395,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2006
4396,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2006
4397,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2006
4398,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2006
4399,U-384,TREATMENT OF CMV RETINITIS,2006
4400,U-385,TREATMENT OF PEPTIC ULCERS,2006
4401,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2006
4402,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2006
4403,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2006
4404,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2006
4405,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2006
4406,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2006
4407,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2006
4408,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2006
4409,U-394,METHOD OF USE OF ALPHAGAN,2006
4410,U-395,METHOD OF USE OF ALPHAGAN P,2006
4411,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2006
4412,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2006
4413,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2006
4414,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2006
4415,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2006
4416,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2006
4417,U-402,TREATMENT OF ACTINIC KERATOSES,2006
4418,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2006
4419,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2006
4420,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2006
4421,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2006
4422,U-407,METHOD OF TREATING OTOPATHY,2006
4423,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2006
4424,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2006
4425,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2006
4426,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2006
4427,U-412,TREATMENT OF TYPE 2 DIABETES,2006
4428,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2006
4429,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2006
4430,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2006
4431,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2006
4432,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2006
4433,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2006
4434,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2006
4435,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2006
4436,U-421,USE FOR SEDATION,2006
4437,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2006
4438,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2006
4439,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2006
4440,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2006
4441,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2006
4442,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2006
4443,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2006
4444,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2006
4445,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2006
4446,U-431,POSTTRAUMATIC STRESS DISORDER,2006
4447,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2006
4448,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2006
4449,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2006
4450,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2006
4451,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2006
4452,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2006
4453,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2006
4454,U-439,TREATMENT OF OBESITY,2006
4455,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2006
4456,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2006
4457,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2006
4458,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2006
4459,U-444,TREATMENT OF MIGRAINE,2006
4460,U-445,USE AS AN ANTIMYCOTIC AGENT,2006
4461,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2006
4462,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2006
4463,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2006
4464,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2006
4465,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2006
4466,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2006
4467,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2006
4468,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2006
4469,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2006
4470,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2006
4471,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2006
4472,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2006
4473,U-458,METHOD OF USE OF IMAGENT,2006
4474,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2006
4475,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2006
4476,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2006
4477,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2006
4478,U-463,VENOGRAPHY,2006
4479,U-464,PERIPHERAL ARTERIOGRAPHY,2006
4480,U-465,CT IMAGING OF THE HEAD,2006
4481,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2006
4482,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2006
4483,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2006
4484,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2006
4485,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2006
4486,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2006
4487,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2006
4488,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2006
4489,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2006
4490,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2006
4491,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2006
4492,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2006
4493,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2006
4494,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2006
4495,U-480,CONTRAST AGENT FOR MRI,2006
4496,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2006
4497,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2006
4498,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2006
4499,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2006
4500,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2006
4501,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2006
4502,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2006
4503,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2006
4504,U-489,EXPECTORANT,2006
4505,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2006
4506,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2006
4507,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2006
4508,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2006
4509,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2006
4510,U-495,PERITONEAL DIALYSIS SOLUTION,2006
4511,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2006
4512,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2006
4513,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2006
4514,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2006
4515,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2006
4516,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2006
4517,U-502,PITYRIASIS VERSICOLOR,2006
4518,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2006
4519,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2006
4520,U-505,ULTRASOUND CONTRAST AGENT,2006
4521,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2006
4522,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2006
4523,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2006
4524,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2006
4525,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2006
4526,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2006
4527,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2006
4528,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2006
4529,U-514,PREVENTION OF OVULATION IN A WOMAN,2006
4530,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2006
4531,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2006
4532,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2006
4533,U-518,OBSESSIVE COMPULSIVE DISORDER,2006
4534,U-519,POST OPERATIVE NAUSEA AND VOMITING,2006
4535,U-520,PREMENOPAUSAL OSTEOPOROSIS,2006
4536,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2006
4537,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2006
4538,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2006
4539,U-524,METHOD OF TREATING DIARRHEA,2006
4540,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2006
4541,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2006
4542,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2006
4543,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2006
4544,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2006
4545,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2006
4546,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2006
4547,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2006
4548,U-533,ERECTILE DYSFUNCTION,2006
4549,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2006
4550,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2006
4551,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2006
4552,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2006
4553,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2006
4554,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2006
4555,U-540,TREATMENT OF FUNGAL INFECTIONS,2006
4556,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2006
4557,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2006
4558,U-543,TREATMENT OF SCHIZOPHRENIA,2006
4559,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2006
4560,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2006
4561,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2006
4562,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2006
4563,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2006
4564,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2006
4565,U-550,TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA,2006
4566,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2006
4567,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2006
4568,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2006
4569,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2006
4570,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2006
4571,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2006
4572,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2006
4573,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2006
4574,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2006
4575,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2006
4576,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2006
4577,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2006
4578,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2006
4579,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2006
4580,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2006
4581,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2006
4582,U-567,METHOD OF TREATING INFERTILITY,2006
4583,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2006
4584,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2006
4585,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2006
4586,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2006
4587,U-572,INTENSIVE CARE UNIT SEDATION,2006
4588,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2006
4589,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2006
4590,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2006
4591,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2006
4592,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2006
4593,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2006
4594,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2006
4595,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2006
4596,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2006
4597,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2006
4598,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2006
4599,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2006
4600,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2006
4601,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2006
4602,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2006
4603,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2006
4604,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2006
4605,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2006
4606,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2006
4607,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)",2006
4608,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2006
4609,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2006
4610,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2006
4611,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2006
4612,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2006
4613,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2006
4614,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2006
4615,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2006
4616,U-601,TREATMENT OF BIPOLAR DISORDERS,2006
4617,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2006
4618,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2006
4619,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2006
4620,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2006
4621,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2006
4622,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2006
4623,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2006
4624,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2006
4625,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2006
4626,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2006
4627,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2006
4628,U-613,REDUCTION OF SERUM PHOSPHATE,2006
4629,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2006
4630,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2006
4631,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2006
4632,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2006
4633,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB,NONHDL-C OR TG LEVELS;TO INCREASE HDL-C; AND TO TREAT PATIENTS WITH PRIMARY HYPERCHOLESTROLEMIA",2006
4634,U-619,TREATMENT OF MALIGNANT NEOPLASM,2006
4635,U-620,TREATMENT OF INSOMNIA,2006
4636,U-621,METHOD OF TREATING CANCER,2006
4637,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2006
4638,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2006
4639,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2006
4640,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2006
4641,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2006
4642,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2006
4643,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2006
4644,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2006
4645,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2006
4646,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2006
4647,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2006
4648,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2006
4649,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2006
4650,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2006
4651,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2006
4652,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2006
4653,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2006
4654,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2006
4655,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2006
4656,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2006
4657,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2006
4658,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2006
4659,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2006
4660,U-645,TREATMENT OF ASTHMA,2006
4661,U-646,METHOD OF TREATING OTITIS,2006
4662,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2006
4663,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2006
4664,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2006
4665,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2006
4666,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2006
4667,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2006
4668,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2006
4669,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2006
4670,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2006
4671,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2006
4672,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2006
4673,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2006
4674,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2006
4675,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2006
4676,U-661,TREATMENT OF SEIZURE DISORDER,2006
4677,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2006
4678,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2006
4679,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2006
4680,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2006
4681,U-666,METHOD OF TREATING ADHD,2006
4682,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2006
4683,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2006
4684,U-669,INDICATION OF TYPE II DIABETES,2006
4685,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2006
4686,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2006
4687,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2006
4688,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2006
4689,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2006
4690,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2006
4691,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2006
4692,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2006
4693,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2006
4694,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2006
4695,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2006
4696,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2006
4697,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2006
4698,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2006
4699,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2006
4700,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2006
4701,U-686,EXPECTORANT AND NASAL DECONGESTANT,2006
4702,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2006
4703,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2006
4704,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2006
4705,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2006
4706,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2006
4707,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2006
4708,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2006
4709,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2007
4710,U-1,PREVENTION OF PREGNANCY,2007
4711,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2007
4712,U-3,TREATMENT OF HYPERTENSION,2007
4713,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2007
4714,U-5,METHOD OF PRODUCING BRONCHODILATION,2007
4715,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2007
4716,U-7,INCREASING CARDIAC CONTRACTILITY,2007
4717,U-8,ACUTE MYOCARDIAL INFARCTION,2007
4718,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2007
4719,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2007
4720,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2007
4721,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2007
4722,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2007
4723,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2007
4724,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2007
4725,U-16,USE IN LUNG SCANNING PROCEDURES,2007
4726,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2007
4727,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2007
4728,U-19,TREATMENT OF INFLAMMATION,2007
4729,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2007
4730,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2007
4731,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2007
4732,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2007
4733,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2007
4734,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2007
4735,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2007
4736,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2007
4737,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2007
4738,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2007
4739,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2007
4740,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2007
4741,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2007
4742,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2007
4743,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2007
4744,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2007
4745,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2007
4746,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2007
4747,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2007
4748,U-39,ANGINA PECTORIS,2007
4749,U-40,METHOD OF TREATMENT OF BURNS,2007
4750,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2007
4751,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2007
4752,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2007
4753,U-44,RELIEF OF NAUSEA AND VOMITING,2007
4754,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2007
4755,U-46,TREATMENT OF PANIC DISORDER,2007
4756,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2007
4757,U-48,ANALGESIA,2007
4758,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2007
4759,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2007
4760,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2007
4761,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2007
4762,U-53,HYPERCALCEMIA OF MALIGNANCY,2007
4763,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2007
4764,U-55,TREATMENT OF PAIN,2007
4765,U-56,AID TO SMOKING CESSATION,2007
4766,U-57,OPHTHALMIC USE OF NORFLOXACIN,2007
4767,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2007
4768,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2007
4769,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2007
4770,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2007
4771,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2007
4772,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2007
4773,U-64,TREATMENT OF VIRAL INFECTIONS,2007
4774,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2007
4775,U-66,TRIPHASIC REGIMEN,2007
4776,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2007
4777,U-68,TREATMENT OF ACTINIC KERATOSIS,2007
4778,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2007
4779,U-70,TREATMENT OF TRANSIENT INSOMNIA,2007
4780,U-71,METHOD OF TREATMENT OF HEART FAILURE,2007
4781,U-72,TREATMENT OF MIGRAINE,2007
4782,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2007
4783,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2007
4784,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2007
4785,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2007
4786,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2007
4787,U-78,ULCERATIVE COLITIS,2007
4788,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2007
4789,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2007
4790,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2007
4791,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2007
4792,U-83,TREATMENT OF SEIZURES,2007
4793,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2007
4794,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2007
4795,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2007
4796,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2007
4797,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2007
4798,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2007
4799,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2007
4800,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2007
4801,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2007
4802,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2007
4803,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2007
4804,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2007
4805,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2007
4806,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2007
4807,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2007
4808,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2007
4809,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2007
4810,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2007
4811,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2007
4812,U-103,TREATMENT OF OCULAR HYPERTENSION,2007
4813,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2007
4814,U-105,EMESIS,2007
4815,U-106,TREATMENT OF EPILEPSY,2007
4816,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2007
4817,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2007
4818,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2007
4819,U-110,USE AS A RETRIEVABLE PERSSARY,2007
4820,U-111,DIABETES,2007
4821,U-112,CONTRACEPTION,2007
4822,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2007
4823,U-114,USE FOR INHIBITING BONE RESORPTION,2007
4824,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2007
4825,U-116,METHOD OF MYOCARDIAL IMAGING,2007
4826,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2007
4827,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2007
4828,U-119,TREATMENT OF NASAL HYPERSECRETION,2007
4829,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2007
4830,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2007
4831,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2007
4832,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2007
4833,U-124,TREATMENT OF ACNE,2007
4834,U-125,TREATMENT NEUROGENERATIVE DISEASES,2007
4835,U-126,TREATMENT OF GASTRITIS,2007
4836,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2007
4837,U-128,METHOD FOR TREATMENT OF TUMORS,2007
4838,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2007
4839,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2007
4840,U-131,PHOTODAMAGED SKIN,2007
4841,U-132,INHIBITING HIV PROTEASE,2007
4842,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED CALORIE DIET,2007
4843,U-134,TREATMENT OF ACNE VULGARIS,2007
4844,U-135,ANTITUMOR AGENT,2007
4845,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2007
4846,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2007
4847,U-138,TREATMENT OF ALLERGIC RHINITIS,2007
4848,U-139,TREATMENT OF ALLERGIC REACTIONS,2007
4849,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2007
4850,U-141,TREATMENT OF ULCERATIVE COLITIS,2007
4851,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2007
4852,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2007
4853,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2007
4854,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2007
4855,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2007
4856,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2007
4857,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2007
4858,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2007
4859,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2007
4860,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2007
4861,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2007
4862,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2007
4863,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2007
4864,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2007
4865,U-156,METHOD OF PROVIDING ANESTHESIA,2007
4866,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2007
4867,U-158,ANGINA,2007
4868,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2007
4869,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2007
4870,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2007
4871,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2007
4872,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2007
4873,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2007
4874,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2007
4875,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2007
4876,U-167,METHOD FOR TREATING HIV-1 INFECTION,2007
4877,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2007
4878,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2007
4879,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2007
4880,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2007
4881,U-172,TREATMENT OF GENITAL WARTS,2007
4882,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2007
4883,U-174,USE AS AN ANTIHISTAMINE AGENT,2007
4884,U-175,METHOD OF TREATING MALIGNANT TUMORS,2007
4885,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2007
4886,U-177,FUNGICIDE,2007
4887,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2007
4888,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2007
4889,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2007
4890,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2007
4891,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2007
4892,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2007
4893,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2007
4894,U-185,METHOD OF TREATING HYPERTENSION,2007
4895,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2007
4896,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2007
4897,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2007
4898,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2007
4899,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2007
4900,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2007
4901,U-192,USE IN TREATING ALLERGIC REACTIONS,2007
4902,U-193,PSORIASIS,2007
4903,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2007
4904,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2007
4905,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2007
4906,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2007
4907,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2007
4908,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2007
4909,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2007
4910,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2007
4911,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2007
4912,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2007
4913,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2007
4914,U-205,METHOD FOR TREATING HEARTBURN,2007
4915,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2007
4916,U-207,USE AS NASAL SPRAY,2007
4917,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2007
4918,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2007
4919,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2007
4920,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2007
4921,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2007
4922,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2007
4923,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2007
4924,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2007
4925,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2007
4926,U-217,METHOD OF PRODUCING ANESTHESIA,2007
4927,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2007
4928,U-219,TREATMENT OF PARKINSON'S DISEASE,2007
4929,U-220,METHOD OF DIAGNOSIS,2007
4930,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2007
4931,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2007
4932,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2007
4933,U-224,CONTROLLING INTRAOCULAR PRESSURE,2007
4934,U-225,MEHTOD FOR DELIVERY,2007
4935,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2007
4936,U-227,NASAL ADMINISTRATION,2007
4937,U-228,ASTHMA,2007
4938,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2007
4939,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2007
4940,U-231,USE IN PARKINSON'S DISEASE,2007
4941,U-232,METHOD OF TREATING MIGRAINE,2007
4942,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2007
4943,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2007
4944,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2007
4945,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2007
4946,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2007
4947,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2007
4948,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2007
4949,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2007
4950,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2007
4951,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2007
4952,U-243,TOPICAL ADMINISTRATION,2007
4953,U-244,PLATELET AGGREGATION INHIBITORS,2007
4954,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2007
4955,U-246,PHOSPHATE BINDING,2007
4956,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2007
4957,U-248,TREATMENT OF HIV,2007
4958,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2007
4959,U-250,TREATMENT OF HEPATITIS B INFECTION,2007
4960,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2007
4961,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2007
4962,U-253,ORAL TRANSMUCOSAL USE,2007
4963,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2007
4964,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2007
4965,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2007
4966,U-257,TREATMENT OF HIV INFECTION,2007
4967,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2007
4968,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2007
4969,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2007
4970,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2007
4971,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2007
4972,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2007
4973,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2007
4974,U-265,USE AS LAXATIVE,2007
4975,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2007
4976,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2007
4977,U-268,ACROMEGALY,2007
4978,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2007
4979,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2007
4980,U-271,METHOD OF TREATING TUMORS,2007
4981,U-272,METHOD OF TREATING CARCINOMA,2007
4982,U-273,CUTANEOUS T-CELL LYMPHOMA,2007
4983,U-274,ZANAMIVIR FOR INHALATION,2007
4984,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2007
4985,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2007
4986,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2007
4987,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2007
4988,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2007
4989,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2007
4990,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2007
4991,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2007
4992,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2007
4993,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2007
4994,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2007
4995,U-286,DEPRESSION,2007
4996,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2007
4997,U-288,THERAPY OF INFLUENZA,2007
4998,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2007
4999,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2007
5000,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2007
5001,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2007
5002,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2007
5003,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2007
5004,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2007
5005,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2007
5006,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2007
5007,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2007
5008,U-299,TREATMENT OF ADENOMATOUS POLYPS,2007
5009,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2007
5010,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2007
5011,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2007
5012,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2007
5013,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2007
5014,U-305,METHODS FOR USING THE DRUG PRODUCT,2007
5015,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2007
5016,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2007
5017,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2007
5018,U-309,TREATING SJOEGREN SYNDROME,2007
5019,U-310,TREATMENT OF XEROSTOMIA,2007
5020,U-311,HORMONE REPLACEMENT,2007
5021,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2007
5022,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2007
5023,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2007
5024,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2007
5025,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2007
5026,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2007
5027,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2007
5028,U-319,TREATMENT OF MICROBIAL INFECTIONS,2007
5029,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2007
5030,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2007
5031,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2007
5032,U-323,USE AS A BILE ACID SEQUESTRANT,2007
5033,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2007
5034,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2007
5035,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2007
5036,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2007
5037,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2007
5038,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2007
5039,U-330,TREATMENT OF NAUSEA AND VOMITING,2007
5040,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2007
5041,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2007
5042,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2007
5043,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2007
5044,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2007
5045,U-336,DIAGNOSTIC RADIOIMAGING,2007
5046,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2007
5047,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2007
5048,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2007
5049,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2007
5050,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2007
5051,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2007
5052,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2007
5053,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2007
5054,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2007
5055,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2007
5056,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2007
5057,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2007
5058,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2007
5059,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2007
5060,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2007
5061,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2007
5062,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2007
5063,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2007
5064,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2007
5065,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2007
5066,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2007
5067,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2007
5068,U-359,METHOD OF USE OF VISICOL,2007
5069,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2007
5070,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2007
5071,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2007
5072,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2007
5073,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2007
5074,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2007
5075,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2007
5076,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2007
5077,U-368,HEARTBURN,2007
5078,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2007
5079,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2007
5080,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2007
5081,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2007
5082,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2007
5083,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2007
5084,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2007
5085,U-376,TREATMENT OF INFLUENZA,2007
5086,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2007
5087,U-378,METHOD FOR TREATING INCONTINENCE,2007
5088,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2007
5089,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2007
5090,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2007
5091,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2007
5092,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2007
5093,U-384,TREATMENT OF CMV RETINITIS,2007
5094,U-385,TREATMENT OF PEPTIC ULCERS,2007
5095,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2007
5096,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2007
5097,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2007
5098,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2007
5099,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2007
5100,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2007
5101,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2007
5102,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2007
5103,U-394,METHOD OF USE OF ALPHAGAN,2007
5104,U-395,METHOD OF USE OF ALPHAGAN P,2007
5105,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2007
5106,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2007
5107,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2007
5108,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2007
5109,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2007
5110,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2007
5111,U-402,TREATMENT OF ACTINIC KERATOSES,2007
5112,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2007
5113,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2007
5114,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2007
5115,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2007
5116,U-407,METHOD OF TREATING OTOPATHY,2007
5117,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2007
5118,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2007
5119,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2007
5120,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2007
5121,U-412,TREATMENT OF TYPE 2 DIABETES,2007
5122,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2007
5123,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2007
5124,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2007
5125,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2007
5126,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2007
5127,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2007
5128,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2007
5129,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2007
5130,U-421,USE FOR SEDATION,2007
5131,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2007
5132,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2007
5133,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2007
5134,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2007
5135,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2007
5136,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2007
5137,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2007
5138,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2007
5139,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2007
5140,U-431,POSTTRAUMATIC STRESS DISORDER,2007
5141,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2007
5142,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2007
5143,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2007
5144,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2007
5145,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2007
5146,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2007
5147,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2007
5148,U-439,TREATMENT OF OBESITY,2007
5149,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2007
5150,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2007
5151,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2007
5152,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2007
5153,U-444,TREATMENT OF MIGRAINE,2007
5154,U-445,USE AS AN ANTIMYCOTIC AGENT,2007
5155,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2007
5156,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2007
5157,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2007
5158,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2007
5159,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2007
5160,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2007
5161,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2007
5162,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2007
5163,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2007
5164,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2007
5165,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2007
5166,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2007
5167,U-458,METHOD OF USE OF IMAGENT,2007
5168,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2007
5169,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2007
5170,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2007
5171,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2007
5172,U-463,VENOGRAPHY,2007
5173,U-464,PERIPHERAL ARTERIOGRAPHY,2007
5174,U-465,CT IMAGING OF THE HEAD,2007
5175,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2007
5176,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2007
5177,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2007
5178,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2007
5179,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2007
5180,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2007
5181,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2007
5182,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2007
5183,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2007
5184,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2007
5185,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2007
5186,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2007
5187,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2007
5188,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2007
5189,U-480,CONTRAST AGENT FOR MRI,2007
5190,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2007
5191,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2007
5192,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2007
5193,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2007
5194,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2007
5195,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2007
5196,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2007
5197,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2007
5198,U-489,EXPECTORANT,2007
5199,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2007
5200,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2007
5201,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2007
5202,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2007
5203,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2007
5204,U-495,PERITONEAL DIALYSIS SOLUTION,2007
5205,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2007
5206,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2007
5207,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2007
5208,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2007
5209,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2007
5210,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2007
5211,U-502,PITYRIASIS VERSICOLOR,2007
5212,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2007
5213,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2007
5214,U-505,ULTRASOUND CONTRAST AGENT,2007
5215,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2007
5216,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2007
5217,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2007
5218,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2007
5219,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2007
5220,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2007
5221,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2007
5222,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2007
5223,U-514,PREVENTION OF OVULATION IN A WOMAN,2007
5224,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2007
5225,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2007
5226,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2007
5227,U-518,OBSESSIVE COMPULSIVE DISORDER,2007
5228,U-519,POST OPERATIVE NAUSEA AND VOMITING,2007
5229,U-520,PREMENOPAUSAL OSTEOPOROSIS,2007
5230,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2007
5231,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2007
5232,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2007
5233,U-524,METHOD OF TREATING DIARRHEA,2007
5234,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2007
5235,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2007
5236,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2007
5237,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2007
5238,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2007
5239,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2007
5240,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2007
5241,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2007
5242,U-533,ERECTILE DYSFUNCTION,2007
5243,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2007
5244,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2007
5245,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2007
5246,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2007
5247,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2007
5248,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2007
5249,U-540,TREATMENT OF FUNGAL INFECTIONS,2007
5250,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2007
5251,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2007
5252,U-543,TREATMENT OF SCHIZOPHRENIA,2007
5253,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2007
5254,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2007
5255,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2007
5256,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2007
5257,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2007
5258,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2007
5259,U-550,TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA,2007
5260,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2007
5261,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2007
5262,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2007
5263,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2007
5264,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2007
5265,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2007
5266,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2007
5267,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2007
5268,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2007
5269,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2007
5270,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2007
5271,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2007
5272,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2007
5273,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2007
5274,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2007
5275,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2007
5276,U-567,METHOD OF TREATING INFERTILITY,2007
5277,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2007
5278,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2007
5279,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2007
5280,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2007
5281,U-572,INTENSIVE CARE UNIT SEDATION,2007
5282,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2007
5283,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2007
5284,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2007
5285,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2007
5286,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2007
5287,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2007
5288,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2007
5289,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2007
5290,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2007
5291,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2007
5292,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2007
5293,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2007
5294,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2007
5295,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2007
5296,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2007
5297,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2007
5298,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2007
5299,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2007
5300,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2007
5301,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)",2007
5302,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2007
5303,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2007
5304,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
5305,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2007
5306,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2007
5307,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2007
5308,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2007
5309,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2007
5310,U-601,TREATMENT OF BIPOLAR DISORDERS,2007
5311,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2007
5312,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2007
5313,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2007
5314,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2007
5315,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2007
5316,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2007
5317,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2007
5318,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2007
5319,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2007
5320,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2007
5321,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2007
5322,U-613,REDUCTION OF SERUM PHOSPHATE,2007
5323,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2007
5324,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2007
5325,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2007
5326,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2007
5327,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB,NONHDL-C OR TG LEVELS;TO INCREASE HDL-C; AND TO TREAT PATIENTS WITH PRIMARY HYPERCHOLESTROLEMIA",2007
5328,U-619,TREATMENT OF MALIGNANT NEOPLASM,2007
5329,U-620,TREATMENT OF INSOMNIA,2007
5330,U-621,METHOD OF TREATING CANCER,2007
5331,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2007
5332,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2007
5333,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2007
5334,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2007
5335,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2007
5336,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2007
5337,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2007
5338,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2007
5339,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2007
5340,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2007
5341,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2007
5342,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2007
5343,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2007
5344,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2007
5345,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2007
5346,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2007
5347,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2007
5348,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2007
5349,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2007
5350,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2007
5351,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2007
5352,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2007
5353,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2007
5354,U-645,TREATMENT OF ASTHMA,2007
5355,U-646,METHOD OF TREATING OTITIS,2007
5356,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2007
5357,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2007
5358,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2007
5359,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2007
5360,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2007
5361,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2007
5362,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2007
5363,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2007
5364,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2007
5365,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2007
5366,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
5367,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2007
5368,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2007
5369,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2007
5370,U-661,TREATMENT OF SEIZURE DISORDER,2007
5371,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
5372,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2007
5373,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2007
5374,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2007
5375,U-666,METHOD OF TREATING ADHD,2007
5376,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2007
5377,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2007
5378,U-669,INDICATION OF TYPE II DIABETES,2007
5379,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2007
5380,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2007
5381,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2007
5382,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2007
5383,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2007
5384,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2007
5385,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2007
5386,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2007
5387,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2007
5388,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2007
5389,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2007
5390,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2007
5391,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2007
5392,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2007
5393,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2007
5394,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2007
5395,U-686,EXPECTORANT AND NASAL DECONGESTANT,2007
5396,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2007
5397,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2007
5398,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2007
5399,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2007
5400,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2007
5401,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2007
5402,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2007
5403,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2007
5404,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2007
5405,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2007
5406,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF 1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2007
5407,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2007
5408,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2007
5409,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2007
5410,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2007
5411,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2007
5412,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2007
5413,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2007
5414,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2007
5415,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2007
5416,U-707,ALLERGIC RHINITIS,2007
5417,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2007
5418,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2007
5419,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2007
5420,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2007
5421,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2007
5422,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2007
5423,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2007
5424,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2007
5425,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2007
5426,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2007
5427,U-718,TREATMENT OF FUNGAL INFECTIONS,2007
5428,U-719,TREATENT OF PSYCHOSIS,2007
5429,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2007
5430,U-721,TREATMENT OF INFLUENZA,2007
5431,U-722,PROPHYLAXIS OF INFLUENZA,2007
5432,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2007
5433,U-724,METHOD OF TREATING SEIZURES,2007
5434,U-725,ALLERGIC RHINITIS AND URTICARIA,2007
5435,U-726,ALLERGIC RHINITIS,2007
5436,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2007
5437,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2007
5438,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2007
5439,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2007
5440,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2007
5441,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2007
5442,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2007
5443,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2007
5444,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2007
5445,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2007
5446,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2007
5447,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2007
5448,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2007
5449,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2007
5450,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2007
5451,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2007
5452,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2007
5453,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2007
5454,U-745,TREATMENT OR PREVENTION OF EMESIS,2007
5455,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2007
5456,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2007
5457,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2007
5458,U-749,METHOD OF CONTRACEPTION,2007
5459,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2007
5460,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2007
5461,U-752,SUNSCREEN,2007
5462,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2007
5463,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2007
5464,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2007
5465,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2007
5466,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2007
5467,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2007
5468,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2007
5469,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2007
5470,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2007
5471,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2007
5472,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2007
5473,U-764,TREATMENT OF SCHIZOPHRENIA,2007
5474,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2007
5475,U-766,TREATMENT OF SEIZURES,2007
5476,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2007
5477,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2007
5478,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2007
5479,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2007
5480,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2007
5481,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2007
5482,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2007
5483,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2007
5484,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN OR A PPAR-GAMMA AGONIST,2007
5485,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2007
5486,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2007
5487,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSUE IN PATEINTS WITH OPEN ANGLE GLAUCOME OR OCULAR HYPERTENSION,2007
5488,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2007
5489,U-780,A METHOD FOR THE TREATMENT OF CANCER,2007
5490,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2007
5491,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2007
5492,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2007
5493,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2007
5494,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2007
5495,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2007
5496,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2007
5497,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2008
5498,U-1,PREVENTION OF PREGNANCY,2008
5499,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2008
5500,U-3,TREATMENT OF HYPERTENSION,2008
5501,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2008
5502,U-5,METHOD OF PRODUCING BRONCHODILATION,2008
5503,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2008
5504,U-7,INCREASING CARDIAC CONTRACTILITY,2008
5505,U-8,ACUTE MYOCARDIAL INFARCTION,2008
5506,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2008
5507,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2008
5508,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2008
5509,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2008
5510,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2008
5511,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2008
5512,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2008
5513,U-16,USE IN LUNG SCANNING PROCEDURES,2008
5514,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2008
5515,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2008
5516,U-19,TREATMENT OF INFLAMMATION,2008
5517,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2008
5518,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2008
5519,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2008
5520,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2008
5521,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2008
5522,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2008
5523,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2008
5524,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2008
5525,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2008
5526,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2008
5527,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2008
5528,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2008
5529,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2008
5530,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2008
5531,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2008
5532,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2008
5533,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2008
5534,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2008
5535,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2008
5536,U-39,ANGINA PECTORIS,2008
5537,U-40,METHOD OF TREATMENT OF BURNS,2008
5538,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2008
5539,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2008
5540,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2008
5541,U-44,RELIEF OF NAUSEA AND VOMITING,2008
5542,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2008
5543,U-46,TREATMENT OF PANIC DISORDER,2008
5544,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2008
5545,U-48,ANALGESIA,2008
5546,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2008
5547,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2008
5548,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2008
5549,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2008
5550,U-53,HYPERCALCEMIA OF MALIGNANCY,2008
5551,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2008
5552,U-55,TREATMENT OF PAIN,2008
5553,U-56,AID TO SMOKING CESSATION,2008
5554,U-57,OPHTHALMIC USE OF NORFLOXACIN,2008
5555,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2008
5556,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2008
5557,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2008
5558,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2008
5559,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2008
5560,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2008
5561,U-64,TREATMENT OF VIRAL INFECTIONS,2008
5562,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2008
5563,U-66,TRIPHASIC REGIMEN,2008
5564,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2008
5565,U-68,TREATMENT OF ACTINIC KERATOSIS,2008
5566,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2008
5567,U-70,TREATMENT OF TRANSIENT INSOMNIA,2008
5568,U-71,METHOD OF TREATMENT OF HEART FAILURE,2008
5569,U-72,TREATMENT OF MIGRAINE,2008
5570,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2008
5571,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2008
5572,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2008
5573,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2008
5574,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2008
5575,U-78,ULCERATIVE COLITIS,2008
5576,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2008
5577,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2008
5578,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2008
5579,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2008
5580,U-83,TREATMENT OF SEIZURES,2008
5581,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2008
5582,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2008
5583,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2008
5584,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2008
5585,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2008
5586,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2008
5587,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2008
5588,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2008
5589,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2008
5590,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2008
5591,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2008
5592,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2008
5593,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2008
5594,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2008
5595,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2008
5596,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2008
5597,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2008
5598,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2008
5599,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2008
5600,U-103,TREATMENT OF OCULAR HYPERTENSION,2008
5601,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2008
5602,U-105,EMESIS,2008
5603,U-106,TREATMENT OF EPILEPSY,2008
5604,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2008
5605,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2008
5606,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2008
5607,U-110,USE AS A RETRIEVABLE PERSSARY,2008
5608,U-111,DIABETES,2008
5609,U-112,CONTRACEPTION,2008
5610,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2008
5611,U-114,USE FOR INHIBITING BONE RESORPTION,2008
5612,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2008
5613,U-116,METHOD OF MYOCARDIAL IMAGING,2008
5614,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2008
5615,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2008
5616,U-119,TREATMENT OF NASAL HYPERSECRETION,2008
5617,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2008
5618,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2008
5619,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2008
5620,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2008
5621,U-124,TREATMENT OF ACNE,2008
5622,U-125,TREATMENT NEUROGENERATIVE DISEASES,2008
5623,U-126,TREATMENT OF GASTRITIS,2008
5624,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2008
5625,U-128,METHOD FOR TREATMENT OF TUMORS,2008
5626,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2008
5627,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2008
5628,U-131,PHOTODAMAGED SKIN,2008
5629,U-132,INHIBITING HIV PROTEASE,2008
5630,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED CALORIE DIET,2008
5631,U-134,TREATMENT OF ACNE VULGARIS,2008
5632,U-135,ANTITUMOR AGENT,2008
5633,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2008
5634,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2008
5635,U-138,TREATMENT OF ALLERGIC RHINITIS,2008
5636,U-139,TREATMENT OF ALLERGIC REACTIONS,2008
5637,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2008
5638,U-141,TREATMENT OF ULCERATIVE COLITIS,2008
5639,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2008
5640,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2008
5641,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2008
5642,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2008
5643,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2008
5644,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2008
5645,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2008
5646,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2008
5647,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2008
5648,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2008
5649,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2008
5650,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2008
5651,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2008
5652,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2008
5653,U-156,METHOD OF PROVIDING ANESTHESIA,2008
5654,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2008
5655,U-158,ANGINA,2008
5656,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2008
5657,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2008
5658,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2008
5659,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2008
5660,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2008
5661,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2008
5662,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2008
5663,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2008
5664,U-167,METHOD FOR TREATING HIV-1 INFECTION,2008
5665,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2008
5666,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2008
5667,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2008
5668,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2008
5669,U-172,TREATMENT OF GENITAL WARTS,2008
5670,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2008
5671,U-174,USE AS AN ANTIHISTAMINE AGENT,2008
5672,U-175,METHOD OF TREATING MALIGNANT TUMORS,2008
5673,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2008
5674,U-177,FUNGICIDE,2008
5675,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2008
5676,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2008
5677,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2008
5678,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2008
5679,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2008
5680,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2008
5681,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2008
5682,U-185,METHOD OF TREATING HYPERTENSION,2008
5683,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2008
5684,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2008
5685,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2008
5686,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2008
5687,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2008
5688,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2008
5689,U-192,USE IN TREATING ALLERGIC REACTIONS,2008
5690,U-193,PSORIASIS,2008
5691,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2008
5692,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2008
5693,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2008
5694,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2008
5695,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2008
5696,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2008
5697,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2008
5698,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2008
5699,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2008
5700,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2008
5701,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2008
5702,U-205,METHOD FOR TREATING HEARTBURN,2008
5703,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2008
5704,U-207,USE AS NASAL SPRAY,2008
5705,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2008
5706,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2008
5707,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2008
5708,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2008
5709,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2008
5710,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2008
5711,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2008
5712,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2008
5713,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2008
5714,U-217,METHOD OF PRODUCING ANESTHESIA,2008
5715,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2008
5716,U-219,TREATMENT OF PARKINSON'S DISEASE,2008
5717,U-220,METHOD OF DIAGNOSIS,2008
5718,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2008
5719,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2008
5720,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2008
5721,U-224,CONTROLLING INTRAOCULAR PRESSURE,2008
5722,U-225,MEHTOD FOR DELIVERY,2008
5723,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2008
5724,U-227,NASAL ADMINISTRATION,2008
5725,U-228,ASTHMA,2008
5726,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2008
5727,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2008
5728,U-231,USE IN PARKINSON'S DISEASE,2008
5729,U-232,METHOD OF TREATING MIGRAINE,2008
5730,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2008
5731,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2008
5732,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2008
5733,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2008
5734,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2008
5735,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2008
5736,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2008
5737,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2008
5738,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2008
5739,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2008
5740,U-243,TOPICAL ADMINISTRATION,2008
5741,U-244,PLATELET AGGREGATION INHIBITORS,2008
5742,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2008
5743,U-246,PHOSPHATE BINDING,2008
5744,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2008
5745,U-248,TREATMENT OF HIV,2008
5746,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2008
5747,U-250,TREATMENT OF HEPATITIS B INFECTION,2008
5748,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2008
5749,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2008
5750,U-253,ORAL TRANSMUCOSAL USE,2008
5751,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2008
5752,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2008
5753,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2008
5754,U-257,TREATMENT OF HIV INFECTION,2008
5755,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2008
5756,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2008
5757,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2008
5758,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2008
5759,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2008
5760,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2008
5761,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2008
5762,U-265,USE AS LAXATIVE,2008
5763,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2008
5764,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2008
5765,U-268,ACROMEGALY,2008
5766,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2008
5767,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2008
5768,U-271,METHOD OF TREATING TUMORS,2008
5769,U-272,METHOD OF TREATING CARCINOMA,2008
5770,U-273,CUTANEOUS T-CELL LYMPHOMA,2008
5771,U-274,ZANAMIVIR FOR INHALATION,2008
5772,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2008
5773,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2008
5774,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2008
5775,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2008
5776,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2008
5777,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2008
5778,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2008
5779,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2008
5780,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2008
5781,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2008
5782,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2008
5783,U-286,DEPRESSION,2008
5784,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2008
5785,U-288,THERAPY OF INFLUENZA,2008
5786,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2008
5787,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2008
5788,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2008
5789,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2008
5790,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2008
5791,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2008
5792,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2008
5793,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2008
5794,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2008
5795,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2008
5796,U-299,TREATMENT OF ADENOMATOUS POLYPS,2008
5797,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2008
5798,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2008
5799,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2008
5800,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2008
5801,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2008
5802,U-305,METHODS FOR USING THE DRUG PRODUCT,2008
5803,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2008
5804,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2008
5805,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2008
5806,U-309,TREATING SJOEGREN SYNDROME,2008
5807,U-310,TREATMENT OF XEROSTOMIA,2008
5808,U-311,HORMONE REPLACEMENT,2008
5809,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2008
5810,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2008
5811,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2008
5812,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2008
5813,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2008
5814,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2008
5815,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2008
5816,U-319,TREATMENT OF MICROBIAL INFECTIONS,2008
5817,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2008
5818,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2008
5819,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2008
5820,U-323,USE AS A BILE ACID SEQUESTRANT,2008
5821,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2008
5822,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2008
5823,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2008
5824,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2008
5825,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2008
5826,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2008
5827,U-330,TREATMENT OF NAUSEA AND VOMITING,2008
5828,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2008
5829,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2008
5830,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2008
5831,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2008
5832,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2008
5833,U-336,DIAGNOSTIC RADIOIMAGING,2008
5834,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2008
5835,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2008
5836,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2008
5837,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2008
5838,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2008
5839,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2008
5840,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2008
5841,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2008
5842,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2008
5843,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2008
5844,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2008
5845,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2008
5846,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2008
5847,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2008
5848,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2008
5849,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2008
5850,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2008
5851,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2008
5852,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2008
5853,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2008
5854,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2008
5855,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2008
5856,U-359,METHOD OF USE OF VISICOL,2008
5857,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2008
5858,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2008
5859,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2008
5860,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2008
5861,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2008
5862,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2008
5863,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2008
5864,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2008
5865,U-368,HEARTBURN,2008
5866,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2008
5867,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2008
5868,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2008
5869,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2008
5870,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2008
5871,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2008
5872,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2008
5873,U-376,TREATMENT OF INFLUENZA,2008
5874,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2008
5875,U-378,METHOD FOR TREATING INCONTINENCE,2008
5876,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2008
5877,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2008
5878,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2008
5879,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2008
5880,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2008
5881,U-384,TREATMENT OF CMV RETINITIS,2008
5882,U-385,TREATMENT OF PEPTIC ULCERS,2008
5883,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2008
5884,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2008
5885,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2008
5886,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2008
5887,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2008
5888,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2008
5889,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2008
5890,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2008
5891,U-394,METHOD OF USE OF ALPHAGAN,2008
5892,U-395,METHOD OF USE OF ALPHAGAN P,2008
5893,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2008
5894,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2008
5895,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2008
5896,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2008
5897,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2008
5898,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2008
5899,U-402,TREATMENT OF ACTINIC KERATOSES,2008
5900,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2008
5901,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2008
5902,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2008
5903,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2008
5904,U-407,METHOD OF TREATING OTOPATHY,2008
5905,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2008
5906,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2008
5907,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2008
5908,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2008
5909,U-412,TREATMENT OF TYPE 2 DIABETES,2008
5910,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2008
5911,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2008
5912,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2008
5913,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2008
5914,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2008
5915,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2008
5916,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2008
5917,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2008
5918,U-421,USE FOR SEDATION,2008
5919,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2008
5920,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2008
5921,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2008
5922,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2008
5923,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2008
5924,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2008
5925,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2008
5926,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2008
5927,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2008
5928,U-431,POSTTRAUMATIC STRESS DISORDER,2008
5929,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2008
5930,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2008
5931,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2008
5932,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2008
5933,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2008
5934,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2008
5935,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2008
5936,U-439,TREATMENT OF OBESITY,2008
5937,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2008
5938,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2008
5939,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2008
5940,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2008
5941,U-444,TREATMENT OF MIGRAINE,2008
5942,U-445,USE AS AN ANTIMYCOTIC AGENT,2008
5943,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2008
5944,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2008
5945,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2008
5946,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2008
5947,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2008
5948,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2008
5949,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2008
5950,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2008
5951,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2008
5952,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2008
5953,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2008
5954,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2008
5955,U-458,METHOD OF USE OF IMAGENT,2008
5956,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2008
5957,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2008
5958,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2008
5959,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2008
5960,U-463,VENOGRAPHY,2008
5961,U-464,PERIPHERAL ARTERIOGRAPHY,2008
5962,U-465,CT IMAGING OF THE HEAD,2008
5963,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2008
5964,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2008
5965,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2008
5966,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2008
5967,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2008
5968,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2008
5969,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2008
5970,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2008
5971,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2008
5972,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2008
5973,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2008
5974,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2008
5975,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2008
5976,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2008
5977,U-480,CONTRAST AGENT FOR MRI,2008
5978,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2008
5979,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2008
5980,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2008
5981,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2008
5982,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2008
5983,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2008
5984,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2008
5985,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2008
5986,U-489,EXPECTORANT,2008
5987,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2008
5988,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2008
5989,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2008
5990,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2008
5991,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2008
5992,U-495,PERITONEAL DIALYSIS SOLUTION,2008
5993,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2008
5994,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2008
5995,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2008
5996,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2008
5997,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2008
5998,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2008
5999,U-502,PITYRIASIS VERSICOLOR,2008
6000,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2008
6001,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2008
6002,U-505,ULTRASOUND CONTRAST AGENT,2008
6003,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2008
6004,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2008
6005,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2008
6006,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2008
6007,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2008
6008,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2008
6009,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2008
6010,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2008
6011,U-514,PREVENTION OF OVULATION IN A WOMAN,2008
6012,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2008
6013,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2008
6014,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2008
6015,U-518,OBSESSIVE COMPULSIVE DISORDER,2008
6016,U-519,POST OPERATIVE NAUSEA AND VOMITING,2008
6017,U-520,PREMENOPAUSAL OSTEOPOROSIS,2008
6018,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2008
6019,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2008
6020,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2008
6021,U-524,METHOD OF TREATING DIARRHEA,2008
6022,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2008
6023,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2008
6024,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2008
6025,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2008
6026,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2008
6027,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2008
6028,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2008
6029,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2008
6030,U-533,ERECTILE DYSFUNCTION,2008
6031,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2008
6032,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2008
6033,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2008
6034,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2008
6035,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2008
6036,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2008
6037,U-540,TREATMENT OF FUNGAL INFECTIONS,2008
6038,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2008
6039,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2008
6040,U-543,TREATMENT OF SCHIZOPHRENIA,2008
6041,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2008
6042,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2008
6043,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2008
6044,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2008
6045,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2008
6046,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2008
6047,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2008
6048,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2008
6049,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2008
6050,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2008
6051,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2008
6052,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2008
6053,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2008
6054,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2008
6055,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2008
6056,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2008
6057,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2008
6058,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2008
6059,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2008
6060,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2008
6061,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2008
6062,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2008
6063,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2008
6064,U-567,METHOD OF TREATING INFERTILITY,2008
6065,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2008
6066,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2008
6067,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2008
6068,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2008
6069,U-572,INTENSIVE CARE UNIT SEDATION,2008
6070,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2008
6071,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2008
6072,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2008
6073,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2008
6074,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2008
6075,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2008
6076,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2008
6077,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2008
6078,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2008
6079,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2008
6080,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2008
6081,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2008
6082,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2008
6083,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2008
6084,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2008
6085,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2008
6086,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2008
6087,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2008
6088,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2008
6089,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2008
6090,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2008
6091,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2008
6092,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6093,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2008
6094,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2008
6095,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2008
6096,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2008
6097,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2008
6098,U-601,TREATMENT OF BIPOLAR DISORDERS,2008
6099,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2008
6100,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2008
6101,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2008
6102,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2008
6103,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2008
6104,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2008
6105,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2008
6106,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2008
6107,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2008
6108,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2008
6109,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2008
6110,U-613,REDUCTION OF SERUM PHOSPHATE,2008
6111,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2008
6112,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2008
6113,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2008
6114,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2008
6115,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2008
6116,U-619,TREATMENT OF MALIGNANT NEOPLASM,2008
6117,U-620,TREATMENT OF INSOMNIA,2008
6118,U-621,METHOD OF TREATING CANCER,2008
6119,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2008
6120,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2008
6121,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2008
6122,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2008
6123,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2008
6124,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2008
6125,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2008
6126,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2008
6127,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2008
6128,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2008
6129,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2008
6130,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2008
6131,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2008
6132,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2008
6133,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2008
6134,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2008
6135,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2008
6136,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2008
6137,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2008
6138,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2008
6139,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2008
6140,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2008
6141,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2008
6142,U-645,TREATMENT OF ASTHMA,2008
6143,U-646,METHOD OF TREATING OTITIS,2008
6144,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2008
6145,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2008
6146,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2008
6147,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2008
6148,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2008
6149,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2008
6150,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2008
6151,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2008
6152,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2008
6153,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2008
6154,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6155,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2008
6156,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2008
6157,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2008
6158,U-661,TREATMENT OF SEIZURE DISORDER,2008
6159,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6160,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2008
6161,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2008
6162,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2008
6163,U-666,METHOD OF TREATING ADHD,2008
6164,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2008
6165,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2008
6166,U-669,INDICATION OF TYPE II DIABETES,2008
6167,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2008
6168,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2008
6169,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2008
6170,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2008
6171,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2008
6172,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2008
6173,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2008
6174,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2008
6175,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2008
6176,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2008
6177,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2008
6178,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2008
6179,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2008
6180,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2008
6181,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2008
6182,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2008
6183,U-686,EXPECTORANT AND NASAL DECONGESTANT,2008
6184,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2008
6185,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2008
6186,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2008
6187,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2008
6188,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2008
6189,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2008
6190,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2008
6191,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2008
6192,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2008
6193,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2008
6194,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF 1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2008
6195,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2008
6196,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2008
6197,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2008
6198,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2008
6199,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2008
6200,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2008
6201,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2008
6202,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2008
6203,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2008
6204,U-707,ALLERGIC RHINITIS,2008
6205,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2008
6206,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2008
6207,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2008
6208,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2008
6209,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2008
6210,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2008
6211,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2008
6212,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2008
6213,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2008
6214,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2008
6215,U-718,TREATMENT OF FUNGAL INFECTIONS,2008
6216,U-719,TREATENT OF PSYCHOSIS,2008
6217,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2008
6218,U-721,TREATMENT OF INFLUENZA,2008
6219,U-722,PROPHYLAXIS OF INFLUENZA,2008
6220,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2008
6221,U-724,METHOD OF TREATING SEIZURES,2008
6222,U-725,ALLERGIC RHINITIS AND URTICARIA,2008
6223,U-726,ALLERGIC RHINITIS,2008
6224,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2008
6225,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2008
6226,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2008
6227,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2008
6228,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2008
6229,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2008
6230,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2008
6231,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2008
6232,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2008
6233,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2008
6234,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2008
6235,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2008
6236,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2008
6237,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2008
6238,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2008
6239,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2008
6240,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2008
6241,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2008
6242,U-745,TREATMENT OR PREVENTION OF EMESIS,2008
6243,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2008
6244,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2008
6245,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2008
6246,U-749,METHOD OF CONTRACEPTION,2008
6247,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2008
6248,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2008
6249,U-752,SUNSCREEN,2008
6250,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2008
6251,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2008
6252,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2008
6253,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2008
6254,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2008
6255,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2008
6256,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2008
6257,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2008
6258,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2008
6259,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2008
6260,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2008
6261,U-764,TREATMENT OF SCHIZOPHRENIA,2008
6262,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2008
6263,U-766,TREATMENT OF SEIZURES,2008
6264,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2008
6265,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2008
6266,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2008
6267,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2008
6268,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2008
6269,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2008
6270,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2008
6271,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2008
6272,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2008
6273,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2008
6274,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2008
6275,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSUE IN PATEINTS WITH OPEN ANGLE GLAUCOME OR OCULAR HYPERTENSION,2008
6276,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2008
6277,U-780,A METHOD FOR THE TREATMENT OF CANCER,2008
6278,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2008
6279,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2008
6280,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2008
6281,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2008
6282,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2008
6283,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2008
6284,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2008
6285,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2008
6286,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2008
6287,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2008
6288,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2008
6289,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2008
6290,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2008
6291,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2008
6292,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2008
6293,U-796,METHOD OF TREATING DEPRESSION,2008
6294,U-797,METHOD OF TREATING ANXIETY,2008
6295,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2008
6296,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2008
6297,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2008
6298,U-801,METHOD OF TREATING CANCER,2008
6299,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2008
6300,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2008
6301,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2008
6302,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2008
6303,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2008
6304,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2008
6305,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2008
6306,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2008
6307,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2008
6308,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2008
6309,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2008
6310,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2008
6311,U-814,TREATMENT OF SCHIZOPHRENIA,2008
6312,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2008
6313,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2008
6314,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2008
6315,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2008
6316,U-819,MANAGEMENT OF FIBROMYALGIA,2008
6317,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2008
6318,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2008
6319,U-822,USE IN LIPID MANAGEMENT,2008
6320,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2008
6321,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2008
6322,U-825,USE FOR PREVENTION OF BREAST CANCER,2008
6323,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2008
6324,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2008
6325,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2008
6326,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2008
6327,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2008
6328,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2008
6329,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2008
6330,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2008
6331,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2008
6332,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2008
6333,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2008
6334,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2008
6335,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2008
6336,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2008
6337,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2008
6338,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2008
6339,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2009
6340,U-1,PREVENTION OF PREGNANCY,2009
6341,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2009
6342,U-3,TREATMENT OF HYPERTENSION,2009
6343,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2009
6344,U-5,METHOD OF PRODUCING BRONCHODILATION,2009
6345,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2009
6346,U-7,INCREASING CARDIAC CONTRACTILITY,2009
6347,U-8,ACUTE MYOCARDIAL INFARCTION,2009
6348,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2009
6349,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2009
6350,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2009
6351,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2009
6352,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2009
6353,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2009
6354,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2009
6355,U-16,USE IN LUNG SCANNING PROCEDURES,2009
6356,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2009
6357,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2009
6358,U-19,TREATMENT OF INFLAMMATION,2009
6359,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2009
6360,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2009
6361,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2009
6362,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2009
6363,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2009
6364,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2009
6365,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2009
6366,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2009
6367,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2009
6368,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2009
6369,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2009
6370,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2009
6371,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2009
6372,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2009
6373,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2009
6374,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2009
6375,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2009
6376,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2009
6377,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2009
6378,U-39,ANGINA PECTORIS,2009
6379,U-40,METHOD OF TREATMENT OF BURNS,2009
6380,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2009
6381,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2009
6382,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2009
6383,U-44,RELIEF OF NAUSEA AND VOMITING,2009
6384,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2009
6385,U-46,TREATMENT OF PANIC DISORDER,2009
6386,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2009
6387,U-48,ANALGESIA,2009
6388,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2009
6389,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2009
6390,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2009
6391,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2009
6392,U-53,HYPERCALCEMIA OF MALIGNANCY,2009
6393,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2009
6394,U-55,TREATMENT OF PAIN,2009
6395,U-56,AID TO SMOKING CESSATION,2009
6396,U-57,OPHTHALMIC USE OF NORFLOXACIN,2009
6397,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2009
6398,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2009
6399,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2009
6400,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2009
6401,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2009
6402,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2009
6403,U-64,TREATMENT OF VIRAL INFECTIONS,2009
6404,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2009
6405,U-66,TRIPHASIC REGIMEN,2009
6406,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2009
6407,U-68,TREATMENT OF ACTINIC KERATOSIS,2009
6408,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2009
6409,U-70,TREATMENT OF TRANSIENT INSOMNIA,2009
6410,U-71,METHOD OF TREATMENT OF HEART FAILURE,2009
6411,U-72,TREATMENT OF MIGRAINE,2009
6412,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2009
6413,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2009
6414,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2009
6415,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2009
6416,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2009
6417,U-78,ULCERATIVE COLITIS,2009
6418,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2009
6419,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2009
6420,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2009
6421,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2009
6422,U-83,TREATMENT OF SEIZURES,2009
6423,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2009
6424,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2009
6425,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2009
6426,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2009
6427,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2009
6428,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2009
6429,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2009
6430,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2009
6431,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2009
6432,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2009
6433,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2009
6434,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2009
6435,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2009
6436,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2009
6437,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2009
6438,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2009
6439,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2009
6440,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2009
6441,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2009
6442,U-103,TREATMENT OF OCULAR HYPERTENSION,2009
6443,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2009
6444,U-105,EMESIS,2009
6445,U-106,TREATMENT OF EPILEPSY,2009
6446,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2009
6447,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2009
6448,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2009
6449,U-110,USE AS A RETRIEVABLE PERSSARY,2009
6450,U-111,DIABETES,2009
6451,U-112,CONTRACEPTION,2009
6452,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2009
6453,U-114,USE FOR INHIBITING BONE RESORPTION,2009
6454,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2009
6455,U-116,METHOD OF MYOCARDIAL IMAGING,2009
6456,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2009
6457,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2009
6458,U-119,TREATMENT OF NASAL HYPERSECRETION,2009
6459,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2009
6460,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2009
6461,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2009
6462,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2009
6463,U-124,TREATMENT OF ACNE,2009
6464,U-125,TREATMENT NEUROGENERATIVE DISEASES,2009
6465,U-126,TREATMENT OF GASTRITIS,2009
6466,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2009
6467,U-128,METHOD FOR TREATMENT OF TUMORS,2009
6468,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2009
6469,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2009
6470,U-131,PHOTODAMAGED SKIN,2009
6471,U-132,INHIBITING HIV PROTEASE,2009
6472,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2009
6473,U-134,TREATMENT OF ACNE VULGARIS,2009
6474,U-135,ANTITUMOR AGENT,2009
6475,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2009
6476,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2009
6477,U-138,TREATMENT OF ALLERGIC RHINITIS,2009
6478,U-139,TREATMENT OF ALLERGIC REACTIONS,2009
6479,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2009
6480,U-141,TREATMENT OF ULCERATIVE COLITIS,2009
6481,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2009
6482,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2009
6483,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2009
6484,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2009
6485,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2009
6486,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2009
6487,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2009
6488,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2009
6489,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2009
6490,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2009
6491,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2009
6492,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2009
6493,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2009
6494,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2009
6495,U-156,METHOD OF PROVIDING ANESTHESIA,2009
6496,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2009
6497,U-158,ANGINA,2009
6498,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2009
6499,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2009
6500,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2009
6501,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2009
6502,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2009
6503,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2009
6504,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2009
6505,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2009
6506,U-167,METHOD FOR TREATING HIV-1 INFECTION,2009
6507,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2009
6508,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2009
6509,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2009
6510,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2009
6511,U-172,TREATMENT OF GENITAL WARTS,2009
6512,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2009
6513,U-174,USE AS AN ANTIHISTAMINE AGENT,2009
6514,U-175,METHOD OF TREATING MALIGNANT TUMORS,2009
6515,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2009
6516,U-177,FUNGICIDE,2009
6517,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2009
6518,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2009
6519,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2009
6520,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2009
6521,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2009
6522,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2009
6523,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2009
6524,U-185,METHOD OF TREATING HYPERTENSION,2009
6525,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2009
6526,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2009
6527,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2009
6528,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2009
6529,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2009
6530,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2009
6531,U-192,USE IN TREATING ALLERGIC REACTIONS,2009
6532,U-193,PSORIASIS,2009
6533,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2009
6534,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2009
6535,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2009
6536,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2009
6537,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2009
6538,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2009
6539,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2009
6540,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2009
6541,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2009
6542,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2009
6543,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2009
6544,U-205,METHOD FOR TREATING HEARTBURN,2009
6545,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2009
6546,U-207,USE AS NASAL SPRAY,2009
6547,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2009
6548,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2009
6549,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2009
6550,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2009
6551,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2009
6552,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2009
6553,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2009
6554,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2009
6555,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2009
6556,U-217,METHOD OF PRODUCING ANESTHESIA,2009
6557,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2009
6558,U-219,TREATMENT OF PARKINSON'S DISEASE,2009
6559,U-220,METHOD OF DIAGNOSIS,2009
6560,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2009
6561,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2009
6562,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2009
6563,U-224,CONTROLLING INTRAOCULAR PRESSURE,2009
6564,U-225,MEHTOD FOR DELIVERY,2009
6565,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2009
6566,U-227,NASAL ADMINISTRATION,2009
6567,U-228,ASTHMA,2009
6568,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2009
6569,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2009
6570,U-231,USE IN PARKINSON'S DISEASE,2009
6571,U-232,METHOD OF TREATING MIGRAINE,2009
6572,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2009
6573,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2009
6574,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2009
6575,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2009
6576,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2009
6577,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2009
6578,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2009
6579,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2009
6580,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2009
6581,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2009
6582,U-243,TOPICAL ADMINISTRATION,2009
6583,U-244,PLATELET AGGREGATION INHIBITORS,2009
6584,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2009
6585,U-246,PHOSPHATE BINDING,2009
6586,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2009
6587,U-248,TREATMENT OF HIV,2009
6588,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2009
6589,U-250,TREATMENT OF HEPATITIS B INFECTION,2009
6590,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2009
6591,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2009
6592,U-253,ORAL TRANSMUCOSAL USE,2009
6593,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2009
6594,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2009
6595,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2009
6596,U-257,TREATMENT OF HIV INFECTION,2009
6597,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2009
6598,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2009
6599,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2009
6600,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2009
6601,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2009
6602,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2009
6603,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2009
6604,U-265,USE AS LAXATIVE,2009
6605,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2009
6606,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2009
6607,U-268,ACROMEGALY,2009
6608,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2009
6609,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2009
6610,U-271,METHOD OF TREATING TUMORS,2009
6611,U-272,METHOD OF TREATING CARCINOMA,2009
6612,U-273,CUTANEOUS T-CELL LYMPHOMA,2009
6613,U-274,ZANAMIVIR FOR INHALATION,2009
6614,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2009
6615,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2009
6616,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2009
6617,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2009
6618,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2009
6619,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2009
6620,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2009
6621,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2009
6622,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2009
6623,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2009
6624,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2009
6625,U-286,DEPRESSION,2009
6626,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2009
6627,U-288,THERAPY OF INFLUENZA,2009
6628,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2009
6629,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2009
6630,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2009
6631,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2009
6632,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2009
6633,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2009
6634,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2009
6635,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2009
6636,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2009
6637,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2009
6638,U-299,TREATMENT OF ADENOMATOUS POLYPS,2009
6639,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2009
6640,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2009
6641,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2009
6642,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2009
6643,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2009
6644,U-305,METHODS FOR USING THE DRUG PRODUCT,2009
6645,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2009
6646,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2009
6647,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2009
6648,U-309,TREATING SJOEGREN SYNDROME,2009
6649,U-310,TREATMENT OF XEROSTOMIA,2009
6650,U-311,HORMONE REPLACEMENT,2009
6651,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2009
6652,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2009
6653,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2009
6654,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2009
6655,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2009
6656,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2009
6657,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2009
6658,U-319,TREATMENT OF MICROBIAL INFECTIONS,2009
6659,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2009
6660,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2009
6661,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2009
6662,U-323,USE AS A BILE ACID SEQUESTRANT,2009
6663,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2009
6664,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2009
6665,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2009
6666,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2009
6667,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2009
6668,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2009
6669,U-330,TREATMENT OF NAUSEA AND VOMITING,2009
6670,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2009
6671,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2009
6672,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2009
6673,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2009
6674,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2009
6675,U-336,DIAGNOSTIC RADIOIMAGING,2009
6676,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2009
6677,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2009
6678,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2009
6679,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2009
6680,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2009
6681,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2009
6682,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2009
6683,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2009
6684,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2009
6685,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2009
6686,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2009
6687,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2009
6688,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2009
6689,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2009
6690,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2009
6691,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2009
6692,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2009
6693,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2009
6694,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2009
6695,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2009
6696,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2009
6697,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2009
6698,U-359,METHOD OF USE OF VISICOL,2009
6699,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2009
6700,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2009
6701,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2009
6702,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2009
6703,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2009
6704,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2009
6705,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2009
6706,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2009
6707,U-368,HEARTBURN,2009
6708,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2009
6709,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2009
6710,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2009
6711,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2009
6712,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2009
6713,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2009
6714,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2009
6715,U-376,TREATMENT OF INFLUENZA,2009
6716,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2009
6717,U-378,METHOD FOR TREATING INCONTINENCE,2009
6718,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2009
6719,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2009
6720,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2009
6721,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2009
6722,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2009
6723,U-384,TREATMENT OF CMV RETINITIS,2009
6724,U-385,TREATMENT OF PEPTIC ULCERS,2009
6725,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2009
6726,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2009
6727,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2009
6728,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2009
6729,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2009
6730,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2009
6731,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2009
6732,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2009
6733,U-394,METHOD OF USE OF ALPHAGAN,2009
6734,U-395,METHOD OF USE OF ALPHAGAN P,2009
6735,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2009
6736,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2009
6737,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2009
6738,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2009
6739,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2009
6740,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2009
6741,U-402,TREATMENT OF ACTINIC KERATOSES,2009
6742,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2009
6743,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2009
6744,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2009
6745,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2009
6746,U-407,METHOD OF TREATING OTOPATHY,2009
6747,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2009
6748,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2009
6749,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2009
6750,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2009
6751,U-412,TREATMENT OF TYPE 2 DIABETES,2009
6752,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2009
6753,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2009
6754,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2009
6755,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2009
6756,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2009
6757,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2009
6758,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2009
6759,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2009
6760,U-421,USE FOR SEDATION,2009
6761,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2009
6762,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2009
6763,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2009
6764,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2009
6765,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2009
6766,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2009
6767,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2009
6768,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2009
6769,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2009
6770,U-431,POSTTRAUMATIC STRESS DISORDER,2009
6771,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2009
6772,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2009
6773,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2009
6774,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2009
6775,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2009
6776,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2009
6777,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2009
6778,U-439,TREATMENT OF OBESITY,2009
6779,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2009
6780,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2009
6781,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2009
6782,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2009
6783,U-444,TREATMENT OF MIGRAINE,2009
6784,U-445,USE AS AN ANTIMYCOTIC AGENT,2009
6785,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2009
6786,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2009
6787,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2009
6788,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2009
6789,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2009
6790,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2009
6791,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2009
6792,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2009
6793,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2009
6794,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2009
6795,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2009
6796,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2009
6797,U-458,METHOD OF USE OF IMAGENT,2009
6798,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2009
6799,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2009
6800,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2009
6801,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2009
6802,U-463,VENOGRAPHY,2009
6803,U-464,PERIPHERAL ARTERIOGRAPHY,2009
6804,U-465,CT IMAGING OF THE HEAD,2009
6805,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2009
6806,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2009
6807,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2009
6808,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2009
6809,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2009
6810,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2009
6811,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2009
6812,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2009
6813,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2009
6814,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2009
6815,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2009
6816,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2009
6817,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2009
6818,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2009
6819,U-480,CONTRAST AGENT FOR MRI,2009
6820,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2009
6821,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2009
6822,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2009
6823,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2009
6824,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2009
6825,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2009
6826,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2009
6827,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2009
6828,U-489,EXPECTORANT,2009
6829,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2009
6830,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2009
6831,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2009
6832,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2009
6833,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2009
6834,U-495,PERITONEAL DIALYSIS SOLUTION,2009
6835,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2009
6836,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2009
6837,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2009
6838,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2009
6839,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2009
6840,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2009
6841,U-502,PITYRIASIS VERSICOLOR,2009
6842,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2009
6843,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2009
6844,U-505,ULTRASOUND CONTRAST AGENT,2009
6845,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2009
6846,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2009
6847,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2009
6848,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2009
6849,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2009
6850,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2009
6851,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2009
6852,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2009
6853,U-514,PREVENTION OF OVULATION IN A WOMAN,2009
6854,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2009
6855,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2009
6856,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2009
6857,U-518,OBSESSIVE COMPULSIVE DISORDER,2009
6858,U-519,POST OPERATIVE NAUSEA AND VOMITING,2009
6859,U-520,PREMENOPAUSAL OSTEOPOROSIS,2009
6860,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2009
6861,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2009
6862,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2009
6863,U-524,METHOD OF TREATING DIARRHEA,2009
6864,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2009
6865,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2009
6866,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2009
6867,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2009
6868,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2009
6869,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2009
6870,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2009
6871,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2009
6872,U-533,ERECTILE DYSFUNCTION,2009
6873,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2009
6874,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2009
6875,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2009
6876,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2009
6877,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2009
6878,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2009
6879,U-540,TREATMENT OF FUNGAL INFECTIONS,2009
6880,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2009
6881,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2009
6882,U-543,TREATMENT OF SCHIZOPHRENIA,2009
6883,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2009
6884,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2009
6885,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2009
6886,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2009
6887,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2009
6888,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2009
6889,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2009
6890,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2009
6891,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2009
6892,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2009
6893,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2009
6894,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2009
6895,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2009
6896,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2009
6897,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2009
6898,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2009
6899,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2009
6900,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2009
6901,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2009
6902,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2009
6903,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2009
6904,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2009
6905,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2009
6906,U-567,METHOD OF TREATING INFERTILITY,2009
6907,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2009
6908,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2009
6909,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2009
6910,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2009
6911,U-572,INTENSIVE CARE UNIT SEDATION,2009
6912,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2009
6913,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2009
6914,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2009
6915,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2009
6916,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2009
6917,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2009
6918,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2009
6919,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2009
6920,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2009
6921,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2009
6922,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2009
6923,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2009
6924,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2009
6925,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2009
6926,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2009
6927,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2009
6928,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2009
6929,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2009
6930,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2009
6931,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2009
6932,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2009
6933,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2009
6934,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
6935,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2009
6936,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2009
6937,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2009
6938,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2009
6939,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2009
6940,U-601,TREATMENT OF BIPOLAR DISORDERS,2009
6941,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2009
6942,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2009
6943,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2009
6944,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2009
6945,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2009
6946,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2009
6947,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2009
6948,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2009
6949,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2009
6950,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2009
6951,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2009
6952,U-613,REDUCTION OF SERUM PHOSPHATE,2009
6953,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2009
6954,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2009
6955,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2009
6956,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2009
6957,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2009
6958,U-619,TREATMENT OF MALIGNANT NEOPLASM,2009
6959,U-620,TREATMENT OF INSOMNIA,2009
6960,U-621,METHOD OF TREATING CANCER,2009
6961,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2009
6962,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2009
6963,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2009
6964,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2009
6965,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2009
6966,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2009
6967,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2009
6968,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2009
6969,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2009
6970,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2009
6971,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2009
6972,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2009
6973,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2009
6974,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2009
6975,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2009
6976,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2009
6977,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2009
6978,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2009
6979,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2009
6980,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2009
6981,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2009
6982,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2009
6983,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2009
6984,U-645,TREATMENT OF ASTHMA,2009
6985,U-646,METHOD OF TREATING OTITIS,2009
6986,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2009
6987,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2009
6988,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2009
6989,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2009
6990,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2009
6991,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2009
6992,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2009
6993,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2009
6994,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2009
6995,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2009
6996,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
6997,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2009
6998,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2009
6999,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2009
7000,U-661,TREATMENT OF SEIZURE DISORDER,2009
7001,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
7002,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2009
7003,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2009
7004,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2009
7005,U-666,METHOD OF TREATING ADHD,2009
7006,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2009
7007,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2009
7008,U-669,INDICATION OF TYPE II DIABETES,2009
7009,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2009
7010,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2009
7011,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2009
7012,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2009
7013,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2009
7014,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2009
7015,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2009
7016,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2009
7017,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2009
7018,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2009
7019,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2009
7020,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2009
7021,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2009
7022,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2009
7023,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2009
7024,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2009
7025,U-686,EXPECTORANT AND NASAL DECONGESTANT,2009
7026,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2009
7027,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2009
7028,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2009
7029,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2009
7030,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2009
7031,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2009
7032,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2009
7033,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2009
7034,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2009
7035,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2009
7036,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2009
7037,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2009
7038,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2009
7039,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2009
7040,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2009
7041,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2009
7042,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2009
7043,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2009
7044,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2009
7045,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2009
7046,U-707,ALLERGIC RHINITIS,2009
7047,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2009
7048,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2009
7049,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2009
7050,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2009
7051,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2009
7052,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2009
7053,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2009
7054,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2009
7055,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2009
7056,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2009
7057,U-718,TREATMENT OF FUNGAL INFECTIONS,2009
7058,U-719,TREATENT OF PSYCHOSIS,2009
7059,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2009
7060,U-721,TREATMENT OF INFLUENZA,2009
7061,U-722,PROPHYLAXIS OF INFLUENZA,2009
7062,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2009
7063,U-724,METHOD OF TREATING SEIZURES,2009
7064,U-725,ALLERGIC RHINITIS AND URTICARIA,2009
7065,U-726,ALLERGIC RHINITIS,2009
7066,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2009
7067,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2009
7068,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2009
7069,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2009
7070,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2009
7071,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2009
7072,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2009
7073,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2009
7074,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2009
7075,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2009
7076,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2009
7077,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2009
7078,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2009
7079,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2009
7080,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2009
7081,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2009
7082,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2009
7083,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2009
7084,U-745,TREATMENT OR PREVENTION OF EMESIS,2009
7085,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2009
7086,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2009
7087,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2009
7088,U-749,METHOD OF CONTRACEPTION,2009
7089,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2009
7090,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2009
7091,U-752,SUNSCREEN,2009
7092,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2009
7093,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2009
7094,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2009
7095,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2009
7096,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2009
7097,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2009
7098,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2009
7099,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2009
7100,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2009
7101,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2009
7102,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2009
7103,U-764,TREATMENT OF SCHIZOPHRENIA,2009
7104,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2009
7105,U-766,TREATMENT OF SEIZURES,2009
7106,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2009
7107,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2009
7108,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2009
7109,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2009
7110,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2009
7111,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2009
7112,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2009
7113,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2009
7114,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2009
7115,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2009
7116,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2009
7117,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSUE IN PATEINTS WITH OPEN ANGLE GLAUCOME OR OCULAR HYPERTENSION,2009
7118,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2009
7119,U-780,A METHOD FOR THE TREATMENT OF CANCER,2009
7120,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2009
7121,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2009
7122,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2009
7123,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2009
7124,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2009
7125,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2009
7126,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2009
7127,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2009
7128,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2009
7129,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2009
7130,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2009
7131,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2009
7132,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2009
7133,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2009
7134,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2009
7135,U-796,METHOD OF TREATING DEPRESSION,2009
7136,U-797,METHOD OF TREATING ANXIETY,2009
7137,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2009
7138,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2009
7139,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2009
7140,U-801,METHOD OF TREATING CANCER,2009
7141,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2009
7142,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2009
7143,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2009
7144,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2009
7145,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2009
7146,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2009
7147,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2009
7148,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2009
7149,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2009
7150,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2009
7151,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2009
7152,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2009
7153,U-814,TREATMENT OF SCHIZOPHRENIA,2009
7154,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2009
7155,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2009
7156,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2009
7157,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2009
7158,U-819,MANAGEMENT OF FIBROMYALGIA,2009
7159,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2009
7160,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2009
7161,U-822,USE IN LIPID MANAGEMENT,2009
7162,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2009
7163,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2009
7164,U-825,USE FOR PREVENTION OF BREAST CANCER,2009
7165,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2009
7166,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2009
7167,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2009
7168,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2009
7169,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2009
7170,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2009
7171,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2009
7172,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2009
7173,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2009
7174,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2009
7175,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2009
7176,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2009
7177,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2009
7178,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2009
7179,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2009
7180,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2009
7181,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2009
7182,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2009
7183,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2009
7184,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2009
7185,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2009
7186,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2009
7187,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2009
7188,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2009
7189,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2009
7190,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2009
7191,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2009
7192,U-853,TREATMENT OR PREVENTION OF EMESIS,2009
7193,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2009
7194,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2009
7195,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2009
7196,U-857,INHIBITION OF TRANSPLANT REJECTION,2009
7197,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2009
7198,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2009
7199,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2009
7200,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2009
7201,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2009
7202,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2009
7203,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2009
7204,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2009
7205,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2009
7206,U-867,TREATMENT OF MIGRAINE,2009
7207,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2009
7208,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2009
7209,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2009
7210,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2009
7211,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2009
7212,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2009
7213,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2009
7214,U-875,FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2009
7215,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2009
7216,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2009
7217,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2009
7218,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2009
7219,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2009
7220,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2009
7221,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2009
7222,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2009
7223,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2009
7224,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2009
7225,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2009
7226,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2009
7227,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMENï¿½,2009
7228,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2009
7229,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2009
7230,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2009
7231,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2009
7232,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2009
7233,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2009
7234,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2009
7235,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2009
7236,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2009
7237,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2009
7238,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2009
7239,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2009
7240,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2009
7241,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2009
7242,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2009
7243,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2009
7244,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2009
7245,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2009
7246,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2009
7247,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2009
7248,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2009
7249,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2009
7250,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2009
7251,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2009
7252,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2009
7253,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2009
7254,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2009
7255,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2009
7256,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2009
7257,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2009
7258,U-919,FOR THE TREATMENT OF DERMATITIS,2009
7259,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2009
7260,U-921,TREATMENT OF ACNE VULGARIS,2009
7261,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2009
7262,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2009
7263,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2009
7264,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2009
7265,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2009
7266,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2009
7267,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2009
7268,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2009
7269,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2009
7270,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2009
7271,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2009
7272,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2009
7273,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2009
7274,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2009
7275,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2009
7276,U-937,TREATMENT OF PROSTATE CANCER,2009
7277,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2009
7278,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2009
7279,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMAï¿½,2009
7280,U-941,METHOD TO TREAT OVARIAN CANCER,2009
7281,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2009
7282,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2010
7283,U-1,PREVENTION OF PREGNANCY,2010
7284,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2010
7285,U-3,TREATMENT OF HYPERTENSION,2010
7286,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2010
7287,U-5,METHOD OF PRODUCING BRONCHODILATION,2010
7288,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2010
7289,U-7,INCREASING CARDIAC CONTRACTILITY,2010
7290,U-8,ACUTE MYOCARDIAL INFARCTION,2010
7291,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2010
7292,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2010
7293,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2010
7294,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2010
7295,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2010
7296,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2010
7297,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2010
7298,U-16,USE IN LUNG SCANNING PROCEDURES,2010
7299,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2010
7300,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2010
7301,U-19,TREATMENT OF INFLAMMATION,2010
7302,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2010
7303,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2010
7304,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2010
7305,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2010
7306,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2010
7307,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2010
7308,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2010
7309,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2010
7310,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2010
7311,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2010
7312,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2010
7313,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2010
7314,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2010
7315,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2010
7316,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2010
7317,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2010
7318,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2010
7319,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2010
7320,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2010
7321,U-39,ANGINA PECTORIS,2010
7322,U-40,METHOD OF TREATMENT OF BURNS,2010
7323,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2010
7324,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2010
7325,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2010
7326,U-44,RELIEF OF NAUSEA AND VOMITING,2010
7327,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2010
7328,U-46,TREATMENT OF PANIC DISORDER,2010
7329,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2010
7330,U-48,ANALGESIA,2010
7331,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2010
7332,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2010
7333,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2010
7334,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2010
7335,U-53,HYPERCALCEMIA OF MALIGNANCY,2010
7336,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2010
7337,U-55,TREATMENT OF PAIN,2010
7338,U-56,AID TO SMOKING CESSATION,2010
7339,U-57,OPHTHALMIC USE OF NORFLOXACIN,2010
7340,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2010
7341,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2010
7342,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2010
7343,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2010
7344,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2010
7345,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2010
7346,U-64,TREATMENT OF VIRAL INFECTIONS,2010
7347,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2010
7348,U-66,TRIPHASIC REGIMEN,2010
7349,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2010
7350,U-68,TREATMENT OF ACTINIC KERATOSIS,2010
7351,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2010
7352,U-70,TREATMENT OF TRANSIENT INSOMNIA,2010
7353,U-71,METHOD OF TREATMENT OF HEART FAILURE,2010
7354,U-72,TREATMENT OF MIGRAINE,2010
7355,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2010
7356,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2010
7357,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2010
7358,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2010
7359,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2010
7360,U-78,ULCERATIVE COLITIS,2010
7361,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2010
7362,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2010
7363,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2010
7364,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2010
7365,U-83,TREATMENT OF SEIZURES,2010
7366,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2010
7367,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2010
7368,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2010
7369,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2010
7370,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2010
7371,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2010
7372,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2010
7373,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2010
7374,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2010
7375,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2010
7376,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2010
7377,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2010
7378,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2010
7379,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2010
7380,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2010
7381,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2010
7382,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2010
7383,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2010
7384,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2010
7385,U-103,TREATMENT OF OCULAR HYPERTENSION,2010
7386,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2010
7387,U-105,EMESIS,2010
7388,U-106,TREATMENT OF EPILEPSY,2010
7389,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2010
7390,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2010
7391,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2010
7392,U-110,USE AS A RETRIEVABLE PERSSARY,2010
7393,U-111,DIABETES,2010
7394,U-112,CONTRACEPTION,2010
7395,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2010
7396,U-114,USE FOR INHIBITING BONE RESORPTION,2010
7397,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2010
7398,U-116,METHOD OF MYOCARDIAL IMAGING,2010
7399,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2010
7400,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2010
7401,U-119,TREATMENT OF NASAL HYPERSECRETION,2010
7402,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2010
7403,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2010
7404,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2010
7405,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2010
7406,U-124,TREATMENT OF ACNE,2010
7407,U-125,TREATMENT NEUROGENERATIVE DISEASES,2010
7408,U-126,TREATMENT OF GASTRITIS,2010
7409,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2010
7410,U-128,METHOD FOR TREATMENT OF TUMORS,2010
7411,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2010
7412,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2010
7413,U-131,PHOTODAMAGED SKIN,2010
7414,U-132,INHIBITING HIV PROTEASE,2010
7415,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2010
7416,U-134,TREATMENT OF ACNE VULGARIS,2010
7417,U-135,ANTITUMOR AGENT,2010
7418,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2010
7419,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2010
7420,U-138,TREATMENT OF ALLERGIC RHINITIS,2010
7421,U-139,TREATMENT OF ALLERGIC REACTIONS,2010
7422,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2010
7423,U-141,TREATMENT OF ULCERATIVE COLITIS,2010
7424,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2010
7425,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2010
7426,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2010
7427,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2010
7428,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2010
7429,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2010
7430,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2010
7431,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2010
7432,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2010
7433,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2010
7434,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2010
7435,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2010
7436,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2010
7437,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2010
7438,U-156,METHOD OF PROVIDING ANESTHESIA,2010
7439,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2010
7440,U-158,ANGINA,2010
7441,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2010
7442,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2010
7443,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2010
7444,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2010
7445,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2010
7446,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2010
7447,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2010
7448,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2010
7449,U-167,METHOD FOR TREATING HIV-1 INFECTION,2010
7450,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2010
7451,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2010
7452,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2010
7453,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2010
7454,U-172,TREATMENT OF GENITAL WARTS,2010
7455,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2010
7456,U-174,USE AS AN ANTIHISTAMINE AGENT,2010
7457,U-175,METHOD OF TREATING MALIGNANT TUMORS,2010
7458,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2010
7459,U-177,FUNGICIDE,2010
7460,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2010
7461,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2010
7462,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2010
7463,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2010
7464,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2010
7465,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2010
7466,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2010
7467,U-185,METHOD OF TREATING HYPERTENSION,2010
7468,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2010
7469,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2010
7470,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2010
7471,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2010
7472,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2010
7473,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2010
7474,U-192,USE IN TREATING ALLERGIC REACTIONS,2010
7475,U-193,PSORIASIS,2010
7476,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2010
7477,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2010
7478,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2010
7479,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2010
7480,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2010
7481,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2010
7482,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2010
7483,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2010
7484,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2010
7485,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2010
7486,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2010
7487,U-205,METHOD FOR TREATING HEARTBURN,2010
7488,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2010
7489,U-207,USE AS NASAL SPRAY,2010
7490,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2010
7491,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2010
7492,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2010
7493,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2010
7494,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2010
7495,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2010
7496,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2010
7497,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2010
7498,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2010
7499,U-217,METHOD OF PRODUCING ANESTHESIA,2010
7500,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2010
7501,U-219,TREATMENT OF PARKINSON'S DISEASE,2010
7502,U-220,METHOD OF DIAGNOSIS,2010
7503,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2010
7504,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2010
7505,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2010
7506,U-224,CONTROLLING INTRAOCULAR PRESSURE,2010
7507,U-225,MEHTOD FOR DELIVERY,2010
7508,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2010
7509,U-227,NASAL ADMINISTRATION,2010
7510,U-228,ASTHMA,2010
7511,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2010
7512,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2010
7513,U-231,USE IN PARKINSON'S DISEASE,2010
7514,U-232,METHOD OF TREATING MIGRAINE,2010
7515,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2010
7516,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2010
7517,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2010
7518,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2010
7519,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2010
7520,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2010
7521,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2010
7522,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2010
7523,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2010
7524,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2010
7525,U-243,TOPICAL ADMINISTRATION,2010
7526,U-244,PLATELET AGGREGATION INHIBITORS,2010
7527,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2010
7528,U-246,PHOSPHATE BINDING,2010
7529,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2010
7530,U-248,TREATMENT OF HIV,2010
7531,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2010
7532,U-250,TREATMENT OF HEPATITIS B INFECTION,2010
7533,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2010
7534,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2010
7535,U-253,ORAL TRANSMUCOSAL USE,2010
7536,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2010
7537,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2010
7538,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2010
7539,U-257,TREATMENT OF HIV INFECTION,2010
7540,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2010
7541,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2010
7542,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2010
7543,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2010
7544,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2010
7545,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2010
7546,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2010
7547,U-265,USE AS LAXATIVE,2010
7548,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2010
7549,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2010
7550,U-268,ACROMEGALY,2010
7551,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2010
7552,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2010
7553,U-271,METHOD OF TREATING TUMORS,2010
7554,U-272,METHOD OF TREATING CARCINOMA,2010
7555,U-273,CUTANEOUS T-CELL LYMPHOMA,2010
7556,U-274,ZANAMIVIR FOR INHALATION,2010
7557,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2010
7558,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2010
7559,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2010
7560,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2010
7561,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2010
7562,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2010
7563,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2010
7564,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2010
7565,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2010
7566,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2010
7567,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2010
7568,U-286,DEPRESSION,2010
7569,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2010
7570,U-288,THERAPY OF INFLUENZA,2010
7571,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2010
7572,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2010
7573,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2010
7574,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2010
7575,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2010
7576,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2010
7577,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2010
7578,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2010
7579,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2010
7580,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2010
7581,U-299,TREATMENT OF ADENOMATOUS POLYPS,2010
7582,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2010
7583,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2010
7584,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2010
7585,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2010
7586,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2010
7587,U-305,METHODS FOR USING THE DRUG PRODUCT,2010
7588,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2010
7589,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2010
7590,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2010
7591,U-309,TREATING SJOEGREN SYNDROME,2010
7592,U-310,TREATMENT OF XEROSTOMIA,2010
7593,U-311,HORMONE REPLACEMENT,2010
7594,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2010
7595,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2010
7596,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2010
7597,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2010
7598,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2010
7599,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2010
7600,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2010
7601,U-319,TREATMENT OF MICROBIAL INFECTIONS,2010
7602,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2010
7603,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2010
7604,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2010
7605,U-323,USE AS A BILE ACID SEQUESTRANT,2010
7606,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2010
7607,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2010
7608,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2010
7609,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2010
7610,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2010
7611,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2010
7612,U-330,TREATMENT OF NAUSEA AND VOMITING,2010
7613,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2010
7614,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2010
7615,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2010
7616,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2010
7617,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2010
7618,U-336,DIAGNOSTIC RADIOIMAGING,2010
7619,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2010
7620,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2010
7621,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2010
7622,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2010
7623,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2010
7624,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2010
7625,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2010
7626,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2010
7627,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2010
7628,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2010
7629,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2010
7630,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2010
7631,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2010
7632,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2010
7633,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2010
7634,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2010
7635,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2010
7636,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2010
7637,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2010
7638,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2010
7639,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2010
7640,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2010
7641,U-359,METHOD OF USE OF VISICOL,2010
7642,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2010
7643,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2010
7644,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2010
7645,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2010
7646,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2010
7647,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2010
7648,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2010
7649,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2010
7650,U-368,HEARTBURN,2010
7651,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2010
7652,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2010
7653,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2010
7654,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2010
7655,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2010
7656,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2010
7657,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2010
7658,U-376,TREATMENT OF INFLUENZA,2010
7659,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2010
7660,U-378,METHOD FOR TREATING INCONTINENCE,2010
7661,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2010
7662,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2010
7663,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2010
7664,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2010
7665,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2010
7666,U-384,TREATMENT OF CMV RETINITIS,2010
7667,U-385,TREATMENT OF PEPTIC ULCERS,2010
7668,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2010
7669,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2010
7670,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2010
7671,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2010
7672,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2010
7673,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2010
7674,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2010
7675,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2010
7676,U-394,METHOD OF USE OF ALPHAGAN,2010
7677,U-395,METHOD OF USE OF ALPHAGAN P,2010
7678,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2010
7679,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2010
7680,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2010
7681,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2010
7682,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2010
7683,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2010
7684,U-402,TREATMENT OF ACTINIC KERATOSES,2010
7685,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2010
7686,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2010
7687,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2010
7688,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2010
7689,U-407,METHOD OF TREATING OTOPATHY,2010
7690,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2010
7691,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2010
7692,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2010
7693,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2010
7694,U-412,TREATMENT OF TYPE 2 DIABETES,2010
7695,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2010
7696,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2010
7697,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2010
7698,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2010
7699,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2010
7700,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2010
7701,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2010
7702,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2010
7703,U-421,USE FOR SEDATION,2010
7704,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2010
7705,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2010
7706,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2010
7707,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2010
7708,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2010
7709,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2010
7710,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2010
7711,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2010
7712,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2010
7713,U-431,POSTTRAUMATIC STRESS DISORDER,2010
7714,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2010
7715,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2010
7716,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2010
7717,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2010
7718,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2010
7719,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2010
7720,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2010
7721,U-439,TREATMENT OF OBESITY,2010
7722,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2010
7723,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2010
7724,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2010
7725,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2010
7726,U-444,TREATMENT OF MIGRAINE,2010
7727,U-445,USE AS AN ANTIMYCOTIC AGENT,2010
7728,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2010
7729,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2010
7730,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2010
7731,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2010
7732,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2010
7733,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2010
7734,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2010
7735,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2010
7736,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2010
7737,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2010
7738,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2010
7739,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2010
7740,U-458,METHOD OF USE OF IMAGENT,2010
7741,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2010
7742,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2010
7743,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2010
7744,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2010
7745,U-463,VENOGRAPHY,2010
7746,U-464,PERIPHERAL ARTERIOGRAPHY,2010
7747,U-465,CT IMAGING OF THE HEAD,2010
7748,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2010
7749,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2010
7750,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2010
7751,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2010
7752,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2010
7753,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2010
7754,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2010
7755,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2010
7756,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2010
7757,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2010
7758,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2010
7759,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2010
7760,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2010
7761,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2010
7762,U-480,CONTRAST AGENT FOR MRI,2010
7763,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2010
7764,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2010
7765,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2010
7766,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2010
7767,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2010
7768,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2010
7769,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2010
7770,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2010
7771,U-489,EXPECTORANT,2010
7772,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2010
7773,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2010
7774,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2010
7775,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2010
7776,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2010
7777,U-495,PERITONEAL DIALYSIS SOLUTION,2010
7778,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2010
7779,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2010
7780,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2010
7781,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2010
7782,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2010
7783,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2010
7784,U-502,PITYRIASIS VERSICOLOR,2010
7785,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2010
7786,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2010
7787,U-505,ULTRASOUND CONTRAST AGENT,2010
7788,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2010
7789,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2010
7790,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2010
7791,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2010
7792,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2010
7793,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2010
7794,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2010
7795,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2010
7796,U-514,PREVENTION OF OVULATION IN A WOMAN,2010
7797,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2010
7798,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2010
7799,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2010
7800,U-518,OBSESSIVE COMPULSIVE DISORDER,2010
7801,U-519,POST OPERATIVE NAUSEA AND VOMITING,2010
7802,U-520,PREMENOPAUSAL OSTEOPOROSIS,2010
7803,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2010
7804,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2010
7805,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2010
7806,U-524,METHOD OF TREATING DIARRHEA,2010
7807,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2010
7808,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2010
7809,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2010
7810,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2010
7811,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2010
7812,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2010
7813,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2010
7814,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2010
7815,U-533,ERECTILE DYSFUNCTION,2010
7816,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2010
7817,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2010
7818,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2010
7819,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2010
7820,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2010
7821,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2010
7822,U-540,TREATMENT OF FUNGAL INFECTIONS,2010
7823,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2010
7824,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2010
7825,U-543,TREATMENT OF SCHIZOPHRENIA,2010
7826,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2010
7827,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2010
7828,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2010
7829,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2010
7830,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2010
7831,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2010
7832,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2010
7833,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2010
7834,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2010
7835,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2010
7836,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2010
7837,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2010
7838,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2010
7839,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2010
7840,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2010
7841,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2010
7842,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2010
7843,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2010
7844,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2010
7845,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2010
7846,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2010
7847,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2010
7848,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2010
7849,U-567,METHOD OF TREATING INFERTILITY,2010
7850,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2010
7851,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2010
7852,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2010
7853,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2010
7854,U-572,INTENSIVE CARE UNIT SEDATION,2010
7855,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2010
7856,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2010
7857,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2010
7858,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2010
7859,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2010
7860,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2010
7861,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2010
7862,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2010
7863,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2010
7864,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2010
7865,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2010
7866,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2010
7867,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2010
7868,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2010
7869,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2010
7870,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2010
7871,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2010
7872,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2010
7873,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2010
7874,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2010
7875,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2010
7876,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2010
7877,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
7878,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2010
7879,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2010
7880,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2010
7881,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2010
7882,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2010
7883,U-601,TREATMENT OF BIPOLAR DISORDER,2010
7884,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2010
7885,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2010
7886,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2010
7887,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2010
7888,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2010
7889,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2010
7890,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2010
7891,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2010
7892,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2010
7893,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2010
7894,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2010
7895,U-613,REDUCTION OF SERUM PHOSPHATE,2010
7896,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2010
7897,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2010
7898,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2010
7899,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2010
7900,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2010
7901,U-619,TREATMENT OF MALIGNANT NEOPLASM,2010
7902,U-620,TREATMENT OF INSOMNIA,2010
7903,U-621,METHOD OF TREATING CANCER,2010
7904,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2010
7905,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2010
7906,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2010
7907,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2010
7908,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2010
7909,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2010
7910,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2010
7911,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2010
7912,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2010
7913,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2010
7914,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2010
7915,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2010
7916,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2010
7917,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2010
7918,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2010
7919,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2010
7920,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2010
7921,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2010
7922,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2010
7923,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2010
7924,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2010
7925,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2010
7926,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2010
7927,U-645,TREATMENT OF ASTHMA,2010
7928,U-646,METHOD OF TREATING OTITIS,2010
7929,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2010
7930,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2010
7931,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2010
7932,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2010
7933,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2010
7934,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2010
7935,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2010
7936,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2010
7937,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2010
7938,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2010
7939,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
7940,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2010
7941,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2010
7942,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2010
7943,U-661,TREATMENT OF SEIZURE DISORDER,2010
7944,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
7945,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2010
7946,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2010
7947,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2010
7948,U-666,METHOD OF TREATING ADHD,2010
7949,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2010
7950,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2010
7951,U-669,INDICATION OF TYPE II DIABETES,2010
7952,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2010
7953,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2010
7954,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2010
7955,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2010
7956,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2010
7957,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2010
7958,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2010
7959,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2010
7960,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2010
7961,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2010
7962,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2010
7963,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2010
7964,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2010
7965,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2010
7966,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2010
7967,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2010
7968,U-686,EXPECTORANT AND NASAL DECONGESTANT,2010
7969,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2010
7970,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2010
7971,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2010
7972,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2010
7973,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2010
7974,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2010
7975,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2010
7976,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2010
7977,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2010
7978,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2010
7979,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2010
7980,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2010
7981,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2010
7982,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2010
7983,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2010
7984,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2010
7985,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2010
7986,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2010
7987,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2010
7988,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2010
7989,U-707,ALLERGIC RHINITIS,2010
7990,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2010
7991,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2010
7992,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2010
7993,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2010
7994,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2010
7995,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2010
7996,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2010
7997,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2010
7998,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2010
7999,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2010
8000,U-718,TREATMENT OF FUNGAL INFECTIONS,2010
8001,U-719,TREATENT OF PSYCHOSIS,2010
8002,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2010
8003,U-721,TREATMENT OF INFLUENZA,2010
8004,U-722,PROPHYLAXIS OF INFLUENZA,2010
8005,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2010
8006,U-724,METHOD OF TREATING SEIZURES,2010
8007,U-725,ALLERGIC RHINITIS AND URTICARIA,2010
8008,U-726,ALLERGIC RHINITIS,2010
8009,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2010
8010,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2010
8011,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2010
8012,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2010
8013,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2010
8014,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2010
8015,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2010
8016,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2010
8017,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2010
8018,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2010
8019,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2010
8020,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2010
8021,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2010
8022,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2010
8023,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2010
8024,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2010
8025,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2010
8026,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2010
8027,U-745,TREATMENT OR PREVENTION OF EMESIS,2010
8028,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2010
8029,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2010
8030,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2010
8031,U-749,METHOD OF CONTRACEPTION,2010
8032,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2010
8033,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2010
8034,U-752,SUNSCREEN,2010
8035,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2010
8036,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2010
8037,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2010
8038,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2010
8039,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2010
8040,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2010
8041,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2010
8042,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2010
8043,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2010
8044,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2010
8045,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2010
8046,U-764,TREATMENT OF SCHIZOPHRENIA,2010
8047,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2010
8048,U-766,TREATMENT OF SEIZURES,2010
8049,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2010
8050,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2010
8051,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2010
8052,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2010
8053,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2010
8054,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2010
8055,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2010
8056,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2010
8057,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2010
8058,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2010
8059,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2010
8060,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSUE IN PATEINTS WITH OPEN ANGLE GLAUCOME OR OCULAR HYPERTENSION,2010
8061,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2010
8062,U-780,A METHOD FOR THE TREATMENT OF CANCER,2010
8063,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2010
8064,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2010
8065,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2010
8066,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2010
8067,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2010
8068,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2010
8069,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2010
8070,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2010
8071,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2010
8072,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2010
8073,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2010
8074,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2010
8075,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2010
8076,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2010
8077,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2010
8078,U-796,METHOD OF TREATING DEPRESSION,2010
8079,U-797,METHOD OF TREATING ANXIETY,2010
8080,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2010
8081,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2010
8082,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2010
8083,U-801,METHOD OF TREATING CANCER,2010
8084,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2010
8085,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2010
8086,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2010
8087,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2010
8088,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2010
8089,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2010
8090,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2010
8091,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2010
8092,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2010
8093,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2010
8094,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2010
8095,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2010
8096,U-814,TREATMENT OF SCHIZOPHRENIA,2010
8097,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2010
8098,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2010
8099,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2010
8100,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2010
8101,U-819,MANAGEMENT OF FIBROMYALGIA,2010
8102,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2010
8103,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2010
8104,U-822,USE IN LIPID MANAGEMENT,2010
8105,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2010
8106,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2010
8107,U-825,USE FOR PREVENTION OF BREAST CANCER,2010
8108,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2010
8109,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2010
8110,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2010
8111,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2010
8112,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2010
8113,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2010
8114,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2010
8115,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2010
8116,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2010
8117,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2010
8118,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2010
8119,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2010
8120,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2010
8121,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2010
8122,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2010
8123,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2010
8124,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2010
8125,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2010
8126,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2010
8127,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2010
8128,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2010
8129,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2010
8130,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2010
8131,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2010
8132,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2010
8133,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2010
8134,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2010
8135,U-853,TREATMENT OR PREVENTION OF EMESIS,2010
8136,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2010
8137,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2010
8138,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2010
8139,U-857,INHIBITION OF TRANSPLANT REJECTION,2010
8140,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2010
8141,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2010
8142,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2010
8143,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2010
8144,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2010
8145,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2010
8146,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2010
8147,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2010
8148,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2010
8149,U-867,TREATMENT OF MIGRAINE,2010
8150,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2010
8151,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2010
8152,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2010
8153,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2010
8154,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2010
8155,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2010
8156,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2010
8157,U-875,FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER,2010
8158,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2010
8159,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2010
8160,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2010
8161,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2010
8162,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2010
8163,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2010
8164,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2010
8165,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2010
8166,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2010
8167,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2010
8168,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2010
8169,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2010
8170,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2010
8171,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2010
8172,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2010
8173,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2010
8174,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2010
8175,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2010
8176,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2010
8177,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2010
8178,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2010
8179,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2010
8180,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2010
8181,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2010
8182,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2010
8183,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2010
8184,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2010
8185,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2010
8186,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2010
8187,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2010
8188,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2010
8189,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2010
8190,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2010
8191,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2010
8192,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2010
8193,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2010
8194,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2010
8195,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2010
8196,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2010
8197,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2010
8198,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2010
8199,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2010
8200,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2010
8201,U-919,FOR THE TREATMENT OF DERMATITIS,2010
8202,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2010
8203,U-921,TREATMENT OF ACNE VULGARIS,2010
8204,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2010
8205,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2010
8206,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2010
8207,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2010
8208,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2010
8209,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2010
8210,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2010
8211,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2010
8212,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2010
8213,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2010
8214,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2010
8215,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2010
8216,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2010
8217,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2010
8218,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2010
8219,U-937,TREATMENT OF PROSTATE CANCER,2010
8220,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2010
8221,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2010
8222,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2010
8223,U-941,METHOD TO TREAT OVARIAN CANCER,2010
8224,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2010
8225,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2010
8226,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2010
8227,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2010
8228,U-946,TREATMENT OF BREAST CANCER,2010
8229,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2010
8230,U-948,TREATMENT OF DIABETES MELLITUS,2010
8231,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2010
8232,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2010
8233,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2010
8234,U-952,USE AS AN ANALGESIC,2010
8235,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2010
8236,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2010
8237,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2010
8238,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2010
8239,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2010
8240,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2010
8241,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2010
8242,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2010
8243,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2010
8244,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2010
8245,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2010
8246,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2010
8247,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2010
8248,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2010
8249,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2010
8250,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2010
8251,U-969,TREATMENT OF MIGRAINE,2010
8252,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2010
8253,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2010
8254,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2010
8255,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2010
8256,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2010
8257,U-975,TREATMENT OF PULMONARY HYPERTENSION,2010
8258,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2010
8259,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2010
8260,U-978,METHOD OF TREATING HYPONATREMIA,2010
8261,U-979,RELIEF OF MUSCLE SPASM,2010
8262,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2010
8263,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2010
8264,U-982,A METHOD OF TREATING OSTEOPOROSIS,2010
8265,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2010
8266,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2010
8267,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2010
8268,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2010
8269,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2010
8270,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2010
8271,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2010
8272,U-990,TREATMENT OF PROTOZOAL INFECTION,2010
8273,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2010
8274,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2010
8275,U-993,METHOD OF TREATING INFERTILITY,2010
8276,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2010
8277,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2010
8278,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2010
8279,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2010
8280,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2010
8281,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2010
8282,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2010
8283,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2010
8284,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2010
8285,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2010
8286,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2010
8287,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2010
8288,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2010
8289,U-1007,METHOD OF TREATING GOUT FLARES,2010
8290,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2010
8291,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2010
8292,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2010
8293,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2010
8294,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2010
8295,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TRAT PATIENTS WITH CHRONIC HEPATITIS C,2010
8296,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON 2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2010
8297,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2010
8298,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2010
8299,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2010
8300,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2010
8301,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2010
8302,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2010
8303,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2010
8304,U-1022,FOR THE PREPARATIO NOF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2010
8305,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2010
8306,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2010
8307,U-1025,TREATING FREQUENT HEARTBURN,2010
8308,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2010
8309,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2011
8310,U-1,PREVENTION OF PREGNANCY,2011
8311,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2011
8312,U-3,TREATMENT OF HYPERTENSION,2011
8313,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2011
8314,U-5,METHOD OF PRODUCING BRONCHODILATION,2011
8315,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2011
8316,U-7,INCREASING CARDIAC CONTRACTILITY,2011
8317,U-8,ACUTE MYOCARDIAL INFARCTION,2011
8318,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2011
8319,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2011
8320,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2011
8321,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2011
8322,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2011
8323,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2011
8324,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2011
8325,U-16,USE IN LUNG SCANNING PROCEDURES,2011
8326,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2011
8327,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2011
8328,U-19,TREATMENT OF INFLAMMATION,2011
8329,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2011
8330,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2011
8331,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2011
8332,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2011
8333,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2011
8334,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2011
8335,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2011
8336,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2011
8337,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2011
8338,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2011
8339,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2011
8340,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2011
8341,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2011
8342,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2011
8343,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2011
8344,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2011
8345,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2011
8346,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2011
8347,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2011
8348,U-39,ANGINA PECTORIS,2011
8349,U-40,METHOD OF TREATMENT OF BURNS,2011
8350,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2011
8351,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2011
8352,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2011
8353,U-44,RELIEF OF NAUSEA AND VOMITING,2011
8354,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2011
8355,U-46,TREATMENT OF PANIC DISORDER,2011
8356,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2011
8357,U-48,ANALGESIA,2011
8358,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2011
8359,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2011
8360,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2011
8361,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2011
8362,U-53,HYPERCALCEMIA OF MALIGNANCY,2011
8363,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2011
8364,U-55,TREATMENT OF PAIN,2011
8365,U-56,AID TO SMOKING CESSATION,2011
8366,U-57,OPHTHALMIC USE OF NORFLOXACIN,2011
8367,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2011
8368,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2011
8369,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2011
8370,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2011
8371,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2011
8372,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2011
8373,U-64,TREATMENT OF VIRAL INFECTIONS,2011
8374,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2011
8375,U-66,TRIPHASIC REGIMEN,2011
8376,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2011
8377,U-68,TREATMENT OF ACTINIC KERATOSIS,2011
8378,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2011
8379,U-70,TREATMENT OF TRANSIENT INSOMNIA,2011
8380,U-71,METHOD OF TREATMENT OF HEART FAILURE,2011
8381,U-72,TREATMENT OF MIGRAINE,2011
8382,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2011
8383,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2011
8384,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2011
8385,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2011
8386,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2011
8387,U-78,ULCERATIVE COLITIS,2011
8388,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2011
8389,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2011
8390,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2011
8391,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2011
8392,U-83,TREATMENT OF SEIZURES,2011
8393,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2011
8394,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2011
8395,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2011
8396,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2011
8397,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2011
8398,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2011
8399,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2011
8400,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2011
8401,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2011
8402,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2011
8403,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2011
8404,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2011
8405,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2011
8406,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2011
8407,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2011
8408,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2011
8409,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2011
8410,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2011
8411,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2011
8412,U-103,TREATMENT OF OCULAR HYPERTENSION,2011
8413,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2011
8414,U-105,EMESIS,2011
8415,U-106,TREATMENT OF EPILEPSY,2011
8416,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2011
8417,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2011
8418,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2011
8419,U-110,USE AS A RETRIEVABLE PERSSARY,2011
8420,U-111,DIABETES,2011
8421,U-112,CONTRACEPTION,2011
8422,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2011
8423,U-114,USE FOR INHIBITING BONE RESORPTION,2011
8424,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2011
8425,U-116,METHOD OF MYOCARDIAL IMAGING,2011
8426,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2011
8427,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2011
8428,U-119,TREATMENT OF NASAL HYPERSECRETION,2011
8429,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2011
8430,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2011
8431,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2011
8432,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2011
8433,U-124,TREATMENT OF ACNE,2011
8434,U-125,TREATMENT NEUROGENERATIVE DISEASES,2011
8435,U-126,TREATMENT OF GASTRITIS,2011
8436,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2011
8437,U-128,METHOD FOR TREATMENT OF TUMORS,2011
8438,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2011
8439,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2011
8440,U-131,PHOTODAMAGED SKIN,2011
8441,U-132,INHIBITING HIV PROTEASE,2011
8442,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2011
8443,U-134,TREATMENT OF ACNE VULGARIS,2011
8444,U-135,ANTITUMOR AGENT,2011
8445,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2011
8446,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2011
8447,U-138,TREATMENT OF ALLERGIC RHINITIS,2011
8448,U-139,TREATMENT OF ALLERGIC REACTIONS,2011
8449,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2011
8450,U-141,TREATMENT OF ULCERATIVE COLITIS,2011
8451,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2011
8452,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2011
8453,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2011
8454,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2011
8455,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2011
8456,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2011
8457,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2011
8458,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2011
8459,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2011
8460,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2011
8461,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2011
8462,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2011
8463,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2011
8464,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2011
8465,U-156,METHOD OF PROVIDING ANESTHESIA,2011
8466,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2011
8467,U-158,ANGINA,2011
8468,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2011
8469,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2011
8470,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2011
8471,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2011
8472,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2011
8473,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2011
8474,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2011
8475,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2011
8476,U-167,METHOD FOR TREATING HIV-1 INFECTION,2011
8477,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2011
8478,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2011
8479,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2011
8480,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2011
8481,U-172,TREATMENT OF GENITAL WARTS,2011
8482,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2011
8483,U-174,USE AS AN ANTIHISTAMINE AGENT,2011
8484,U-175,METHOD OF TREATING MALIGNANT TUMORS,2011
8485,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2011
8486,U-177,FUNGICIDE,2011
8487,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2011
8488,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2011
8489,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2011
8490,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2011
8491,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2011
8492,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2011
8493,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2011
8494,U-185,METHOD OF TREATING HYPERTENSION,2011
8495,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2011
8496,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2011
8497,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2011
8498,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2011
8499,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2011
8500,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2011
8501,U-192,USE IN TREATING ALLERGIC REACTIONS,2011
8502,U-193,PSORIASIS,2011
8503,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2011
8504,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2011
8505,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2011
8506,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2011
8507,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2011
8508,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2011
8509,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2011
8510,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2011
8511,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2011
8512,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2011
8513,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2011
8514,U-205,METHOD FOR TREATING HEARTBURN,2011
8515,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2011
8516,U-207,USE AS NASAL SPRAY,2011
8517,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2011
8518,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2011
8519,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2011
8520,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2011
8521,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2011
8522,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2011
8523,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2011
8524,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2011
8525,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2011
8526,U-217,METHOD OF PRODUCING ANESTHESIA,2011
8527,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2011
8528,U-219,TREATMENT OF PARKINSON'S DISEASE,2011
8529,U-220,METHOD OF DIAGNOSIS,2011
8530,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2011
8531,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2011
8532,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2011
8533,U-224,CONTROLLING INTRAOCULAR PRESSURE,2011
8534,U-225,MEHTOD FOR DELIVERY,2011
8535,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2011
8536,U-227,NASAL ADMINISTRATION,2011
8537,U-228,ASTHMA,2011
8538,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2011
8539,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2011
8540,U-231,USE IN PARKINSON'S DISEASE,2011
8541,U-232,METHOD OF TREATING MIGRAINE,2011
8542,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2011
8543,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2011
8544,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2011
8545,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2011
8546,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2011
8547,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2011
8548,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2011
8549,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2011
8550,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2011
8551,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2011
8552,U-243,TOPICAL ADMINISTRATION,2011
8553,U-244,PLATELET AGGREGATION INHIBITORS,2011
8554,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2011
8555,U-246,PHOSPHATE BINDING,2011
8556,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2011
8557,U-248,TREATMENT OF HIV,2011
8558,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2011
8559,U-250,TREATMENT OF HEPATITIS B INFECTION,2011
8560,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2011
8561,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2011
8562,U-253,ORAL TRANSMUCOSAL USE,2011
8563,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2011
8564,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2011
8565,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2011
8566,U-257,TREATMENT OF HIV INFECTION,2011
8567,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2011
8568,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2011
8569,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2011
8570,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2011
8571,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2011
8572,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2011
8573,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2011
8574,U-265,USE AS LAXATIVE,2011
8575,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2011
8576,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2011
8577,U-268,ACROMEGALY,2011
8578,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2011
8579,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2011
8580,U-271,METHOD OF TREATING TUMORS,2011
8581,U-272,METHOD OF TREATING CARCINOMA,2011
8582,U-273,CUTANEOUS T-CELL LYMPHOMA,2011
8583,U-274,ZANAMIVIR FOR INHALATION,2011
8584,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2011
8585,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2011
8586,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2011
8587,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2011
8588,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2011
8589,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2011
8590,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2011
8591,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2011
8592,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2011
8593,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2011
8594,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2011
8595,U-286,DEPRESSION,2011
8596,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2011
8597,U-288,THERAPY OF INFLUENZA,2011
8598,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2011
8599,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2011
8600,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2011
8601,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2011
8602,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2011
8603,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2011
8604,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2011
8605,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2011
8606,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2011
8607,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2011
8608,U-299,TREATMENT OF ADENOMATOUS POLYPS,2011
8609,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2011
8610,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2011
8611,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2011
8612,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2011
8613,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2011
8614,U-305,METHODS FOR USING THE DRUG PRODUCT,2011
8615,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2011
8616,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2011
8617,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2011
8618,U-309,TREATING SJOEGREN SYNDROME,2011
8619,U-310,TREATMENT OF XEROSTOMIA,2011
8620,U-311,HORMONE REPLACEMENT,2011
8621,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2011
8622,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2011
8623,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2011
8624,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2011
8625,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2011
8626,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2011
8627,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2011
8628,U-319,TREATMENT OF MICROBIAL INFECTIONS,2011
8629,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2011
8630,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2011
8631,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2011
8632,U-323,USE AS A BILE ACID SEQUESTRANT,2011
8633,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2011
8634,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2011
8635,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2011
8636,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2011
8637,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2011
8638,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2011
8639,U-330,TREATMENT OF NAUSEA AND VOMITING,2011
8640,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2011
8641,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2011
8642,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2011
8643,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2011
8644,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2011
8645,U-336,DIAGNOSTIC RADIOIMAGING,2011
8646,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2011
8647,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2011
8648,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2011
8649,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2011
8650,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2011
8651,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2011
8652,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2011
8653,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2011
8654,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2011
8655,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2011
8656,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2011
8657,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2011
8658,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2011
8659,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2011
8660,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2011
8661,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2011
8662,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2011
8663,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2011
8664,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2011
8665,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2011
8666,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2011
8667,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2011
8668,U-359,METHOD OF USE OF VISICOL,2011
8669,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2011
8670,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2011
8671,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2011
8672,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2011
8673,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2011
8674,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2011
8675,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2011
8676,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2011
8677,U-368,HEARTBURN,2011
8678,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2011
8679,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2011
8680,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2011
8681,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2011
8682,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2011
8683,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2011
8684,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2011
8685,U-376,TREATMENT OF INFLUENZA,2011
8686,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2011
8687,U-378,METHOD FOR TREATING INCONTINENCE,2011
8688,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2011
8689,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2011
8690,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2011
8691,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2011
8692,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2011
8693,U-384,TREATMENT OF CMV RETINITIS,2011
8694,U-385,TREATMENT OF PEPTIC ULCERS,2011
8695,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2011
8696,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2011
8697,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2011
8698,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2011
8699,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2011
8700,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2011
8701,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2011
8702,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2011
8703,U-394,METHOD OF USE OF ALPHAGAN,2011
8704,U-395,METHOD OF USE OF ALPHAGAN P,2011
8705,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2011
8706,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2011
8707,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2011
8708,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2011
8709,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2011
8710,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2011
8711,U-402,TREATMENT OF ACTINIC KERATOSES,2011
8712,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2011
8713,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2011
8714,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2011
8715,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2011
8716,U-407,METHOD OF TREATING OTOPATHY,2011
8717,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2011
8718,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2011
8719,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2011
8720,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2011
8721,U-412,TREATMENT OF TYPE 2 DIABETES,2011
8722,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2011
8723,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2011
8724,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2011
8725,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2011
8726,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2011
8727,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2011
8728,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2011
8729,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2011
8730,U-421,USE FOR SEDATION,2011
8731,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2011
8732,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2011
8733,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2011
8734,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2011
8735,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2011
8736,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2011
8737,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2011
8738,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2011
8739,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2011
8740,U-431,POSTTRAUMATIC STRESS DISORDER,2011
8741,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2011
8742,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2011
8743,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2011
8744,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2011
8745,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2011
8746,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2011
8747,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2011
8748,U-439,TREATMENT OF OBESITY,2011
8749,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2011
8750,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2011
8751,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2011
8752,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2011
8753,U-444,TREATMENT OF MIGRAINE,2011
8754,U-445,USE AS AN ANTIMYCOTIC AGENT,2011
8755,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2011
8756,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2011
8757,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2011
8758,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2011
8759,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2011
8760,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2011
8761,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2011
8762,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2011
8763,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2011
8764,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2011
8765,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2011
8766,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2011
8767,U-458,METHOD OF USE OF IMAGENT,2011
8768,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2011
8769,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2011
8770,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2011
8771,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2011
8772,U-463,VENOGRAPHY,2011
8773,U-464,PERIPHERAL ARTERIOGRAPHY,2011
8774,U-465,CT IMAGING OF THE HEAD,2011
8775,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2011
8776,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2011
8777,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2011
8778,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2011
8779,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2011
8780,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2011
8781,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2011
8782,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2011
8783,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2011
8784,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2011
8785,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2011
8786,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2011
8787,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2011
8788,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2011
8789,U-480,CONTRAST AGENT FOR MRI,2011
8790,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2011
8791,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2011
8792,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2011
8793,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2011
8794,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2011
8795,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2011
8796,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2011
8797,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2011
8798,U-489,EXPECTORANT,2011
8799,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2011
8800,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2011
8801,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2011
8802,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2011
8803,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2011
8804,U-495,PERITONEAL DIALYSIS SOLUTION,2011
8805,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2011
8806,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2011
8807,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2011
8808,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2011
8809,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2011
8810,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2011
8811,U-502,PITYRIASIS VERSICOLOR,2011
8812,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2011
8813,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2011
8814,U-505,ULTRASOUND CONTRAST AGENT,2011
8815,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2011
8816,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2011
8817,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2011
8818,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2011
8819,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2011
8820,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2011
8821,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2011
8822,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2011
8823,U-514,PREVENTION OF OVULATION IN A WOMAN,2011
8824,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2011
8825,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2011
8826,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2011
8827,U-518,OBSESSIVE COMPULSIVE DISORDER,2011
8828,U-519,POST OPERATIVE NAUSEA AND VOMITING,2011
8829,U-520,PREMENOPAUSAL OSTEOPOROSIS,2011
8830,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2011
8831,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2011
8832,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2011
8833,U-524,METHOD OF TREATING DIARRHEA,2011
8834,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2011
8835,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2011
8836,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2011
8837,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2011
8838,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2011
8839,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2011
8840,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2011
8841,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2011
8842,U-533,ERECTILE DYSFUNCTION,2011
8843,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2011
8844,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2011
8845,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2011
8846,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2011
8847,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2011
8848,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2011
8849,U-540,TREATMENT OF FUNGAL INFECTIONS,2011
8850,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2011
8851,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2011
8852,U-543,TREATMENT OF SCHIZOPHRENIA,2011
8853,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2011
8854,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2011
8855,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2011
8856,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2011
8857,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2011
8858,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2011
8859,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2011
8860,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2011
8861,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2011
8862,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2011
8863,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2011
8864,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2011
8865,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2011
8866,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2011
8867,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2011
8868,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2011
8869,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2011
8870,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2011
8871,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2011
8872,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2011
8873,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2011
8874,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2011
8875,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2011
8876,U-567,METHOD OF TREATING INFERTILITY,2011
8877,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2011
8878,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2011
8879,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2011
8880,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2011
8881,U-572,INTENSIVE CARE UNIT SEDATION,2011
8882,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2011
8883,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2011
8884,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2011
8885,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2011
8886,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2011
8887,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2011
8888,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2011
8889,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2011
8890,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2011
8891,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2011
8892,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2011
8893,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2011
8894,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2011
8895,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2011
8896,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2011
8897,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2011
8898,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2011
8899,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2011
8900,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2011
8901,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2011
8902,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2011
8903,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2011
8904,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
8905,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2011
8906,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2011
8907,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2011
8908,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2011
8909,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2011
8910,U-601,TREATMENT OF BIPOLAR DISORDER,2011
8911,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2011
8912,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2011
8913,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2011
8914,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2011
8915,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2011
8916,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2011
8917,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2011
8918,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2011
8919,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2011
8920,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2011
8921,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2011
8922,U-613,REDUCTION OF SERUM PHOSPHATE,2011
8923,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2011
8924,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2011
8925,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2011
8926,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2011
8927,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2011
8928,U-619,TREATMENT OF MALIGNANT NEOPLASM,2011
8929,U-620,TREATMENT OF INSOMNIA,2011
8930,U-621,METHOD OF TREATING CANCER,2011
8931,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2011
8932,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2011
8933,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2011
8934,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2011
8935,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2011
8936,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2011
8937,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2011
8938,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2011
8939,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2011
8940,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2011
8941,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2011
8942,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2011
8943,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2011
8944,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2011
8945,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2011
8946,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2011
8947,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2011
8948,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2011
8949,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2011
8950,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2011
8951,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2011
8952,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2011
8953,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2011
8954,U-645,TREATMENT OF ASTHMA,2011
8955,U-646,METHOD OF TREATING OTITIS,2011
8956,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2011
8957,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2011
8958,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2011
8959,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2011
8960,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2011
8961,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2011
8962,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2011
8963,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2011
8964,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2011
8965,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2011
8966,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
8967,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2011
8968,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2011
8969,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2011
8970,U-661,TREATMENT OF SEIZURE DISORDER,2011
8971,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
8972,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2011
8973,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2011
8974,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2011
8975,U-666,METHOD OF TREATING ADHD,2011
8976,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2011
8977,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2011
8978,U-669,INDICATION OF TYPE II DIABETES,2011
8979,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2011
8980,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2011
8981,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2011
8982,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2011
8983,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2011
8984,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2011
8985,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2011
8986,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2011
8987,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2011
8988,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2011
8989,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2011
8990,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2011
8991,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2011
8992,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2011
8993,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2011
8994,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2011
8995,U-686,EXPECTORANT AND NASAL DECONGESTANT,2011
8996,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2011
8997,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2011
8998,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2011
8999,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2011
9000,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2011
9001,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2011
9002,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2011
9003,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2011
9004,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2011
9005,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2011
9006,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2011
9007,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2011
9008,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2011
9009,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2011
9010,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2011
9011,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2011
9012,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2011
9013,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2011
9014,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2011
9015,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2011
9016,U-707,ALLERGIC RHINITIS,2011
9017,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2011
9018,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2011
9019,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2011
9020,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2011
9021,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2011
9022,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2011
9023,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2011
9024,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2011
9025,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2011
9026,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2011
9027,U-718,TREATMENT OF FUNGAL INFECTIONS,2011
9028,U-719,TREATENT OF PSYCHOSIS,2011
9029,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2011
9030,U-721,TREATMENT OF INFLUENZA,2011
9031,U-722,PROPHYLAXIS OF INFLUENZA,2011
9032,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2011
9033,U-724,METHOD OF TREATING SEIZURES,2011
9034,U-725,ALLERGIC RHINITIS AND URTICARIA,2011
9035,U-726,ALLERGIC RHINITIS,2011
9036,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2011
9037,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2011
9038,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2011
9039,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2011
9040,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2011
9041,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2011
9042,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2011
9043,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2011
9044,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2011
9045,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2011
9046,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2011
9047,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2011
9048,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2011
9049,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2011
9050,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2011
9051,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2011
9052,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2011
9053,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2011
9054,U-745,TREATMENT OR PREVENTION OF EMESIS,2011
9055,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2011
9056,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2011
9057,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2011
9058,U-749,METHOD OF CONTRACEPTION,2011
9059,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2011
9060,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2011
9061,U-752,SUNSCREEN,2011
9062,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2011
9063,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2011
9064,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2011
9065,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2011
9066,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2011
9067,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2011
9068,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2011
9069,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2011
9070,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2011
9071,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2011
9072,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2011
9073,U-764,TREATMENT OF SCHIZOPHRENIA,2011
9074,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2011
9075,U-766,TREATMENT OF SEIZURES,2011
9076,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2011
9077,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2011
9078,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2011
9079,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2011
9080,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2011
9081,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2011
9082,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2011
9083,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2011
9084,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2011
9085,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2011
9086,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2011
9087,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSUE IN PATEINTS WITH OPEN ANGLE GLAUCOME OR OCULAR HYPERTENSION,2011
9088,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2011
9089,U-780,A METHOD FOR THE TREATMENT OF CANCER,2011
9090,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2011
9091,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2011
9092,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2011
9093,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2011
9094,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2011
9095,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2011
9096,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2011
9097,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2011
9098,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2011
9099,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2011
9100,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2011
9101,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2011
9102,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2011
9103,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2011
9104,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2011
9105,U-796,METHOD OF TREATING DEPRESSION,2011
9106,U-797,METHOD OF TREATING ANXIETY,2011
9107,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2011
9108,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2011
9109,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2011
9110,U-801,METHOD OF TREATING CANCER,2011
9111,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2011
9112,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2011
9113,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2011
9114,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2011
9115,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2011
9116,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2011
9117,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2011
9118,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2011
9119,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2011
9120,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2011
9121,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2011
9122,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2011
9123,U-814,TREATMENT OF SCHIZOPHRENIA,2011
9124,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2011
9125,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2011
9126,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2011
9127,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2011
9128,U-819,MANAGEMENT OF FIBROMYALGIA,2011
9129,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2011
9130,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2011
9131,U-822,USE IN LIPID MANAGEMENT,2011
9132,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2011
9133,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2011
9134,U-825,USE FOR PREVENTION OF BREAST CANCER,2011
9135,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2011
9136,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2011
9137,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2011
9138,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2011
9139,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2011
9140,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2011
9141,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2011
9142,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2011
9143,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2011
9144,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2011
9145,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2011
9146,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2011
9147,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2011
9148,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2011
9149,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2011
9150,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2011
9151,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2011
9152,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2011
9153,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2011
9154,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2011
9155,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2011
9156,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2011
9157,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2011
9158,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2011
9159,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2011
9160,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2011
9161,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2011
9162,U-853,TREATMENT OR PREVENTION OF EMESIS,2011
9163,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2011
9164,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2011
9165,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2011
9166,U-857,INHIBITION OF TRANSPLANT REJECTION,2011
9167,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2011
9168,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2011
9169,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2011
9170,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2011
9171,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2011
9172,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2011
9173,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2011
9174,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2011
9175,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2011
9176,U-867,TREATMENT OF MIGRAINE,2011
9177,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2011
9178,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2011
9179,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2011
9180,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2011
9181,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2011
9182,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2011
9183,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2011
9184,U-875,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE",2011
9185,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2011
9186,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2011
9187,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2011
9188,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2011
9189,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2011
9190,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2011
9191,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2011
9192,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2011
9193,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2011
9194,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2011
9195,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2011
9196,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2011
9197,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2011
9198,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2011
9199,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2011
9200,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2011
9201,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2011
9202,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2011
9203,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2011
9204,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2011
9205,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2011
9206,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2011
9207,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2011
9208,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2011
9209,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2011
9210,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2011
9211,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2011
9212,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2011
9213,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2011
9214,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2011
9215,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2011
9216,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2011
9217,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2011
9218,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2011
9219,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2011
9220,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2011
9221,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2011
9222,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2011
9223,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2011
9224,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2011
9225,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2011
9226,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2011
9227,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2011
9228,U-919,FOR THE TREATMENT OF DERMATITIS,2011
9229,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2011
9230,U-921,TREATMENT OF ACNE VULGARIS,2011
9231,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2011
9232,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2011
9233,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2011
9234,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2011
9235,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2011
9236,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2011
9237,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2011
9238,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2011
9239,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2011
9240,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2011
9241,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2011
9242,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2011
9243,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2011
9244,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2011
9245,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2011
9246,U-937,TREATMENT OF PROSTATE CANCER,2011
9247,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2011
9248,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2011
9249,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2011
9250,U-941,METHOD TO TREAT OVARIAN CANCER,2011
9251,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2011
9252,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2011
9253,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2011
9254,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2011
9255,U-946,TREATMENT OF BREAST CANCER,2011
9256,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2011
9257,U-948,TREATMENT OF DIABETES MELLITUS,2011
9258,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2011
9259,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2011
9260,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2011
9261,U-952,USE AS AN ANALGESIC,2011
9262,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2011
9263,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2011
9264,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2011
9265,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2011
9266,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2011
9267,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2011
9268,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2011
9269,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2011
9270,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2011
9271,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2011
9272,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2011
9273,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2011
9274,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2011
9275,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2011
9276,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2011
9277,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2011
9278,U-969,TREATMENT OF MIGRAINE,2011
9279,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2011
9280,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2011
9281,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2011
9282,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2011
9283,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2011
9284,U-975,TREATMENT OF PULMONARY HYPERTENSION,2011
9285,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2011
9286,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2011
9287,U-978,METHOD OF TREATING HYPONATREMIA,2011
9288,U-979,RELIEF OF MUSCLE SPASM,2011
9289,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2011
9290,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2011
9291,U-982,A METHOD OF TREATING OSTEOPOROSIS,2011
9292,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2011
9293,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2011
9294,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2011
9295,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2011
9296,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2011
9297,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2011
9298,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2011
9299,U-990,TREATMENT OF PROTOZOAL INFECTION,2011
9300,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2011
9301,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2011
9302,U-993,METHOD OF TREATING INFERTILITY,2011
9303,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2011
9304,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2011
9305,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2011
9306,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2011
9307,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2011
9308,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2011
9309,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2011
9310,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2011
9311,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2011
9312,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2011
9313,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2011
9314,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2011
9315,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2011
9316,U-1007,METHOD OF TREATING GOUT FLARES,2011
9317,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2011
9318,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2011
9319,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2011
9320,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2011
9321,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2011
9322,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2011
9323,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2011
9324,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2011
9325,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2011
9326,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2011
9327,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2011
9328,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2011
9329,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2011
9330,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2011
9331,U-1022,FOR THE PREPARATIO NOF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2011
9332,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2011
9333,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2011
9334,U-1025,TREATING FREQUENT HEARTBURN,2011
9335,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2011
9336,U-1027,REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL,2011
9337,U-1028,A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY,2011
9338,U-1029,METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF,2011
9339,U-1030,IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS),2011
9340,U-1031,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2011
9341,U-1032,USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS,2011
9342,U-1033,TOPICAL TREATMENT OF ACNE VULGARIS,2011
9343,U-1034,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2011
9344,U-1035,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2011
9345,U-1036,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN,2011
9346,U-1037,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST,2011
9347,U-1038,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST,2011
9348,U-1039,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN,2011
9349,U-1040,INHIBITION OF THROMBIN IN A PATIENT,2011
9350,U-1041,TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE,2011
9351,U-1042,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2011
9352,U-1043,MANAGEMENT OF MODERATE TO SEVERE PAIN,2011
9353,U-1044,TOPICAL TREATMENT OF SCALP PSORIASIS,2011
9354,U-1045,MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY,2011
9355,U-1046,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY,2011
9356,U-1047,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)",2011
9357,U-1048,WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES,2011
9358,U-1049,PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT,2011
9359,U-1050,USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS,2011
9360,U-1051,TREATMENT OF OROPHARYNGEAL CANDIDIASIS,2011
9361,U-1052,RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2011
9362,U-1053,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2011
9363,U-1054,"ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS",2011
9364,U-1055,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE,2011
9365,U-1056,TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2011
9366,U-1057,TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2011
9367,U-1058,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2011
9368,U-1059,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,2011
9369,U-1060,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS,2011
9370,U-1061,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,2011
9371,U-1062,ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE,2011
9372,U-1063,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,2011
9373,U-1064,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2011
9374,U-1065,METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY,2011
9375,U-1066,METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA,2011
9376,U-1067,TREATMENT OF CANCER,2011
9377,U-1068,TREATMENT OF ASTHMA,2011
9378,U-1069,A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2011
9379,U-1070,A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE,2011
9380,U-1071,METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION,2011
9381,U-1072,"THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME",2011
9382,U-1073,USE FOR THE TREATMENT OF ASTHMA AND COPD,2011
9383,U-1074,USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT,2011
9384,U-1075,USE FOR THE TREATMENT OF ASTHA,2011
9385,U-1076,"REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING",2011
9386,U-1077,PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRAION,2011
9387,U-1078,TREATMENT OF ACNE,2011
9388,U-1079,REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2011
9389,U-1080,METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT,2011
9390,U-1081,LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2011
9391,U-1082,USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS,2011
9392,U-1083,"ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES",2011
9393,U-1084,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2011
9394,U-1085,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,2011
9395,U-1086,TREATMENT OF AUTOIMMUNE DISEASE,2011
9396,U-1087,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,2011
9397,U-1088,RELIEF OF MUSCLE SPASM,2011
9398,U-1089,INHIBITION OF THROMBIN,2011
9399,U-1090,LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION,2011
9400,U-1091,ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA,2011
9401,U-1092,TREATMENT OF BREAST CANCER,2011
9402,U-1093,TREATMENT OF PSEUDOBULBAR AFFECT,2011
9403,U-1094,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2011
9404,U-1095,METHOD OF TREATING OCULAR INFLAMMATION,2011
9405,U-1096,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,2011
9406,U-1097,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,2011
9407,U-1098,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,2011
9408,U-1099,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2011
9409,U-1100,REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY,2011
9410,U-1101,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2011
9411,U-1102,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,2011
9412,U-1103,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2011
9413,U-1104,USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN,2011
9414,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2012
9415,U-1,PREVENTION OF PREGNANCY,2012
9416,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2012
9417,U-3,TREATMENT OF HYPERTENSION,2012
9418,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2012
9419,U-5,METHOD OF PRODUCING BRONCHODILATION,2012
9420,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2012
9421,U-7,INCREASING CARDIAC CONTRACTILITY,2012
9422,U-8,ACUTE MYOCARDIAL INFARCTION,2012
9423,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2012
9424,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2012
9425,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2012
9426,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2012
9427,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2012
9428,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2012
9429,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2012
9430,U-16,USE IN LUNG SCANNING PROCEDURES,2012
9431,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2012
9432,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2012
9433,U-19,TREATMENT OF INFLAMMATION,2012
9434,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2012
9435,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2012
9436,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2012
9437,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2012
9438,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2012
9439,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2012
9440,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2012
9441,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2012
9442,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2012
9443,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2012
9444,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2012
9445,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2012
9446,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2012
9447,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2012
9448,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2012
9449,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2012
9450,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2012
9451,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2012
9452,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2012
9453,U-39,ANGINA PECTORIS,2012
9454,U-40,METHOD OF TREATMENT OF BURNS,2012
9455,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2012
9456,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2012
9457,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2012
9458,U-44,RELIEF OF NAUSEA AND VOMITING,2012
9459,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2012
9460,U-46,TREATMENT OF PANIC DISORDER,2012
9461,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2012
9462,U-48,ANALGESIA,2012
9463,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2012
9464,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2012
9465,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2012
9466,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2012
9467,U-53,HYPERCALCEMIA OF MALIGNANCY,2012
9468,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2012
9469,U-55,TREATMENT OF PAIN,2012
9470,U-56,AID TO SMOKING CESSATION,2012
9471,U-57,OPHTHALMIC USE OF NORFLOXACIN,2012
9472,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2012
9473,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2012
9474,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2012
9475,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2012
9476,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2012
9477,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2012
9478,U-64,TREATMENT OF VIRAL INFECTIONS,2012
9479,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2012
9480,U-66,TRIPHASIC REGIMEN,2012
9481,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2012
9482,U-68,TREATMENT OF ACTINIC KERATOSIS,2012
9483,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2012
9484,U-70,TREATMENT OF TRANSIENT INSOMNIA,2012
9485,U-71,METHOD OF TREATMENT OF HEART FAILURE,2012
9486,U-72,TREATMENT OF MIGRAINE,2012
9487,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2012
9488,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2012
9489,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2012
9490,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2012
9491,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2012
9492,U-78,ULCERATIVE COLITIS,2012
9493,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2012
9494,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2012
9495,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2012
9496,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2012
9497,U-83,TREATMENT OF SEIZURES,2012
9498,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2012
9499,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2012
9500,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2012
9501,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2012
9502,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2012
9503,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2012
9504,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2012
9505,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2012
9506,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2012
9507,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2012
9508,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2012
9509,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2012
9510,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2012
9511,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2012
9512,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2012
9513,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2012
9514,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2012
9515,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2012
9516,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2012
9517,U-103,TREATMENT OF OCULAR HYPERTENSION,2012
9518,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2012
9519,U-105,EMESIS,2012
9520,U-106,TREATMENT OF EPILEPSY,2012
9521,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2012
9522,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2012
9523,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2012
9524,U-110,USE AS A RETRIEVABLE PERSSARY,2012
9525,U-111,DIABETES,2012
9526,U-112,CONTRACEPTION,2012
9527,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2012
9528,U-114,USE FOR INHIBITING BONE RESORPTION,2012
9529,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2012
9530,U-116,METHOD OF MYOCARDIAL IMAGING,2012
9531,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2012
9532,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2012
9533,U-119,TREATMENT OF NASAL HYPERSECRETION,2012
9534,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2012
9535,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2012
9536,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2012
9537,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2012
9538,U-124,TREATMENT OF ACNE,2012
9539,U-125,TREATMENT NEUROGENERATIVE DISEASES,2012
9540,U-126,TREATMENT OF GASTRITIS,2012
9541,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2012
9542,U-128,METHOD FOR TREATMENT OF TUMORS,2012
9543,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2012
9544,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2012
9545,U-131,PHOTODAMAGED SKIN,2012
9546,U-132,INHIBITING HIV PROTEASE,2012
9547,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2012
9548,U-134,TREATMENT OF ACNE VULGARIS,2012
9549,U-135,ANTITUMOR AGENT,2012
9550,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2012
9551,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2012
9552,U-138,TREATMENT OF ALLERGIC RHINITIS,2012
9553,U-139,TREATMENT OF ALLERGIC REACTIONS,2012
9554,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2012
9555,U-141,TREATMENT OF ULCERATIVE COLITIS,2012
9556,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2012
9557,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2012
9558,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2012
9559,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2012
9560,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2012
9561,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2012
9562,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2012
9563,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2012
9564,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2012
9565,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2012
9566,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2012
9567,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2012
9568,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2012
9569,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2012
9570,U-156,METHOD OF PROVIDING ANESTHESIA,2012
9571,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2012
9572,U-158,ANGINA,2012
9573,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2012
9574,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2012
9575,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2012
9576,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2012
9577,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2012
9578,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2012
9579,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2012
9580,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2012
9581,U-167,METHOD FOR TREATING HIV-1 INFECTION,2012
9582,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2012
9583,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2012
9584,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2012
9585,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2012
9586,U-172,TREATMENT OF GENITAL WARTS,2012
9587,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2012
9588,U-174,USE AS AN ANTIHISTAMINE AGENT,2012
9589,U-175,METHOD OF TREATING MALIGNANT TUMORS,2012
9590,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2012
9591,U-177,FUNGICIDE,2012
9592,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2012
9593,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2012
9594,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2012
9595,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2012
9596,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2012
9597,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2012
9598,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2012
9599,U-185,METHOD OF TREATING HYPERTENSION,2012
9600,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2012
9601,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2012
9602,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2012
9603,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2012
9604,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2012
9605,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2012
9606,U-192,USE IN TREATING ALLERGIC REACTIONS,2012
9607,U-193,PSORIASIS,2012
9608,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2012
9609,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2012
9610,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2012
9611,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2012
9612,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2012
9613,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2012
9614,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2012
9615,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2012
9616,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2012
9617,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2012
9618,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2012
9619,U-205,METHOD FOR TREATING HEARTBURN,2012
9620,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2012
9621,U-207,USE AS NASAL SPRAY,2012
9622,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2012
9623,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2012
9624,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2012
9625,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2012
9626,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2012
9627,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2012
9628,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2012
9629,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2012
9630,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2012
9631,U-217,METHOD OF PRODUCING ANESTHESIA,2012
9632,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2012
9633,U-219,TREATMENT OF PARKINSON'S DISEASE,2012
9634,U-220,METHOD OF DIAGNOSIS,2012
9635,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2012
9636,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2012
9637,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2012
9638,U-224,CONTROLLING INTRAOCULAR PRESSURE,2012
9639,U-225,MEHTOD FOR DELIVERY,2012
9640,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2012
9641,U-227,NASAL ADMINISTRATION,2012
9642,U-228,ASTHMA,2012
9643,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2012
9644,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2012
9645,U-231,USE IN PARKINSON'S DISEASE,2012
9646,U-232,METHOD OF TREATING MIGRAINE,2012
9647,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2012
9648,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2012
9649,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2012
9650,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2012
9651,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2012
9652,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2012
9653,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2012
9654,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2012
9655,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2012
9656,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2012
9657,U-243,TOPICAL ADMINISTRATION,2012
9658,U-244,PLATELET AGGREGATION INHIBITORS,2012
9659,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2012
9660,U-246,PHOSPHATE BINDING,2012
9661,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2012
9662,U-248,TREATMENT OF HIV,2012
9663,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2012
9664,U-250,TREATMENT OF HEPATITIS B INFECTION,2012
9665,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2012
9666,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2012
9667,U-253,ORAL TRANSMUCOSAL USE,2012
9668,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2012
9669,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2012
9670,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2012
9671,U-257,TREATMENT OF HIV INFECTION,2012
9672,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2012
9673,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2012
9674,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2012
9675,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2012
9676,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2012
9677,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2012
9678,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2012
9679,U-265,USE AS LAXATIVE,2012
9680,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2012
9681,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2012
9682,U-268,ACROMEGALY,2012
9683,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2012
9684,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2012
9685,U-271,METHOD OF TREATING TUMORS,2012
9686,U-272,METHOD OF TREATING CARCINOMA,2012
9687,U-273,CUTANEOUS T-CELL LYMPHOMA,2012
9688,U-274,ZANAMIVIR FOR INHALATION,2012
9689,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2012
9690,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2012
9691,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2012
9692,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2012
9693,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2012
9694,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2012
9695,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2012
9696,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2012
9697,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2012
9698,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2012
9699,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2012
9700,U-286,DEPRESSION,2012
9701,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2012
9702,U-288,THERAPY OF INFLUENZA,2012
9703,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2012
9704,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2012
9705,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2012
9706,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2012
9707,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2012
9708,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2012
9709,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2012
9710,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2012
9711,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2012
9712,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2012
9713,U-299,TREATMENT OF ADENOMATOUS POLYPS,2012
9714,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2012
9715,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2012
9716,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2012
9717,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2012
9718,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2012
9719,U-305,METHODS FOR USING THE DRUG PRODUCT,2012
9720,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2012
9721,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2012
9722,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2012
9723,U-309,TREATING SJOEGREN SYNDROME,2012
9724,U-310,TREATMENT OF XEROSTOMIA,2012
9725,U-311,HORMONE REPLACEMENT,2012
9726,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2012
9727,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2012
9728,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2012
9729,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2012
9730,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2012
9731,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2012
9732,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2012
9733,U-319,TREATMENT OF MICROBIAL INFECTIONS,2012
9734,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2012
9735,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2012
9736,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2012
9737,U-323,USE AS A BILE ACID SEQUESTRANT,2012
9738,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2012
9739,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2012
9740,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2012
9741,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2012
9742,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2012
9743,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2012
9744,U-330,TREATMENT OF NAUSEA AND VOMITING,2012
9745,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
9746,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2012
9747,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2012
9748,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2012
9749,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2012
9750,U-336,DIAGNOSTIC RADIOIMAGING,2012
9751,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2012
9752,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2012
9753,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2012
9754,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2012
9755,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2012
9756,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2012
9757,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2012
9758,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2012
9759,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2012
9760,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2012
9761,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2012
9762,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2012
9763,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2012
9764,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2012
9765,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2012
9766,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2012
9767,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2012
9768,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2012
9769,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2012
9770,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2012
9771,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2012
9772,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2012
9773,U-359,METHOD OF USE OF VISICOL,2012
9774,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2012
9775,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2012
9776,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2012
9777,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2012
9778,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2012
9779,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2012
9780,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2012
9781,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2012
9782,U-368,HEARTBURN,2012
9783,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2012
9784,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2012
9785,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2012
9786,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2012
9787,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2012
9788,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2012
9789,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2012
9790,U-376,TREATMENT OF INFLUENZA,2012
9791,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2012
9792,U-378,METHOD FOR TREATING INCONTINENCE,2012
9793,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2012
9794,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2012
9795,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2012
9796,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2012
9797,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2012
9798,U-384,TREATMENT OF CMV RETINITIS,2012
9799,U-385,TREATMENT OF PEPTIC ULCERS,2012
9800,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2012
9801,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2012
9802,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2012
9803,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2012
9804,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2012
9805,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2012
9806,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2012
9807,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2012
9808,U-394,METHOD OF USE OF ALPHAGAN,2012
9809,U-395,METHOD OF USE OF ALPHAGAN P,2012
9810,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2012
9811,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2012
9812,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2012
9813,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2012
9814,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2012
9815,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2012
9816,U-402,TREATMENT OF ACTINIC KERATOSES,2012
9817,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2012
9818,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2012
9819,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2012
9820,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2012
9821,U-407,METHOD OF TREATING OTOPATHY,2012
9822,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2012
9823,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2012
9824,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2012
9825,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2012
9826,U-412,TREATMENT OF TYPE 2 DIABETES,2012
9827,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2012
9828,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2012
9829,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2012
9830,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2012
9831,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2012
9832,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2012
9833,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2012
9834,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2012
9835,U-421,USE FOR SEDATION,2012
9836,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2012
9837,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2012
9838,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2012
9839,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2012
9840,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2012
9841,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2012
9842,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2012
9843,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2012
9844,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2012
9845,U-431,POSTTRAUMATIC STRESS DISORDER,2012
9846,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2012
9847,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2012
9848,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2012
9849,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2012
9850,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2012
9851,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2012
9852,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2012
9853,U-439,TREATMENT OF OBESITY,2012
9854,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2012
9855,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2012
9856,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2012
9857,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2012
9858,U-444,TREATMENT OF MIGRAINE,2012
9859,U-445,USE AS AN ANTIMYCOTIC AGENT,2012
9860,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2012
9861,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
9862,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2012
9863,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2012
9864,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2012
9865,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2012
9866,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2012
9867,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2012
9868,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2012
9869,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2012
9870,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2012
9871,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2012
9872,U-458,METHOD OF USE OF IMAGENT,2012
9873,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2012
9874,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2012
9875,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2012
9876,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2012
9877,U-463,VENOGRAPHY,2012
9878,U-464,PERIPHERAL ARTERIOGRAPHY,2012
9879,U-465,CT IMAGING OF THE HEAD,2012
9880,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2012
9881,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2012
9882,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2012
9883,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2012
9884,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2012
9885,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2012
9886,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2012
9887,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2012
9888,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2012
9889,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2012
9890,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2012
9891,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2012
9892,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2012
9893,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2012
9894,U-480,CONTRAST AGENT FOR MRI,2012
9895,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2012
9896,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2012
9897,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2012
9898,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2012
9899,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2012
9900,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2012
9901,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2012
9902,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2012
9903,U-489,EXPECTORANT,2012
9904,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2012
9905,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2012
9906,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2012
9907,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2012
9908,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2012
9909,U-495,PERITONEAL DIALYSIS SOLUTION,2012
9910,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2012
9911,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2012
9912,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2012
9913,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2012
9914,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2012
9915,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2012
9916,U-502,PITYRIASIS VERSICOLOR,2012
9917,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2012
9918,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2012
9919,U-505,ULTRASOUND CONTRAST AGENT,2012
9920,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2012
9921,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2012
9922,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2012
9923,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2012
9924,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2012
9925,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2012
9926,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2012
9927,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2012
9928,U-514,PREVENTION OF OVULATION IN A WOMAN,2012
9929,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2012
9930,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2012
9931,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2012
9932,U-518,OBSESSIVE COMPULSIVE DISORDER,2012
9933,U-519,POST OPERATIVE NAUSEA AND VOMITING,2012
9934,U-520,PREMENOPAUSAL OSTEOPOROSIS,2012
9935,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2012
9936,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2012
9937,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2012
9938,U-524,METHOD OF TREATING DIARRHEA,2012
9939,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2012
9940,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2012
9941,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2012
9942,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2012
9943,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2012
9944,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2012
9945,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2012
9946,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2012
9947,U-533,ERECTILE DYSFUNCTION,2012
9948,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2012
9949,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2012
9950,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2012
9951,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2012
9952,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2012
9953,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2012
9954,U-540,TREATMENT OF FUNGAL INFECTIONS,2012
9955,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2012
9956,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2012
9957,U-543,TREATMENT OF SCHIZOPHRENIA,2012
9958,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2012
9959,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2012
9960,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2012
9961,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2012
9962,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2012
9963,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2012
9964,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2012
9965,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2012
9966,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2012
9967,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2012
9968,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2012
9969,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2012
9970,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2012
9971,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2012
9972,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2012
9973,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2012
9974,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2012
9975,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2012
9976,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2012
9977,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2012
9978,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2012
9979,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2012
9980,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2012
9981,U-567,METHOD OF TREATING INFERTILITY,2012
9982,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2012
9983,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2012
9984,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2012
9985,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2012
9986,U-572,INTENSIVE CARE UNIT SEDATION,2012
9987,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2012
9988,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2012
9989,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2012
9990,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2012
9991,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2012
9992,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2012
9993,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2012
9994,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2012
9995,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2012
9996,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2012
9997,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2012
9998,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2012
9999,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2012
10000,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2012
10001,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2012
10002,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2012
10003,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2012
10004,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2012
10005,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2012
10006,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2012
10007,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2012
10008,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2012
10009,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
10010,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2012
10011,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2012
10012,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2012
10013,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2012
10014,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2012
10015,U-601,TREATMENT OF BIPOLAR DISORDER,2012
10016,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2012
10017,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2012
10018,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2012
10019,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2012
10020,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2012
10021,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2012
10022,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2012
10023,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2012
10024,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2012
10025,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2012
10026,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2012
10027,U-613,REDUCTION OF SERUM PHOSPHATE,2012
10028,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2012
10029,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2012
10030,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2012
10031,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2012
10032,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2012
10033,U-619,TREATMENT OF MALIGNANT NEOPLASM,2012
10034,U-620,TREATMENT OF INSOMNIA,2012
10035,U-621,METHOD OF TREATING CANCER,2012
10036,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2012
10037,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2012
10038,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2012
10039,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2012
10040,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2012
10041,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2012
10042,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2012
10043,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2012
10044,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2012
10045,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2012
10046,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2012
10047,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2012
10048,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2012
10049,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2012
10050,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2012
10051,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2012
10052,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2012
10053,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2012
10054,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2012
10055,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2012
10056,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2012
10057,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2012
10058,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2012
10059,U-645,TREATMENT OF ASTHMA,2012
10060,U-646,METHOD OF TREATING OTITIS,2012
10061,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
10062,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2012
10063,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2012
10064,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2012
10065,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2012
10066,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2012
10067,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2012
10068,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2012
10069,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2012
10070,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2012
10071,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
10072,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2012
10073,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2012
10074,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2012
10075,U-661,TREATMENT OF SEIZURE DISORDER,2012
10076,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
10077,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2012
10078,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2012
10079,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2012
10080,U-666,METHOD OF TREATING ADHD,2012
10081,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2012
10082,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2012
10083,U-669,INDICATION OF TYPE II DIABETES,2012
10084,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2012
10085,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2012
10086,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2012
10087,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2012
10088,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2012
10089,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2012
10090,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2012
10091,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2012
10092,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2012
10093,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2012
10094,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2012
10095,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2012
10096,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2012
10097,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2012
10098,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2012
10099,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2012
10100,U-686,EXPECTORANT AND NASAL DECONGESTANT,2012
10101,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2012
10102,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2012
10103,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2012
10104,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2012
10105,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2012
10106,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2012
10107,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2012
10108,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2012
10109,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2012
10110,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2012
10111,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2012
10112,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2012
10113,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2012
10114,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2012
10115,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2012
10116,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2012
10117,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2012
10118,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2012
10119,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2012
10120,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2012
10121,U-707,ALLERGIC RHINITIS,2012
10122,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2012
10123,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2012
10124,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2012
10125,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2012
10126,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2012
10127,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2012
10128,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2012
10129,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2012
10130,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2012
10131,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2012
10132,U-718,TREATMENT OF FUNGAL INFECTIONS,2012
10133,U-719,TREATENT OF PSYCHOSIS,2012
10134,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2012
10135,U-721,TREATMENT OF INFLUENZA,2012
10136,U-722,PROPHYLAXIS OF INFLUENZA,2012
10137,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2012
10138,U-724,METHOD OF TREATING SEIZURES,2012
10139,U-725,ALLERGIC RHINITIS AND URTICARIA,2012
10140,U-726,ALLERGIC RHINITIS,2012
10141,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2012
10142,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2012
10143,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2012
10144,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2012
10145,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2012
10146,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2012
10147,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2012
10148,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2012
10149,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2012
10150,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2012
10151,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2012
10152,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2012
10153,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2012
10154,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2012
10155,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2012
10156,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2012
10157,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2012
10158,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2012
10159,U-745,TREATMENT OR PREVENTION OF EMESIS,2012
10160,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2012
10161,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2012
10162,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2012
10163,U-749,METHOD OF CONTRACEPTION,2012
10164,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2012
10165,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2012
10166,U-752,SUNSCREEN,2012
10167,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2012
10168,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2012
10169,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2012
10170,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
10171,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2012
10172,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2012
10173,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2012
10174,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2012
10175,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2012
10176,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2012
10177,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2012
10178,U-764,TREATMENT OF SCHIZOPHRENIA,2012
10179,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2012
10180,U-766,TREATMENT OF SEIZURES,2012
10181,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2012
10182,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2012
10183,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2012
10184,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2012
10185,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2012
10186,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2012
10187,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2012
10188,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2012
10189,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2012
10190,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2012
10191,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2012
10192,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSUE IN PATEINTS WITH OPEN ANGLE GLAUCOME OR OCULAR HYPERTENSION,2012
10193,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2012
10194,U-780,A METHOD FOR THE TREATMENT OF CANCER,2012
10195,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2012
10196,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2012
10197,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2012
10198,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2012
10199,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2012
10200,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2012
10201,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2012
10202,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2012
10203,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2012
10204,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2012
10205,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2012
10206,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2012
10207,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2012
10208,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2012
10209,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2012
10210,U-796,METHOD OF TREATING DEPRESSION,2012
10211,U-797,METHOD OF TREATING ANXIETY,2012
10212,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2012
10213,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2012
10214,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2012
10215,U-801,METHOD OF TREATING CANCER,2012
10216,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2012
10217,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2012
10218,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2012
10219,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2012
10220,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2012
10221,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2012
10222,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2012
10223,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2012
10224,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2012
10225,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2012
10226,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2012
10227,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2012
10228,U-814,TREATMENT OF SCHIZOPHRENIA,2012
10229,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2012
10230,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2012
10231,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2012
10232,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2012
10233,U-819,MANAGEMENT OF FIBROMYALGIA,2012
10234,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2012
10235,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2012
10236,U-822,USE IN LIPID MANAGEMENT,2012
10237,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2012
10238,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2012
10239,U-825,USE FOR PREVENTION OF BREAST CANCER,2012
10240,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2012
10241,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2012
10242,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2012
10243,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2012
10244,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2012
10245,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2012
10246,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2012
10247,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2012
10248,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2012
10249,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2012
10250,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2012
10251,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2012
10252,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2012
10253,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2012
10254,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2012
10255,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2012
10256,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2012
10257,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2012
10258,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2012
10259,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2012
10260,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2012
10261,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2012
10262,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2012
10263,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2012
10264,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2012
10265,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2012
10266,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2012
10267,U-853,TREATMENT OR PREVENTION OF EMESIS,2012
10268,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2012
10269,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2012
10270,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2012
10271,U-857,INHIBITION OF TRANSPLANT REJECTION,2012
10272,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2012
10273,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2012
10274,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2012
10275,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2012
10276,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2012
10277,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2012
10278,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2012
10279,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2012
10280,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2012
10281,U-867,TREATMENT OF MIGRAINE,2012
10282,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2012
10283,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2012
10284,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2012
10285,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2012
10286,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2012
10287,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2012
10288,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2012
10289,U-875,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE",2012
10290,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2012
10291,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2012
10292,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2012
10293,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2012
10294,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2012
10295,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2012
10296,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2012
10297,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2012
10298,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2012
10299,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2012
10300,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2012
10301,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2012
10302,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2012
10303,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2012
10304,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2012
10305,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2012
10306,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2012
10307,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2012
10308,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2012
10309,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2012
10310,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2012
10311,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2012
10312,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2012
10313,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2012
10314,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2012
10315,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2012
10316,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2012
10317,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2012
10318,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2012
10319,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2012
10320,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2012
10321,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2012
10322,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2012
10323,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2012
10324,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2012
10325,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2012
10326,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2012
10327,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2012
10328,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2012
10329,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2012
10330,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2012
10331,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2012
10332,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2012
10333,U-919,FOR THE TREATMENT OF DERMATITIS,2012
10334,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2012
10335,U-921,TREATMENT OF ACNE VULGARIS,2012
10336,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2012
10337,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2012
10338,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2012
10339,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2012
10340,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2012
10341,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2012
10342,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2012
10343,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2012
10344,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2012
10345,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2012
10346,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2012
10347,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2012
10348,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2012
10349,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2012
10350,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2012
10351,U-937,TREATMENT OF PROSTATE CANCER,2012
10352,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2012
10353,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2012
10354,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2012
10355,U-941,METHOD TO TREAT OVARIAN CANCER,2012
10356,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2012
10357,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2012
10358,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2012
10359,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2012
10360,U-946,TREATMENT OF BREAST CANCER,2012
10361,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2012
10362,U-948,TREATMENT OF DIABETES MELLITUS,2012
10363,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2012
10364,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2012
10365,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2012
10366,U-952,USE AS AN ANALGESIC,2012
10367,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2012
10368,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2012
10369,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2012
10370,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2012
10371,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2012
10372,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2012
10373,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2012
10374,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2012
10375,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2012
10376,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2012
10377,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2012
10378,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2012
10379,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2012
10380,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2012
10381,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2012
10382,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2012
10383,U-969,TREATMENT OF MIGRAINE,2012
10384,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2012
10385,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2012
10386,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2012
10387,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2012
10388,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2012
10389,U-975,TREATMENT OF PULMONARY HYPERTENSION,2012
10390,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2012
10391,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2012
10392,U-978,METHOD OF TREATING HYPONATREMIA,2012
10393,U-979,RELIEF OF MUSCLE SPASM,2012
10394,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2012
10395,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2012
10396,U-982,A METHOD OF TREATING OSTEOPOROSIS,2012
10397,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2012
10398,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2012
10399,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2012
10400,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2012
10401,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2012
10402,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2012
10403,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2012
10404,U-990,TREATMENT OF PROTOZOAL INFECTION,2012
10405,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2012
10406,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2012
10407,U-993,METHOD OF TREATING INFERTILITY,2012
10408,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2012
10409,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2012
10410,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2012
10411,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2012
10412,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2012
10413,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2012
10414,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2012
10415,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2012
10416,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2012
10417,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2012
10418,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2012
10419,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2012
10420,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2012
10421,U-1007,METHOD OF TREATING GOUT FLARES,2012
10422,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2012
10423,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2012
10424,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2012
10425,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2012
10426,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2012
10427,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2012
10428,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2012
10429,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2012
10430,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2012
10431,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2012
10432,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2012
10433,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2012
10434,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2012
10435,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2012
10436,U-1022,FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2012
10437,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2012
10438,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2012
10439,U-1025,TREATING FREQUENT HEARTBURN,2012
10440,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2012
10441,U-1027,REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL,2012
10442,U-1028,A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY,2012
10443,U-1029,METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF,2012
10444,U-1030,IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS),2012
10445,U-1031,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2012
10446,U-1032,USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS,2012
10447,U-1033,TOPICAL TREATMENT OF ACNE VULGARIS,2012
10448,U-1034,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2012
10449,U-1035,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2012
10450,U-1036,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN,2012
10451,U-1037,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST,2012
10452,U-1038,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST,2012
10453,U-1039,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN,2012
10454,U-1040,INHIBITION OF THROMBIN IN A PATIENT,2012
10455,U-1041,TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE,2012
10456,U-1042,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2012
10457,U-1043,MANAGEMENT OF MODERATE TO SEVERE PAIN,2012
10458,U-1044,TOPICAL TREATMENT OF SCALP PSORIASIS,2012
10459,U-1045,MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY,2012
10460,U-1046,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY,2012
10461,U-1047,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)",2012
10462,U-1048,WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES,2012
10463,U-1049,PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT,2012
10464,U-1050,USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS,2012
10465,U-1051,TREATMENT OF OROPHARYNGEAL CANDIDIASIS,2012
10466,U-1052,RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2012
10467,U-1053,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2012
10468,U-1054,"ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS",2012
10469,U-1055,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE,2012
10470,U-1056,TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2012
10471,U-1057,TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2012
10472,U-1058,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2012
10473,U-1059,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,2012
10474,U-1060,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS,2012
10475,U-1061,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,2012
10476,U-1062,ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE,2012
10477,U-1063,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,2012
10478,U-1064,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2012
10479,U-1065,METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY,2012
10480,U-1066,METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA,2012
10481,U-1067,TREATMENT OF CANCER,2012
10482,U-1068,TREATMENT OF ASTHMA,2012
10483,U-1069,A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2012
10484,U-1070,A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE,2012
10485,U-1071,METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION,2012
10486,U-1072,"THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME",2012
10487,U-1073,USE FOR THE TREATMENT OF ASTHMA AND COPD,2012
10488,U-1074,USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT,2012
10489,U-1075,USE FOR THE TREATMENT OF ASTHA,2012
10490,U-1076,"REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING",2012
10491,U-1077,PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRAION,2012
10492,U-1078,TREATMENT OF ACNE,2012
10493,U-1079,REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2012
10494,U-1080,METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT,2012
10495,U-1081,LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2012
10496,U-1082,USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS,2012
10497,U-1083,"ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES",2012
10498,U-1084,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2012
10499,U-1085,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,2012
10500,U-1086,TREATMENT OF AUTOIMMUNE DISEASE,2012
10501,U-1087,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,2012
10502,U-1088,RELIEF OF MUSCLE SPASM,2012
10503,U-1089,INHIBITION OF THROMBIN,2012
10504,U-1090,LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION,2012
10505,U-1091,ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA,2012
10506,U-1092,TREATMENT OF BREAST CANCER,2012
10507,U-1093,TREATMENT OF PSEUDOBULBAR AFFECT,2012
10508,U-1094,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2012
10509,U-1095,METHOD OF TREATING OCULAR INFLAMMATION,2012
10510,U-1096,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,2012
10511,U-1097,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,2012
10512,U-1098,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,2012
10513,U-1099,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2012
10514,U-1100,REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY,2012
10515,U-1101,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2012
10516,U-1102,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,2012
10517,U-1103,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2012
10518,U-1104,USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN,2012
10519,U-1105,TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER,2012
10520,U-1106,TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT,2012
10521,U-1107,TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT,2012
10522,U-1108,TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE,2012
10523,U-1109,"TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2012
10524,U-1110,METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2012
10525,U-1111,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2012
10526,U-1112,METHOD OF MR IMAGING OF A MAMMAL,2012
10527,U-1113,TREATMENT AND PROPHYLAXIS OF INFLUENZA,2012
10528,U-1114,"TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA",2012
10529,U-1115,TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS,2012
10530,U-1116,METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS,2012
10531,U-1117,TREATMENT OF BREAST CANCER,2012
10532,U-1118,"USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2012
10533,U-1119,CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING,2012
10534,U-1120,TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL,2012
10535,U-1121,METHOD OF TREATING TRAVELERS' DIARRHEA,2012
10536,U-1122,TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES,2012
10537,U-1123,TREATMENT OF ALCOHOL DEPENDENCE,2012
10538,U-1124,"PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION",2012
10539,U-1125,METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS,2012
10540,U-1126,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL,2012
10541,U-1127,TREATMENT OF PATENT DUCTUS ARTERIOSUS,2012
10542,U-1128,TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE,2012
10543,U-1129,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2012
10544,U-1130,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN,2012
10545,U-1131,"TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2012
10546,U-1132,TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10547,U-1133,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10548,U-1134,TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10549,U-1135,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C",2012
10550,U-1136,"SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2012
10551,U-1137,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2012
10552,U-1138,TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10553,U-1139,REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10554,U-1140,REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10555,U-1141,REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10556,U-1142,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2012
10557,U-1143,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2012
10558,U-1144,"REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2012
10559,U-1145,"REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2012
10560,U-1146,REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2012
10561,U-1147,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2012
10562,U-1148,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2012
10563,U-1149,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2012
10564,U-1150,"TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C",2012
10565,U-1151,"TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C",2012
10566,U-1152,CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION,2012
10567,U-1153,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION",2012
10568,U-1154,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB",2012
10569,U-1155,USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL),2012
10570,U-1156,TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA),2012
10571,U-1157,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2012
10572,U-1158,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2012
10573,U-1159,"RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER",2012
10574,U-1160,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER,2012
10575,U-1161,FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER,2012
10576,U-1162,TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP,2012
10577,U-1163,METHOD OF TREATING THROMBOSIS,2012
10578,U-1164,METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION,2012
10579,U-1165,USE FOR THE TREATMENT OF MULTIPLE MYELOMA,2012
10580,U-1166,A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS,2012
10581,U-1167,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),2012
10582,U-1168,"THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA",2012
10583,U-1169,MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN,2012
10584,U-1170,TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2012
10585,U-1171,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,2012
10586,U-1172,"TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN",2012
10587,U-1173,"TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE",2012
10588,U-1174,"ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION",2012
10589,U-1175,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2012
10590,U-1176,TREATMENT OR PREVENTION OF STROKE,2012
10591,U-1177,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2012
10592,U-1178,RELIEF OF MODERATE TO SEVERE CHRONIC PAIN,2012
10593,U-1179,TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK),2012
10594,U-1180,TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS,2012
10595,U-1181,A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT,2012
10596,U-1182,TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING,2012
10597,U-1183,A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN,2012
10598,U-1184,TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA,2012
10599,U-1185,TREATMENT OF OPIOID-INDUCED CONSTIPATION,2012
10600,U-1186,ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE,2012
10601,U-1187,TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE),2012
10602,U-1188,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE,2012
10603,U-1189,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN",2012
10604,U-1190,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN",2012
10605,U-1191,"METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)",2012
10606,U-1192,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)",2012
10607,U-1193,"METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)",2012
10608,U-1194,METHOD FOR TREATING INSOMNIA,2012
10609,U-1195,"PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA",2012
10610,U-1196,RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS,2012
10611,U-1197,METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY,2012
10612,U-1198,RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE,2012
10613,U-1199,TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2012
10614,U-1200,REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM,2012
10615,U-1201,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,2012
10616,U-1202,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2012
10617,U-1203,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2012
10618,U-1204,TREATMENT OF UVEITIS,2012
10619,U-1205,TREATMENT OF MACULAR EDEMA,2012
10620,U-1206,DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX,2012
10621,U-1207,"INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS",2012
10622,U-1208,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2012
10623,U,PATENT USE CODE (SEE INDIVIDUAL REFERENCES),2013
10624,U-1,PREVENTION OF PREGNANCY,2013
10625,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2013
10626,U-3,TREATMENT OF HYPERTENSION,2013
10627,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2013
10628,U-5,METHOD OF PRODUCING BRONCHODILATION,2013
10629,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2013
10630,U-7,INCREASING CARDIAC CONTRACTILITY,2013
10631,U-8,ACUTE MYOCARDIAL INFARCTION,2013
10632,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2013
10633,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2013
10634,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2013
10635,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2013
10636,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2013
10637,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2013
10638,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2013
10639,U-16,USE IN LUNG SCANNING PROCEDURES,2013
10640,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2013
10641,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2013
10642,U-19,TREATMENT OF INFLAMMATION,2013
10643,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2013
10644,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2013
10645,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2013
10646,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2013
10647,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2013
10648,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2013
10649,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2013
10650,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2013
10651,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2013
10652,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2013
10653,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2013
10654,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2013
10655,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2013
10656,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2013
10657,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2013
10658,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2013
10659,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2013
10660,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2013
10661,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2013
10662,U-39,ANGINA PECTORIS,2013
10663,U-40,METHOD OF TREATMENT OF BURNS,2013
10664,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2013
10665,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2013
10666,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2013
10667,U-44,RELIEF OF NAUSEA AND VOMITING,2013
10668,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2013
10669,U-46,TREATMENT OF PANIC DISORDER,2013
10670,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2013
10671,U-48,ANALGESIA,2013
10672,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2013
10673,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2013
10674,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2013
10675,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2013
10676,U-53,HYPERCALCEMIA OF MALIGNANCY,2013
10677,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2013
10678,U-55,TREATMENT OF PAIN,2013
10679,U-56,AID TO SMOKING CESSATION,2013
10680,U-57,OPHTHALMIC USE OF NORFLOXACIN,2013
10681,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2013
10682,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2013
10683,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2013
10684,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2013
10685,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2013
10686,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2013
10687,U-64,TREATMENT OF VIRAL INFECTIONS,2013
10688,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2013
10689,U-66,TRIPHASIC REGIMEN,2013
10690,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2013
10691,U-68,TREATMENT OF ACTINIC KERATOSIS,2013
10692,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2013
10693,U-70,TREATMENT OF TRANSIENT INSOMNIA,2013
10694,U-71,METHOD OF TREATMENT OF HEART FAILURE,2013
10695,U-72,TREATMENT OF MIGRAINE,2013
10696,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2013
10697,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2013
10698,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2013
10699,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2013
10700,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2013
10701,U-78,ULCERATIVE COLITIS,2013
10702,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2013
10703,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2013
10704,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2013
10705,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2013
10706,U-83,TREATMENT OF SEIZURES,2013
10707,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2013
10708,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2013
10709,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2013
10710,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2013
10711,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2013
10712,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2013
10713,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2013
10714,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2013
10715,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2013
10716,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2013
10717,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2013
10718,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2013
10719,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2013
10720,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2013
10721,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2013
10722,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2013
10723,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2013
10724,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2013
10725,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2013
10726,U-103,TREATMENT OF OCULAR HYPERTENSION,2013
10727,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2013
10728,U-105,EMESIS,2013
10729,U-106,TREATMENT OF EPILEPSY,2013
10730,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2013
10731,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2013
10732,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2013
10733,U-110,USE AS A RETRIEVABLE PERSSARY,2013
10734,U-111,DIABETES,2013
10735,U-112,CONTRACEPTION,2013
10736,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2013
10737,U-114,USE FOR INHIBITING BONE RESORPTION,2013
10738,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2013
10739,U-116,METHOD OF MYOCARDIAL IMAGING,2013
10740,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2013
10741,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2013
10742,U-119,TREATMENT OF NASAL HYPERSECRETION,2013
10743,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2013
10744,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2013
10745,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2013
10746,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2013
10747,U-124,TREATMENT OF ACNE,2013
10748,U-125,TREATMENT NEUROGENERATIVE DISEASES,2013
10749,U-126,TREATMENT OF GASTRITIS,2013
10750,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2013
10751,U-128,METHOD FOR TREATMENT OF TUMORS,2013
10752,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2013
10753,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2013
10754,U-131,PHOTODAMAGED SKIN,2013
10755,U-132,INHIBITING HIV PROTEASE,2013
10756,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2013
10757,U-134,TREATMENT OF ACNE VULGARIS,2013
10758,U-135,ANTITUMOR AGENT,2013
10759,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2013
10760,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2013
10761,U-138,TREATMENT OF ALLERGIC RHINITIS,2013
10762,U-139,TREATMENT OF ALLERGIC REACTIONS,2013
10763,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2013
10764,U-141,TREATMENT OF ULCERATIVE COLITIS,2013
10765,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2013
10766,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2013
10767,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2013
10768,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2013
10769,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2013
10770,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2013
10771,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2013
10772,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2013
10773,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2013
10774,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2013
10775,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2013
10776,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2013
10777,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2013
10778,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2013
10779,U-156,METHOD OF PROVIDING ANESTHESIA,2013
10780,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2013
10781,U-158,ANGINA,2013
10782,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2013
10783,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2013
10784,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2013
10785,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2013
10786,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2013
10787,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2013
10788,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2013
10789,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2013
10790,U-167,METHOD FOR TREATING HIV-1 INFECTION,2013
10791,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2013
10792,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2013
10793,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2013
10794,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2013
10795,U-172,TREATMENT OF GENITAL WARTS,2013
10796,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2013
10797,U-174,USE AS AN ANTIHISTAMINE AGENT,2013
10798,U-175,METHOD OF TREATING MALIGNANT TUMORS,2013
10799,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2013
10800,U-177,FUNGICIDE,2013
10801,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2013
10802,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2013
10803,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2013
10804,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2013
10805,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2013
10806,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2013
10807,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2013
10808,U-185,METHOD OF TREATING HYPERTENSION,2013
10809,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2013
10810,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2013
10811,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2013
10812,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2013
10813,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2013
10814,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2013
10815,U-192,USE IN TREATING ALLERGIC REACTIONS,2013
10816,U-193,PSORIASIS,2013
10817,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2013
10818,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2013
10819,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2013
10820,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2013
10821,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2013
10822,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2013
10823,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2013
10824,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2013
10825,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2013
10826,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2013
10827,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2013
10828,U-205,METHOD FOR TREATING HEARTBURN,2013
10829,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2013
10830,U-207,USE AS NASAL SPRAY,2013
10831,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2013
10832,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2013
10833,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2013
10834,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2013
10835,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2013
10836,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2013
10837,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2013
10838,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2013
10839,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2013
10840,U-217,METHOD OF PRODUCING ANESTHESIA,2013
10841,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2013
10842,U-219,TREATMENT OF PARKINSON'S DISEASE,2013
10843,U-220,METHOD OF DIAGNOSIS,2013
10844,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2013
10845,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2013
10846,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2013
10847,U-224,CONTROLLING INTRAOCULAR PRESSURE,2013
10848,U-225,METHOD FOR DELIVERY,2013
10849,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2013
10850,U-227,NASAL ADMINISTRATION,2013
10851,U-228,ASTHMA,2013
10852,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2013
10853,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2013
10854,U-231,USE IN PARKINSON'S DISEASE,2013
10855,U-232,METHOD OF TREATING MIGRAINE,2013
10856,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2013
10857,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2013
10858,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2013
10859,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2013
10860,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2013
10861,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2013
10862,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2013
10863,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2013
10864,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2013
10865,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2013
10866,U-243,TOPICAL ADMINISTRATION,2013
10867,U-244,PLATELET AGGREGATION INHIBITORS,2013
10868,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2013
10869,U-246,PHOSPHATE BINDING,2013
10870,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2013
10871,U-248,TREATMENT OF HIV,2013
10872,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2013
10873,U-250,TREATMENT OF HEPATITIS B INFECTION,2013
10874,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2013
10875,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2013
10876,U-253,ORAL TRANSMUCOSAL USE,2013
10877,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2013
10878,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2013
10879,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2013
10880,U-257,TREATMENT OF HIV INFECTION,2013
10881,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2013
10882,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2013
10883,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2013
10884,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2013
10885,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2013
10886,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2013
10887,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2013
10888,U-265,USE AS LAXATIVE,2013
10889,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2013
10890,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2013
10891,U-268,ACROMEGALY,2013
10892,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2013
10893,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2013
10894,U-271,METHOD OF TREATING TUMORS,2013
10895,U-272,METHOD OF TREATING CARCINOMA,2013
10896,U-273,CUTANEOUS T-CELL LYMPHOMA,2013
10897,U-274,ZANAMIVIR FOR INHALATION,2013
10898,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2013
10899,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2013
10900,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2013
10901,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2013
10902,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2013
10903,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2013
10904,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2013
10905,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2013
10906,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2013
10907,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2013
10908,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2013
10909,U-286,DEPRESSION,2013
10910,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2013
10911,U-288,THERAPY OF INFLUENZA,2013
10912,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2013
10913,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2013
10914,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2013
10915,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2013
10916,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2013
10917,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2013
10918,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2013
10919,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2013
10920,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2013
10921,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2013
10922,U-299,TREATMENT OF ADENOMATOUS POLYPS,2013
10923,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2013
10924,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2013
10925,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2013
10926,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2013
10927,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2013
10928,U-305,METHODS FOR USING THE DRUG PRODUCT,2013
10929,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2013
10930,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2013
10931,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2013
10932,U-309,TREATING SJOEGREN SYNDROME,2013
10933,U-310,TREATMENT OF XEROSTOMIA,2013
10934,U-311,HORMONE REPLACEMENT,2013
10935,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2013
10936,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2013
10937,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2013
10938,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2013
10939,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2013
10940,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2013
10941,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2013
10942,U-319,TREATMENT OF MICROBIAL INFECTIONS,2013
10943,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2013
10944,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2013
10945,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2013
10946,U-323,USE AS A BILE ACID SEQUESTRANT,2013
10947,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2013
10948,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2013
10949,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2013
10950,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2013
10951,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2013
10952,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2013
10953,U-330,TREATMENT OF NAUSEA AND VOMITING,2013
10954,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
10955,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2013
10956,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2013
10957,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2013
10958,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2013
10959,U-336,DIAGNOSTIC RADIOIMAGING,2013
10960,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2013
10961,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2013
10962,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2013
10963,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2013
10964,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2013
10965,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2013
10966,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2013
10967,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2013
10968,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2013
10969,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2013
10970,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2013
10971,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2013
10972,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2013
10973,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2013
10974,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2013
10975,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2013
10976,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2013
10977,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2013
10978,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2013
10979,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2013
10980,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2013
10981,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2013
10982,U-359,METHOD OF USE OF VISICOL,2013
10983,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2013
10984,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2013
10985,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2013
10986,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2013
10987,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2013
10988,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2013
10989,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2013
10990,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2013
10991,U-368,HEARTBURN,2013
10992,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2013
10993,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2013
10994,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2013
10995,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2013
10996,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2013
10997,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2013
10998,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2013
10999,U-376,TREATMENT OF INFLUENZA,2013
11000,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2013
11001,U-378,METHOD FOR TREATING INCONTINENCE,2013
11002,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2013
11003,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2013
11004,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2013
11005,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2013
11006,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2013
11007,U-384,TREATMENT OF CMV RETINITIS,2013
11008,U-385,TREATMENT OF PEPTIC ULCERS,2013
11009,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2013
11010,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2013
11011,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2013
11012,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2013
11013,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2013
11014,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2013
11015,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2013
11016,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2013
11017,U-394,METHOD OF USE OF ALPHAGAN,2013
11018,U-395,METHOD OF USE OF ALPHAGAN P,2013
11019,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2013
11020,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2013
11021,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2013
11022,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2013
11023,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2013
11024,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2013
11025,U-402,TREATMENT OF ACTINIC KERATOSES,2013
11026,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2013
11027,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2013
11028,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2013
11029,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2013
11030,U-407,METHOD OF TREATING OTOPATHY,2013
11031,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2013
11032,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2013
11033,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2013
11034,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2013
11035,U-412,TREATMENT OF TYPE 2 DIABETES,2013
11036,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2013
11037,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2013
11038,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2013
11039,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2013
11040,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2013
11041,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2013
11042,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2013
11043,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2013
11044,U-421,USE FOR SEDATION,2013
11045,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2013
11046,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2013
11047,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2013
11048,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2013
11049,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2013
11050,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2013
11051,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2013
11052,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2013
11053,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2013
11054,U-431,POSTTRAUMATIC STRESS DISORDER,2013
11055,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2013
11056,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2013
11057,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2013
11058,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2013
11059,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2013
11060,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2013
11061,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2013
11062,U-439,TREATMENT OF OBESITY,2013
11063,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2013
11064,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2013
11065,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2013
11066,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2013
11067,U-444,TREATMENT OF MIGRAINE,2013
11068,U-445,USE AS AN ANTIMYCOTIC AGENT,2013
11069,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2013
11070,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11071,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2013
11072,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2013
11073,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2013
11074,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2013
11075,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2013
11076,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2013
11077,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2013
11078,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2013
11079,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2013
11080,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2013
11081,U-458,METHOD OF USE OF IMAGENT,2013
11082,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2013
11083,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2013
11084,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2013
11085,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2013
11086,U-463,VENOGRAPHY,2013
11087,U-464,PERIPHERAL ARTERIOGRAPHY,2013
11088,U-465,CT IMAGING OF THE HEAD,2013
11089,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2013
11090,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2013
11091,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2013
11092,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2013
11093,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2013
11094,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2013
11095,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2013
11096,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2013
11097,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2013
11098,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2013
11099,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2013
11100,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2013
11101,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2013
11102,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2013
11103,U-480,CONTRAST AGENT FOR MRI,2013
11104,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2013
11105,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2013
11106,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2013
11107,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2013
11108,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2013
11109,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2013
11110,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2013
11111,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2013
11112,U-489,EXPECTORANT,2013
11113,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2013
11114,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2013
11115,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2013
11116,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2013
11117,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2013
11118,U-495,PERITONEAL DIALYSIS SOLUTION,2013
11119,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2013
11120,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2013
11121,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2013
11122,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2013
11123,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2013
11124,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2013
11125,U-502,PITYRIASIS VERSICOLOR,2013
11126,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2013
11127,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2013
11128,U-505,ULTRASOUND CONTRAST AGENT,2013
11129,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2013
11130,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2013
11131,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2013
11132,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2013
11133,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2013
11134,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2013
11135,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2013
11136,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2013
11137,U-514,PREVENTION OF OVULATION IN A WOMAN,2013
11138,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2013
11139,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2013
11140,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2013
11141,U-518,OBSESSIVE COMPULSIVE DISORDER,2013
11142,U-519,POST OPERATIVE NAUSEA AND VOMITING,2013
11143,U-520,PREMENOPAUSAL OSTEOPOROSIS,2013
11144,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2013
11145,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2013
11146,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2013
11147,U-524,METHOD OF TREATING DIARRHEA,2013
11148,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2013
11149,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2013
11150,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2013
11151,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2013
11152,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2013
11153,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2013
11154,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2013
11155,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2013
11156,U-533,ERECTILE DYSFUNCTION,2013
11157,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2013
11158,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2013
11159,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2013
11160,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2013
11161,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2013
11162,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2013
11163,U-540,TREATMENT OF FUNGAL INFECTIONS,2013
11164,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2013
11165,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2013
11166,U-543,TREATMENT OF SCHIZOPHRENIA,2013
11167,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2013
11168,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2013
11169,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2013
11170,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2013
11171,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2013
11172,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2013
11173,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2013
11174,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2013
11175,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2013
11176,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2013
11177,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2013
11178,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2013
11179,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2013
11180,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2013
11181,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2013
11182,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2013
11183,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2013
11184,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2013
11185,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2013
11186,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2013
11187,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2013
11188,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2013
11189,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2013
11190,U-567,METHOD OF TREATING INFERTILITY,2013
11191,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2013
11192,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2013
11193,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2013
11194,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2013
11195,U-572,INTENSIVE CARE UNIT SEDATION,2013
11196,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2013
11197,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2013
11198,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2013
11199,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2013
11200,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2013
11201,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2013
11202,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2013
11203,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2013
11204,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2013
11205,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2013
11206,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2013
11207,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2013
11208,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2013
11209,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2013
11210,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2013
11211,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2013
11212,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2013
11213,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2013
11214,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2013
11215,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2013
11216,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2013
11217,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2013
11218,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
11219,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2013
11220,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2013
11221,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2013
11222,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2013
11223,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2013
11224,U-601,TREATMENT OF BIPOLAR DISORDER,2013
11225,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2013
11226,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2013
11227,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2013
11228,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2013
11229,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2013
11230,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2013
11231,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2013
11232,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2013
11233,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2013
11234,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2013
11235,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2013
11236,U-613,REDUCTION OF SERUM PHOSPHATE,2013
11237,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2013
11238,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2013
11239,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2013
11240,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2013
11241,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2013
11242,U-619,TREATMENT OF MALIGNANT NEOPLASM,2013
11243,U-620,TREATMENT OF INSOMNIA,2013
11244,U-621,METHOD OF TREATING CANCER,2013
11245,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2013
11246,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2013
11247,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2013
11248,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2013
11249,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2013
11250,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2013
11251,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2013
11252,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2013
11253,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2013
11254,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2013
11255,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2013
11256,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2013
11257,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2013
11258,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2013
11259,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2013
11260,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2013
11261,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2013
11262,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2013
11263,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2013
11264,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2013
11265,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2013
11266,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2013
11267,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2013
11268,U-645,TREATMENT OF ASTHMA,2013
11269,U-646,METHOD OF TREATING OTITIS,2013
11270,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
11271,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2013
11272,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2013
11273,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2013
11274,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2013
11275,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2013
11276,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2013
11277,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2013
11278,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2013
11279,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2013
11280,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
11281,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2013
11282,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2013
11283,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2013
11284,U-661,TREATMENT OF SEIZURE DISORDER,2013
11285,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
11286,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2013
11287,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2013
11288,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2013
11289,U-666,METHOD OF TREATING ADHD,2013
11290,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2013
11291,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2013
11292,U-669,INDICATION OF TYPE II DIABETES,2013
11293,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2013
11294,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2013
11295,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2013
11296,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2013
11297,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2013
11298,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2013
11299,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2013
11300,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2013
11301,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2013
11302,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2013
11303,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2013
11304,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2013
11305,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2013
11306,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2013
11307,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2013
11308,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2013
11309,U-686,EXPECTORANT AND NASAL DECONGESTANT,2013
11310,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2013
11311,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2013
11312,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2013
11313,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2013
11314,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2013
11315,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2013
11316,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2013
11317,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2013
11318,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2013
11319,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2013
11320,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2013
11321,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2013
11322,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2013
11323,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2013
11324,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2013
11325,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2013
11326,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2013
11327,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2013
11328,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2013
11329,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2013
11330,U-707,ALLERGIC RHINITIS,2013
11331,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2013
11332,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2013
11333,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2013
11334,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2013
11335,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2013
11336,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2013
11337,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2013
11338,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2013
11339,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2013
11340,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2013
11341,U-718,TREATMENT OF FUNGAL INFECTIONS,2013
11342,U-719,TREATENT OF PSYCHOSIS,2013
11343,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2013
11344,U-721,TREATMENT OF INFLUENZA,2013
11345,U-722,PROPHYLAXIS OF INFLUENZA,2013
11346,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2013
11347,U-724,METHOD OF TREATING SEIZURES,2013
11348,U-725,ALLERGIC RHINITIS AND URTICARIA,2013
11349,U-726,ALLERGIC RHINITIS,2013
11350,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2013
11351,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2013
11352,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2013
11353,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2013
11354,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2013
11355,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2013
11356,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2013
11357,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2013
11358,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2013
11359,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2013
11360,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2013
11361,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2013
11362,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2013
11363,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2013
11364,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2013
11365,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2013
11366,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2013
11367,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2013
11368,U-745,TREATMENT OR PREVENTION OF EMESIS,2013
11369,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2013
11370,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2013
11371,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2013
11372,U-749,METHOD OF CONTRACEPTION,2013
11373,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2013
11374,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2013
11375,U-752,SUNSCREEN,2013
11376,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2013
11377,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2013
11378,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2013
11379,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
11380,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2013
11381,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2013
11382,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2013
11383,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2013
11384,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2013
11385,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2013
11386,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2013
11387,U-764,TREATMENT OF SCHIZOPHRENIA,2013
11388,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2013
11389,U-766,TREATMENT OF SEIZURES,2013
11390,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2013
11391,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2013
11392,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2013
11393,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2013
11394,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2013
11395,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2013
11396,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2013
11397,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2013
11398,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2013
11399,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2013
11400,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2013
11401,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2013
11402,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2013
11403,U-780,A METHOD FOR THE TREATMENT OF CANCER,2013
11404,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2013
11405,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2013
11406,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2013
11407,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2013
11408,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2013
11409,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2013
11410,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2013
11411,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2013
11412,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2013
11413,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2013
11414,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2013
11415,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2013
11416,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2013
11417,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2013
11418,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2013
11419,U-796,METHOD OF TREATING DEPRESSION,2013
11420,U-797,METHOD OF TREATING ANXIETY,2013
11421,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2013
11422,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2013
11423,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2013
11424,U-801,METHOD OF TREATING CANCER,2013
11425,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2013
11426,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2013
11427,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2013
11428,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2013
11429,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2013
11430,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2013
11431,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2013
11432,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2013
11433,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2013
11434,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2013
11435,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2013
11436,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2013
11437,U-814,TREATMENT OF SCHIZOPHRENIA,2013
11438,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2013
11439,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2013
11440,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2013
11441,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2013
11442,U-819,MANAGEMENT OF FIBROMYALGIA,2013
11443,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2013
11444,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2013
11445,U-822,USE IN LIPID MANAGEMENT,2013
11446,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2013
11447,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2013
11448,U-825,USE FOR PREVENTION OF BREAST CANCER,2013
11449,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2013
11450,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2013
11451,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2013
11452,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2013
11453,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2013
11454,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2013
11455,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2013
11456,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2013
11457,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2013
11458,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2013
11459,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2013
11460,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2013
11461,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2013
11462,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2013
11463,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2013
11464,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2013
11465,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2013
11466,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2013
11467,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2013
11468,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2013
11469,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2013
11470,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2013
11471,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2013
11472,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2013
11473,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2013
11474,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2013
11475,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2013
11476,U-853,TREATMENT OR PREVENTION OF EMESIS,2013
11477,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2013
11478,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2013
11479,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2013
11480,U-857,INHIBITION OF TRANSPLANT REJECTION,2013
11481,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2013
11482,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2013
11483,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2013
11484,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2013
11485,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2013
11486,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2013
11487,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2013
11488,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2013
11489,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2013
11490,U-867,TREATMENT OF MIGRAINE,2013
11491,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2013
11492,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2013
11493,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2013
11494,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2013
11495,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2013
11496,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2013
11497,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2013
11498,U-875,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE",2013
11499,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2013
11500,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2013
11501,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2013
11502,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2013
11503,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2013
11504,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2013
11505,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2013
11506,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2013
11507,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2013
11508,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2013
11509,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2013
11510,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2013
11511,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2013
11512,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2013
11513,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2013
11514,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2013
11515,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2013
11516,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2013
11517,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2013
11518,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2013
11519,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2013
11520,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2013
11521,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2013
11522,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2013
11523,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2013
11524,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2013
11525,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2013
11526,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2013
11527,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2013
11528,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2013
11529,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2013
11530,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2013
11531,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2013
11532,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2013
11533,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2013
11534,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2013
11535,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2013
11536,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2013
11537,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2013
11538,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2013
11539,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2013
11540,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2013
11541,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2013
11542,U-919,FOR THE TREATMENT OF DERMATITIS,2013
11543,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2013
11544,U-921,TREATMENT OF ACNE VULGARIS,2013
11545,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2013
11546,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2013
11547,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2013
11548,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2013
11549,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2013
11550,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2013
11551,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2013
11552,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2013
11553,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2013
11554,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2013
11555,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2013
11556,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2013
11557,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2013
11558,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2013
11559,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2013
11560,U-937,TREATMENT OF PROSTATE CANCER,2013
11561,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2013
11562,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2013
11563,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2013
11564,U-941,METHOD TO TREAT OVARIAN CANCER,2013
11565,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2013
11566,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2013
11567,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2013
11568,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2013
11569,U-946,TREATMENT OF BREAST CANCER,2013
11570,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2013
11571,U-948,TREATMENT OF DIABETES MELLITUS,2013
11572,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2013
11573,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2013
11574,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2013
11575,U-952,USE AS AN ANALGESIC,2013
11576,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2013
11577,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2013
11578,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2013
11579,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2013
11580,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2013
11581,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2013
11582,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2013
11583,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2013
11584,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2013
11585,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2013
11586,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2013
11587,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2013
11588,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2013
11589,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2013
11590,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2013
11591,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2013
11592,U-969,TREATMENT OF MIGRAINE,2013
11593,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2013
11594,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2013
11595,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2013
11596,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2013
11597,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2013
11598,U-975,TREATMENT OF PULMONARY HYPERTENSION,2013
11599,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2013
11600,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2013
11601,U-978,METHOD OF TREATING HYPONATREMIA,2013
11602,U-979,RELIEF OF MUSCLE SPASM,2013
11603,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2013
11604,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2013
11605,U-982,A METHOD OF TREATING OSTEOPOROSIS,2013
11606,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2013
11607,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2013
11608,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2013
11609,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2013
11610,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2013
11611,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2013
11612,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2013
11613,U-990,TREATMENT OF PROTOZOAL INFECTION,2013
11614,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2013
11615,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2013
11616,U-993,METHOD OF TREATING INFERTILITY,2013
11617,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2013
11618,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2013
11619,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2013
11620,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2013
11621,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2013
11622,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2013
11623,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2013
11624,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2013
11625,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2013
11626,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2013
11627,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2013
11628,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2013
11629,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2013
11630,U-1007,METHOD OF TREATING GOUT FLARES,2013
11631,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2013
11632,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2013
11633,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2013
11634,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2013
11635,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2013
11636,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2013
11637,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2013
11638,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2013
11639,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2013
11640,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2013
11641,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2013
11642,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2013
11643,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2013
11644,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2013
11645,U-1022,FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2013
11646,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2013
11647,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2013
11648,U-1025,TREATING FREQUENT HEARTBURN,2013
11649,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2013
11650,U-1027,REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL,2013
11651,U-1028,A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY,2013
11652,U-1029,METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF,2013
11653,U-1030,IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS),2013
11654,U-1031,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2013
11655,U-1032,USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS,2013
11656,U-1033,TOPICAL TREATMENT OF ACNE VULGARIS,2013
11657,U-1034,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2013
11658,U-1035,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2013
11659,U-1036,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN,2013
11660,U-1037,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST,2013
11661,U-1038,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST,2013
11662,U-1039,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN,2013
11663,U-1040,INHIBITION OF THROMBIN IN A PATIENT,2013
11664,U-1041,TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE,2013
11665,U-1042,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2013
11666,U-1043,MANAGEMENT OF MODERATE TO SEVERE PAIN,2013
11667,U-1044,TOPICAL TREATMENT OF SCALP PSORIASIS,2013
11668,U-1045,MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY,2013
11669,U-1046,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY,2013
11670,U-1047,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)",2013
11671,U-1048,WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES,2013
11672,U-1049,PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT,2013
11673,U-1050,USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS,2013
11674,U-1051,TREATMENT OF OROPHARYNGEAL CANDIDIASIS,2013
11675,U-1052,RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2013
11676,U-1053,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2013
11677,U-1054,"ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS",2013
11678,U-1055,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE,2013
11679,U-1056,TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2013
11680,U-1057,TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2013
11681,U-1058,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2013
11682,U-1059,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,2013
11683,U-1060,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS,2013
11684,U-1061,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,2013
11685,U-1062,ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE,2013
11686,U-1063,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,2013
11687,U-1064,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2013
11688,U-1065,METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY,2013
11689,U-1066,METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA,2013
11690,U-1067,TREATMENT OF CANCER,2013
11691,U-1068,TREATMENT OF ASTHMA,2013
11692,U-1069,A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2013
11693,U-1070,A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE,2013
11694,U-1071,METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION,2013
11695,U-1072,"THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME",2013
11696,U-1073,USE FOR THE TREATMENT OF ASTHMA AND COPD,2013
11697,U-1074,USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT,2013
11698,U-1075,USE FOR THE TREATMENT OF ASTHMA,2013
11699,U-1076,"REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING",2013
11700,U-1077,PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION,2013
11701,U-1078,TREATMENT OF ACNE,2013
11702,U-1079,REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2013
11703,U-1080,METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT,2013
11704,U-1081,LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2013
11705,U-1082,USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS,2013
11706,U-1083,"ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES",2013
11707,U-1084,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2013
11708,U-1085,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,2013
11709,U-1086,TREATMENT OF AUTOIMMUNE DISEASE,2013
11710,U-1087,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,2013
11711,U-1088,RELIEF OF MUSCLE SPASM,2013
11712,U-1089,INHIBITION OF THROMBIN,2013
11713,U-1090,LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION,2013
11714,U-1091,ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA,2013
11715,U-1092,TREATMENT OF BREAST CANCER,2013
11716,U-1093,TREATMENT OF PSEUDOBULBAR AFFECT,2013
11717,U-1094,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2013
11718,U-1095,METHOD OF TREATING OCULAR INFLAMMATION,2013
11719,U-1096,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,2013
11720,U-1097,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,2013
11721,U-1098,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,2013
11722,U-1099,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2013
11723,U-1100,REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY,2013
11724,U-1101,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2013
11725,U-1102,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,2013
11726,U-1103,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2013
11727,U-1104,USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN,2013
11728,U-1105,TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER,2013
11729,U-1106,TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT,2013
11730,U-1107,TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT,2013
11731,U-1108,TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE,2013
11732,U-1109,"TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2013
11733,U-1110,METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2013
11734,U-1111,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2013
11735,U-1112,METHOD OF MR IMAGING OF A MAMMAL,2013
11736,U-1113,TREATMENT AND PROPHYLAXIS OF INFLUENZA,2013
11737,U-1114,"TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA",2013
11738,U-1115,TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS,2013
11739,U-1116,METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS,2013
11740,U-1117,TREATMENT OF BREAST CANCER,2013
11741,U-1118,"USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2013
11742,U-1119,CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING,2013
11743,U-1120,TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL,2013
11744,U-1121,METHOD OF TREATING TRAVELERS' DIARRHEA,2013
11745,U-1122,TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES,2013
11746,U-1123,TREATMENT OF ALCOHOL DEPENDENCE,2013
11747,U-1124,"PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION",2013
11748,U-1125,METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS,2013
11749,U-1126,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL,2013
11750,U-1127,TREATMENT OF PATENT DUCTUS ARTERIOSUS,2013
11751,U-1128,TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE,2013
11752,U-1129,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2013
11753,U-1130,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN,2013
11754,U-1131,"TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2013
11755,U-1132,TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11756,U-1133,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11757,U-1134,TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11758,U-1135,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C",2013
11759,U-1136,"SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2013
11760,U-1137,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2013
11761,U-1138,TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11762,U-1139,REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11763,U-1140,REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11764,U-1141,REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11765,U-1142,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2013
11766,U-1143,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2013
11767,U-1144,"REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2013
11768,U-1145,"REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2013
11769,U-1146,REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2013
11770,U-1147,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2013
11771,U-1148,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2013
11772,U-1149,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2013
11773,U-1150,"TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C",2013
11774,U-1151,"TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C",2013
11775,U-1152,CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION,2013
11776,U-1153,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION",2013
11777,U-1154,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB",2013
11778,U-1155,USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL),2013
11779,U-1156,TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA),2013
11780,U-1157,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2013
11781,U-1158,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2013
11782,U-1159,"RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER",2013
11783,U-1160,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER,2013
11784,U-1161,FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER,2013
11785,U-1162,TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP,2013
11786,U-1163,METHOD OF TREATING THROMBOSIS,2013
11787,U-1164,METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION,2013
11788,U-1165,USE FOR THE TREATMENT OF MULTIPLE MYELOMA,2013
11789,U-1166,A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS,2013
11790,U-1167,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),2013
11791,U-1168,"THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA",2013
11792,U-1169,MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN,2013
11793,U-1170,TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2013
11794,U-1171,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,2013
11795,U-1172,"TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN",2013
11796,U-1173,"TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE",2013
11797,U-1174,"ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION",2013
11798,U-1175,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2013
11799,U-1176,TREATMENT OR PREVENTION OF STROKE,2013
11800,U-1177,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2013
11801,U-1178,RELIEF OF MODERATE TO SEVERE CHRONIC PAIN,2013
11802,U-1179,TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK),2013
11803,U-1180,TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS,2013
11804,U-1181,A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT,2013
11805,U-1182,TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING,2013
11806,U-1183,A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN,2013
11807,U-1184,TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA,2013
11808,U-1185,TREATMENT OF OPIOID-INDUCED CONSTIPATION,2013
11809,U-1186,ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE,2013
11810,U-1187,TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE),2013
11811,U-1188,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE,2013
11812,U-1189,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN",2013
11813,U-1190,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN",2013
11814,U-1191,"METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)",2013
11815,U-1192,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)",2013
11816,U-1193,"METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)",2013
11817,U-1194,METHOD FOR TREATING INSOMNIA,2013
11818,U-1195,"PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA",2013
11819,U-1196,RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS,2013
11820,U-1197,METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY,2013
11821,U-1198,RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE,2013
11822,U-1199,TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2013
11823,U-1200,REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM,2013
11824,U-1201,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,2013
11825,U-1202,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2013
11826,U-1203,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2013
11827,U-1204,TREATMENT OF UVEITIS,2013
11828,U-1205,TREATMENT OF MACULAR EDEMA,2013
11829,U-1206,DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX,2013
11830,U-1207,"INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS",2013
11831,U-1208,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2013
11832,U-1209,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER",2013
11833,U-1210,USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE),2013
11834,U-1211,"USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2013
11835,U-1212,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2013
11836,U-1213,TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETETENT PATIENTS 12 YEARS OF AGE AND OLDER,2013
11837,U-1214,METHOF FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2013
11838,U-1215,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2013
11839,U-1216,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2013
11840,U-1217,METHOD OF INCREASING HAIR GROWTH,2013
11841,U-1218,METHOD OF STIMULATING HAIR GROWTH,2013
11842,U-1219,METHOD OF INCREASING THE NUMBER OF HAIRS,2013
11843,U-1220,TREATMENT OF RENAL CELL CARCINOMA,2013
11844,U-1221,TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION,2013
11845,U-1222,TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS,2013
11846,U-1223,METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE,2013
11847,U-1224,REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE,2013
11848,U-1225,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS,2013
11849,U-1226,A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT,2013
11850,U-1227,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE,2013
11851,U-1228,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN,2013
11852,U-1229,TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS,2013
11853,U-1230,A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT,2013
11854,U-1231,TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS,2013
11855,U-1232,"USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENTED FOR USE W/ASPIRIN",2013
11856,U-1233,"TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD",2013
11857,U-1234,"FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA",2013
11858,U-1235,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION,2013
11859,U-1236,USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2013
11860,U-1237,"COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS",2013
11861,U-1238,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,2013
11862,U-1239,MAGNETIC RESONANCE IMAGING OF THE LIVER,2013
11863,U-1240,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2013
11864,U-1241,MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED,2013
11865,U-1242,PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS,2013
11866,U-1243,"WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER",2013
11867,U-1244,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA,2013
11868,U-1245,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE,2013
11869,U-1246,SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA,2013
11870,U-1247,MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS,2013
11871,U-1248,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE,2013
11872,U-1249,TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG,2013
11873,U-1250,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2013
11874,U-1251,A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT,2013
11875,U-1252,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE,2013
11876,U-1253,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY,2013
11877,U-1254,METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN,2013
11878,U-1255,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY,2013
11879,U-1256,TREATMENT OF SEBORRHEIC DERMATITIS,2013
11880,U-1257,TREATMENT OF OPHTHALMIC DISORDERS,2013
11881,U-1258,VISUALIZATION DURING VITRECTOMY PROCEDURES,2013
11882,U-1259,PROPHYLAXIS OF HIV-1 INFECTION,2013
11883,U-1260,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,2013
11884,U-1261,REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION,2013
11885,U-1262,"USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT",2013
11886,U-1263,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS,2013
11887,U-1264,TREATMENT OF A RESPIRATORY DISEASE,2013
11888,U-1265,PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2013
11889,U-1266,METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA,2013
11890,U-1267,TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE,2013
11891,U-1268,"TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE",2013
11892,U-1269,"TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET",2013
11893,U-1270,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE),2013
11894,U-1271,TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES,2013
11895,U-1272,TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM,2013
11896,U-1273,TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM,2013
11897,U-1274,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS,2013
11898,U-1275,TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2013
11899,U-1276,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,2013
11900,U-1277,"METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN",2013
11901,U-1278,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS,2013
11902,U-1279,TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE,2013
11903,U-1280,USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS,2013
11904,U-1281,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL,2013
11905,U-1282,PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING,2013
11906,U-1283,A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA,2013
11907,U-1284,A METHOD OF TREATING A NEOPLASM,2013
11908,U-1285,TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,2013
11909,U-1286,A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE,2013
11910,U-1287,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2013
11911,U-1288,TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET,2013
11912,U-1289,MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN,2013
11913,U-1290,TREATMENT OF LUNG CANCER,2013
11914,U-1291,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION,2013
11915,U-1292,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET",2013
11916,U-1293,A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2013
11917,U-1294,METHOD OF TREATING GLAUCOMA IN A PATIENT,2013
11918,U-1295,A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION,2013
11919,U-1296,USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION,2013
11920,U-1297,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS,2013
11921,U-1298,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES,2013
11922,U-1299,TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2013
11923,U-1300,TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2013
11924,U-1301,TREATMENT OF DEEP VEIN THROMBOSIS (DVT),2013
11925,U-1302,TREATMENT OF PULMONARY EMBOLISM (PE),2013
11926,U-1303,REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM,2013
11927,U-1304,USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES,2013
11928,U-1305,"TREATMENT OF HIV-1INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS",2013
11929,U-1306,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2013
11930,U-1307,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY",2013
11931,U-1308,MULTIPLE MYELOMA,2013
11932,U-1309,BONE METASTASES,2013
11933,U-1310,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2013
11934,U-1311,METHOD OF TREATING CYSTIC FIBROSIS,2013
11935,U-1312,USE FOR THE TREATMENT OF HYPERGLYCEMIA,2013
11936,U-1313,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2013
11937,U-1314,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2013
11938,U-1315,THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2013
11939,U-1316,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,2013
11940,U-1317,"TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2013
11941,U-1318,TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATINETS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2013
11942,U-1319,SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA,2013
11943,U-1320,TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT,2013
11944,U-1321,TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS,2013
11945,U-1322,METHOD OF REDUCING OCULAR HYPERTENSION,2013
11946,U-1323,REDUCING THE RISK OF STROKE,2013
11947,U-1324,MANAGEMENT OF CYSTIC FIBROSIS PATIENTS,2013
11948,U-1325,"INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS",2013
11949,U,PATENT USE CODE,2014
11950,U-1,PREVENTION OF PREGNANCY,2014
11951,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2014
11952,U-3,TREATMENT OF HYPERTENSION,2014
11953,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2014
11954,U-5,METHOD OF PRODUCING BRONCHODILATION,2014
11955,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2014
11956,U-7,INCREASING CARDIAC CONTRACTILITY,2014
11957,U-8,ACUTE MYOCARDIAL INFARCTION,2014
11958,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2014
11959,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2014
11960,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2014
11961,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2014
11962,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2014
11963,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2014
11964,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2014
11965,U-16,USE IN LUNG SCANNING PROCEDURES,2014
11966,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2014
11967,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2014
11968,U-19,TREATMENT OF INFLAMMATION,2014
11969,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2014
11970,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2014
11971,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2014
11972,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2014
11973,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2014
11974,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2014
11975,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2014
11976,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2014
11977,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2014
11978,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2014
11979,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2014
11980,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2014
11981,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2014
11982,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2014
11983,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2014
11984,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2014
11985,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2014
11986,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2014
11987,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2014
11988,U-39,ANGINA PECTORIS,2014
11989,U-40,METHOD OF TREATMENT OF BURNS,2014
11990,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2014
11991,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2014
11992,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2014
11993,U-44,RELIEF OF NAUSEA AND VOMITING,2014
11994,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2014
11995,U-46,TREATMENT OF PANIC DISORDER,2014
11996,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2014
11997,U-48,ANALGESIA,2014
11998,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2014
11999,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2014
12000,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2014
12001,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2014
12002,U-53,HYPERCALCEMIA OF MALIGNANCY,2014
12003,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2014
12004,U-55,TREATMENT OF PAIN,2014
12005,U-56,AID TO SMOKING CESSATION,2014
12006,U-57,OPHTHALMIC USE OF NORFLOXACIN,2014
12007,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2014
12008,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2014
12009,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2014
12010,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2014
12011,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2014
12012,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2014
12013,U-64,TREATMENT OF VIRAL INFECTIONS,2014
12014,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2014
12015,U-66,TRIPHASIC REGIMEN,2014
12016,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2014
12017,U-68,TREATMENT OF ACTINIC KERATOSIS,2014
12018,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2014
12019,U-70,TREATMENT OF TRANSIENT INSOMNIA,2014
12020,U-71,METHOD OF TREATMENT OF HEART FAILURE,2014
12021,U-72,TREATMENT OF MIGRAINE,2014
12022,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2014
12023,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2014
12024,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2014
12025,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2014
12026,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2014
12027,U-78,ULCERATIVE COLITIS,2014
12028,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2014
12029,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2014
12030,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2014
12031,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2014
12032,U-83,TREATMENT OF SEIZURES,2014
12033,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2014
12034,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2014
12035,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2014
12036,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2014
12037,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2014
12038,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2014
12039,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2014
12040,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2014
12041,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2014
12042,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2014
12043,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2014
12044,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2014
12045,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2014
12046,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2014
12047,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2014
12048,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2014
12049,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2014
12050,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2014
12051,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2014
12052,U-103,TREATMENT OF OCULAR HYPERTENSION,2014
12053,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2014
12054,U-105,EMESIS,2014
12055,U-106,TREATMENT OF EPILEPSY,2014
12056,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2014
12057,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2014
12058,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2014
12059,U-110,USE AS A RETRIEVABLE PERSSARY,2014
12060,U-111,DIABETES,2014
12061,U-112,CONTRACEPTION,2014
12062,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2014
12063,U-114,USE FOR INHIBITING BONE RESORPTION,2014
12064,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2014
12065,U-116,METHOD OF MYOCARDIAL IMAGING,2014
12066,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2014
12067,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2014
12068,U-119,TREATMENT OF NASAL HYPERSECRETION,2014
12069,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2014
12070,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2014
12071,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2014
12072,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2014
12073,U-124,TREATMENT OF ACNE,2014
12074,U-125,TREATMENT NEUROGENERATIVE DISEASES,2014
12075,U-126,TREATMENT OF GASTRITIS,2014
12076,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2014
12077,U-128,METHOD FOR TREATMENT OF TUMORS,2014
12078,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2014
12079,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2014
12080,U-131,PHOTODAMAGED SKIN,2014
12081,U-132,INHIBITING HIV PROTEASE,2014
12082,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2014
12083,U-134,TREATMENT OF ACNE VULGARIS,2014
12084,U-135,ANTITUMOR AGENT,2014
12085,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2014
12086,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2014
12087,U-138,TREATMENT OF ALLERGIC RHINITIS,2014
12088,U-139,TREATMENT OF ALLERGIC REACTIONS,2014
12089,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2014
12090,U-141,TREATMENT OF ULCERATIVE COLITIS,2014
12091,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2014
12092,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2014
12093,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2014
12094,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2014
12095,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2014
12096,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2014
12097,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2014
12098,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2014
12099,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2014
12100,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2014
12101,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2014
12102,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2014
12103,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2014
12104,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2014
12105,U-156,METHOD OF PROVIDING ANESTHESIA,2014
12106,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2014
12107,U-158,ANGINA,2014
12108,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2014
12109,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2014
12110,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2014
12111,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2014
12112,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2014
12113,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2014
12114,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2014
12115,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2014
12116,U-167,METHOD FOR TREATING HIV-1 INFECTION,2014
12117,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2014
12118,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2014
12119,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2014
12120,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2014
12121,U-172,TREATMENT OF GENITAL WARTS,2014
12122,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2014
12123,U-174,USE AS AN ANTIHISTAMINE AGENT,2014
12124,U-175,METHOD OF TREATING MALIGNANT TUMORS,2014
12125,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2014
12126,U-177,FUNGICIDE,2014
12127,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2014
12128,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2014
12129,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2014
12130,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2014
12131,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2014
12132,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2014
12133,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2014
12134,U-185,METHOD OF TREATING HYPERTENSION,2014
12135,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2014
12136,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2014
12137,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2014
12138,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2014
12139,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2014
12140,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2014
12141,U-192,USE IN TREATING ALLERGIC REACTIONS,2014
12142,U-193,PSORIASIS,2014
12143,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2014
12144,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2014
12145,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2014
12146,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2014
12147,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2014
12148,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2014
12149,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2014
12150,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2014
12151,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2014
12152,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2014
12153,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2014
12154,U-205,METHOD FOR TREATING HEARTBURN,2014
12155,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2014
12156,U-207,USE AS NASAL SPRAY,2014
12157,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2014
12158,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2014
12159,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2014
12160,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2014
12161,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2014
12162,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2014
12163,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2014
12164,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2014
12165,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2014
12166,U-217,METHOD OF PRODUCING ANESTHESIA,2014
12167,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2014
12168,U-219,TREATMENT OF PARKINSON'S DISEASE,2014
12169,U-220,METHOD OF DIAGNOSIS,2014
12170,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2014
12171,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2014
12172,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2014
12173,U-224,CONTROLLING INTRAOCULAR PRESSURE,2014
12174,U-225,METHOD FOR DELIVERY,2014
12175,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2014
12176,U-227,NASAL ADMINISTRATION,2014
12177,U-228,ASTHMA,2014
12178,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2014
12179,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2014
12180,U-231,USE IN PARKINSON'S DISEASE,2014
12181,U-232,METHOD OF TREATING MIGRAINE,2014
12182,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2014
12183,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2014
12184,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2014
12185,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2014
12186,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2014
12187,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2014
12188,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2014
12189,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2014
12190,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2014
12191,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2014
12192,U-243,TOPICAL ADMINISTRATION,2014
12193,U-244,PLATELET AGGREGATION INHIBITORS,2014
12194,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2014
12195,U-246,PHOSPHATE BINDING,2014
12196,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2014
12197,U-248,TREATMENT OF HIV,2014
12198,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2014
12199,U-250,TREATMENT OF HEPATITIS B INFECTION,2014
12200,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2014
12201,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2014
12202,U-253,ORAL TRANSMUCOSAL USE,2014
12203,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2014
12204,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2014
12205,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2014
12206,U-257,TREATMENT OF HIV INFECTION,2014
12207,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2014
12208,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2014
12209,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2014
12210,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2014
12211,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2014
12212,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2014
12213,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2014
12214,U-265,USE AS LAXATIVE,2014
12215,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2014
12216,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2014
12217,U-268,ACROMEGALY,2014
12218,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2014
12219,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2014
12220,U-271,METHOD OF TREATING TUMORS,2014
12221,U-272,METHOD OF TREATING CARCINOMA,2014
12222,U-273,CUTANEOUS T-CELL LYMPHOMA,2014
12223,U-274,ZANAMIVIR FOR INHALATION,2014
12224,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2014
12225,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2014
12226,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2014
12227,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2014
12228,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2014
12229,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2014
12230,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2014
12231,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2014
12232,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2014
12233,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2014
12234,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2014
12235,U-286,DEPRESSION,2014
12236,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2014
12237,U-288,THERAPY OF INFLUENZA,2014
12238,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2014
12239,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2014
12240,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2014
12241,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2014
12242,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2014
12243,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2014
12244,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2014
12245,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2014
12246,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2014
12247,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2014
12248,U-299,TREATMENT OF ADENOMATOUS POLYPS,2014
12249,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2014
12250,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2014
12251,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2014
12252,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2014
12253,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2014
12254,U-305,METHODS FOR USING THE DRUG PRODUCT,2014
12255,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2014
12256,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2014
12257,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2014
12258,U-309,TREATING SJOEGREN SYNDROME,2014
12259,U-310,TREATMENT OF XEROSTOMIA,2014
12260,U-311,HORMONE REPLACEMENT,2014
12261,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2014
12262,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2014
12263,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2014
12264,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2014
12265,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2014
12266,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2014
12267,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2014
12268,U-319,TREATMENT OF MICROBIAL INFECTIONS,2014
12269,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2014
12270,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2014
12271,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2014
12272,U-323,USE AS A BILE ACID SEQUESTRANT,2014
12273,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2014
12274,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2014
12275,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2014
12276,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2014
12277,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2014
12278,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2014
12279,U-330,TREATMENT OF NAUSEA AND VOMITING,2014
12280,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
12281,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2014
12282,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2014
12283,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2014
12284,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2014
12285,U-336,DIAGNOSTIC RADIOIMAGING,2014
12286,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2014
12287,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2014
12288,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2014
12289,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2014
12290,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2014
12291,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2014
12292,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2014
12293,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2014
12294,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2014
12295,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2014
12296,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2014
12297,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2014
12298,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2014
12299,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2014
12300,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2014
12301,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2014
12302,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2014
12303,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2014
12304,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2014
12305,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2014
12306,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2014
12307,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2014
12308,U-359,METHOD OF USE OF VISICOL,2014
12309,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2014
12310,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2014
12311,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2014
12312,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2014
12313,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2014
12314,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2014
12315,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2014
12316,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2014
12317,U-368,HEARTBURN,2014
12318,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2014
12319,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2014
12320,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2014
12321,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2014
12322,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2014
12323,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2014
12324,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2014
12325,U-376,TREATMENT OF INFLUENZA,2014
12326,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2014
12327,U-378,METHOD FOR TREATING INCONTINENCE,2014
12328,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2014
12329,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2014
12330,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2014
12331,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2014
12332,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2014
12333,U-384,TREATMENT OF CMV RETINITIS,2014
12334,U-385,TREATMENT OF PEPTIC ULCERS,2014
12335,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2014
12336,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2014
12337,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2014
12338,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2014
12339,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2014
12340,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2014
12341,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2014
12342,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2014
12343,U-394,METHOD OF USE OF ALPHAGAN,2014
12344,U-395,METHOD OF USE OF ALPHAGAN P,2014
12345,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2014
12346,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2014
12347,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2014
12348,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2014
12349,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2014
12350,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2014
12351,U-402,TREATMENT OF ACTINIC KERATOSES,2014
12352,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2014
12353,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2014
12354,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2014
12355,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2014
12356,U-407,METHOD OF TREATING OTOPATHY,2014
12357,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2014
12358,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2014
12359,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
12360,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2014
12361,U-412,TREATMENT OF TYPE 2 DIABETES,2014
12362,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2014
12363,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2014
12364,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2014
12365,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2014
12366,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2014
12367,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
12368,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2014
12369,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2014
12370,U-421,USE FOR SEDATION,2014
12371,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2014
12372,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2014
12373,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2014
12374,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
12375,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2014
12376,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2014
12377,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2014
12378,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2014
12379,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2014
12380,U-431,POSTTRAUMATIC STRESS DISORDER,2014
12381,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2014
12382,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2014
12383,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2014
12384,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2014
12385,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2014
12386,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2014
12387,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2014
12388,U-439,TREATMENT OF OBESITY,2014
12389,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2014
12390,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2014
12391,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2014
12392,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2014
12393,U-444,TREATMENT OF MIGRAINE,2014
12394,U-445,USE AS AN ANTIMYCOTIC AGENT,2014
12395,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2014
12396,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
12397,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2014
12398,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2014
12399,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2014
12400,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2014
12401,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2014
12402,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2014
12403,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2014
12404,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2014
12405,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2014
12406,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2014
12407,U-458,METHOD OF USE OF IMAGENT,2014
12408,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2014
12409,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2014
12410,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2014
12411,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2014
12412,U-463,VENOGRAPHY,2014
12413,U-464,PERIPHERAL ARTERIOGRAPHY,2014
12414,U-465,CT IMAGING OF THE HEAD,2014
12415,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2014
12416,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2014
12417,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2014
12418,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2014
12419,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2014
12420,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2014
12421,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2014
12422,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2014
12423,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2014
12424,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2014
12425,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2014
12426,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2014
12427,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2014
12428,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2014
12429,U-480,CONTRAST AGENT FOR MRI,2014
12430,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2014
12431,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2014
12432,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2014
12433,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2014
12434,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2014
12435,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2014
12436,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2014
12437,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2014
12438,U-489,EXPECTORANT,2014
12439,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2014
12440,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2014
12441,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2014
12442,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2014
12443,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2014
12444,U-495,PERITONEAL DIALYSIS SOLUTION,2014
12445,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2014
12446,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2014
12447,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2014
12448,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2014
12449,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2014
12450,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2014
12451,U-502,PITYRIASIS VERSICOLOR,2014
12452,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2014
12453,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2014
12454,U-505,ULTRASOUND CONTRAST AGENT,2014
12455,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2014
12456,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2014
12457,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2014
12458,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2014
12459,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2014
12460,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2014
12461,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2014
12462,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2014
12463,U-514,PREVENTION OF OVULATION IN A WOMAN,2014
12464,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2014
12465,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2014
12466,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2014
12467,U-518,OBSESSIVE COMPULSIVE DISORDER,2014
12468,U-519,POST OPERATIVE NAUSEA AND VOMITING,2014
12469,U-520,PREMENOPAUSAL OSTEOPOROSIS,2014
12470,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2014
12471,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2014
12472,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2014
12473,U-524,METHOD OF TREATING DIARRHEA,2014
12474,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2014
12475,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2014
12476,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2014
12477,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2014
12478,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2014
12479,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2014
12480,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2014
12481,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2014
12482,U-533,ERECTILE DYSFUNCTION,2014
12483,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2014
12484,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2014
12485,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2014
12486,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2014
12487,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2014
12488,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2014
12489,U-540,TREATMENT OF FUNGAL INFECTIONS,2014
12490,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2014
12491,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2014
12492,U-543,TREATMENT OF SCHIZOPHRENIA,2014
12493,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2014
12494,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2014
12495,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2014
12496,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2014
12497,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2014
12498,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2014
12499,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2014
12500,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2014
12501,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2014
12502,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2014
12503,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2014
12504,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2014
12505,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2014
12506,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2014
12507,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2014
12508,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2014
12509,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2014
12510,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2014
12511,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2014
12512,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2014
12513,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2014
12514,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2014
12515,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2014
12516,U-567,METHOD OF TREATING INFERTILITY,2014
12517,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2014
12518,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2014
12519,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2014
12520,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2014
12521,U-572,INTENSIVE CARE UNIT SEDATION,2014
12522,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2014
12523,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2014
12524,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2014
12525,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2014
12526,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2014
12527,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2014
12528,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2014
12529,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2014
12530,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2014
12531,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2014
12532,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2014
12533,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2014
12534,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2014
12535,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2014
12536,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2014
12537,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2014
12538,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2014
12539,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2014
12540,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2014
12541,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2014
12542,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2014
12543,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2014
12544,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
12545,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2014
12546,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2014
12547,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2014
12548,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2014
12549,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2014
12550,U-601,TREATMENT OF BIPOLAR DISORDER,2014
12551,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2014
12552,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2014
12553,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2014
12554,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2014
12555,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2014
12556,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2014
12557,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2014
12558,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2014
12559,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2014
12560,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2014
12561,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2014
12562,U-613,REDUCTION OF SERUM PHOSPHATE,2014
12563,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2014
12564,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2014
12565,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2014
12566,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2014
12567,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2014
12568,U-619,TREATMENT OF MALIGNANT NEOPLASM,2014
12569,U-620,TREATMENT OF INSOMNIA,2014
12570,U-621,METHOD OF TREATING CANCER,2014
12571,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2014
12572,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2014
12573,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2014
12574,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2014
12575,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2014
12576,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2014
12577,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2014
12578,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2014
12579,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2014
12580,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2014
12581,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2014
12582,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2014
12583,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2014
12584,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2014
12585,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2014
12586,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2014
12587,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2014
12588,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2014
12589,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2014
12590,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2014
12591,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2014
12592,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2014
12593,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2014
12594,U-645,TREATMENT OF ASTHMA,2014
12595,U-646,METHOD OF TREATING OTITIS,2014
12596,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
12597,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2014
12598,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2014
12599,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2014
12600,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2014
12601,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2014
12602,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2014
12603,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2014
12604,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2014
12605,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2014
12606,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
12607,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2014
12608,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2014
12609,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2014
12610,U-661,TREATMENT OF SEIZURE DISORDER,2014
12611,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
12612,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2014
12613,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2014
12614,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2014
12615,U-666,METHOD OF TREATING ADHD,2014
12616,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2014
12617,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2014
12618,U-669,INDICATION OF TYPE II DIABETES,2014
12619,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2014
12620,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2014
12621,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2014
12622,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2014
12623,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2014
12624,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2014
12625,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2014
12626,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2014
12627,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2014
12628,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2014
12629,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2014
12630,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2014
12631,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2014
12632,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2014
12633,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2014
12634,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2014
12635,U-686,EXPECTORANT AND NASAL DECONGESTANT,2014
12636,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2014
12637,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2014
12638,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2014
12639,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2014
12640,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2014
12641,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2014
12642,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2014
12643,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2014
12644,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2014
12645,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2014
12646,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2014
12647,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2014
12648,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2014
12649,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2014
12650,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2014
12651,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2014
12652,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2014
12653,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2014
12654,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2014
12655,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2014
12656,U-707,ALLERGIC RHINITIS,2014
12657,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2014
12658,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2014
12659,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2014
12660,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2014
12661,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2014
12662,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2014
12663,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2014
12664,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2014
12665,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2014
12666,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2014
12667,U-718,TREATMENT OF FUNGAL INFECTIONS,2014
12668,U-719,TREATENT OF PSYCHOSIS,2014
12669,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2014
12670,U-721,TREATMENT OF INFLUENZA,2014
12671,U-722,PROPHYLAXIS OF INFLUENZA,2014
12672,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2014
12673,U-724,METHOD OF TREATING SEIZURES,2014
12674,U-725,ALLERGIC RHINITIS AND URTICARIA,2014
12675,U-726,ALLERGIC RHINITIS,2014
12676,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2014
12677,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2014
12678,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2014
12679,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2014
12680,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2014
12681,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2014
12682,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2014
12683,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2014
12684,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2014
12685,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2014
12686,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2014
12687,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2014
12688,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2014
12689,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2014
12690,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2014
12691,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2014
12692,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2014
12693,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2014
12694,U-745,TREATMENT OR PREVENTION OF EMESIS,2014
12695,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2014
12696,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2014
12697,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2014
12698,U-749,METHOD OF CONTRACEPTION,2014
12699,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2014
12700,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2014
12701,U-752,SUNSCREEN,2014
12702,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2014
12703,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2014
12704,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2014
12705,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
12706,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2014
12707,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2014
12708,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2014
12709,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2014
12710,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2014
12711,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2014
12712,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2014
12713,U-764,TREATMENT OF SCHIZOPHRENIA,2014
12714,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2014
12715,U-766,TREATMENT OF SEIZURES,2014
12716,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2014
12717,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2014
12718,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2014
12719,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2014
12720,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2014
12721,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2014
12722,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2014
12723,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2014
12724,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2014
12725,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2014
12726,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2014
12727,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2014
12728,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2014
12729,U-780,A METHOD FOR THE TREATMENT OF CANCER,2014
12730,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2014
12731,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2014
12732,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2014
12733,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2014
12734,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2014
12735,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2014
12736,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2014
12737,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2014
12738,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2014
12739,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2014
12740,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2014
12741,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2014
12742,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2014
12743,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2014
12744,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2014
12745,U-796,METHOD OF TREATING DEPRESSION,2014
12746,U-797,METHOD OF TREATING ANXIETY,2014
12747,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2014
12748,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2014
12749,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2014
12750,U-801,METHOD OF TREATING CANCER,2014
12751,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2014
12752,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2014
12753,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2014
12754,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2014
12755,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2014
12756,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2014
12757,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2014
12758,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2014
12759,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2014
12760,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2014
12761,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2014
12762,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2014
12763,U-814,TREATMENT OF SCHIZOPHRENIA,2014
12764,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2014
12765,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2014
12766,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2014
12767,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2014
12768,U-819,MANAGEMENT OF FIBROMYALGIA,2014
12769,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2014
12770,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2014
12771,U-822,USE IN LIPID MANAGEMENT,2014
12772,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2014
12773,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2014
12774,U-825,USE FOR PREVENTION OF BREAST CANCER,2014
12775,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2014
12776,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2014
12777,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2014
12778,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2014
12779,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2014
12780,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2014
12781,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2014
12782,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2014
12783,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2014
12784,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2014
12785,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2014
12786,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2014
12787,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2014
12788,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2014
12789,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2014
12790,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2014
12791,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2014
12792,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2014
12793,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2014
12794,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2014
12795,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2014
12796,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2014
12797,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2014
12798,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2014
12799,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2014
12800,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2014
12801,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2014
12802,U-853,TREATMENT OR PREVENTION OF EMESIS,2014
12803,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2014
12804,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2014
12805,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2014
12806,U-857,INHIBITION OF TRANSPLANT REJECTION,2014
12807,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2014
12808,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2014
12809,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2014
12810,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2014
12811,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2014
12812,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2014
12813,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2014
12814,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2014
12815,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2014
12816,U-867,TREATMENT OF MIGRAINE,2014
12817,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2014
12818,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2014
12819,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2014
12820,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2014
12821,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2014
12822,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2014
12823,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2014
12824,U-875,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE",2014
12825,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2014
12826,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2014
12827,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2014
12828,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2014
12829,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2014
12830,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2014
12831,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2014
12832,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2014
12833,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2014
12834,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2014
12835,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2014
12836,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2014
12837,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2014
12838,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2014
12839,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2014
12840,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2014
12841,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2014
12842,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2014
12843,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2014
12844,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2014
12845,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2014
12846,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2014
12847,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2014
12848,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2014
12849,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2014
12850,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2014
12851,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2014
12852,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2014
12853,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2014
12854,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2014
12855,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2014
12856,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2014
12857,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2014
12858,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2014
12859,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2014
12860,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2014
12861,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2014
12862,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2014
12863,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2014
12864,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2014
12865,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2014
12866,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2014
12867,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2014
12868,U-919,FOR THE TREATMENT OF DERMATITIS,2014
12869,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2014
12870,U-921,TREATMENT OF ACNE VULGARIS,2014
12871,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2014
12872,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2014
12873,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2014
12874,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2014
12875,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2014
12876,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2014
12877,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2014
12878,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2014
12879,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2014
12880,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2014
12881,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2014
12882,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2014
12883,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2014
12884,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2014
12885,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2014
12886,U-937,TREATMENT OF PROSTATE CANCER,2014
12887,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2014
12888,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2014
12889,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2014
12890,U-941,METHOD TO TREAT OVARIAN CANCER,2014
12891,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2014
12892,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2014
12893,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2014
12894,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2014
12895,U-946,TREATMENT OF BREAST CANCER,2014
12896,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2014
12897,U-948,TREATMENT OF DIABETES MELLITUS,2014
12898,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2014
12899,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2014
12900,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2014
12901,U-952,USE AS AN ANALGESIC,2014
12902,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2014
12903,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2014
12904,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2014
12905,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2014
12906,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2014
12907,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2014
12908,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2014
12909,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2014
12910,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2014
12911,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2014
12912,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2014
12913,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2014
12914,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2014
12915,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2014
12916,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2014
12917,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2014
12918,U-969,TREATMENT OF MIGRAINE,2014
12919,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2014
12920,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2014
12921,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2014
12922,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2014
12923,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2014
12924,U-975,TREATMENT OF PULMONARY HYPERTENSION,2014
12925,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2014
12926,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2014
12927,U-978,METHOD OF TREATING HYPONATREMIA,2014
12928,U-979,RELIEF OF MUSCLE SPASM,2014
12929,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2014
12930,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2014
12931,U-982,A METHOD OF TREATING OSTEOPOROSIS,2014
12932,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2014
12933,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2014
12934,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2014
12935,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2014
12936,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2014
12937,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2014
12938,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2014
12939,U-990,TREATMENT OF PROTOZOAL INFECTION,2014
12940,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2014
12941,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2014
12942,U-993,METHOD OF TREATING INFERTILITY,2014
12943,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2014
12944,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2014
12945,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2014
12946,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2014
12947,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2014
12948,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2014
12949,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2014
12950,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2014
12951,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2014
12952,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2014
12953,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2014
12954,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2014
12955,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2014
12956,U-1007,METHOD OF TREATING GOUT FLARES,2014
12957,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2014
12958,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2014
12959,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2014
12960,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2014
12961,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2014
12962,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2014
12963,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2014
12964,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2014
12965,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2014
12966,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2014
12967,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2014
12968,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2014
12969,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2014
12970,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2014
12971,U-1022,FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2014
12972,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2014
12973,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2014
12974,U-1025,TREATING FREQUENT HEARTBURN,2014
12975,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2014
12976,U-1027,REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL,2014
12977,U-1028,A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY,2014
12978,U-1029,METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF,2014
12979,U-1030,IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS),2014
12980,U-1031,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2014
12981,U-1032,USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS,2014
12982,U-1033,TOPICAL TREATMENT OF ACNE VULGARIS,2014
12983,U-1034,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2014
12984,U-1035,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2014
12985,U-1036,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN,2014
12986,U-1037,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST,2014
12987,U-1038,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST,2014
12988,U-1039,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN,2014
12989,U-1040,INHIBITION OF THROMBIN IN A PATIENT,2014
12990,U-1041,TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE,2014
12991,U-1042,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2014
12992,U-1043,MANAGEMENT OF MODERATE TO SEVERE PAIN,2014
12993,U-1044,TOPICAL TREATMENT OF SCALP PSORIASIS,2014
12994,U-1045,MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY,2014
12995,U-1046,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY,2014
12996,U-1047,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)",2014
12997,U-1048,WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES,2014
12998,U-1049,PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT,2014
12999,U-1050,USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS,2014
13000,U-1051,TREATMENT OF OROPHARYNGEAL CANDIDIASIS,2014
13001,U-1052,RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2014
13002,U-1053,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2014
13003,U-1054,"ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS",2014
13004,U-1055,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE,2014
13005,U-1056,TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2014
13006,U-1057,TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2014
13007,U-1058,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2014
13008,U-1059,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,2014
13009,U-1060,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS,2014
13010,U-1061,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,2014
13011,U-1062,ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE,2014
13012,U-1063,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,2014
13013,U-1064,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2014
13014,U-1065,METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY,2014
13015,U-1066,METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA,2014
13016,U-1067,TREATMENT OF CANCER,2014
13017,U-1068,TREATMENT OF ASTHMA,2014
13018,U-1069,A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2014
13019,U-1070,A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE,2014
13020,U-1071,METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION,2014
13021,U-1072,"THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME",2014
13022,U-1073,USE FOR THE TREATMENT OF ASTHMA AND COPD,2014
13023,U-1074,USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT,2014
13024,U-1075,USE FOR THE TREATMENT OF ASTHMA,2014
13025,U-1076,"REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING",2014
13026,U-1077,PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION,2014
13027,U-1078,TREATMENT OF ACNE,2014
13028,U-1079,REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2014
13029,U-1080,METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT,2014
13030,U-1081,LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2014
13031,U-1082,USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS,2014
13032,U-1083,"ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES",2014
13033,U-1084,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2014
13034,U-1085,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,2014
13035,U-1086,TREATMENT OF AUTOIMMUNE DISEASE,2014
13036,U-1087,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,2014
13037,U-1088,RELIEF OF MUSCLE SPASM,2014
13038,U-1089,INHIBITION OF THROMBIN,2014
13039,U-1090,LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION,2014
13040,U-1091,ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA,2014
13041,U-1092,TREATMENT OF BREAST CANCER,2014
13042,U-1093,TREATMENT OF PSEUDOBULBAR AFFECT,2014
13043,U-1094,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2014
13044,U-1095,METHOD OF TREATING OCULAR INFLAMMATION,2014
13045,U-1096,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,2014
13046,U-1097,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,2014
13047,U-1098,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,2014
13048,U-1099,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2014
13049,U-1100,REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY,2014
13050,U-1101,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2014
13051,U-1102,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,2014
13052,U-1103,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2014
13053,U-1104,USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN,2014
13054,U-1105,TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER,2014
13055,U-1106,TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT,2014
13056,U-1107,TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT,2014
13057,U-1108,TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE,2014
13058,U-1109,"TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2014
13059,U-1110,METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2014
13060,U-1111,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2014
13061,U-1112,METHOD OF MR IMAGING OF A MAMMAL,2014
13062,U-1113,TREATMENT AND PROPHYLAXIS OF INFLUENZA,2014
13063,U-1114,"TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA",2014
13064,U-1115,TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS,2014
13065,U-1116,METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS,2014
13066,U-1117,TREATMENT OF BREAST CANCER,2014
13067,U-1118,"USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2014
13068,U-1119,CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING,2014
13069,U-1120,TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL,2014
13070,U-1121,METHOD OF TREATING TRAVELERS' DIARRHEA,2014
13071,U-1122,TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES,2014
13072,U-1123,TREATMENT OF ALCOHOL DEPENDENCE,2014
13073,U-1124,"PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION",2014
13074,U-1125,METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS,2014
13075,U-1126,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL,2014
13076,U-1127,TREATMENT OF PATENT DUCTUS ARTERIOSUS,2014
13077,U-1128,TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE,2014
13078,U-1129,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2014
13079,U-1130,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN,2014
13080,U-1131,"TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2014
13081,U-1132,TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13082,U-1133,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13083,U-1134,TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13084,U-1135,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C",2014
13085,U-1136,"SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2014
13086,U-1137,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2014
13087,U-1138,TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13088,U-1139,REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13089,U-1140,REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13090,U-1141,REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13091,U-1142,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2014
13092,U-1143,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2014
13093,U-1144,"REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2014
13094,U-1145,"REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2014
13095,U-1146,REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2014
13096,U-1147,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2014
13097,U-1148,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2014
13098,U-1149,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2014
13099,U-1150,"TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C",2014
13100,U-1151,"TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C",2014
13101,U-1152,CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION,2014
13102,U-1153,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION",2014
13103,U-1154,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB",2014
13104,U-1155,USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL),2014
13105,U-1156,TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA),2014
13106,U-1157,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2014
13107,U-1158,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2014
13108,U-1159,"RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER",2014
13109,U-1160,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER,2014
13110,U-1161,FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER,2014
13111,U-1162,TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP,2014
13112,U-1163,METHOD OF TREATING THROMBOSIS,2014
13113,U-1164,METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION,2014
13114,U-1165,USE FOR THE TREATMENT OF MULTIPLE MYELOMA,2014
13115,U-1166,A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS,2014
13116,U-1167,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),2014
13117,U-1168,"THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA",2014
13118,U-1169,MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN,2014
13119,U-1170,TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2014
13120,U-1171,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,2014
13121,U-1172,"TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN",2014
13122,U-1173,"TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE",2014
13123,U-1174,"ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION",2014
13124,U-1175,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2014
13125,U-1176,TREATMENT OR PREVENTION OF STROKE,2014
13126,U-1177,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2014
13127,U-1178,RELIEF OF MODERATE TO SEVERE CHRONIC PAIN,2014
13128,U-1179,TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK),2014
13129,U-1180,TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS,2014
13130,U-1181,A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT,2014
13131,U-1182,TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING,2014
13132,U-1183,A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN,2014
13133,U-1184,TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA,2014
13134,U-1185,TREATMENT OF OPIOID-INDUCED CONSTIPATION,2014
13135,U-1186,ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE,2014
13136,U-1187,TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE),2014
13137,U-1188,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE,2014
13138,U-1189,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN",2014
13139,U-1190,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN",2014
13140,U-1191,"METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)",2014
13141,U-1192,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)",2014
13142,U-1193,"METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)",2014
13143,U-1194,METHOD FOR TREATING INSOMNIA,2014
13144,U-1195,"PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA",2014
13145,U-1196,RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS,2014
13146,U-1197,METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY,2014
13147,U-1198,RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE,2014
13148,U-1199,TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2014
13149,U-1200,REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM,2014
13150,U-1201,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,2014
13151,U-1202,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2014
13152,U-1203,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2014
13153,U-1204,TREATMENT OF UVEITIS,2014
13154,U-1205,TREATMENT OF MACULAR EDEMA,2014
13155,U-1206,DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX,2014
13156,U-1207,"INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS",2014
13157,U-1208,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2014
13158,U-1209,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER",2014
13159,U-1210,USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE),2014
13160,U-1211,"USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2014
13161,U-1212,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2014
13162,U-1213,TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETETENT PATIENTS 12 YEARS OF AGE AND OLDER,2014
13163,U-1214,METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2014
13164,U-1215,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2014
13165,U-1216,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2014
13166,U-1217,METHOD OF INCREASING HAIR GROWTH,2014
13167,U-1218,METHOD OF STIMULATING HAIR GROWTH,2014
13168,U-1219,METHOD OF INCREASING THE NUMBER OF HAIRS,2014
13169,U-1220,TREATMENT OF RENAL CELL CARCINOMA,2014
13170,U-1221,TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION,2014
13171,U-1222,TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS,2014
13172,U-1223,METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE,2014
13173,U-1224,REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE,2014
13174,U-1225,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS,2014
13175,U-1226,A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT,2014
13176,U-1227,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE,2014
13177,U-1228,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN,2014
13178,U-1229,TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS,2014
13179,U-1230,A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT,2014
13180,U-1231,TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS,2014
13181,U-1232,"USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENTED FOR USE W/ASPIRIN",2014
13182,U-1233,"TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD",2014
13183,U-1234,"FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA",2014
13184,U-1235,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION,2014
13185,U-1236,USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2014
13186,U-1237,"COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS",2014
13187,U-1238,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,2014
13188,U-1239,MAGNETIC RESONANCE IMAGING OF THE LIVER,2014
13189,U-1240,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2014
13190,U-1241,MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED,2014
13191,U-1242,PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS,2014
13192,U-1243,"WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER",2014
13193,U-1244,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA,2014
13194,U-1245,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE,2014
13195,U-1246,SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA,2014
13196,U-1247,MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS,2014
13197,U-1248,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE,2014
13198,U-1249,TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG,2014
13199,U-1250,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2014
13200,U-1251,A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT,2014
13201,U-1252,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE,2014
13202,U-1253,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY,2014
13203,U-1254,METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN,2014
13204,U-1255,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY,2014
13205,U-1256,TREATMENT OF SEBORRHEIC DERMATITIS,2014
13206,U-1257,TREATMENT OF OPHTHALMIC DISORDERS,2014
13207,U-1258,VISUALIZATION DURING VITRECTOMY PROCEDURES,2014
13208,U-1259,PROPHYLAXIS OF HIV-1 INFECTION,2014
13209,U-1260,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,2014
13210,U-1261,REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION,2014
13211,U-1262,"USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT",2014
13212,U-1263,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS,2014
13213,U-1264,TREATMENT OF A RESPIRATORY DISEASE,2014
13214,U-1265,PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2014
13215,U-1266,METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA,2014
13216,U-1267,TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE,2014
13217,U-1268,"TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE",2014
13218,U-1269,"TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET",2014
13219,U-1270,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE),2014
13220,U-1271,TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES,2014
13221,U-1272,TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM,2014
13222,U-1273,TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM,2014
13223,U-1274,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS,2014
13224,U-1275,TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2014
13225,U-1276,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,2014
13226,U-1277,"METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN",2014
13227,U-1278,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS,2014
13228,U-1279,TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE,2014
13229,U-1280,USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS,2014
13230,U-1281,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL,2014
13231,U-1282,PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING,2014
13232,U-1283,A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA,2014
13233,U-1284,A METHOD OF TREATING A NEOPLASM,2014
13234,U-1285,TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,2014
13235,U-1286,A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE,2014
13236,U-1287,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2014
13237,U-1288,TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET,2014
13238,U-1289,MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN,2014
13239,U-1290,TREATMENT OF LUNG CANCER,2014
13240,U-1291,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION,2014
13241,U-1292,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET",2014
13242,U-1293,A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2014
13243,U-1294,METHOD OF TREATING GLAUCOMA IN A PATIENT,2014
13244,U-1295,A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION,2014
13245,U-1296,USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION,2014
13246,U-1297,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS,2014
13247,U-1298,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES,2014
13248,U-1299,TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2014
13249,U-1300,TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2014
13250,U-1301,TREATMENT OF DEEP VEIN THROMBOSIS (DVT),2014
13251,U-1302,TREATMENT OF PULMONARY EMBOLISM (PE),2014
13252,U-1303,REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM,2014
13253,U-1304,USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES,2014
13254,U-1305,"TREATMENT OF HIV-1INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS",2014
13255,U-1306,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2014
13256,U-1307,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY",2014
13257,U-1308,MULTIPLE MYELOMA,2014
13258,U-1309,BONE METASTASES,2014
13259,U-1310,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2014
13260,U-1311,METHOD OF TREATING CYSTIC FIBROSIS,2014
13261,U-1312,USE FOR THE TREATMENT OF HYPERGLYCEMIA,2014
13262,U-1313,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2014
13263,U-1314,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2014
13264,U-1315,THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2014
13265,U-1316,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,2014
13266,U-1317,"TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2014
13267,U-1318,TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2014
13268,U-1319,SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA,2014
13269,U-1320,TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT,2014
13270,U-1321,TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS,2014
13271,U-1322,METHOD OF REDUCING OCULAR HYPERTENSION,2014
13272,U-1323,REDUCING THE RISK OF STROKE,2014
13273,U-1324,MANAGEMENT OF CYSTIC FIBROSIS PATIENTS,2014
13274,U-1325,"INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS",2014
13275,U-1326,METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE,2014
13276,U-1327,"METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION",2014
13277,U-1328,"METHOF FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF",2014
13278,U-1329,TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER,2014
13279,U-1330,METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
13280,U-1331,METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
13281,U-1332,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
13282,U-1333,METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR,2014
13283,U-1334,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2014
13284,U-1335,METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN,2014
13285,U-1336,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN,2014
13286,U-1337,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,2014
13287,U-1338,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN,2014
13288,U-1339,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2014
13289,U-1340,METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2014
13290,U-1341,METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2014
13291,U-1342,METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2014
13292,U-1343,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2014
13293,U-1344,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION,2014
13294,U-1345,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/-10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,2014
13295,U-1346,"USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE",2014
13296,U-1347,TREATMENT OF A SKIN DISORDER,2014
13297,U-1348,TREATMENT OF OSTEOARTHRITIS,2014
13298,U-1349,TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS,2014
13299,U-1350,TREATMENT OF ANKYLOSING SPONDYLITIS,2014
13300,U-1351,TREATMENT OF ACUTE PAIN,2014
13301,U-1352,TREATMENT OF PRIMARY DYSMENORRHEA,2014
13302,U-1353,"ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2014
13303,U-1354,INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH,2014
13304,U-1355,MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD,2014
13305,U-1356,TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER,2014
13306,U-1357,TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD,2014
13307,U-1358,TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS,2014
13308,U-1359,"USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2014
13309,U-1360,USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA,2014
13310,U-1361,USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE,2014
13311,U-1362,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET",2014
13312,U-1363,A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY,2014
13313,U-1364,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2014
13314,U-1365,PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT,2014
13315,U-1366,TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN,2014
13316,U-1367,METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN,2014
13317,U-1368,"TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB",2014
13318,U-1369,TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE,2014
13319,U-1370,TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE,2014
13320,U-1371,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA,2014
13321,U-1372,ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION,2014
13322,U-1373,METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS,2014
13323,U-1374,TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML),2014
13324,U-1375,ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS,2014
13325,U-1376,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2014
13326,U-1377,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2014
13327,U-1378,TREATMENT OF A NITROGEN METAOLISM DISORDER,2014
13328,U-1379,IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS,2014
13329,U-1380,IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE,2014
13330,U-1381,USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,2014
13331,U-1382,TREATMETN OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT,2014
13332,U-1383,DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER,2014
13333,U-1384,METHOD OF TREATING MULTIPLE SCLEROSIS,2014
13334,U-1385,METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS,2014
13335,U-1386,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF,2014
13336,U-1387,REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS,2014
13337,U-1388,TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS,2014
13338,U-1389,ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD,2014
13339,U-1390,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF,2014
13340,U-1391,METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION,2014
13341,U-1392,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION,2014
13342,U-1393,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION,2014
13343,U-1394,METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2014
13344,U-1395,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/-10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,2014
13345,U-1396,"TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2014
13346,U-1397,USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY,2014
13347,U-1398,METHOD OF TREATING CHRONIC HEPATITIS C,2014
13348,U-1399,MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES,2014
13349,U-1400,"FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2014
13350,U-1401,"INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS",2014
13351,U-1402,FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL),2014
13352,U-1403,FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST,2014
13353,U-1404,METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS,2014
13354,U-1405,THERAPEUTIC TREATMENT OF BONE METASTASES,2014
13355,U-1406,TREATMENT OF MELANOMA,2014
13356,U-1407,TREATMENT OF NEWLY DIAGNOSED PHILADELPIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML),2014
13357,U-1408,TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER,2014
13358,U-1409,TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION,2014
13359,U-1410,TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES,2014
13360,U-1411,THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE,2014
13361,U-1412,TREATMENT OF ATOPIC DERMATITIS,2014
13362,U-1413,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION,2014
13363,U-1414,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL),2014
13364,U-1415,"TREATMING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2",2014
13365,U-1416,"USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES",2014
13366,U-1417,USE FOR TREATMENT OF HELICOBACTER INFECTIONS,2014
13367,U-1418,TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST,2014
13368,U-1419,TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING,2014
13369,U-1420,METHOD OF ONCE A DAY ADMINISTRATION,2014
13370,U-1421,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE,2014
13371,U-1422,METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT,2014
13372,U-1423,AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT,2014
13373,U-1424,"LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSOTO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2014
13374,U-1425,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE,2014
13375,U-1426,USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS,2014
13376,U-1427,ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY,2014
13377,U-1428,TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA,2014
13378,U-1429,TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR,2014
13379,U-1430,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS",2014
13380,U-1431,"METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE",2014
13381,U-1432,METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX,2014
13382,U-1433,IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS,2014
13383,U-1434,TREATMENT OF PANCREATIC CANCER,2014
13384,U-1435,COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AN DADMINISTRATION OF AN ORAL NSAID.,2014
13385,U-1436,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT,2014
13386,U-1437,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION,2014
13387,U-1438,ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION,2014
13388,U-1439,METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION,2014
13389,U-1440,USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS,2014
13390,U-1441,A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING,2014
13391,U-1442,SUBCUTANEOUS INJECTION OF METHOTREXATE,2014
13392,U-1443,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS,2014
13393,U-1444,A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS,2014
13394,U-1445,"METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION",2014
13395,U-1446,METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES,2014
13396,U-1447,TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA,2014
13397,U-1448,TREATING SEVERE HYPERTRIGLYCERIDEMIA,2014
13398,U-1449,METHOD OF ALLEVIATING A SKIN CONDITION,2014
13399,U-1450,TREATMENT OF ALLERGIC RHINITIS SYMPTOMS,2014
13400,U-1451,APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY,2014
13401,U-1452,METHOD FOR CHRONIC WEIGHT MANAGEMENT,2014
13402,U-1453,A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT,2014
13403,U-1454,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS,2014
13404,U-1455,TREATMENT OF PERIANAL WARTS,2014
13405,U-1456,TREATMENT OF MANTLE CELL LYMPHOMA,2014
13406,U-1457,A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM,2014
13407,U-1458,A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2014
13408,U-1459,TREATMENT OF CARCINOMA OF THE THYROID,2014
13409,U-1460,TREATMENT OF HERPES LABIALIS,2014
13410,U-1461,A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE,2014
13411,U-1462,"A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE",2014
13412,U-1463,"A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES",2014
13413,U-1464,TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION,2014
13414,U-1465,USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE,2014
13415,U-1466,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2014
13416,U-1467,METHOD OF TREATING HEPATITIS C,2014
13417,U-1468,CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS,2014
13418,U-1469,USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS,2014
13419,U-1470,FOR THE TREATMENT OF HEPATITIS C,2014
13420,U-1471,"A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.",2014
13421,U-1472,"INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES",2014
13422,U-1473,MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF,2014
13423,U-1474,"A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT",2014
13424,U-1475,USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).,2014
13425,U-1476,"INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.",2014
13426,U-1477,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE,2014
13427,U-1478,METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2014
13428,U-1479,INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).,2014
13429,U-1480,TREATMENT OF ADVANCED RENAL CELL CARCINOMA,2014
13430,U,PATENT USE CODE,2015
13431,U-1,PREVENTION OF PREGNANCY,2015
13432,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2015
13433,U-3,TREATMENT OF HYPERTENSION,2015
13434,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2015
13435,U-5,METHOD OF PRODUCING BRONCHODILATION,2015
13436,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2015
13437,U-7,INCREASING CARDIAC CONTRACTILITY,2015
13438,U-8,ACUTE MYOCARDIAL INFARCTION,2015
13439,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2015
13440,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2015
13441,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2015
13442,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2015
13443,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2015
13444,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2015
13445,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2015
13446,U-16,USE IN LUNG SCANNING PROCEDURES,2015
13447,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2015
13448,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2015
13449,U-19,TREATMENT OF INFLAMMATION,2015
13450,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2015
13451,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2015
13452,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2015
13453,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2015
13454,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2015
13455,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2015
13456,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2015
13457,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2015
13458,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2015
13459,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2015
13460,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2015
13461,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2015
13462,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2015
13463,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2015
13464,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2015
13465,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2015
13466,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2015
13467,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2015
13468,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2015
13469,U-39,ANGINA PECTORIS,2015
13470,U-40,METHOD OF TREATMENT OF BURNS,2015
13471,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2015
13472,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2015
13473,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2015
13474,U-44,RELIEF OF NAUSEA AND VOMITING,2015
13475,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2015
13476,U-46,TREATMENT OF PANIC DISORDER,2015
13477,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2015
13478,U-48,ANALGESIA,2015
13479,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2015
13480,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2015
13481,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2015
13482,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2015
13483,U-53,HYPERCALCEMIA OF MALIGNANCY,2015
13484,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2015
13485,U-55,TREATMENT OF PAIN,2015
13486,U-56,AID TO SMOKING CESSATION,2015
13487,U-57,OPHTHALMIC USE OF NORFLOXACIN,2015
13488,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2015
13489,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2015
13490,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2015
13491,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2015
13492,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2015
13493,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2015
13494,U-64,TREATMENT OF VIRAL INFECTIONS,2015
13495,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2015
13496,U-66,TRIPHASIC REGIMEN,2015
13497,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2015
13498,U-68,TREATMENT OF ACTINIC KERATOSIS,2015
13499,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2015
13500,U-70,TREATMENT OF TRANSIENT INSOMNIA,2015
13501,U-71,METHOD OF TREATMENT OF HEART FAILURE,2015
13502,U-72,TREATMENT OF MIGRAINE,2015
13503,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2015
13504,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2015
13505,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2015
13506,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2015
13507,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2015
13508,U-78,ULCERATIVE COLITIS,2015
13509,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2015
13510,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2015
13511,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2015
13512,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2015
13513,U-83,TREATMENT OF SEIZURES,2015
13514,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2015
13515,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2015
13516,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2015
13517,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2015
13518,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2015
13519,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2015
13520,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2015
13521,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2015
13522,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2015
13523,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2015
13524,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2015
13525,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2015
13526,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2015
13527,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2015
13528,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2015
13529,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2015
13530,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2015
13531,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2015
13532,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2015
13533,U-103,TREATMENT OF OCULAR HYPERTENSION,2015
13534,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2015
13535,U-105,EMESIS,2015
13536,U-106,TREATMENT OF EPILEPSY,2015
13537,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2015
13538,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2015
13539,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2015
13540,U-110,USE AS A RETRIEVABLE PERSSARY,2015
13541,U-111,DIABETES,2015
13542,U-112,CONTRACEPTION,2015
13543,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2015
13544,U-114,USE FOR INHIBITING BONE RESORPTION,2015
13545,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2015
13546,U-116,METHOD OF MYOCARDIAL IMAGING,2015
13547,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2015
13548,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2015
13549,U-119,TREATMENT OF NASAL HYPERSECRETION,2015
13550,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2015
13551,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2015
13552,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2015
13553,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2015
13554,U-124,TREATMENT OF ACNE,2015
13555,U-125,TREATMENT NEUROGENERATIVE DISEASES,2015
13556,U-126,TREATMENT OF GASTRITIS,2015
13557,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2015
13558,U-128,METHOD FOR TREATMENT OF TUMORS,2015
13559,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2015
13560,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2015
13561,U-131,PHOTODAMAGED SKIN,2015
13562,U-132,INHIBITING HIV PROTEASE,2015
13563,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2015
13564,U-134,TREATMENT OF ACNE VULGARIS,2015
13565,U-135,ANTITUMOR AGENT,2015
13566,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2015
13567,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2015
13568,U-138,TREATMENT OF ALLERGIC RHINITIS,2015
13569,U-139,TREATMENT OF ALLERGIC REACTIONS,2015
13570,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2015
13571,U-141,TREATMENT OF ULCERATIVE COLITIS,2015
13572,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2015
13573,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2015
13574,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2015
13575,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2015
13576,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2015
13577,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2015
13578,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2015
13579,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2015
13580,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2015
13581,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2015
13582,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2015
13583,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2015
13584,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2015
13585,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2015
13586,U-156,METHOD OF PROVIDING ANESTHESIA,2015
13587,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2015
13588,U-158,ANGINA,2015
13589,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2015
13590,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2015
13591,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2015
13592,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2015
13593,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2015
13594,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2015
13595,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2015
13596,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2015
13597,U-167,METHOD FOR TREATING HIV-1 INFECTION,2015
13598,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2015
13599,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2015
13600,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2015
13601,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2015
13602,U-172,TREATMENT OF GENITAL WARTS,2015
13603,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2015
13604,U-174,USE AS AN ANTIHISTAMINE AGENT,2015
13605,U-175,METHOD OF TREATING MALIGNANT TUMORS,2015
13606,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2015
13607,U-177,FUNGICIDE,2015
13608,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2015
13609,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2015
13610,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2015
13611,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2015
13612,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2015
13613,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2015
13614,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2015
13615,U-185,METHOD OF TREATING HYPERTENSION,2015
13616,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2015
13617,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2015
13618,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2015
13619,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2015
13620,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2015
13621,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2015
13622,U-192,USE IN TREATING ALLERGIC REACTIONS,2015
13623,U-193,PSORIASIS,2015
13624,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2015
13625,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2015
13626,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2015
13627,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2015
13628,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2015
13629,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2015
13630,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2015
13631,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2015
13632,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2015
13633,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2015
13634,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2015
13635,U-205,METHOD FOR TREATING HEARTBURN,2015
13636,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2015
13637,U-207,USE AS NASAL SPRAY,2015
13638,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2015
13639,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2015
13640,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2015
13641,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2015
13642,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2015
13643,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2015
13644,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2015
13645,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2015
13646,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2015
13647,U-217,METHOD OF PRODUCING ANESTHESIA,2015
13648,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2015
13649,U-219,TREATMENT OF PARKINSON'S DISEASE,2015
13650,U-220,METHOD OF DIAGNOSIS,2015
13651,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2015
13652,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2015
13653,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2015
13654,U-224,CONTROLLING INTRAOCULAR PRESSURE,2015
13655,U-225,METHOD FOR DELIVERY,2015
13656,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2015
13657,U-227,NASAL ADMINISTRATION,2015
13658,U-228,ASTHMA,2015
13659,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2015
13660,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2015
13661,U-231,USE IN PARKINSON'S DISEASE,2015
13662,U-232,METHOD OF TREATING MIGRAINE,2015
13663,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2015
13664,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2015
13665,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2015
13666,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2015
13667,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2015
13668,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2015
13669,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2015
13670,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2015
13671,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2015
13672,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2015
13673,U-243,TOPICAL ADMINISTRATION,2015
13674,U-244,PLATELET AGGREGATION INHIBITORS,2015
13675,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2015
13676,U-246,PHOSPHATE BINDING,2015
13677,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2015
13678,U-248,TREATMENT OF HIV,2015
13679,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2015
13680,U-250,TREATMENT OF HEPATITIS B INFECTION,2015
13681,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2015
13682,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2015
13683,U-253,ORAL TRANSMUCOSAL USE,2015
13684,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2015
13685,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2015
13686,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2015
13687,U-257,TREATMENT OF HIV INFECTION,2015
13688,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2015
13689,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2015
13690,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2015
13691,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2015
13692,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2015
13693,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2015
13694,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2015
13695,U-265,USE AS LAXATIVE,2015
13696,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2015
13697,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2015
13698,U-268,ACROMEGALY,2015
13699,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2015
13700,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2015
13701,U-271,METHOD OF TREATING TUMORS,2015
13702,U-272,METHOD OF TREATING CARCINOMA,2015
13703,U-273,CUTANEOUS T-CELL LYMPHOMA,2015
13704,U-274,ZANAMIVIR FOR INHALATION,2015
13705,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2015
13706,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2015
13707,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2015
13708,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2015
13709,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2015
13710,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2015
13711,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2015
13712,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2015
13713,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2015
13714,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2015
13715,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2015
13716,U-286,DEPRESSION,2015
13717,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2015
13718,U-288,THERAPY OF INFLUENZA,2015
13719,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2015
13720,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2015
13721,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2015
13722,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2015
13723,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2015
13724,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2015
13725,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2015
13726,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2015
13727,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2015
13728,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2015
13729,U-299,TREATMENT OF ADENOMATOUS POLYPS,2015
13730,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2015
13731,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2015
13732,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2015
13733,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2015
13734,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2015
13735,U-305,METHODS FOR USING THE DRUG PRODUCT,2015
13736,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2015
13737,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2015
13738,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2015
13739,U-309,TREATING SJOEGREN SYNDROME,2015
13740,U-310,TREATMENT OF XEROSTOMIA,2015
13741,U-311,HORMONE REPLACEMENT,2015
13742,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2015
13743,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2015
13744,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2015
13745,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2015
13746,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2015
13747,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2015
13748,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2015
13749,U-319,TREATMENT OF MICROBIAL INFECTIONS,2015
13750,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2015
13751,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2015
13752,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2015
13753,U-323,USE AS A BILE ACID SEQUESTRANT,2015
13754,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2015
13755,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2015
13756,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2015
13757,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2015
13758,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2015
13759,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2015
13760,U-330,TREATMENT OF NAUSEA AND VOMITING,2015
13761,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
13762,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2015
13763,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2015
13764,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2015
13765,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2015
13766,U-336,DIAGNOSTIC RADIOIMAGING,2015
13767,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2015
13768,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2015
13769,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2015
13770,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2015
13771,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2015
13772,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2015
13773,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2015
13774,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2015
13775,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2015
13776,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2015
13777,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2015
13778,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2015
13779,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2015
13780,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2015
13781,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2015
13782,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2015
13783,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2015
13784,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2015
13785,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2015
13786,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2015
13787,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2015
13788,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2015
13789,U-359,METHOD OF USE OF VISICOL,2015
13790,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2015
13791,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2015
13792,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2015
13793,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2015
13794,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2015
13795,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2015
13796,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2015
13797,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2015
13798,U-368,HEARTBURN,2015
13799,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2015
13800,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2015
13801,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2015
13802,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2015
13803,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2015
13804,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2015
13805,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2015
13806,U-376,TREATMENT OF INFLUENZA,2015
13807,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2015
13808,U-378,METHOD FOR TREATING INCONTINENCE,2015
13809,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2015
13810,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2015
13811,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2015
13812,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2015
13813,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2015
13814,U-384,TREATMENT OF CMV RETINITIS,2015
13815,U-385,TREATMENT OF PEPTIC ULCERS,2015
13816,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2015
13817,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2015
13818,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2015
13819,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2015
13820,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2015
13821,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2015
13822,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2015
13823,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2015
13824,U-394,METHOD OF USE OF ALPHAGAN,2015
13825,U-395,METHOD OF USE OF ALPHAGAN P,2015
13826,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2015
13827,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2015
13828,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2015
13829,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2015
13830,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2015
13831,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2015
13832,U-402,TREATMENT OF ACTINIC KERATOSES,2015
13833,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2015
13834,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2015
13835,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2015
13836,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2015
13837,U-407,METHOD OF TREATING OTOPATHY,2015
13838,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2015
13839,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2015
13840,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
13841,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2015
13842,U-412,TREATMENT OF TYPE 2 DIABETES,2015
13843,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2015
13844,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2015
13845,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2015
13846,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2015
13847,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2015
13848,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
13849,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2015
13850,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2015
13851,U-421,USE FOR SEDATION,2015
13852,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2015
13853,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2015
13854,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2015
13855,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
13856,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2015
13857,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2015
13858,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2015
13859,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2015
13860,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2015
13861,U-431,POSTTRAUMATIC STRESS DISORDER,2015
13862,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2015
13863,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2015
13864,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2015
13865,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2015
13866,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2015
13867,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2015
13868,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2015
13869,U-439,TREATMENT OF OBESITY,2015
13870,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2015
13871,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2015
13872,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2015
13873,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2015
13874,U-444,TREATMENT OF MIGRAINE,2015
13875,U-445,USE AS AN ANTIMYCOTIC AGENT,2015
13876,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2015
13877,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
13878,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2015
13879,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2015
13880,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2015
13881,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2015
13882,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2015
13883,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2015
13884,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2015
13885,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2015
13886,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2015
13887,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2015
13888,U-458,METHOD OF USE OF IMAGENT,2015
13889,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2015
13890,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2015
13891,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2015
13892,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2015
13893,U-463,VENOGRAPHY,2015
13894,U-464,PERIPHERAL ARTERIOGRAPHY,2015
13895,U-465,CT IMAGING OF THE HEAD,2015
13896,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2015
13897,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2015
13898,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2015
13899,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2015
13900,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2015
13901,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2015
13902,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2015
13903,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2015
13904,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2015
13905,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2015
13906,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2015
13907,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2015
13908,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2015
13909,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2015
13910,U-480,CONTRAST AGENT FOR MRI,2015
13911,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2015
13912,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2015
13913,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2015
13914,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2015
13915,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2015
13916,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2015
13917,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2015
13918,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2015
13919,U-489,EXPECTORANT,2015
13920,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2015
13921,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2015
13922,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2015
13923,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2015
13924,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2015
13925,U-495,PERITONEAL DIALYSIS SOLUTION,2015
13926,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2015
13927,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2015
13928,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2015
13929,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2015
13930,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2015
13931,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2015
13932,U-502,PITYRIASIS VERSICOLOR,2015
13933,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2015
13934,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2015
13935,U-505,ULTRASOUND CONTRAST AGENT,2015
13936,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2015
13937,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2015
13938,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2015
13939,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2015
13940,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2015
13941,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2015
13942,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2015
13943,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2015
13944,U-514,PREVENTION OF OVULATION IN A WOMAN,2015
13945,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2015
13946,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2015
13947,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2015
13948,U-518,OBSESSIVE COMPULSIVE DISORDER,2015
13949,U-519,POST OPERATIVE NAUSEA AND VOMITING,2015
13950,U-520,PREMENOPAUSAL OSTEOPOROSIS,2015
13951,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2015
13952,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2015
13953,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2015
13954,U-524,METHOD OF TREATING DIARRHEA,2015
13955,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2015
13956,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2015
13957,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2015
13958,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2015
13959,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2015
13960,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2015
13961,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2015
13962,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2015
13963,U-533,ERECTILE DYSFUNCTION,2015
13964,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2015
13965,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2015
13966,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2015
13967,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2015
13968,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2015
13969,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2015
13970,U-540,TREATMENT OF FUNGAL INFECTIONS,2015
13971,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2015
13972,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2015
13973,U-543,TREATMENT OF SCHIZOPHRENIA,2015
13974,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2015
13975,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2015
13976,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2015
13977,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2015
13978,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2015
13979,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2015
13980,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2015
13981,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2015
13982,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2015
13983,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2015
13984,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2015
13985,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2015
13986,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2015
13987,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2015
13988,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2015
13989,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2015
13990,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2015
13991,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2015
13992,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2015
13993,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2015
13994,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2015
13995,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2015
13996,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2015
13997,U-567,METHOD OF TREATING INFERTILITY,2015
13998,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2015
13999,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2015
14000,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2015
14001,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2015
14002,U-572,INTENSIVE CARE UNIT SEDATION,2015
14003,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2015
14004,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2015
14005,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2015
14006,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2015
14007,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2015
14008,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2015
14009,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2015
14010,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2015
14011,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2015
14012,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2015
14013,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2015
14014,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2015
14015,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2015
14016,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2015
14017,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2015
14018,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2015
14019,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2015
14020,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2015
14021,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2015
14022,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2015
14023,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2015
14024,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2015
14025,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
14026,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2015
14027,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2015
14028,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2015
14029,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2015
14030,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2015
14031,U-601,TREATMENT OF BIPOLAR DISORDER,2015
14032,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2015
14033,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2015
14034,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2015
14035,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2015
14036,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2015
14037,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2015
14038,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2015
14039,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2015
14040,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2015
14041,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2015
14042,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2015
14043,U-613,REDUCTION OF SERUM PHOSPHATE,2015
14044,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2015
14045,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2015
14046,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2015
14047,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2015
14048,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2015
14049,U-619,TREATMENT OF MALIGNANT NEOPLASM,2015
14050,U-620,TREATMENT OF INSOMNIA,2015
14051,U-621,METHOD OF TREATING CANCER,2015
14052,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2015
14053,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2015
14054,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2015
14055,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2015
14056,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2015
14057,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2015
14058,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2015
14059,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2015
14060,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2015
14061,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2015
14062,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2015
14063,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2015
14064,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2015
14065,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2015
14066,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2015
14067,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2015
14068,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2015
14069,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2015
14070,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2015
14071,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2015
14072,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2015
14073,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2015
14074,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2015
14075,U-645,TREATMENT OF ASTHMA,2015
14076,U-646,METHOD OF TREATING OTITIS,2015
14077,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
14078,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2015
14079,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2015
14080,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2015
14081,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2015
14082,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2015
14083,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2015
14084,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2015
14085,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2015
14086,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2015
14087,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
14088,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2015
14089,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2015
14090,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2015
14091,U-661,TREATMENT OF SEIZURE DISORDER,2015
14092,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
14093,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2015
14094,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2015
14095,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2015
14096,U-666,METHOD OF TREATING ADHD,2015
14097,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2015
14098,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2015
14099,U-669,INDICATION OF TYPE II DIABETES,2015
14100,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2015
14101,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2015
14102,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2015
14103,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2015
14104,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2015
14105,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2015
14106,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2015
14107,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2015
14108,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2015
14109,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2015
14110,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2015
14111,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2015
14112,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2015
14113,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2015
14114,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2015
14115,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2015
14116,U-686,EXPECTORANT AND NASAL DECONGESTANT,2015
14117,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2015
14118,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2015
14119,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2015
14120,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2015
14121,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2015
14122,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2015
14123,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2015
14124,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2015
14125,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2015
14126,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2015
14127,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2015
14128,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2015
14129,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2015
14130,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2015
14131,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2015
14132,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2015
14133,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2015
14134,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2015
14135,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2015
14136,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2015
14137,U-707,ALLERGIC RHINITIS,2015
14138,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2015
14139,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2015
14140,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2015
14141,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2015
14142,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2015
14143,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2015
14144,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2015
14145,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2015
14146,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2015
14147,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2015
14148,U-718,TREATMENT OF FUNGAL INFECTIONS,2015
14149,U-719,TREATENT OF PSYCHOSIS,2015
14150,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2015
14151,U-721,TREATMENT OF INFLUENZA,2015
14152,U-722,PROPHYLAXIS OF INFLUENZA,2015
14153,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2015
14154,U-724,METHOD OF TREATING SEIZURES,2015
14155,U-725,ALLERGIC RHINITIS AND URTICARIA,2015
14156,U-726,ALLERGIC RHINITIS,2015
14157,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2015
14158,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2015
14159,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2015
14160,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2015
14161,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2015
14162,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2015
14163,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2015
14164,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2015
14165,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2015
14166,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2015
14167,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2015
14168,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2015
14169,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2015
14170,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2015
14171,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2015
14172,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2015
14173,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2015
14174,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2015
14175,U-745,TREATMENT OR PREVENTION OF EMESIS,2015
14176,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2015
14177,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2015
14178,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2015
14179,U-749,METHOD OF CONTRACEPTION,2015
14180,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2015
14181,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2015
14182,U-752,SUNSCREEN,2015
14183,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2015
14184,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2015
14185,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2015
14186,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
14187,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2015
14188,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2015
14189,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2015
14190,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2015
14191,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2015
14192,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2015
14193,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2015
14194,U-764,TREATMENT OF SCHIZOPHRENIA,2015
14195,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2015
14196,U-766,TREATMENT OF SEIZURES,2015
14197,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2015
14198,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2015
14199,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2015
14200,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2015
14201,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2015
14202,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2015
14203,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2015
14204,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2015
14205,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2015
14206,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2015
14207,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2015
14208,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2015
14209,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2015
14210,U-780,A METHOD FOR THE TREATMENT OF CANCER,2015
14211,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2015
14212,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2015
14213,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2015
14214,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2015
14215,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2015
14216,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2015
14217,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2015
14218,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2015
14219,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2015
14220,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2015
14221,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2015
14222,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2015
14223,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2015
14224,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2015
14225,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2015
14226,U-796,METHOD OF TREATING DEPRESSION,2015
14227,U-797,METHOD OF TREATING ANXIETY,2015
14228,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2015
14229,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2015
14230,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2015
14231,U-801,METHOD OF TREATING CANCER,2015
14232,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2015
14233,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2015
14234,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2015
14235,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2015
14236,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2015
14237,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2015
14238,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2015
14239,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2015
14240,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2015
14241,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2015
14242,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2015
14243,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2015
14244,U-814,TREATMENT OF SCHIZOPHRENIA,2015
14245,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2015
14246,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2015
14247,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2015
14248,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2015
14249,U-819,MANAGEMENT OF FIBROMYALGIA,2015
14250,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2015
14251,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2015
14252,U-822,USE IN LIPID MANAGEMENT,2015
14253,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2015
14254,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2015
14255,U-825,USE FOR PREVENTION OF BREAST CANCER,2015
14256,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2015
14257,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2015
14258,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2015
14259,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2015
14260,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2015
14261,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2015
14262,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2015
14263,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2015
14264,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2015
14265,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2015
14266,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2015
14267,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2015
14268,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2015
14269,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2015
14270,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2015
14271,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2015
14272,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2015
14273,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2015
14274,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2015
14275,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2015
14276,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2015
14277,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2015
14278,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2015
14279,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2015
14280,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2015
14281,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2015
14282,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2015
14283,U-853,TREATMENT OR PREVENTION OF EMESIS,2015
14284,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2015
14285,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2015
14286,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2015
14287,U-857,INHIBITION OF TRANSPLANT REJECTION,2015
14288,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2015
14289,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2015
14290,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2015
14291,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2015
14292,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2015
14293,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2015
14294,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2015
14295,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2015
14296,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2015
14297,U-867,TREATMENT OF MIGRAINE,2015
14298,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2015
14299,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2015
14300,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2015
14301,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2015
14302,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2015
14303,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2015
14304,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2015
14305,U-875,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE",2015
14306,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2015
14307,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2015
14308,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2015
14309,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2015
14310,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2015
14311,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2015
14312,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2015
14313,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2015
14314,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2015
14315,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2015
14316,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2015
14317,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2015
14318,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2015
14319,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2015
14320,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2015
14321,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2015
14322,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2015
14323,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2015
14324,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2015
14325,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2015
14326,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2015
14327,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2015
14328,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2015
14329,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2015
14330,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2015
14331,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2015
14332,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2015
14333,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2015
14334,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2015
14335,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2015
14336,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2015
14337,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2015
14338,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2015
14339,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2015
14340,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2015
14341,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2015
14342,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2015
14343,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2015
14344,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2015
14345,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2015
14346,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2015
14347,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2015
14348,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2015
14349,U-919,FOR THE TREATMENT OF DERMATITIS,2015
14350,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2015
14351,U-921,TREATMENT OF ACNE VULGARIS,2015
14352,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2015
14353,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2015
14354,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2015
14355,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2015
14356,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2015
14357,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2015
14358,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2015
14359,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2015
14360,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2015
14361,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2015
14362,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2015
14363,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2015
14364,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2015
14365,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2015
14366,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2015
14367,U-937,TREATMENT OF PROSTATE CANCER,2015
14368,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2015
14369,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2015
14370,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2015
14371,U-941,METHOD TO TREAT OVARIAN CANCER,2015
14372,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2015
14373,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2015
14374,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2015
14375,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2015
14376,U-946,TREATMENT OF BREAST CANCER,2015
14377,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2015
14378,U-948,TREATMENT OF DIABETES MELLITUS,2015
14379,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2015
14380,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2015
14381,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2015
14382,U-952,USE AS AN ANALGESIC,2015
14383,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2015
14384,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2015
14385,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2015
14386,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2015
14387,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2015
14388,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2015
14389,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2015
14390,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2015
14391,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2015
14392,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2015
14393,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2015
14394,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2015
14395,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2015
14396,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2015
14397,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2015
14398,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2015
14399,U-969,TREATMENT OF MIGRAINE,2015
14400,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2015
14401,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2015
14402,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2015
14403,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2015
14404,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2015
14405,U-975,TREATMENT OF PULMONARY HYPERTENSION,2015
14406,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2015
14407,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2015
14408,U-978,METHOD OF TREATING HYPONATREMIA,2015
14409,U-979,RELIEF OF MUSCLE SPASM,2015
14410,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2015
14411,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2015
14412,U-982,A METHOD OF TREATING OSTEOPOROSIS,2015
14413,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2015
14414,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2015
14415,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2015
14416,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2015
14417,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2015
14418,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2015
14419,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2015
14420,U-990,TREATMENT OF PROTOZOAL INFECTION,2015
14421,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2015
14422,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2015
14423,U-993,METHOD OF TREATING INFERTILITY,2015
14424,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2015
14425,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2015
14426,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2015
14427,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2015
14428,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2015
14429,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2015
14430,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2015
14431,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2015
14432,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2015
14433,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2015
14434,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2015
14435,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2015
14436,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2015
14437,U-1007,METHOD OF TREATING GOUT FLARES,2015
14438,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2015
14439,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2015
14440,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2015
14441,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2015
14442,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2015
14443,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2015
14444,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2015
14445,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2015
14446,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2015
14447,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2015
14448,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2015
14449,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2015
14450,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2015
14451,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2015
14452,U-1022,FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2015
14453,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2015
14454,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2015
14455,U-1025,TREATING FREQUENT HEARTBURN,2015
14456,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2015
14457,U-1027,REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL,2015
14458,U-1028,A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY,2015
14459,U-1029,METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF,2015
14460,U-1030,IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS),2015
14461,U-1031,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2015
14462,U-1032,USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS,2015
14463,U-1033,TOPICAL TREATMENT OF ACNE VULGARIS,2015
14464,U-1034,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2015
14465,U-1035,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2015
14466,U-1036,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN,2015
14467,U-1037,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST,2015
14468,U-1038,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST,2015
14469,U-1039,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN,2015
14470,U-1040,INHIBITION OF THROMBIN IN A PATIENT,2015
14471,U-1041,TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE,2015
14472,U-1042,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2015
14473,U-1043,MANAGEMENT OF MODERATE TO SEVERE PAIN,2015
14474,U-1044,TOPICAL TREATMENT OF SCALP PSORIASIS,2015
14475,U-1045,MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY,2015
14476,U-1046,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY,2015
14477,U-1047,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)",2015
14478,U-1048,WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES,2015
14479,U-1049,PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT,2015
14480,U-1050,USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS,2015
14481,U-1051,TREATMENT OF OROPHARYNGEAL CANDIDIASIS,2015
14482,U-1052,RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2015
14483,U-1053,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2015
14484,U-1054,"ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS",2015
14485,U-1055,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE,2015
14486,U-1056,TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2015
14487,U-1057,TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2015
14488,U-1058,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2015
14489,U-1059,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,2015
14490,U-1060,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS,2015
14491,U-1061,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,2015
14492,U-1062,ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE,2015
14493,U-1063,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,2015
14494,U-1064,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2015
14495,U-1065,METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY,2015
14496,U-1066,METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA,2015
14497,U-1067,TREATMENT OF CANCER,2015
14498,U-1068,TREATMENT OF ASTHMA,2015
14499,U-1069,A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2015
14500,U-1070,A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE,2015
14501,U-1071,METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION,2015
14502,U-1072,"THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME",2015
14503,U-1073,USE FOR THE TREATMENT OF ASTHMA AND COPD,2015
14504,U-1074,USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT,2015
14505,U-1075,USE FOR THE TREATMENT OF ASTHMA,2015
14506,U-1076,"REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING",2015
14507,U-1077,PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION,2015
14508,U-1078,TREATMENT OF ACNE,2015
14509,U-1079,REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2015
14510,U-1080,METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT,2015
14511,U-1081,LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2015
14512,U-1082,USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS,2015
14513,U-1083,"ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES",2015
14514,U-1084,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2015
14515,U-1085,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,2015
14516,U-1086,TREATMENT OF AUTOIMMUNE DISEASE,2015
14517,U-1087,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,2015
14518,U-1088,RELIEF OF MUSCLE SPASM,2015
14519,U-1089,INHIBITION OF THROMBIN,2015
14520,U-1090,LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION,2015
14521,U-1091,ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA,2015
14522,U-1092,TREATMENT OF BREAST CANCER,2015
14523,U-1093,TREATMENT OF PSEUDOBULBAR AFFECT,2015
14524,U-1094,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2015
14525,U-1095,METHOD OF TREATING OCULAR INFLAMMATION,2015
14526,U-1096,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,2015
14527,U-1097,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,2015
14528,U-1098,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,2015
14529,U-1099,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2015
14530,U-1100,REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY,2015
14531,U-1101,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2015
14532,U-1102,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,2015
14533,U-1103,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2015
14534,U-1104,USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN,2015
14535,U-1105,TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER,2015
14536,U-1106,TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT,2015
14537,U-1107,TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT,2015
14538,U-1108,TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE,2015
14539,U-1109,"TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2015
14540,U-1110,METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2015
14541,U-1111,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2015
14542,U-1112,METHOD OF MR IMAGING OF A MAMMAL,2015
14543,U-1113,TREATMENT AND PROPHYLAXIS OF INFLUENZA,2015
14544,U-1114,"TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA",2015
14545,U-1115,TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS,2015
14546,U-1116,METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS,2015
14547,U-1117,TREATMENT OF BREAST CANCER,2015
14548,U-1118,"USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2015
14549,U-1119,CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING,2015
14550,U-1120,TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL,2015
14551,U-1121,METHOD OF TREATING TRAVELERS' DIARRHEA,2015
14552,U-1122,TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES,2015
14553,U-1123,TREATMENT OF ALCOHOL DEPENDENCE,2015
14554,U-1124,"PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION",2015
14555,U-1125,METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS,2015
14556,U-1126,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL,2015
14557,U-1127,TREATMENT OF PATENT DUCTUS ARTERIOSUS,2015
14558,U-1128,TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE,2015
14559,U-1129,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2015
14560,U-1130,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN,2015
14561,U-1131,"TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2015
14562,U-1132,TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14563,U-1133,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14564,U-1134,TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14565,U-1135,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C",2015
14566,U-1136,"SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2015
14567,U-1137,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2015
14568,U-1138,TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14569,U-1139,REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14570,U-1140,REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14571,U-1141,REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14572,U-1142,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2015
14573,U-1143,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2015
14574,U-1144,"REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2015
14575,U-1145,"REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2015
14576,U-1146,REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2015
14577,U-1147,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2015
14578,U-1148,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2015
14579,U-1149,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2015
14580,U-1150,"TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C",2015
14581,U-1151,"TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C",2015
14582,U-1152,CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION,2015
14583,U-1153,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION",2015
14584,U-1154,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB",2015
14585,U-1155,USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL),2015
14586,U-1156,TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA),2015
14587,U-1157,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2015
14588,U-1158,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2015
14589,U-1159,"RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER",2015
14590,U-1160,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER,2015
14591,U-1161,FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER,2015
14592,U-1162,TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP,2015
14593,U-1163,METHOD OF TREATING THROMBOSIS,2015
14594,U-1164,METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION,2015
14595,U-1165,USE FOR THE TREATMENT OF MULTIPLE MYELOMA,2015
14596,U-1166,A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS,2015
14597,U-1167,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),2015
14598,U-1168,"THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA",2015
14599,U-1169,MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN,2015
14600,U-1170,TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2015
14601,U-1171,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,2015
14602,U-1172,"TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN",2015
14603,U-1173,"TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE",2015
14604,U-1174,"ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION",2015
14605,U-1175,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2015
14606,U-1176,TREATMENT OR PREVENTION OF STROKE,2015
14607,U-1177,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2015
14608,U-1178,RELIEF OF MODERATE TO SEVERE CHRONIC PAIN,2015
14609,U-1179,TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK),2015
14610,U-1180,TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS,2015
14611,U-1181,A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT,2015
14612,U-1182,TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING,2015
14613,U-1183,A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN,2015
14614,U-1184,TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA,2015
14615,U-1185,TREATMENT OF OPIOID-INDUCED CONSTIPATION,2015
14616,U-1186,ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE,2015
14617,U-1187,TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE),2015
14618,U-1188,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE,2015
14619,U-1189,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN",2015
14620,U-1190,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN",2015
14621,U-1191,"METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)",2015
14622,U-1192,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)",2015
14623,U-1193,"METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)",2015
14624,U-1194,METHOD FOR TREATING INSOMNIA,2015
14625,U-1195,"PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA",2015
14626,U-1196,RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS,2015
14627,U-1197,METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY,2015
14628,U-1198,RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE,2015
14629,U-1199,TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2015
14630,U-1200,REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM,2015
14631,U-1201,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,2015
14632,U-1202,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2015
14633,U-1203,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2015
14634,U-1204,TREATMENT OF UVEITIS,2015
14635,U-1205,TREATMENT OF MACULAR EDEMA,2015
14636,U-1206,DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX,2015
14637,U-1207,"INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS",2015
14638,U-1208,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2015
14639,U-1209,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER",2015
14640,U-1210,USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE),2015
14641,U-1211,"USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2015
14642,U-1212,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2015
14643,U-1213,TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETETENT PATIENTS 12 YEARS OF AGE AND OLDER,2015
14644,U-1214,METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2015
14645,U-1215,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2015
14646,U-1216,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2015
14647,U-1217,METHOD OF INCREASING HAIR GROWTH,2015
14648,U-1218,METHOD OF STIMULATING HAIR GROWTH,2015
14649,U-1219,METHOD OF INCREASING THE NUMBER OF HAIRS,2015
14650,U-1220,TREATMENT OF RENAL CELL CARCINOMA,2015
14651,U-1221,TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION,2015
14652,U-1222,TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS,2015
14653,U-1223,METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE,2015
14654,U-1224,REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE,2015
14655,U-1225,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS,2015
14656,U-1226,A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT,2015
14657,U-1227,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE,2015
14658,U-1228,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN,2015
14659,U-1229,TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS,2015
14660,U-1230,A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT,2015
14661,U-1231,TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS,2015
14662,U-1232,"USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENTED FOR USE W/ASPIRIN",2015
14663,U-1233,"TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD",2015
14664,U-1234,"FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA",2015
14665,U-1235,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION,2015
14666,U-1236,USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2015
14667,U-1237,"COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS",2015
14668,U-1238,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,2015
14669,U-1239,MAGNETIC RESONANCE IMAGING OF THE LIVER,2015
14670,U-1240,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2015
14671,U-1241,MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED,2015
14672,U-1242,PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS,2015
14673,U-1243,"WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER",2015
14674,U-1244,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA,2015
14675,U-1245,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE,2015
14676,U-1246,SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA,2015
14677,U-1247,MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS,2015
14678,U-1248,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE,2015
14679,U-1249,TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG,2015
14680,U-1250,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2015
14681,U-1251,A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT,2015
14682,U-1252,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE,2015
14683,U-1253,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY,2015
14684,U-1254,METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN,2015
14685,U-1255,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY,2015
14686,U-1256,TREATMENT OF SEBORRHEIC DERMATITIS,2015
14687,U-1257,TREATMENT OF OPHTHALMIC DISORDERS,2015
14688,U-1258,VISUALIZATION DURING VITRECTOMY PROCEDURES,2015
14689,U-1259,PROPHYLAXIS OF HIV-1 INFECTION,2015
14690,U-1260,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,2015
14691,U-1261,REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION,2015
14692,U-1262,"USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT",2015
14693,U-1263,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS,2015
14694,U-1264,TREATMENT OF A RESPIRATORY DISEASE,2015
14695,U-1265,PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2015
14696,U-1266,METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA,2015
14697,U-1267,TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE,2015
14698,U-1268,"TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE",2015
14699,U-1269,"TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET",2015
14700,U-1270,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE),2015
14701,U-1271,TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES,2015
14702,U-1272,TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM,2015
14703,U-1273,TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM,2015
14704,U-1274,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS,2015
14705,U-1275,TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2015
14706,U-1276,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,2015
14707,U-1277,"METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN",2015
14708,U-1278,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS,2015
14709,U-1279,TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE,2015
14710,U-1280,USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS,2015
14711,U-1281,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL,2015
14712,U-1282,PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING,2015
14713,U-1283,A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA,2015
14714,U-1284,A METHOD OF TREATING A NEOPLASM,2015
14715,U-1285,TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,2015
14716,U-1286,A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE,2015
14717,U-1287,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2015
14718,U-1288,TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET,2015
14719,U-1289,MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN,2015
14720,U-1290,TREATMENT OF LUNG CANCER,2015
14721,U-1291,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION,2015
14722,U-1292,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET",2015
14723,U-1293,A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2015
14724,U-1294,METHOD OF TREATING GLAUCOMA IN A PATIENT,2015
14725,U-1295,A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION,2015
14726,U-1296,USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION,2015
14727,U-1297,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS,2015
14728,U-1298,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES,2015
14729,U-1299,TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2015
14730,U-1300,TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2015
14731,U-1301,TREATMENT OF DEEP VEIN THROMBOSIS (DVT),2015
14732,U-1302,TREATMENT OF PULMONARY EMBOLISM (PE),2015
14733,U-1303,REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM,2015
14734,U-1304,USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES,2015
14735,U-1305,"TREATMENT OF HIV-1INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS",2015
14736,U-1306,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2015
14737,U-1307,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY",2015
14738,U-1308,MULTIPLE MYELOMA,2015
14739,U-1309,BONE METASTASES,2015
14740,U-1310,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2015
14741,U-1311,METHOD OF TREATING CYSTIC FIBROSIS,2015
14742,U-1312,USE FOR THE TREATMENT OF HYPERGLYCEMIA,2015
14743,U-1313,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2015
14744,U-1314,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2015
14745,U-1315,THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2015
14746,U-1316,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,2015
14747,U-1317,"TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2015
14748,U-1318,TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2015
14749,U-1319,SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA,2015
14750,U-1320,TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT,2015
14751,U-1321,TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS,2015
14752,U-1322,METHOD OF REDUCING OCULAR HYPERTENSION,2015
14753,U-1323,REDUCING THE RISK OF STROKE,2015
14754,U-1324,MANAGEMENT OF CYSTIC FIBROSIS PATIENTS,2015
14755,U-1325,"INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS",2015
14756,U-1326,METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE,2015
14757,U-1327,"METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION",2015
14758,U-1328,"METHOF FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF",2015
14759,U-1329,TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER,2015
14760,U-1330,METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
14761,U-1331,METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
14762,U-1332,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
14763,U-1333,METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR,2015
14764,U-1334,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2015
14765,U-1335,METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN,2015
14766,U-1336,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN,2015
14767,U-1337,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,2015
14768,U-1338,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN,2015
14769,U-1339,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2015
14770,U-1340,METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2015
14771,U-1341,METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2015
14772,U-1342,METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2015
14773,U-1343,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2015
14774,U-1344,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION,2015
14775,U-1345,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/-10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,2015
14776,U-1346,"USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE",2015
14777,U-1347,TREATMENT OF A SKIN DISORDER,2015
14778,U-1348,TREATMENT OF OSTEOARTHRITIS,2015
14779,U-1349,TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS,2015
14780,U-1350,TREATMENT OF ANKYLOSING SPONDYLITIS,2015
14781,U-1351,TREATMENT OF ACUTE PAIN,2015
14782,U-1352,TREATMENT OF PRIMARY DYSMENORRHEA,2015
14783,U-1353,"ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2015
14784,U-1354,INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH,2015
14785,U-1355,MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD,2015
14786,U-1356,TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER,2015
14787,U-1357,TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD,2015
14788,U-1358,TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS,2015
14789,U-1359,"USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2015
14790,U-1360,USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA,2015
14791,U-1361,USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE,2015
14792,U-1362,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET",2015
14793,U-1363,A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY,2015
14794,U-1364,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2015
14795,U-1365,PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT,2015
14796,U-1366,TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN,2015
14797,U-1367,METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN,2015
14798,U-1368,"TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB",2015
14799,U-1369,TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE,2015
14800,U-1370,TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE,2015
14801,U-1371,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA,2015
14802,U-1372,ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION,2015
14803,U-1373,METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS,2015
14804,U-1374,TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML),2015
14805,U-1375,ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS,2015
14806,U-1376,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2015
14807,U-1377,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2015
14808,U-1378,TREATMENT OF A NITROGEN METAOLISM DISORDER,2015
14809,U-1379,IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS,2015
14810,U-1380,IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE,2015
14811,U-1381,USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,2015
14812,U-1382,TREATMETN OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT,2015
14813,U-1383,DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER,2015
14814,U-1384,METHOD OF TREATING MULTIPLE SCLEROSIS,2015
14815,U-1385,METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS,2015
14816,U-1386,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF,2015
14817,U-1387,REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS,2015
14818,U-1388,TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS,2015
14819,U-1389,ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD,2015
14820,U-1390,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF,2015
14821,U-1391,METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION,2015
14822,U-1392,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION,2015
14823,U-1393,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION,2015
14824,U-1394,METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2015
14825,U-1395,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/-10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,2015
14826,U-1396,"TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2015
14827,U-1397,USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY,2015
14828,U-1398,METHOD OF TREATING CHRONIC HEPATITIS C,2015
14829,U-1399,MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES,2015
14830,U-1400,"FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2015
14831,U-1401,"INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS",2015
14832,U-1402,FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL),2015
14833,U-1403,FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST,2015
14834,U-1404,METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS,2015
14835,U-1405,THERAPEUTIC TREATMENT OF BONE METASTASES,2015
14836,U-1406,TREATMENT OF MELANOMA,2015
14837,U-1407,TREATMENT OF NEWLY DIAGNOSED PHILADELPIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML),2015
14838,U-1408,TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER,2015
14839,U-1409,TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION,2015
14840,U-1410,TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES,2015
14841,U-1411,THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE,2015
14842,U-1412,TREATMENT OF ATOPIC DERMATITIS,2015
14843,U-1413,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION,2015
14844,U-1414,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL),2015
14845,U-1415,"TREATMING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2",2015
14846,U-1416,"USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES",2015
14847,U-1417,USE FOR TREATMENT OF HELICOBACTER INFECTIONS,2015
14848,U-1418,TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST,2015
14849,U-1419,TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING,2015
14850,U-1420,METHOD OF ONCE A DAY ADMINISTRATION,2015
14851,U-1421,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE,2015
14852,U-1422,METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT,2015
14853,U-1423,AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT,2015
14854,U-1424,"LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSOTO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2015
14855,U-1425,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE,2015
14856,U-1426,USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS,2015
14857,U-1427,ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY,2015
14858,U-1428,TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA,2015
14859,U-1429,TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR,2015
14860,U-1430,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS",2015
14861,U-1431,"METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE",2015
14862,U-1432,METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX,2015
14863,U-1433,IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS,2015
14864,U-1434,TREATMENT OF PANCREATIC CANCER,2015
14865,U-1435,COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AN DADMINISTRATION OF AN ORAL NSAID.,2015
14866,U-1436,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT,2015
14867,U-1437,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION,2015
14868,U-1438,ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION,2015
14869,U-1439,METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION,2015
14870,U-1440,USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS,2015
14871,U-1441,A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING,2015
14872,U-1442,SUBCUTANEOUS INJECTION OF METHOTREXATE,2015
14873,U-1443,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS,2015
14874,U-1444,A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS,2015
14875,U-1445,"METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION",2015
14876,U-1446,METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES,2015
14877,U-1447,TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA,2015
14878,U-1448,TREATING SEVERE HYPERTRIGLYCERIDEMIA,2015
14879,U-1449,METHOD OF ALLEVIATING A SKIN CONDITION,2015
14880,U-1450,TREATMENT OF ALLERGIC RHINITIS SYMPTOMS,2015
14881,U-1451,APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY,2015
14882,U-1452,METHOD FOR CHRONIC WEIGHT MANAGEMENT,2015
14883,U-1453,A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT,2015
14884,U-1454,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS,2015
14885,U-1455,TREATMENT OF PERIANAL WARTS,2015
14886,U-1456,TREATMENT OF MANTLE CELL LYMPHOMA,2015
14887,U-1457,A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM,2015
14888,U-1458,A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2015
14889,U-1459,TREATMENT OF CARCINOMA OF THE THYROID,2015
14890,U-1460,TREATMENT OF HERPES LABIALIS,2015
14891,U-1461,A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE,2015
14892,U-1462,"A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE",2015
14893,U-1463,"A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES",2015
14894,U-1464,TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION,2015
14895,U-1465,USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE,2015
14896,U-1466,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2015
14897,U-1467,METHOD OF TREATING HEPATITIS C,2015
14898,U-1468,CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS,2015
14899,U-1469,USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS,2015
14900,U-1470,FOR THE TREATMENT OF HEPATITIS C,2015
14901,U-1471,"A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.",2015
14902,U-1472,"INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES",2015
14903,U-1473,MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF,2015
14904,U-1474,"A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT",2015
14905,U-1475,USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).,2015
14906,U-1476,"INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.",2015
14907,U-1477,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE,2015
14908,U-1478,METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2015
14909,U-1479,INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).,2015
14910,U-1480,TREATMENT OF ADVANCED RENAL CELL CARCINOMA,2015
14911,U-1481,REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE,2015
14912,U-1482,DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2015
14913,U-1483,INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).,2015
14914,U-1484,COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER),2015
14915,U-1485,TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS,2015
14916,U-1486,TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER,2015
14917,U-1487,METHOD OF INCREASING EYELASH GROWTH,2015
14918,U-1488,USE OF TOPICAL DICLOFENAC FOR TREATING PAIN,2015
14919,U-1489,USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS,2015
14920,U-1490,"FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE",2015
14921,U-1491,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,2015
14922,U-1492,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER,2015
14923,U-1493,METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS,2015
14924,U-1494,SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE,2015
14925,U-1495,RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.,2015
14926,U-1496,METHOD TO TREAT HEMANGIOMA.,2015
14927,U-1497,NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT,2015
14928,U-1498,METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM,2015
14929,U-1499,MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2015
14930,U-1500,TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).,2015
14931,U-1501,PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM,2015
14932,U-1502,PROPHYLAXIS OF PULMONARY EMBOLISM,2015
14933,U-1503,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN,2015
14934,U-1504,USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4,2015
14935,U-1505,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,2015
14936,U-1506,"TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR",2015
14937,U-1507,TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN,2015
14938,U-1508,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED",2015
14939,U-1509,TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER,2015
14940,U-1510,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOD TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.",2015
14941,U-1511,TREATMENT OF HYPERTRIGLYCERIDEMIA,2015
14942,U-1512,REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,2015
14943,U-1513,TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2015
14944,U-1514,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL,2015
14945,U-1515,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.,2015
14946,U-1516,METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.,2015
14947,U-1517,TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.,2015
14948,U-1518,MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN,2015
14949,U-1519,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME,2015
14950,U-1520,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT,2015
14951,U-1521,MAINTENANCE TREATMENT OF OPIOID DEPENDENCE,2015
14952,U-1522,"TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE",2015
14953,U-1523,METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE,2015
14954,U-1524,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE,2015
14955,U-1525,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2015
14956,U-1526,THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE,2015
14957,U-1527,"FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY",2015
14958,U-1528,A METHOD OF LOWERING INTRAOCULAR PRESSURE,2015
14959,U-1529,ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2015
14960,U-1530,USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION,2015
14961,U-1531,METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE,2015
14962,U-1532,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.,2015
14963,U-1533,PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.,2015
14964,U-1534,ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.,2015
14965,U-1535,ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.,2015
14966,U-1536,ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.,2015
14967,U-1537,TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.,2015
14968,U-1538,ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.,2015
14969,U-1539,PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.,2015
14970,U-1540,"BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.",2015
14971,U-1541,TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.,2015
14972,U-1542,FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA,2015
14973,U-1543,TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23,2015
14974,U-1544,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).,2015
14975,U-1545,A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE,2015
14976,U-1546,FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.,2015
14977,U-1547,"TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA",2015
14978,U-1548,"FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2015
14979,U-1549,FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA,2015
14980,U-1550,METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.,2015
14981,U-1551,"METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.",2015
14982,U-1552,FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE),2015
14983,U-1553,TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN,2015
14984,U-1554,FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD),2015
14985,U-1555,"MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.",2015
14986,U-1556,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.",2015
14987,U-1557,A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.,2015
14988,U-1558,FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA,2015
14989,U-1559,INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER,2015
14990,U-1560,"A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE",2015
14991,U-1561,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,2015
14992,U-1562,TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE),2015
14993,U-1563,A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.,2015
14994,U-1564,A METHOD OF TREATING GAUCHER'S DISEASE,2015
14995,U-1565,"METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE",2015
14996,U-1566,"METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2015
14997,U-1567,"METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER",2015
14998,U-1568,"METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE",2015
14999,U-1569,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,2015
15000,U-1570,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE,2015
15001,U-1571,TREATMENT OF GAUCHER DISEASE TYPE 1,2015
15002,U-1572,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.,2015
15003,U-1573,USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.,2015
15004,U-1574,A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.,2015
15005,U-1575,PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY,2015
15006,U-1576,TREATMENT OF LEUKEMIA,2015
15007,U-1577,CONTROL OF SERUM PHOSPHOROUS LEVELS,2015
15008,U-1578,TREATMENT OF ACUTE OTITIS MEDIA,2015
15009,U-1579,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2015
15010,U-1580,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY,2015
15011,U-1581,IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.,2015
15012,U-1582,TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA,2015
15013,U-1583,FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY,2015
15014,U-1584,USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS,2015
15015,U-1585,USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE,2015
15016,U-1586,FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE,2015
15017,U-1587,SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.,2015
15018,U-1588,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).,2015
15019,U-1589,METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2015
15020,U-1590,KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA,2015
15021,U-1591,TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER,2015
15022,U-1592,TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2015
15023,U-1593,"MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.",2015
15024,U-1594,DILATION OF THE PUPIL,2015
15025,U-1595,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS,2015
15026,U-1596,LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS â¥ 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2015
15027,U-1597,TREATMENT OF DIABETIC MACULAR EDEMA,2015
15028,U-1598,METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE,2015
15029,U-1599,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADNUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2015
15030,U-1600,DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,2015
15031,U-1601,DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,2015
15032,U-1602,METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION,2015
15033,U-1603,METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE,2015
15034,U-1604,METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2,2015
15035,U-1605,METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER,2015
15036,U-1606,METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM,2015
15037,U-1607,METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION,2015
15038,U-1608,DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION,2015
15039,U-1609,CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,2015
15040,U-1610,CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE,2015
15041,U-1611,METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER,2015
15042,U-1612,METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER,2015
15043,U-1613,DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN,2015
15044,U-1614,USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN,2015
15045,U-1615,"FOR THE TREATMENT OF PATIENTS WITH CCL, FL, OR SLL",2015
15046,U-1616,NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2015
15047,U-1617,METHOD OF TREATING MEDULLARY THYROID CANCER,2015
15048,U-1618,"A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FONNULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT",2015
15049,U-1619,TREATMENT OF IMMUNE (IDIOPATIC) THROMBOCYTOPENIA (ITP),2015
15050,U-1620,"METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.",2015
15051,U-1621,PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.,2015
15052,U-1622,FOR THE TREATMENT OF POLYCYTHEMIA VERA,2015
15053,U-1623,USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.,2015
15054,U-1624,"TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.",2015
15055,U-1625,METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6,2015
15056,U-1626,A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING,2015
15057,U-1627,TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS,2015
15058,U-1628,METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION,2015
15059,U-1629,METHOD OF TREATING ACROMEGALY,2015
15060,U-1630,TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED IWTH DOCETAXEL,2015
15061,U-1631,TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.,2015
15062,U-1632,"TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA",2015
15063,U-1633,USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA,2015
15064,U-1634,TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR,2015
15065,U-1635,USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION,2015
15066,U-1636,USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.,2015
15067,U-1637,"TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.",2015
15068,U-1638,TREATMENT OF HCV INFECTION USING PARITAPREVIR,2015
15069,U-1639,USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY,2015
15070,U-1640,TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED,2015
15071,U-1641,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2015
15072,U-1642,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN,2015
15073,U,PATENT USE CODE,2016
15074,U-1,PREVENTION OF PREGNANCY,2016
15075,U-2,TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA,2016
15076,U-3,TREATMENT OF HYPERTENSION,2016
15077,U-4,PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS,2016
15078,U-5,METHOD OF PRODUCING BRONCHODILATION,2016
15079,U-6,METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS,2016
15080,U-7,INCREASING CARDIAC CONTRACTILITY,2016
15081,U-8,ACUTE MYOCARDIAL INFARCTION,2016
15082,U-9,CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT,2016
15083,U-10,DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS,2016
15084,U-11,TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS,2016
15085,U-12,METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION,2016
15086,U-13,A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT,2016
15087,U-14,ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES,2016
15088,U-15,METHOD OF LOWERING INTRAOCULAR PRESSURE,2016
15089,U-16,USE IN LUNG SCANNING PROCEDURES,2016
15090,U-17,TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS,2016
15091,U-18,METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS,2016
15092,U-19,TREATMENT OF INFLAMMATION,2016
15093,U-20,A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT,2016
15094,U-21,TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS,2016
15095,U-22,"METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS",2016
15096,U-23,METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE,2016
15097,U-24,METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST,2016
15098,U-25,REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS,2016
15099,U-26,REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2016
15100,U-27,DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF,2016
15101,U-28,"CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY",2016
15102,U-29,"CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY",2016
15103,U-30,"CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY",2016
15104,U-31,INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY,2016
15105,U-32,"PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN",2016
15106,U-33,TREATING VIRAL INFECTIONS IN A MAMMAL,2016
15107,U-34,TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL,2016
15108,U-35,TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION,2016
15109,U-36,METHODS OF TREATING BACTERIAL ILLNESSES,2016
15110,U-37,METHOD OF TREATING GASTROINTESTINAL DISEASE,2016
15111,U-38,TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,2016
15112,U-39,ANGINA PECTORIS,2016
15113,U-40,METHOD OF TREATMENT OF BURNS,2016
15114,U-41,METHOD OF TREATING CARDIAC ARRHYTHMIAS,2016
15115,U-42,ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER,2016
15116,U-43,MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2016
15117,U-44,RELIEF OF NAUSEA AND VOMITING,2016
15118,U-45,TREATMENT OF INFLAMMATION AND ANALGESIA,2016
15119,U-46,TREATMENT OF PANIC DISORDER,2016
15120,U-47,STIMULATION OF THE RELEASE OF GROWTH HORMONE,2016
15121,U-48,ANALGESIA,2016
15122,U-49,SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA,2016
15123,U-50,USE IN TREATING INFLAMMATORY DERMATOSES,2016
15124,U-51,"BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING",2016
15125,U-52,TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2016
15126,U-53,HYPERCALCEMIA OF MALIGNANCY,2016
15127,U-54,REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS,2016
15128,U-55,TREATMENT OF PAIN,2016
15129,U-56,AID TO SMOKING CESSATION,2016
15130,U-57,OPHTHALMIC USE OF NORFLOXACIN,2016
15131,U-58,METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES,2016
15132,U-59,METHOD OF TREATING HYPERCHOLESTEROLEMIA,2016
15133,U-60,NASAL ADMINISTRATION OF BUTORPHANOL,2016
15134,U-61,CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD,2016
15135,U-62,"CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY",2016
15136,U-63,ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE,2016
15137,U-64,TREATMENT OF VIRAL INFECTIONS,2016
15138,U-65,METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV,2016
15139,U-66,TRIPHASIC REGIMEN,2016
15140,U-67,METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL,2016
15141,U-68,TREATMENT OF ACTINIC KERATOSIS,2016
15142,U-69,TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS,2016
15143,U-70,TREATMENT OF TRANSIENT INSOMNIA,2016
15144,U-71,METHOD OF TREATMENT OF HEART FAILURE,2016
15145,U-72,TREATMENT OF MIGRAINE,2016
15146,U-73,METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES,2016
15147,U-74,METHOD OF PROVIDING HYPNOTIC EFFECT,2016
15148,U-75,RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS,2016
15149,U-76,USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM,2016
15150,U-77,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2016
15151,U-78,ULCERATIVE COLITIS,2016
15152,U-79,SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD,2016
15153,U-80,METHOD OF TREATING OCULAR BACTERIAL INFECTIONS,2016
15154,U-81,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,2016
15155,U-82,TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE,2016
15156,U-83,TREATMENT OF SEIZURES,2016
15157,U-84,A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS,2016
15158,U-85,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2016
15159,U-86,METHOD OF TREATING CERTAIN FORMS OF EPILEPSY,2016
15160,U-87,"METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS",2016
15161,U-88,TREATMENT OF MODERATE PLAQUE PSORIASIS,2016
15162,U-89,TREATMENT OR PROPHYLAXIS OF EMESIS,2016
15163,U-90,TREATMENT OF PYSCHOTIC DISORDERS,2016
15164,U-91,ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS,2016
15165,U-92,TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY,2016
15166,U-93,USE AS AN ANTIHISTAMINE/DECONGESTANT,2016
15167,U-94,"TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED",2016
15168,U-95,SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS,2016
15169,U-96,METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS,2016
15170,U-97,A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT,2016
15171,U-98,A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL,2016
15172,U-99,METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM,2016
15173,U-100,METHOD OF TREATING OCULAR INFLAMMATION,2016
15174,U-101,ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED,2016
15175,U-102,METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN,2016
15176,U-103,TREATMENT OF OCULAR HYPERTENSION,2016
15177,U-104,TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE,2016
15178,U-105,EMESIS,2016
15179,U-106,TREATMENT OF EPILEPSY,2016
15180,U-107,TREATMENT OF HYPERTENSION AND ANGINA PECTORIS,2016
15181,U-108,"SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS",2016
15182,U-109,ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE,2016
15183,U-110,USE AS A RETRIEVABLE PERSSARY,2016
15184,U-111,DIABETES,2016
15185,U-112,CONTRACEPTION,2016
15186,U-113,METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE,2016
15187,U-114,USE FOR INHIBITING BONE RESORPTION,2016
15188,U-115,"USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS",2016
15189,U-116,METHOD OF MYOCARDIAL IMAGING,2016
15190,U-117,TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES,2016
15191,U-118,METHOD OF LOWERING BLOOD SUGAR LEVEL,2016
15192,U-119,TREATMENT OF NASAL HYPERSECRETION,2016
15193,U-120,CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES,2016
15194,U-121,METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS,2016
15195,U-122,A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS,2016
15196,U-123,METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS,2016
15197,U-124,TREATMENT OF ACNE,2016
15198,U-125,TREATMENT NEUROGENERATIVE DISEASES,2016
15199,U-126,TREATMENT OF GASTRITIS,2016
15200,U-127,METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE,2016
15201,U-128,METHOD FOR TREATMENT OF TUMORS,2016
15202,U-129,METHOD TO DESTROY OR IMPAIR TARGET CELLS,2016
15203,U-130,MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS,2016
15204,U-131,PHOTODAMAGED SKIN,2016
15205,U-132,INHIBITING HIV PROTEASE,2016
15206,U-133,MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET,2016
15207,U-134,TREATMENT OF ACNE VULGARIS,2016
15208,U-135,ANTITUMOR AGENT,2016
15209,U-136,PROCESS FOR WASTE NITROGEN REMOVAL,2016
15210,U-137,METHOD OF TREATING BACTERIAL VAGINOSIS,2016
15211,U-138,TREATMENT OF ALLERGIC RHINITIS,2016
15212,U-139,TREATMENT OF ALLERGIC REACTIONS,2016
15213,U-140,USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION,2016
15214,U-141,TREATMENT OF ULCERATIVE COLITIS,2016
15215,U-142,METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE,2016
15216,U-143,BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING,2016
15217,U-144,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS,2016
15218,U-145,BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS,2016
15219,U-146,METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS,2016
15220,U-147,DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2,2016
15221,U-148,DEVICE FOR COLLECTING A BREATH SAMPLE,2016
15222,U-149,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES",2016
15223,U-150,METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE,2016
15224,U-151,RELIEF OF SYMPTOMS OF THE COMMON COLD,2016
15225,U-152,METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER,2016
15226,U-153,TREATMENT OF INITIAL EPISODE GENITAL HERPES,2016
15227,U-154,METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER,2016
15228,U-155,TREATMENT OF ERECTILE DYSFUNCTION,2016
15229,U-156,METHOD OF PROVIDING ANESTHESIA,2016
15230,U-157,TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY,2016
15231,U-158,ANGINA,2016
15232,U-159,TREATMENT OF INTERSTITIAL CYSTITIS,2016
15233,U-160,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2016
15234,U-161,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT,2016
15235,U-162,METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA,2016
15236,U-163,METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS,2016
15237,U-164,METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS,2016
15238,U-165,TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA,2016
15239,U-166,TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER,2016
15240,U-167,METHOD FOR TREATING HIV-1 INFECTION,2016
15241,U-168,METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA,2016
15242,U-169,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING,2016
15243,U-170,METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT,2016
15244,U-171,METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT,2016
15245,U-172,TREATMENT OF GENITAL WARTS,2016
15246,U-173,ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES,2016
15247,U-174,USE AS AN ANTIHISTAMINE AGENT,2016
15248,U-175,METHOD OF TREATING MALIGNANT TUMORS,2016
15249,U-176,"METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES",2016
15250,U-177,FUNGICIDE,2016
15251,U-178,FACILITATED ADHERENCE OF AGENTS TO SKIN,2016
15252,U-179,ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT,2016
15253,U-180,TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION,2016
15254,U-181,PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST,2016
15255,U-182,USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2016
15256,U-183,TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION,2016
15257,U-184,TREATING ALLERGIC EYE DISEASES IN HUMANS,2016
15258,U-185,METHOD OF TREATING HYPERTENSION,2016
15259,U-186,METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT,2016
15260,U-187,THERAPEUTIC TREATMENT OF CALCIFIC TUMORS,2016
15261,U-188,TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER,2016
15262,U-189,ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE,2016
15263,U-190,USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR,2016
15264,U-191,METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN,2016
15265,U-192,USE IN TREATING ALLERGIC REACTIONS,2016
15266,U-193,PSORIASIS,2016
15267,U-194,TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE,2016
15268,U-195,METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON,2016
15269,U-196,TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS,2016
15270,U-197,USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER,2016
15271,U-198,"TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA",2016
15272,U-199,METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT,2016
15273,U-200,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2016
15274,U-201,METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT,2016
15275,U-202,"METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS",2016
15276,U-203,TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2016
15277,U-204,USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2016
15278,U-205,METHOD FOR TREATING HEARTBURN,2016
15279,U-206,"METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION",2016
15280,U-207,USE AS NASAL SPRAY,2016
15281,U-208,VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION,2016
15282,U-209,VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION,2016
15283,U-210,METHOD OF TREATING CONGESTIVE HEART FAILURE,2016
15284,U-211,USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION,2016
15285,U-212,METHOD OF TREATMENT OF PARKINSON'S DISEASE,2016
15286,U-213,METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA,2016
15287,U-214,USE AS A BLOOD GLUCOSE-LOWERING AGENT,2016
15288,U-215,TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS,2016
15289,U-216,"TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE",2016
15290,U-217,METHOD OF PRODUCING ANESTHESIA,2016
15291,U-218,METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT,2016
15292,U-219,TREATMENT OF PARKINSON'S DISEASE,2016
15293,U-220,METHOD OF DIAGNOSIS,2016
15294,U-221,SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION,2016
15295,U-222,METHOD OF TREATING PAGET'S DISEASE USING ACTONEL,2016
15296,U-223,TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS,2016
15297,U-224,CONTROLLING INTRAOCULAR PRESSURE,2016
15298,U-225,METHOD FOR DELIVERY,2016
15299,U-226,METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE,2016
15300,U-227,NASAL ADMINISTRATION,2016
15301,U-228,ASTHMA,2016
15302,U-229,CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE),2016
15303,U-230,PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS,2016
15304,U-231,USE IN PARKINSON'S DISEASE,2016
15305,U-232,METHOD OF TREATING MIGRAINE,2016
15306,U-233,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2016
15307,U-234,METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS,2016
15308,U-235,METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE,2016
15309,U-236,TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY,2016
15310,U-237,METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS,2016
15311,U-238,"IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....",2016
15312,U-239,"TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID",2016
15313,U-240,TREATMENT OF ACUTE MIGRAINE ATTACKS,2016
15314,U-241,"FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS",2016
15315,U-242,USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION,2016
15316,U-243,TOPICAL ADMINISTRATION,2016
15317,U-244,PLATELET AGGREGATION INHIBITORS,2016
15318,U-245,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2016
15319,U-246,PHOSPHATE BINDING,2016
15320,U-247,TREATMENT OF RHEUMATOID ARTHRITIS,2016
15321,U-248,TREATMENT OF HIV,2016
15322,U-249,METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE,2016
15323,U-250,TREATMENT OF HEPATITIS B INFECTION,2016
15324,U-251,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES,2016
15325,U-252,METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE,2016
15326,U-253,ORAL TRANSMUCOSAL USE,2016
15327,U-254,USE OF AGGRASTAT IN COMBINATION WITH HEPARIN,2016
15328,U-255,IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY,2016
15329,U-256,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,2016
15330,U-257,TREATMENT OF HIV INFECTION,2016
15331,U-258,TREATMENT OF NEURODEGENERATIVE DISEASES,2016
15332,U-259,TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE,2016
15333,U-260,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION,2016
15334,U-261,"TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE",2016
15335,U-262,TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE,2016
15336,U-263,METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN,2016
15337,U-264,METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN,2016
15338,U-265,USE AS LAXATIVE,2016
15339,U-266,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS,2016
15340,U-267,"PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE",2016
15341,U-268,ACROMEGALY,2016
15342,U-269,EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS,2016
15343,U-270,METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT,2016
15344,U-271,METHOD OF TREATING TUMORS,2016
15345,U-272,METHOD OF TREATING CARCINOMA,2016
15346,U-273,CUTANEOUS T-CELL LYMPHOMA,2016
15347,U-274,ZANAMIVIR FOR INHALATION,2016
15348,U-275,METHOD OF USE OF THE DRUG SUBSTANCE,2016
15349,U-276,METHOD OF USE OF LEVOBUPIVACAINE,2016
15350,U-277,"NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)",2016
15351,U-278,METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT,2016
15352,U-279,METHOD OF USE OF THE APPROVED PRODUCT,2016
15353,U-280,TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE,2016
15354,U-281,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",2016
15355,U-282,METHOD OF TREATING BACTERIAL INFECTIONS,2016
15356,U-283,METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE,2016
15357,U-284,"MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS",2016
15358,U-285,DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA,2016
15359,U-286,DEPRESSION,2016
15360,U-287,TREATMENT OR PREVENTION OF OSTEOPOROSIS,2016
15361,U-288,THERAPY OF INFLUENZA,2016
15362,U-289,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,2016
15363,U-290,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS),2016
15364,U-291,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN,2016
15365,U-292,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE,2016
15366,U-293,INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID,2016
15367,U-294,TREATMENT OF HYPERPIGMENTARY DISORDERS,2016
15368,U-295,TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2016
15369,U-296,"TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY",2016
15370,U-297,PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS,2016
15371,U-298,METHOD OF COMBATING BACTERIA IN A PATIENT,2016
15372,U-299,TREATMENT OF ADENOMATOUS POLYPS,2016
15373,U-300,INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA,2016
15374,U-301,USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES,2016
15375,U-302,TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS,2016
15376,U-303,"METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS",2016
15377,U-304,A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION,2016
15378,U-305,METHODS FOR USING THE DRUG PRODUCT,2016
15379,U-306,TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY,2016
15380,U-307,"CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA",2016
15381,U-308,"CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA",2016
15382,U-309,TREATING SJOEGREN SYNDROME,2016
15383,U-310,TREATMENT OF XEROSTOMIA,2016
15384,U-311,HORMONE REPLACEMENT,2016
15385,U-312,"PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER",2016
15386,U-313,TREATMENT OF CONGESTIVE HEART FAILURE,2016
15387,U-314,METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY,2016
15388,U-315,METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT,2016
15389,U-316,METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER,2016
15390,U-317,METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE,2016
15391,U-318,"TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE",2016
15392,U-319,TREATMENT OF MICROBIAL INFECTIONS,2016
15393,U-320,INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA,2016
15394,U-321,REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS,2016
15395,U-322,TREATMENT OF ALZHEIMER'S DEMENTIA,2016
15396,U-323,USE AS A BILE ACID SEQUESTRANT,2016
15397,U-324,"METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE",2016
15398,U-325,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING ""BIPOLAR DISORDER NOS"" EMPLOYING OLANZAPINE",2016
15399,U-326,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,2016
15400,U-327,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE,2016
15401,U-328,"METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING ""A PSYCHOTIC CONDITION"" EMPLOYING AN OLANZAPINE POLYMORPH",2016
15402,U-329,"USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2016
15403,U-330,TREATMENT OF NAUSEA AND VOMITING,2016
15404,U-331,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
15405,U-332,TREATMENT OR PREVENTION OF BRONCHOSPASM,2016
15406,U-333,METHOD OF TREATING OCULAR HYPERTENSION,2016
15407,U-334,TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR,2016
15408,U-335,USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS,2016
15409,U-336,DIAGNOSTIC RADIOIMAGING,2016
15410,U-337,USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI,2016
15411,U-338,"METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME",2016
15412,U-339,PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN,2016
15413,U-340,THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN,2016
15414,U-341,METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER,2016
15415,U-342,METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER,2016
15416,U-343,"REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION",2016
15417,U-344,METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR,2016
15418,U-345,RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION,2016
15419,U-346,METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR,2016
15420,U-347,METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS,2016
15421,U-348,METHOD OF USE FOR INHIBITING HIV INFECTION,2016
15422,U-349,METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION,2016
15423,U-350,PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR,2016
15424,U-351,INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR,2016
15425,U-352,INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR,2016
15426,U-353,PREVENTION AND TREATMENT OF OSTEOPOROSIS,2016
15427,U-354,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2016
15428,U-355,METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING,2016
15429,U-356,DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.,2016
15430,U-357,USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE,2016
15431,U-358,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER",2016
15432,U-359,METHOD OF USE OF VISICOL,2016
15433,U-360,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011,2016
15434,U-361,MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY,2016
15435,U-362,USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS,2016
15436,U-363,METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011,2016
15437,U-364,"TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011",2016
15438,U-365,"METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION",2016
15439,U-366,METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION,2016
15440,U-367,TREATMENT OF CARDIOVASCULAR DISORDERS,2016
15441,U-368,HEARTBURN,2016
15442,U-369,METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE,2016
15443,U-370,INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS,2016
15444,U-371,"APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2016
15445,U-372,"METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...",2016
15446,U-373,"GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING ""PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2016
15447,U-374,"KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX",2016
15448,U-375,"METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C",2016
15449,U-376,TREATMENT OF INFLUENZA,2016
15450,U-377,METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS,2016
15451,U-378,METHOD FOR TREATING INCONTINENCE,2016
15452,U-379,METHOD OF TREATING ONYCHROMYCOSIS,2016
15453,U-380,COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS,2016
15454,U-381,TREATMENT OF HYPERPHOSPHATEMIA,2016
15455,U-382,METHOD OF STABLIZING PROSTAGLANDIN,2016
15456,U-383,METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION,2016
15457,U-384,TREATMENT OF CMV RETINITIS,2016
15458,U-385,TREATMENT OF PEPTIC ULCERS,2016
15459,U-386,TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA,2016
15460,U-387,TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS,2016
15461,U-388,SMOKING CESSATION AID APPLIED TO THE SKIN,2016
15462,U-389,SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS,2016
15463,U-390,METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS),2016
15464,U-391,USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER,2016
15465,U-392,TREATMENT OF PATIENTS FOR INFLAMMATION,2016
15466,U-393,"MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT",2016
15467,U-394,METHOD OF USE OF ALPHAGAN,2016
15468,U-395,METHOD OF USE OF ALPHAGAN P,2016
15469,U-396,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION,2016
15470,U-397,METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA,2016
15471,U-398,TREATMENT OF GENERALIZED ANXIETY DISORDER,2016
15472,U-399,IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS,2016
15473,U-400,"USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS",2016
15474,U-401,USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS,2016
15475,U-402,TREATMENT OF ACTINIC KERATOSES,2016
15476,U-403,ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES,2016
15477,U-404,TREATMENT OF ALLERGIC CONJUNCTIVITIS,2016
15478,U-405,FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS),2016
15479,U-406,METHOD OF USE OF ATOVAQUONE AND PROGUANIL,2016
15480,U-407,METHOD OF TREATING OTOPATHY,2016
15481,U-408,FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION,2016
15482,U-409,METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE,2016
15483,U-410,METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
15484,U-411,METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION,2016
15485,U-412,TREATMENT OF TYPE 2 DIABETES,2016
15486,U-413,USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS,2016
15487,U-414,A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2016
15488,U-415,A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2016
15489,U-416,A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS,2016
15490,U-417,COMBINATION USE OF AD-4833 WITH A BIGUANIDE,2016
15491,U-418,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
15492,U-419,A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE,2016
15493,U-420,METHOD OF TREATMENT OF TYPE II DIABETES,2016
15494,U-421,USE FOR SEDATION,2016
15495,U-422,METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER,2016
15496,U-423,"METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA",2016
15497,U-424,"FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS",2016
15498,U-425,METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
15499,U-426,PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION,2016
15500,U-427,METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS,2016
15501,U-428,METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE,2016
15502,U-429,METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS,2016
15503,U-430,"METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT C0MPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER",2016
15504,U-431,POSTTRAUMATIC STRESS DISORDER,2016
15505,U-432,"REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE",2016
15506,U-433,USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS,2016
15507,U-434,"CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS",2016
15508,U-435,A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG,2016
15509,U-436,ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS,2016
15510,U-437,METHOD OF USE EQUAL TO PROCESS OF PREPARATION,2016
15511,U-438,TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE,2016
15512,U-439,TREATMENT OF OBESITY,2016
15513,U-440,METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE,2016
15514,U-441,METHOD OF TREATING MS BY ADMINISTERING COPAXONE,2016
15515,U-442,"METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG",2016
15516,U-443,"MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME",2016
15517,U-444,TREATMENT OF MIGRAINE,2016
15518,U-445,USE AS AN ANTIMYCOTIC AGENT,2016
15519,U-446,TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2016
15520,U-447,METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
15521,U-448,"METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT",2016
15522,U-449,USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER,2016
15523,U-450,"INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING",2016
15524,U-451,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2016
15525,U-452,USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI),2016
15526,U-453,TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS,2016
15527,U-454,"METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN",2016
15528,U-455,TREATMENT OF PULMONARY HYPERTENSION WITH UT-15,2016
15529,U-456,METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE,2016
15530,U-457,METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN,2016
15531,U-458,METHOD OF USE OF IMAGENT,2016
15532,U-459,TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER,2016
15533,U-460,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE,2016
15534,U-461,METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE,2016
15535,U-462,SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA,2016
15536,U-463,VENOGRAPHY,2016
15537,U-464,PERIPHERAL ARTERIOGRAPHY,2016
15538,U-465,CT IMAGING OF THE HEAD,2016
15539,U-466,TREATMENT OF IRRITABLE BOWEL SYNDROME,2016
15540,U-467,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION,2016
15541,U-468,METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS,2016
15542,U-469,TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE,2016
15543,U-470,THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION,2016
15544,U-471,METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS,2016
15545,U-472,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES,2016
15546,U-473,TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL,2016
15547,U-474,TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN,2016
15548,U-475,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2016
15549,U-476,"METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY",2016
15550,U-477,METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA,2016
15551,U-478,"METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B",2016
15552,U-479,METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY,2016
15553,U-480,CONTRAST AGENT FOR MRI,2016
15554,U-481,DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY,2016
15555,U-482,METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....,2016
15556,U-483,METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND,2016
15557,U-484,METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION,2016
15558,U-485,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2016
15559,U-486,EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE,2016
15560,U-487,METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA),2016
15561,U-488,METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA,2016
15562,U-489,EXPECTORANT,2016
15563,U-490,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2016
15564,U-491,METHOD OF DELIVERING A DRUG TO THE LUNG,2016
15565,U-492,"METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID",2016
15566,U-493,TREATMENT OF TYPE 2 DIABETES MELLITUS,2016
15567,U-494,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,2016
15568,U-495,PERITONEAL DIALYSIS SOLUTION,2016
15569,U-496,METHOD FOR TREATING CHRONIC RENAL FAILURE,2016
15570,U-497,RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS,2016
15571,U-498,INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST,2016
15572,U-499,"METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION",2016
15573,U-500,USE AS AN ANTIHYPERTENSIVE AGENT,2016
15574,U-501,TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS,2016
15575,U-502,PITYRIASIS VERSICOLOR,2016
15576,U-503,GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR,2016
15577,U-504,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",2016
15578,U-505,ULTRASOUND CONTRAST AGENT,2016
15579,U-506,"PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..",2016
15580,U-507,"ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE",2016
15581,U-508,METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS,2016
15582,U-509,TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY,2016
15583,U-510,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES,2016
15584,U-511,USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA,2016
15585,U-512,USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA,2016
15586,U-513,METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA,2016
15587,U-514,PREVENTION OF OVULATION IN A WOMAN,2016
15588,U-515,TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY,2016
15589,U-516,METHOD OF TREATING A PSYCHOTIC DISEASE,2016
15590,U-517,STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS,2016
15591,U-518,OBSESSIVE COMPULSIVE DISORDER,2016
15592,U-519,POST OPERATIVE NAUSEA AND VOMITING,2016
15593,U-520,PREMENOPAUSAL OSTEOPOROSIS,2016
15594,U-521,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2016
15595,U-522,TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA,2016
15596,U-523,METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL,2016
15597,U-524,METHOD OF TREATING DIARRHEA,2016
15598,U-525,METHOD OF TREATING PARASITIC INFECTIONS,2016
15599,U-526,METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION,2016
15600,U-527,METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE,2016
15601,U-528,PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING,2016
15602,U-529,ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE,2016
15603,U-530,"TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES",2016
15604,U-531,"TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES",2016
15605,U-532,TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR,2016
15606,U-533,ERECTILE DYSFUNCTION,2016
15607,U-534,HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA,2016
15608,U-535,TREATMENT OF SOCIAL ANXIETY DISORDER,2016
15609,U-536,CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING,2016
15610,U-537,"TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE",2016
15611,U-538,"FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS",2016
15612,U-539,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2016
15613,U-540,TREATMENT OF FUNGAL INFECTIONS,2016
15614,U-541,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,2016
15615,U-542,METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION,2016
15616,U-543,TREATMENT OF SCHIZOPHRENIA,2016
15617,U-544,TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.,2016
15618,U-545,"METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT",2016
15619,U-546,USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE,2016
15620,U-547,MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER,2016
15621,U-548,A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER,2016
15622,U-549,USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER,2016
15623,U-550,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2016
15624,U-551,METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID,2016
15625,U-552,TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION,2016
15626,U-553,MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS,2016
15627,U-554,TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS,2016
15628,U-555,TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS,2016
15629,U-556,USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING,2016
15630,U-557,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2016
15631,U-558,INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE),2016
15632,U-559,METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL,2016
15633,U-560,METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM,2016
15634,U-561,COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS,2016
15635,U-562,TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA,2016
15636,U-563,"MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS",2016
15637,U-564,TREATMENT OF HIV IN CONCOMITANT THERAPY,2016
15638,U-565,"TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA",2016
15639,U-566,"FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2016
15640,U-567,METHOD OF TREATING INFERTILITY,2016
15641,U-568,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION,2016
15642,U-569,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED,2016
15643,U-570,METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG,2016
15644,U-571,TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA,2016
15645,U-572,INTENSIVE CARE UNIT SEDATION,2016
15646,U-573,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2016
15647,U-574,PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2016
15648,U-575,"LOTEMAX OPTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.",2016
15649,U-576,ALREX OPTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.,2016
15650,U-577,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN,2016
15651,U-578,"TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.",2016
15652,U-579,TREATMENT OF EPILEPSY AND/OR MIGRAINE.,2016
15653,U-580,TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS,2016
15654,U-581,"METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413",2016
15655,U-582,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762",2016
15656,U-583,"METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928",2016
15657,U-584,"SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY",2016
15658,U-585,TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS,2016
15659,U-586,AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH,2016
15660,U-587,USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION,2016
15661,U-588,SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS,2016
15662,U-589,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966",2016
15663,U-590,"METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955",2016
15664,U-591,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG,2016
15665,U-592,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2016
15666,U-593,"TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)",2016
15667,U-594,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,2016
15668,U-595,35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
15669,U-596,TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY,2016
15670,U-597,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE,2016
15671,U-598,PROPHYLACTIC TREATMENT OF MIGRAINE,2016
15672,U-599,METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS,2016
15673,U-600,A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN,2016
15674,U-601,TREATMENT OF BIPOLAR DISORDER,2016
15675,U-602,"SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS",2016
15676,U-603,METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION,2016
15677,U-604,METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION,2016
15678,U-605,"TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS",2016
15679,U-606,USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER,2016
15680,U-607,"CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.",2016
15681,U-608,USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA,2016
15682,U-609,USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA,2016
15683,U-610,"ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.",2016
15684,U-611,"METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER",2016
15685,U-612,TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER,2016
15686,U-613,REDUCTION OF SERUM PHOSPHATE,2016
15687,U-614,TREATMENT OF SEXUAL DYSFUNCTION,2016
15688,U-615,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2016
15689,U-616,"MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER",2016
15690,U-617,TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL),2016
15691,U-618,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",2016
15692,U-619,TREATMENT OF MALIGNANT NEOPLASM,2016
15693,U-620,TREATMENT OF INSOMNIA,2016
15694,U-621,METHOD OF TREATING CANCER,2016
15695,U-622,TREATMENT OF VEGF MEDIATED OCULAR DISEASE.,2016
15696,U-623,SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER,2016
15697,U-624,REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS,2016
15698,U-625,ALLERGIC RHINITIS OR NASAL POLYPS,2016
15699,U-626,CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS,2016
15700,U-627,TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE,2016
15701,U-628,"USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2016
15702,U-629,METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE,2016
15703,U-630,TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN,2016
15704,U-631,TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN,2016
15705,U-632,METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING,2016
15706,U-633,METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR,2016
15707,U-634,METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL,2016
15708,U-635,"TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS",2016
15709,U-636,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,2016
15710,U-637,TREATMENT OF DIABETES WITH AN AMYLIN AGONIST,2016
15711,U-638,"TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN",2016
15712,U-639,TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE,2016
15713,U-640,USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA,2016
15714,U-641,"USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION",2016
15715,U-642,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2016
15716,U-643,THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE,2016
15717,U-644,TREATMENT OF SEASONAL ALLERGIC RHINITIS,2016
15718,U-645,TREATMENT OF ASTHMA,2016
15719,U-646,METHOD OF TREATING OTITIS,2016
15720,U-647,TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
15721,U-648,THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN,2016
15722,U-649,A METHOD FOR TREATING A TUMOR DISEASE,2016
15723,U-650,TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS,2016
15724,U-651,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL),2016
15725,U-652,TREATMENT OF CARDIAC ARRHYTHMIA,2016
15726,U-653,STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE,2016
15727,U-654,"LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4",2016
15728,U-655,TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS,2016
15729,U-656,"REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2016
15730,U-657,PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
15731,U-658,TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER,2016
15732,U-659,TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,2016
15733,U-660,TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE,2016
15734,U-661,TREATMENT OF SEIZURE DISORDER,2016
15735,U-662,TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
15736,U-663,THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS,2016
15737,U-664,"TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION",2016
15738,U-665,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,2016
15739,U-666,METHOD OF TREATING ADHD,2016
15740,U-667,MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE,2016
15741,U-668,LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS,2016
15742,U-669,INDICATION OF TYPE II DIABETES,2016
15743,U-670,TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.,2016
15744,U-671,PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4,2016
15745,U-672,TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER,2016
15746,U-673,METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML,2016
15747,U-674,METHOD OF TREATING INSOMNIA CHARACHTERIZED BY DIFFICULTY WITH SLEEP ONSET,2016
15748,U-675,PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS,2016
15749,U-676,METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION,2016
15750,U-677,A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM,2016
15751,U-678,METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER,2016
15752,U-679,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2016
15753,U-680,A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM,2016
15754,U-681,TREATMENT OF PRIMARY IGF-1 DEFICIENCY,2016
15755,U-682,"NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE",2016
15756,U-683,PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE,2016
15757,U-684,TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2016
15758,U-685,EXPECTORANT AND COUGH SUPPRESSANT,2016
15759,U-686,EXPECTORANT AND NASAL DECONGESTANT,2016
15760,U-687,"REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4",2016
15761,U-688,TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2016
15762,U-689,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2016
15763,U-690,TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS,2016
15764,U-691,"USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",2016
15765,U-692,USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION,2016
15766,U-693,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",2016
15767,U-694,"LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.",2016
15768,U-695,TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2016
15769,U-696,TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS,2016
15770,U-697,A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY,2016
15771,U-698,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYPONATREMIA,2016
15772,U-699,NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS,2016
15773,U-700,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN,2016
15774,U-701,TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA,2016
15775,U-702,TOPICAL AEROSOL HAIR REGROWTH TREATMENT,2016
15776,U-703,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB",2016
15777,U-704,METHOD OF ADMINISTERING INSULIN VIA INHALATION,2016
15778,U-705,TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE,2016
15779,U-706,TREATMENT OF BENIGN PROSTATIC HYPERPLASIA,2016
15780,U-707,ALLERGIC RHINITIS,2016
15781,U-708,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,2016
15782,U-709,METHOD OF COMBATING BACTERIA IN A PATIENT,2016
15783,U-710,"A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549",2016
15784,U-711,ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER,2016
15785,U-712,"A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA",2016
15786,U-713,TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE,2016
15787,U-714,"TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM",2016
15788,U-715,"FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER",2016
15789,U-716,THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER,2016
15790,U-717,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2016
15791,U-718,TREATMENT OF FUNGAL INFECTIONS,2016
15792,U-719,TREATENT OF PSYCHOSIS,2016
15793,U-720,TREATMENT OF NEUROLEPTIC DISEASES,2016
15794,U-721,TREATMENT OF INFLUENZA,2016
15795,U-722,PROPHYLAXIS OF INFLUENZA,2016
15796,U-723,PROPHYLACTIC TREATMENT OF MIGRAINE,2016
15797,U-724,METHOD OF TREATING SEIZURES,2016
15798,U-725,ALLERGIC RHINITIS AND URTICARIA,2016
15799,U-726,ALLERGIC RHINITIS,2016
15800,U-727,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),2016
15801,U-728,METHOD FOR TREATING BACTERIAL INFECTION,2016
15802,U-729,"TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE",2016
15803,U-730,USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS,2016
15804,U-731,USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2016
15805,U-732,ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL),2016
15806,U-733,MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE,2016
15807,U-734,FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS,2016
15808,U-735,METHOD OF TREATING CHRONIC IRON OVERLOAD,2016
15809,U-736,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,2016
15810,U-737,DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE,2016
15811,U-738,"INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER",2016
15812,U-739,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT,2016
15813,U-740,FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS,2016
15814,U-741,COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER,2016
15815,U-742,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,2016
15816,U-743,ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA,2016
15817,U-744,TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS,2016
15818,U-745,TREATMENT OR PREVENTION OF EMESIS,2016
15819,U-746,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2016
15820,U-747,PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,2016
15821,U-748,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,2016
15822,U-749,METHOD OF CONTRACEPTION,2016
15823,U-750,TREATMENT OF HIV-1 INFECTION IN ADULTS,2016
15824,U-751,ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA,2016
15825,U-752,SUNSCREEN,2016
15826,U-753,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES,2016
15827,U-754,USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA,2016
15828,U-755,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",2016
15829,U-756,ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
15830,U-757,USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL,2016
15831,U-758,TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER,2016
15832,U-759,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,2016
15833,U-760,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS,2016
15834,U-761,TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA,2016
15835,U-762,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,2016
15836,U-763,ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION,2016
15837,U-764,TREATMENT OF SCHIZOPHRENIA,2016
15838,U-765,METHOD OF TREATING ALLERGIC CONJUNCTIVITIS,2016
15839,U-766,TREATMENT OF SEIZURES,2016
15840,U-767,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,2016
15841,U-768,A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID,2016
15842,U-769,REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY,2016
15843,U-770,LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS,2016
15844,U-771,"METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT",2016
15845,U-772,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS,2016
15846,U-773,PATHOLOGICAL HYPERSECRETORY CONDITIONS,2016
15847,U-774,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR,2016
15848,U-775,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,2016
15849,U-776,"TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.",2016
15850,U-777,DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE,2016
15851,U-778,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2016
15852,U-779,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",2016
15853,U-780,A METHOD FOR THE TREATMENT OF CANCER,2016
15854,U-781,FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY,2016
15855,U-782,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE,2016
15856,U-783,DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER,2016
15857,U-784,TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS),2016
15858,U-785,"USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY",2016
15859,U-786,PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS,2016
15860,U-787,"MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA",2016
15861,U-788,METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE,2016
15862,U-789,TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING,2016
15863,U-790,FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS,2016
15864,U-791,GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST),2016
15865,U-792,TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS,2016
15866,U-793,"FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2016
15867,U-794,"CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE",2016
15868,U-795,METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE,2016
15869,U-796,METHOD OF TREATING DEPRESSION,2016
15870,U-797,METHOD OF TREATING ANXIETY,2016
15871,U-798,TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID,2016
15872,U-799,METHOD FOR INHIBITING SEROTONIN UPTAKE,2016
15873,U-800,"TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB",2016
15874,U-801,METHOD OF TREATING CANCER,2016
15875,U-802,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,2016
15876,U-803,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN,2016
15877,U-804,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,2016
15878,U-805,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,2016
15879,U-806,INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS,2016
15880,U-807,PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION,2016
15881,U-808,THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER,2016
15882,U-809,TREATMENT OF CHRONIC IDIOPATHIC URTICARIA,2016
15883,U-810,METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE,2016
15884,U-811,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA,2016
15885,U-812,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2016
15886,U-813,MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2016
15887,U-814,TREATMENT OF SCHIZOPHRENIA,2016
15888,U-815,"TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING",2016
15889,U-816,"DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER",2016
15890,U-817,NASAL ADMINISTRATION OF CYANOCOBALAMIN,2016
15891,U-818,TOPICAL TREATMENT OF ACNE VULGARIS,2016
15892,U-819,MANAGEMENT OF FIBROMYALGIA,2016
15893,U-820,"IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER",2016
15894,U-821,METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.,2016
15895,U-822,USE IN LIPID MANAGEMENT,2016
15896,U-823,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE,2016
15897,U-824,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,2016
15898,U-825,USE FOR PREVENTION OF BREAST CANCER,2016
15899,U-826,RELIEF OF MODERATE TO SEVERE PAIN,2016
15900,U-827,"USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES",2016
15901,U-828,PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION,2016
15902,U-829,TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY,2016
15903,U-830,TREATMENT OF RELAPSED SMALL CELL LUNG CANCER,2016
15904,U-831,METHOD OF ADMINISTERING LANREOTIDE ACETATE,2016
15905,U-832,ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.,2016
15906,U-833,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE,2016
15907,U-834,INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION,2016
15908,U-835,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER,2016
15909,U-836,A METHOD FOR THE TREATMENT OF LEUKEMIAS,2016
15910,U-837,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,2016
15911,U-838,METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE,2016
15912,U-839,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2016
15913,U-840,TREATMENT FOR TYPE 2 DIABETES MELLITUS,2016
15914,U-841,"INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER",2016
15915,U-842,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),2016
15916,U-843,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2016
15917,U-844,PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS,2016
15918,U-845,"TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES",2016
15919,U-846,USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE,2016
15920,U-847,"ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)",2016
15921,U-848,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2016
15922,U-849,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY,2016
15923,U-850,PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT,2016
15924,U-851,TREATMENT OF TYPE 2 DIABETES MELLITUS,2016
15925,U-852,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS,2016
15926,U-853,TREATMENT OR PREVENTION OF EMESIS,2016
15927,U-854,"PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)",2016
15928,U-855,"METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION",2016
15929,U-856,SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2016
15930,U-857,INHIBITION OF TRANSPLANT REJECTION,2016
15931,U-858,"PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS",2016
15932,U-859,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",2016
15933,U-860,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",2016
15934,U-861,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2016
15935,U-862,"ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA",2016
15936,U-863,"TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY",2016
15937,U-864,"PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS",2016
15938,U-865,TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE,2016
15939,U-866,THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES,2016
15940,U-867,TREATMENT OF MIGRAINE,2016
15941,U-868,METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA,2016
15942,U-869,METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2016
15943,U-870,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,2016
15944,U-871,"METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH",2016
15945,U-872,"TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2016
15946,U-873,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),2016
15947,U-874,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2016
15948,U-875,"FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE",2016
15949,U-876,TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,2016
15950,U-877,FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER,2016
15951,U-878,A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR,2016
15952,U-879,A METHOD OF TREATING OR PREVENTING ILEUS,2016
15953,U-880,ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN,2016
15954,U-881,TREATMENT OF NON-SMALL CELL LUNG CANCER,2016
15955,U-882,MANAGEMENT OF FIBROMYALGIA (FM),2016
15956,U-883,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,2016
15957,U-884,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA,2016
15958,U-885,TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY,2016
15959,U-886,"ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA",2016
15960,U-887,TREATMENT AND PREVENTION OF OSTEOPOROSIS,2016
15961,U-888,FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN,2016
15962,U-889,MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE),2016
15963,U-890,REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2016
15964,U-891,USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE,2016
15965,U-892,TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL),2016
15966,U-893,CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE,2016
15967,U-894,TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER,2016
15968,U-895,TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2016
15969,U-896,TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER,2016
15970,U-897,METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT,2016
15971,U-898,USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME,2016
15972,U-899,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2016
15973,U-900,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,2016
15974,U-901,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,2016
15975,U-902,USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH),2016
15976,U-903,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS,2016
15977,U-904,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,2016
15978,U-905,"TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE",2016
15979,U-906,"PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS",2016
15980,U-907,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER,2016
15981,U-908,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS,2016
15982,U-909,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,2016
15983,U-910,TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY,2016
15984,U-911,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE",2016
15985,U-912,SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES,2016
15986,U-913,"TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY",2016
15987,U-914,"METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2016
15988,U-915,TREATMENT OF MUSCULOSKELETAL CONDITIONS,2016
15989,U-916,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,2016
15990,U-917,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2016
15991,U-918,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,2016
15992,U-919,FOR THE TREATMENT OF DERMATITIS,2016
15993,U-920,STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS,2016
15994,U-921,TREATMENT OF ACNE VULGARIS,2016
15995,U-922,FOR THE TREATMENT OF FUNGAL INFECTIONS,2016
15996,U-923,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2016
15997,U-924,TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS,2016
15998,U-925,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA,2016
15999,U-926,"MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)",2016
16000,U-927,METHOD FOR INCREASING TEAR PRODUCTION,2016
16001,U-928,TREATMENT OF BACTERIAL INFECTIOUS DISEASE,2016
16002,U-929,TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI,2016
16003,U-930,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),2016
16004,U-931,RELIEF OF MODERATE TO SEVERE ACUTE PAIN,2016
16005,U-932,"PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI",2016
16006,U-933,FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE,2016
16007,U-934,IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA,2016
16008,U-935,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER",2016
16009,U-936,USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA,2016
16010,U-937,TREATMENT OF PROSTATE CANCER,2016
16011,U-938,"TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2016
16012,U-939,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2016
16013,U-940,METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA,2016
16014,U-941,METHOD TO TREAT OVARIAN CANCER,2016
16015,U-942,METHOD TO TREAT MULTIPLE MYELOMA,2016
16016,U-943,GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER,2016
16017,U-944,TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),2016
16018,U-945,SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION,2016
16019,U-946,TREATMENT OF BREAST CANCER,2016
16020,U-947,"WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS",2016
16021,U-948,TREATMENT OF DIABETES MELLITUS,2016
16022,U-949,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,2016
16023,U-950,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,2016
16024,U-951,TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS,2016
16025,U-952,USE AS AN ANALGESIC,2016
16026,U-953,METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION,2016
16027,U-954,CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA,2016
16028,U-955,PROPHYLACTIC TREATMENT OF MIGRAINE,2016
16029,U-956,TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE,2016
16030,U-957,A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE,2016
16031,U-958,"METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT",2016
16032,U-959,"METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML",2016
16033,U-960,METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT,2016
16034,U-961,METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE,2016
16035,U-962,SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2016
16036,U-963,PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2016
16037,U-964,ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS,2016
16038,U-965,USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER,2016
16039,U-966,TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY),2016
16040,U-967,"A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC",2016
16041,U-968,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2016
16042,U-969,TREATMENT OF MIGRAINE,2016
16043,U-970,TOPICAL TREATMENT OF LICE INFESTATIONS,2016
16044,U-971,INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA,2016
16045,U-972,MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER,2016
16046,U-973,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE,2016
16047,U-974,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN,2016
16048,U-975,TREATMENT OF PULMONARY HYPERTENSION,2016
16049,U-976,IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES,2016
16050,U-977,"TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE",2016
16051,U-978,METHOD OF TREATING HYPONATREMIA,2016
16052,U-979,RELIEF OF MUSCLE SPASM,2016
16053,U-980,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2016
16054,U-981,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2016
16055,U-982,A METHOD OF TREATING OSTEOPOROSIS,2016
16056,U-983,METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE,2016
16057,U-984,METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE,2016
16058,U-985,TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO),2016
16059,U-986,TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR,2016
16060,U-987,TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS,2016
16061,U-988,TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350,2016
16062,U-989,FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2016
16063,U-990,TREATMENT OF PROTOZOAL INFECTION,2016
16064,U-991,TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS,2016
16065,U-992,REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION,2016
16066,U-993,METHOD OF TREATING INFERTILITY,2016
16067,U-994,METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED,2016
16068,U-995,METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN,2016
16069,U-996,"AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA",2016
16070,U-997,TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS,2016
16071,U-998,"ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA",2016
16072,U-999,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,2016
16073,U-1000,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS,2016
16074,U-1001,"METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION",2016
16075,U-1002,METHOD OF TREATING INFLAMMATORY CONDITIONS,2016
16076,U-1003,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,2016
16077,U-1004,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2016
16078,U-1005,METHOD OF TREATING A STAPHYLOCOCCAL INFECTION,2016
16079,U-1006,NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER),2016
16080,U-1007,METHOD OF TREATING GOUT FLARES,2016
16081,U-1008,APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION,2016
16082,U-1009,METHOD FOR ADMINISTRATION OF TESTOSTERONE,2016
16083,U-1010,TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION,2016
16084,U-1011,USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING,2016
16085,U-1012,METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION,2016
16086,U-1013,METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2016
16087,U-1014,METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C,2016
16088,U-1015,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA,2016
16089,U-1016,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",2016
16090,U-1017,A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,2016
16091,U-1018,TREATMENT OF PULMONARY HYPERTENSION BY INHALATION,2016
16092,U-1019,TREATMENT OF PULMONARY HYPERTENSION,2016
16093,U-1020,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,2016
16094,U-1021,SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER,2016
16095,U-1022,FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION,2016
16096,U-1023,TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE,2016
16097,U-1024,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP,2016
16098,U-1025,TREATING FREQUENT HEARTBURN,2016
16099,U-1026,A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.,2016
16100,U-1027,REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL,2016
16101,U-1028,A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY,2016
16102,U-1029,METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF,2016
16103,U-1030,IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS),2016
16104,U-1031,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2016
16105,U-1032,USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS,2016
16106,U-1033,TOPICAL TREATMENT OF ACNE VULGARIS,2016
16107,U-1034,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,2016
16108,U-1035,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2016
16109,U-1036,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN,2016
16110,U-1037,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST,2016
16111,U-1038,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST,2016
16112,U-1039,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN,2016
16113,U-1040,INHIBITION OF THROMBIN IN A PATIENT,2016
16114,U-1041,TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE,2016
16115,U-1042,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,2016
16116,U-1043,MANAGEMENT OF MODERATE TO SEVERE PAIN,2016
16117,U-1044,TOPICAL TREATMENT OF SCALP PSORIASIS,2016
16118,U-1045,MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY,2016
16119,U-1046,MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY,2016
16120,U-1047,"TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)",2016
16121,U-1048,WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES,2016
16122,U-1049,PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT,2016
16123,U-1050,USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS,2016
16124,U-1051,TREATMENT OF OROPHARYNGEAL CANDIDIASIS,2016
16125,U-1052,RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2016
16126,U-1053,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER,2016
16127,U-1054,"ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS",2016
16128,U-1055,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE,2016
16129,U-1056,TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2016
16130,U-1057,TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE,2016
16131,U-1058,USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA,2016
16132,U-1059,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,2016
16133,U-1060,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS,2016
16134,U-1061,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,2016
16135,U-1062,ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE,2016
16136,U-1063,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,2016
16137,U-1064,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,2016
16138,U-1065,METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY,2016
16139,U-1066,METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA,2016
16140,U-1067,TREATMENT OF CANCER,2016
16141,U-1068,TREATMENT OF ASTHMA,2016
16142,U-1069,A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2016
16143,U-1070,A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE,2016
16144,U-1071,METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION,2016
16145,U-1072,"THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME",2016
16146,U-1073,USE FOR THE TREATMENT OF ASTHMA AND COPD,2016
16147,U-1074,USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT,2016
16148,U-1075,USE FOR THE TREATMENT OF ASTHMA,2016
16149,U-1076,"REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING",2016
16150,U-1077,PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION,2016
16151,U-1078,TREATMENT OF ACNE,2016
16152,U-1079,REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2016
16153,U-1080,METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT,2016
16154,U-1081,LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2016
16155,U-1082,USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS,2016
16156,U-1083,"ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES",2016
16157,U-1084,RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER,2016
16158,U-1085,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,2016
16159,U-1086,TREATMENT OF AUTOIMMUNE DISEASE,2016
16160,U-1087,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,2016
16161,U-1088,RELIEF OF MUSCLE SPASM,2016
16162,U-1089,INHIBITION OF THROMBIN,2016
16163,U-1090,LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION,2016
16164,U-1091,ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA,2016
16165,U-1092,TREATMENT OF BREAST CANCER,2016
16166,U-1093,TREATMENT OF PSEUDOBULBAR AFFECT,2016
16167,U-1094,MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN,2016
16168,U-1095,METHOD OF TREATING OCULAR INFLAMMATION,2016
16169,U-1096,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,2016
16170,U-1097,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,2016
16171,U-1098,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,2016
16172,U-1099,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2016
16173,U-1100,REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY,2016
16174,U-1101,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2016
16175,U-1102,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,2016
16176,U-1103,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2016
16177,U-1104,USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN,2016
16178,U-1105,TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER,2016
16179,U-1106,TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT,2016
16180,U-1107,TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT,2016
16181,U-1108,TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE,2016
16182,U-1109,"TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED ""SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY"" (S.T.E.P.S.)",2016
16183,U-1110,METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION,2016
16184,U-1111,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2016
16185,U-1112,METHOD OF MR IMAGING OF A MAMMAL,2016
16186,U-1113,TREATMENT AND PROPHYLAXIS OF INFLUENZA,2016
16187,U-1114,"TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA",2016
16188,U-1115,TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS,2016
16189,U-1116,METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS,2016
16190,U-1117,TREATMENT OF BREAST CANCER,2016
16191,U-1118,"USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA",2016
16192,U-1119,CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING,2016
16193,U-1120,TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL,2016
16194,U-1121,METHOD OF TREATING TRAVELERS' DIARRHEA,2016
16195,U-1122,TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES,2016
16196,U-1123,TREATMENT OF ALCOHOL DEPENDENCE,2016
16197,U-1124,"PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION",2016
16198,U-1125,METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS,2016
16199,U-1126,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL,2016
16200,U-1127,TREATMENT OF PATENT DUCTUS ARTERIOSUS,2016
16201,U-1128,TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE,2016
16202,U-1129,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2016
16203,U-1130,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN,2016
16204,U-1131,"TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2016
16205,U-1132,TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16206,U-1133,SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16207,U-1134,TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16208,U-1135,"TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C",2016
16209,U-1136,"SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2016
16210,U-1137,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2016
16211,U-1138,TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16212,U-1139,REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16213,U-1140,REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16214,U-1141,REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16215,U-1142,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2016
16216,U-1143,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2016
16217,U-1144,"REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN",2016
16218,U-1145,"REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2016
16219,U-1146,REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT,2016
16220,U-1147,"TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2016
16221,U-1148,"REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C",2016
16222,U-1149,"TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN",2016
16223,U-1150,"TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C",2016
16224,U-1151,"TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C",2016
16225,U-1152,CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION,2016
16226,U-1153,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION",2016
16227,U-1154,"TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB",2016
16228,U-1155,USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL),2016
16229,U-1156,TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA),2016
16230,U-1157,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2016
16231,U-1158,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2016
16232,U-1159,"RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER",2016
16233,U-1160,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER,2016
16234,U-1161,FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER,2016
16235,U-1162,TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP,2016
16236,U-1163,METHOD OF TREATING THROMBOSIS,2016
16237,U-1164,METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION,2016
16238,U-1165,USE FOR THE TREATMENT OF MULTIPLE MYELOMA,2016
16239,U-1166,A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS,2016
16240,U-1167,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),2016
16241,U-1168,"THE LONG TERM, ONCE-DAILY MAINTENANCE BROCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA",2016
16242,U-1169,MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN,2016
16243,U-1170,TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2016
16244,U-1171,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,2016
16245,U-1172,"TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN",2016
16246,U-1173,"TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE",2016
16247,U-1174,"ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION",2016
16248,U-1175,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2016
16249,U-1176,TREATMENT OR PREVENTION OF STROKE,2016
16250,U-1177,REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION,2016
16251,U-1178,RELIEF OF MODERATE TO SEVERE CHRONIC PAIN,2016
16252,U-1179,TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK),2016
16253,U-1180,TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS,2016
16254,U-1181,A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT,2016
16255,U-1182,TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING,2016
16256,U-1183,A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN,2016
16257,U-1184,TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA,2016
16258,U-1185,TREATMENT OF OPIOID-INDUCED CONSTIPATION,2016
16259,U-1186,ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE,2016
16260,U-1187,TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE),2016
16261,U-1188,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE,2016
16262,U-1189,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN",2016
16263,U-1190,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN",2016
16264,U-1191,"METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)",2016
16265,U-1192,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)",2016
16266,U-1193,"METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)",2016
16267,U-1194,METHOD FOR TREATING INSOMNIA,2016
16268,U-1195,"PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA",2016
16269,U-1196,RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS,2016
16270,U-1197,METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY,2016
16271,U-1198,RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE,2016
16272,U-1199,TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,2016
16273,U-1200,REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM,2016
16274,U-1201,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,2016
16275,U-1202,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,2016
16276,U-1203,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,2016
16277,U-1204,TREATMENT OF UVEITIS,2016
16278,U-1205,TREATMENT OF MACULAR EDEMA,2016
16279,U-1206,DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX,2016
16280,U-1207,"INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS",2016
16281,U-1208,"TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS",2016
16282,U-1209,"TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER",2016
16283,U-1210,USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE),2016
16284,U-1211,"USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2016
16285,U-1212,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2016
16286,U-1213,TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETETENT PATIENTS 12 YEARS OF AGE AND OLDER,2016
16287,U-1214,METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2016
16288,U-1215,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS),2016
16289,U-1216,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2016
16290,U-1217,METHOD OF INCREASING HAIR GROWTH,2016
16291,U-1218,METHOD OF STIMULATING HAIR GROWTH,2016
16292,U-1219,METHOD OF INCREASING THE NUMBER OF HAIRS,2016
16293,U-1220,TREATMENT OF RENAL CELL CARCINOMA,2016
16294,U-1221,TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION,2016
16295,U-1222,TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS,2016
16296,U-1223,METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE,2016
16297,U-1224,REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE,2016
16298,U-1225,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS,2016
16299,U-1226,A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT,2016
16300,U-1227,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE,2016
16301,U-1228,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN,2016
16302,U-1229,TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS,2016
16303,U-1230,A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT,2016
16304,U-1231,TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS,2016
16305,U-1232,"USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENTED FOR USE W/ASPIRIN",2016
16306,U-1233,"TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD",2016
16307,U-1234,"FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA",2016
16308,U-1235,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION,2016
16309,U-1236,USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA,2016
16310,U-1237,"COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS",2016
16311,U-1238,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,2016
16312,U-1239,MAGNETIC RESONANCE IMAGING OF THE LIVER,2016
16313,U-1240,TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION,2016
16314,U-1241,MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED,2016
16315,U-1242,PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS,2016
16316,U-1243,"WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER",2016
16317,U-1244,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA,2016
16318,U-1245,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE,2016
16319,U-1246,SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA,2016
16320,U-1247,MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS,2016
16321,U-1248,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE,2016
16322,U-1249,TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG,2016
16323,U-1250,"TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA",2016
16324,U-1251,A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT,2016
16325,U-1252,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE,2016
16326,U-1253,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY,2016
16327,U-1254,METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN,2016
16328,U-1255,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY,2016
16329,U-1256,TREATMENT OF SEBORRHEIC DERMATITIS,2016
16330,U-1257,TREATMENT OF OPHTHALMIC DISORDERS,2016
16331,U-1258,VISUALIZATION DURING VITRECTOMY PROCEDURES,2016
16332,U-1259,PROPHYLAXIS OF HIV-1 INFECTION,2016
16333,U-1260,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,2016
16334,U-1261,REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION,2016
16335,U-1262,"USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT",2016
16336,U-1263,TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS,2016
16337,U-1264,TREATMENT OF A RESPIRATORY DISEASE,2016
16338,U-1265,PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2016
16339,U-1266,METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA,2016
16340,U-1267,TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE,2016
16341,U-1268,"TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE",2016
16342,U-1269,"TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET",2016
16343,U-1270,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE),2016
16344,U-1271,TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES,2016
16345,U-1272,TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM,2016
16346,U-1273,TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM,2016
16347,U-1274,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS,2016
16348,U-1275,TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER,2016
16349,U-1276,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,2016
16350,U-1277,"METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN",2016
16351,U-1278,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS,2016
16352,U-1279,TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKNIETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE,2016
16353,U-1280,USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS,2016
16354,U-1281,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL,2016
16355,U-1282,PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING,2016
16356,U-1283,A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA,2016
16357,U-1284,A METHOD OF TREATING A NEOPLASM,2016
16358,U-1285,TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,2016
16359,U-1286,A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE,2016
16360,U-1287,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2016
16361,U-1288,TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET,2016
16362,U-1289,MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN,2016
16363,U-1290,TREATMENT OF LUNG CANCER,2016
16364,U-1291,TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION,2016
16365,U-1292,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET",2016
16366,U-1293,A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2016
16367,U-1294,METHOD OF TREATING GLAUCOMA IN A PATIENT,2016
16368,U-1295,A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION,2016
16369,U-1296,USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION,2016
16370,U-1297,TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS,2016
16371,U-1298,ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES,2016
16372,U-1299,TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2016
16373,U-1300,TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML),2016
16374,U-1301,TREATMENT OF DEEP VEIN THROMBOSIS (DVT),2016
16375,U-1302,TREATMENT OF PULMONARY EMBOLISM (PE),2016
16376,U-1303,REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM,2016
16377,U-1304,USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES,2016
16378,U-1305,"TREATMENT OF HIV-1INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS",2016
16379,U-1306,TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY,2016
16380,U-1307,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY",2016
16381,U-1308,MULTIPLE MYELOMA,2016
16382,U-1309,BONE METASTASES,2016
16383,U-1310,FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS,2016
16384,U-1311,METHOD OF TREATING CYSTIC FIBROSIS,2016
16385,U-1312,USE FOR THE TREATMENT OF HYPERGLYCEMIA,2016
16386,U-1313,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,2016
16387,U-1314,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2016
16388,U-1315,THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA,2016
16389,U-1316,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,2016
16390,U-1317,"TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2016
16391,U-1318,TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,2016
16392,U-1319,SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA,2016
16393,U-1320,TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT,2016
16394,U-1321,TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS,2016
16395,U-1322,METHOD OF REDUCING OCULAR HYPERTENSION,2016
16396,U-1323,REDUCING THE RISK OF STROKE,2016
16397,U-1324,MANAGEMENT OF CYSTIC FIBROSIS PATIENTS,2016
16398,U-1325,"INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS",2016
16399,U-1326,METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE,2016
16400,U-1327,"METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION",2016
16401,U-1328,"METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF",2016
16402,U-1329,TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER,2016
16403,U-1330,METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
16404,U-1331,METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
16405,U-1332,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
16406,U-1333,METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR,2016
16407,U-1334,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER,2016
16408,U-1335,METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN,2016
16409,U-1336,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN,2016
16410,U-1337,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,2016
16411,U-1338,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN,2016
16412,U-1339,METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2016
16413,U-1340,METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2016
16414,U-1341,METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2016
16415,U-1342,METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2016
16416,U-1343,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN,2016
16417,U-1344,METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION,2016
16418,U-1345,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/-10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,2016
16419,U-1346,"USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE",2016
16420,U-1347,TREATMENT OF A SKIN DISORDER,2016
16421,U-1348,TREATMENT OF OSTEOARTHRITIS,2016
16422,U-1349,TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS,2016
16423,U-1350,TREATMENT OF ANKYLOSING SPONDYLITIS,2016
16424,U-1351,TREATMENT OF ACUTE PAIN,2016
16425,U-1352,TREATMENT OF PRIMARY DYSMENORRHEA,2016
16426,U-1353,"ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2016
16427,U-1354,INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH,2016
16428,U-1355,MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD,2016
16429,U-1356,TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER,2016
16430,U-1357,TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD,2016
16431,U-1358,TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS,2016
16432,U-1359,"USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA",2016
16433,U-1360,USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA,2016
16434,U-1361,USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE,2016
16435,U-1362,"TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET",2016
16436,U-1363,A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY,2016
16437,U-1364,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2016
16438,U-1365,PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT,2016
16439,U-1366,TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN,2016
16440,U-1367,METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN,2016
16441,U-1368,"TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB",2016
16442,U-1369,TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE,2016
16443,U-1370,TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE,2016
16444,U-1371,REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA,2016
16445,U-1372,ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION,2016
16446,U-1373,METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS,2016
16447,U-1374,TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML),2016
16448,U-1375,ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS,2016
16449,U-1376,TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS,2016
16450,U-1377,IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA,2016
16451,U-1378,TREATMENT OF A NITROGEN METABOLISM DISORDER,2016
16452,U-1379,IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS,2016
16453,U-1380,IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE,2016
16454,U-1381,USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,2016
16455,U-1382,TREATMETN OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT,2016
16456,U-1383,DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER,2016
16457,U-1384,METHOD OF TREATING MULTIPLE SCLEROSIS,2016
16458,U-1385,METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS,2016
16459,U-1386,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF,2016
16460,U-1387,REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS,2016
16461,U-1388,TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS,2016
16462,U-1389,ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD,2016
16463,U-1390,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF,2016
16464,U-1391,METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION,2016
16465,U-1392,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION,2016
16466,U-1393,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION,2016
16467,U-1394,METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,2016
16468,U-1395,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/-10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,2016
16469,U-1396,"TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE",2016
16470,U-1397,USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY,2016
16471,U-1398,METHOD OF TREATING CHRONIC HEPATITIS C,2016
16472,U-1399,MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES,2016
16473,U-1400,"FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",2016
16474,U-1401,"INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS",2016
16475,U-1402,FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL),2016
16476,U-1403,FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST,2016
16477,U-1404,METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS,2016
16478,U-1405,THERAPEUTIC TREATMENT OF BONE METASTASES,2016
16479,U-1406,TREATMENT OF MELANOMA,2016
16480,U-1407,TREATMENT OF NEWLY DIAGNOSED PHILADELPIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML),2016
16481,U-1408,TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER,2016
16482,U-1409,TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION,2016
16483,U-1410,TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES,2016
16484,U-1411,THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE,2016
16485,U-1412,TREATMENT OF ATOPIC DERMATITIS,2016
16486,U-1413,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION,2016
16487,U-1414,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL),2016
16488,U-1415,"TREATMING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2",2016
16489,U-1416,"USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES",2016
16490,U-1417,USE FOR TREATMENT OF HELICOBACTER INFECTIONS,2016
16491,U-1418,TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST,2016
16492,U-1419,TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING,2016
16493,U-1420,METHOD OF ONCE A DAY ADMINISTRATION,2016
16494,U-1421,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE,2016
16495,U-1422,METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT,2016
16496,U-1423,AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT,2016
16497,U-1424,"LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSOTO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2016
16498,U-1425,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE,2016
16499,U-1426,USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS,2016
16500,U-1427,ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY,2016
16501,U-1428,TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA,2016
16502,U-1429,TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR,2016
16503,U-1430,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS",2016
16504,U-1431,"METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE",2016
16505,U-1432,METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX,2016
16506,U-1433,IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS,2016
16507,U-1434,TREATMENT OF PANCREATIC CANCER,2016
16508,U-1435,COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AN DADMINISTRATION OF AN ORAL NSAID.,2016
16509,U-1436,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT,2016
16510,U-1437,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION,2016
16511,U-1438,ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION,2016
16512,U-1439,METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION,2016
16513,U-1440,USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS,2016
16514,U-1441,A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING,2016
16515,U-1442,SUBCUTANEOUS INJECTION OF METHOTREXATE,2016
16516,U-1443,ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS,2016
16517,U-1444,A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS,2016
16518,U-1445,"METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION",2016
16519,U-1446,METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES,2016
16520,U-1447,TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA,2016
16521,U-1448,TREATING SEVERE HYPERTRIGLYCERIDEMIA,2016
16522,U-1449,METHOD OF ALLEVIATING A SKIN CONDITION,2016
16523,U-1450,TREATMENT OF ALLERGIC RHINITIS SYMPTOMS,2016
16524,U-1451,APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY,2016
16525,U-1452,METHOD FOR CHRONIC WEIGHT MANAGEMENT,2016
16526,U-1453,A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT,2016
16527,U-1454,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS,2016
16528,U-1455,TREATMENT OF PERIANAL WARTS,2016
16529,U-1456,TREATMENT OF MANTLE CELL LYMPHOMA,2016
16530,U-1457,A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM,2016
16531,U-1458,A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION,2016
16532,U-1459,TREATMENT OF CARCINOMA OF THE THYROID,2016
16533,U-1460,TREATMENT OF HERPES LABIALIS,2016
16534,U-1461,A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE,2016
16535,U-1462,"A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE",2016
16536,U-1463,"A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES",2016
16537,U-1464,TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION,2016
16538,U-1465,USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE,2016
16539,U-1466,RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER,2016
16540,U-1467,METHOD OF TREATING HEPATITIS C,2016
16541,U-1468,CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS,2016
16542,U-1469,USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS,2016
16543,U-1470,FOR THE TREATMENT OF HEPATITIS C,2016
16544,U-1471,"A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.",2016
16545,U-1472,"INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES",2016
16546,U-1473,MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF,2016
16547,U-1474,"A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT",2016
16548,U-1475,USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).,2016
16549,U-1476,"INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.",2016
16550,U-1477,USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE,2016
16551,U-1478,METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,2016
16552,U-1479,INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).,2016
16553,U-1480,TREATMENT OF ADVANCED RENAL CELL CARCINOMA,2016
16554,U-1481,REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE,2016
16555,U-1482,DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,2016
16556,U-1483,INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).,2016
16557,U-1484,COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER),2016
16558,U-1485,TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS,2016
16559,U-1486,TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER,2016
16560,U-1487,METHOD OF INCREASING EYELASH GROWTH,2016
16561,U-1488,USE OF TOPICAL DICLOFENAC FOR TREATING PAIN,2016
16562,U-1489,USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS,2016
16563,U-1490,"FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE",2016
16564,U-1491,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,2016
16565,U-1492,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER,2016
16566,U-1493,METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS,2016
16567,U-1494,SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE,2016
16568,U-1495,RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.,2016
16569,U-1496,METHOD TO TREAT HEMANGIOMA.,2016
16570,U-1497,NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT,2016
16571,U-1498,METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM,2016
16572,U-1499,MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,2016
16573,U-1500,TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).,2016
16574,U-1501,PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM,2016
16575,U-1502,PROPHYLAXIS OF PULMONARY EMBOLISM,2016
16576,U-1503,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN,2016
16577,U-1504,USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4,2016
16578,U-1505,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,2016
16579,U-1506,"TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR",2016
16580,U-1507,TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN,2016
16581,U-1508,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED",2016
16582,U-1509,TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER,2016
16583,U-1510,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOD TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.",2016
16584,U-1511,TREATMENT OF HYPERTRIGLYCERIDEMIA,2016
16585,U-1512,REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,2016
16586,U-1513,TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS,2016
16587,U-1514,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL,2016
16588,U-1515,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.,2016
16589,U-1516,METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.,2016
16590,U-1517,TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.,2016
16591,U-1518,MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN,2016
16592,U-1519,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME,2016
16593,U-1520,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT,2016
16594,U-1521,MAINTENANCE TREATMENT OF OPIOID DEPENDENCE,2016
16595,U-1522,"TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE",2016
16596,U-1523,METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE,2016
16597,U-1524,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE,2016
16598,U-1525,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,2016
16599,U-1526,THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE,2016
16600,U-1527,"FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY",2016
16601,U-1528,A METHOD OF LOWERING INTRAOCULAR PRESSURE,2016
16602,U-1529,ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),2016
16603,U-1530,USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION,2016
16604,U-1531,METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE,2016
16605,U-1532,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.,2016
16606,U-1533,PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.,2016
16607,U-1534,ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.,2016
16608,U-1535,ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.,2016
16609,U-1536,ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.,2016
16610,U-1537,TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.,2016
16611,U-1538,ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.,2016
16612,U-1539,PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.,2016
16613,U-1540,"BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.",2016
16614,U-1541,TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.,2016
16615,U-1542,FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA,2016
16616,U-1543,TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23,2016
16617,U-1544,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).,2016
16618,U-1545,A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE,2016
16619,U-1546,FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.,2016
16620,U-1547,"TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA",2016
16621,U-1548,"FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",2016
16622,U-1549,FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA,2016
16623,U-1550,METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.,2016
16624,U-1551,"METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.",2016
16625,U-1552,FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE),2016
16626,U-1553,TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN,2016
16627,U-1554,FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD),2016
16628,U-1555,"MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.",2016
16629,U-1556,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.",2016
16630,U-1557,A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.,2016
16631,U-1558,FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA,2016
16632,U-1559,INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER,2016
16633,U-1560,"A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE",2016
16634,U-1561,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,2016
16635,U-1562,TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE),2016
16636,U-1563,A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.,2016
16637,U-1564,A METHOD OF TREATING GAUCHER'S DISEASE,2016
16638,U-1565,"METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE",2016
16639,U-1566,"METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER",2016
16640,U-1567,"METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER",2016
16641,U-1568,"METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE",2016
16642,U-1569,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,2016
16643,U-1570,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE,2016
16644,U-1571,TREATMENT OF GAUCHER DISEASE TYPE 1,2016
16645,U-1572,TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.,2016
16646,U-1573,USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.,2016
16647,U-1574,A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.,2016
16648,U-1575,PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY,2016
16649,U-1576,TREATMENT OF LEUKEMIA,2016
16650,U-1577,CONTROL OF SERUM PHOSPHOROUS LEVELS,2016
16651,U-1578,TREATMENT OF ACUTE OTITIS MEDIA,2016
16652,U-1579,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,2016
16653,U-1580,USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY,2016
16654,U-1581,IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.,2016
16655,U-1582,TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA,2016
16656,U-1583,FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY,2016
16657,U-1584,USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS,2016
16658,U-1585,USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE,2016
16659,U-1586,FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE,2016
16660,U-1587,SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.,2016
16661,U-1588,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).,2016
16662,U-1589,METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA,2016
16663,U-1590,KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA,2016
16664,U-1591,TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER,2016
16665,U-1592,TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE,2016
16666,U-1593,"MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.",2016
16667,U-1594,DILATION OF THE PUPIL,2016
16668,U-1595,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS,2016
16669,U-1596,LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES,2016
16670,U-1597,TREATMENT OF DIABETIC MACULAR EDEMA,2016
16671,U-1598,METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE,2016
16672,U-1599,"MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADNUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY",2016
16673,U-1600,DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,2016
16674,U-1601,DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,2016
16675,U-1602,METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION,2016
16676,U-1603,METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE,2016
16677,U-1604,METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2,2016
16678,U-1605,METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER,2016
16679,U-1606,METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM,2016
16680,U-1607,METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION,2016
16681,U-1608,DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION,2016
16682,U-1609,CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,2016
16683,U-1610,CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE,2016
16684,U-1611,METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER,2016
16685,U-1612,METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER,2016
16686,U-1613,DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN,2016
16687,U-1614,USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN,2016
16688,U-1615,"FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL",2016
16689,U-1616,NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,2016
16690,U-1617,METHOD OF TREATING MEDULLARY THYROID CANCER,2016
16691,U-1618,"A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FONNULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT",2016
16692,U-1619,TREATMENT OF IMMUNE (IDIOPATIC) THROMBOCYTOPENIA (ITP),2016
16693,U-1620,"METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.",2016
16694,U-1621,PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.,2016
16695,U-1622,FOR THE TREATMENT OF POLYCYTHEMIA VERA,2016
16696,U-1623,USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.,2016
16697,U-1624,"TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.",2016
16698,U-1625,METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6,2016
16699,U-1626,A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING,2016
16700,U-1627,TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS,2016
16701,U-1628,METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION,2016
16702,U-1629,METHOD OF TREATING ACROMEGALY,2016
16703,U-1630,TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED IWTH DOCETAXEL,2016
16704,U-1631,TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.,2016
16705,U-1632,"TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA",2016
16706,U-1633,USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA,2016
16707,U-1634,TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR,2016
16708,U-1635,USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION,2016
16709,U-1636,USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.,2016
16710,U-1637,"TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.",2016
16711,U-1638,TREATMENT OF HCV INFECTION USING PARITAPREVIR,2016
16712,U-1639,USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY,2016
16713,U-1640,TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED,2016
16714,U-1641,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,2016
16715,U-1642,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN,2016
16716,U-1643,TREATING CUSHING'S SYNDROME,2016
16717,U-1644,TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTININ CHLORIDE GEL TO SKIN,2016
16718,U-1645,"TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",2016
16719,U-1646,"TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",2016
16720,U-1647,TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION,2016
16721,U-1648,"TREATMENT OF PATIENTS WITH PARKINSONâS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",2016
16722,U-1649,TREATMENT OF POST-ENCEPHALITIC PARKINSONISM,2016
16723,U-1650,TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA,2016
16724,U-1651,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN,2016
16725,U-1652,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN,2016
16726,U-1653,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN),2016
16727,U-1654,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA),2016
16728,U-1655,A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY,2016
16729,U-1656,METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT,2016
16730,U-1657,"METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99",2016
16731,U-1658,"TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN",2016
16732,U-1659,MANAGEMENT OF PAIN,2016
16733,U-1660,TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS,2016
16734,U-1661,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN,2016
16735,U-1662,A METHOD OF TREATING OCULAR PAIN,2016
16736,U-1663,TREATMENT OF HIV-1 INFECTION,2016
16737,U-1664,TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL,2016
16738,U-1665,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1,2016
16739,U-1666,PALLIATIVE TREATMENT OF PROSTATE CANCER,2016
16740,U-1667,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS",2016
16741,U-1668,METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER,2016
16742,U-1669,"TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE",2016
16743,U-1670,NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.,2016
16744,U-1671,TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS,2016
16745,U-1672,TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION,2016
16746,U-1673,"TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS",2016
16747,U-1674,DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE,2016
16748,U-1675,USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY,2016
16749,U-1676,METHODS FOR TREATING BACTERIAL INFECTIONS,2016
16750,U-1677,TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF),2016
16751,U-1678,"FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL",2016
16752,U-1679,TREATMENT OF ACUTE OTITIS EXTERNA,2016
16753,U-1680,TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS,2016
16754,U-1681,"TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC",2016
16755,U-1682,TREATMENT OF BACTERIAL VAGINOSIS,2016
16756,U-1683,TREATMENT FRO CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,2016
16757,U-1684,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,2016
16758,U-1685,DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE,2016
16759,U-1686,"A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION",2016
16760,U-1687,TREATMENT OF HCV INFECTION USING OMBITASVIR,2016
16761,U-1688,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD,2016
16762,U-1689,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD,2016
16763,U-1690,METHOD FOR REDUCTION OF SUBMENTAL FAT,2016
16764,U-1691,INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER,2016
16765,U-1692,METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD,2016
16766,U-1693,METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS,2016
16767,U-1694,A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE,2016
16768,U-1695,METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER,2016
16769,U-1696,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,2016
16770,U-1697,PULMONARY ADMINISTRATION OF A COMPISITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.,2016
16771,U-1698,PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS,2016
16772,U-1699,A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA,2016
16773,U-1700,A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA,2016
16774,U-1701,A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN,2016
16775,U-1702,TREATMENT OF COPD,2016
16776,U-1703,TREATMENT OF RESPIRATORY COMPLAINTS,2016
16777,U-1704,USE FOR TREATMENT IN PATIENTS WITH DIABETES,2016
16778,U-1705,USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA,2016
16779,U-1706,TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE,2016
16780,U-1707,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.,2016
16781,U-1708,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.,2016
16782,U-1709,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).,2016
16783,U-1710,TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE,2016
16784,U-1711,"FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL",2016
16785,U-1712,MEKENIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA,2016
16786,U-1713,TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA,2016
16787,U-1714,TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP),2016
16788,U-1715,P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTIONTO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR,2016
16789,U-1716,TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS,2016
16790,U-1717,METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE,2016
16791,U-1718,METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.,2016
16792,U-1719,ACUTE TREATMENT OF MIGRAINE,2016
16793,U-1720,METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA,2016
16794,U-1721,USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2,2016
16795,U-1722,TREATMENT OF BASAL CELL CARCINOMA,2016
16796,U-1723,TREATMENT OF HEART FAILURE,2016
16797,U-1724,METHOD OF INHIBITING HEPATITIS C VIRUS,2016
16798,U-1725,METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY,2016
16799,U-1726,REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS,2016
16800,U-1727,TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA,2016
16801,U-1728,REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS,2016
16802,U-1729,REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT),2016
16803,U-1730,REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM,2016
16804,U-1731,TEMPORARY RELIEF OF MINOR ACHES AND PAINS,2016
16805,U-1732,TEMPORARY REDUCTION OF FEVER,2016
16806,U-1733,TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE,2016
16807,U-1734,USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD),2016
16808,U-1735,"METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL",2016
16809,U-1736,TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP),2016
16810,U-1737,METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE,2016
16811,U-1738,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE),2016
16812,U-1739,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY",2016
16813,U-1740,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY",2016
16814,U-1741,PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY,2016
16815,U-1742,"ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY",2016
16816,U-1743,FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY,2016
16817,U-1744,PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING,2016
16818,U-1745,FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA,2016
16819,U-1746,MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY,2016
16820,U-1747,"FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD",2016
16821,U-1748,"FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS",2016
16822,U-1749,ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,2016
16823,U-1750,TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE,2016
16824,U-1751,"TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY",2016
16825,U-1752,PROPHYLAXIS OF ORGAN REJECTION,2016
16826,U-1753,TREATMENT OF HCV INFECTION USING DISABUVIR,2016
16827,U-1754,FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL,2016
16828,U-1755,FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS,2016
16829,U-1756,"METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF",2016
16830,U-1757,INHIBITION ON PI3K KINASE,2016
16831,U-1758,METHOD OF TREATING ALLERGIC REACTION VIA INJECTION,2016
16832,U-1759,METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB,2016
16833,U-1760,RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT,2016
16834,U-1761,PLAQUE PSORIASIS,2016
16835,U-1762,USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT,2016
16836,U-1763,USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT,2016
16837,U-1764,USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT,2016
16838,U-1765,USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT,2016
16839,U-1766,TREATMENT OF HYPERKALEMIA,2016
16840,U-1767,USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER,2016
16841,U-1768,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN,2016
16842,U-1769,TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE,2016
16843,U-1770,TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA,2016
16844,U-1771,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION,2016
16845,U-1772,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN,2016
16846,U-1773,LONG -TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),2016
16847,U-1774,USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE,2016
16848,U-1775,USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS,2016
16849,U-1776,METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA,2016
16850,U-1777,"TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTORE RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY",2016
16851,U-1778,METHOD FOR TREATING MULTIPLE MYELOMA,2016
16852,U-1779,METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS,2016
16853,U-1780,"METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA",2016
16854,U-1781,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT,2016
16855,U-1782,FOR HEAD LICE INFESTATIONS,2016
16856,U-1783,METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED,2016
16857,U-1784,METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED,2016
16858,U-1785,METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED,2016
16859,U-1786,TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE,2016
16860,U-1787,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY,2016
16861,U-1788,TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN,2016
16862,U-1789,METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION,2016
16863,U-1790,FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA,2016
16864,U-1791,"EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS",2016
16865,U-1792,TREATMENT OF OTIC INFECTION OR INFLAMMATION,2016
16866,U-1793,TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT,2016
16867,U-1794,REVERSAL OF DRUG-INDUCED NEUROMUSCLUAR BLOCK,2016
16868,U-1795,REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE,2016
16869,U-1796,TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA,2016
